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Animal models of depression have provided invaluable insight into the disease neurobiology, 
yet when it comes to novel antidepressant targets, the research progress in this area struggled 
to keep up with the growing prevalence of the disease. Thus this thesis is dedicated to 
improvement and optimisation of two frequently used models in mice, the unpredictable 
chronic mild stress (UCMS) with its good construct and predictive validity, and 
lipopolysaccharide (LPS) exposure relevant for the inflammatory theory of depression. 
The experiments described in this thesis show that following optimisation, UCMS can be a 
reliable model to induce some of the depression-like behaviours, as well as alterations in adult 
hippocampal neurogenesis (AHN) in mice. However, it appeared that the prefrontal cortex 
(PFC) but not the hippocampus responds to UCMS with profound gene expression changes and 
microglial activation. Importantly, UCMS was not associated with a strong profile of systemic 
inflammatory changes seen in depressed patients.  Therefore, the need for an intervention 
specifically targeting the immune system became apparent.  
For this, LPS exposure, which induces a depression-like phenotype by activating the immune 
system, was employed. Results suggested that repeated LPS injections rather than frequently 
used single LPS exposure might be a suitable model to induce chronic immune changes 
relevant for depression, as well as some alteration of AHN. However, measures such as dose 
increment and sufficient recovery time between injections should be taken to avoid 
development of tolerance towards LPS, although they were not successful in sustaining the 
long-term behavioural depressive-like phenotype. 
In conclusion, this research showed that both UCMS and LPS-based interventions induce some 
endophenotypes relevant for depression, yet neither is sufficient to fully model behavioural 
changes and neurobiology of the disease in mice. It is suggested that future work combining 
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Chapter 1 Introduction 
 An introduction to depression and its neurobiology  
 Global burden of depression 
Depression is one of the most prevalent psychiatric disorders. Together with dysthymia it has 
been identified as a leading cause of burden in the Global Burden of Disease (GBD) 2010 study, 
conducted by the World Health Organisation (Ferrari et al., 2013). This conclusion was drawn 
based on the calculation of the number of healthy life years lost to disability or premature 
mortality. The 2013 GBD study identified depression as the second leading cause of years lost 
to disability (Vos et al. 2015). The study also identified a 37.5% increase in the years lived with 
disability due to depression in the last 20 years. While this increase was attributed to the 
population growth and aging, these findings still highlight the enormous burden on and 
implications of depression for global health. Yet the development of efficacious 
pharmacological treatments of depression is struggling to keep pace with the growth of 
disease prevalence (Willner et al., 2013). To advance the development of new therapeutics, we 
first need to better understand the factors increasing susceptibility to depression and the 
neurobiological processes underlying and determining the course of this devastating disorder.  
 Clinical diagnosis and risk factors 
Depression is a highly heterogeneous disorder, therefore its diagnosis is based on multiple 
criteria, but among others must include two key symptoms – depressed mood and/or loss of 
interest or pleasure in all or almost all activities, or in other words inability to experience 
pleasure (anhedonia). The Diagnostic and Statistical Manual (DSM) lists another 7 symptoms 
which represent a mixture of emotional cognitive and neurovegetative impairments, as diverse 
as weight change and sleep disruption, fatigue and psychomotor agitation or retardation, 
feelings of worthlessness and guilt, thoughts of death and suicidal ideation, and diminished 
ability to concentrate or indecisiveness (DSM-5, 2013). To meet the diagnostic criteria, the 
symptoms need to be severe enough to cause “clinically significant distress or impairment in 
social, occupational, or other important areas of functioning”. In the United Kingdom, the 
estimated prevalence of a single episode in a lifetime of major depression is 6.4%, 12.2% for 
recurrent moderate major depression, and 7.2% for recurrent severe depression  (Smith et al., 
2013). Therefore approximately 1 in 6 individuals will experience depression in their lifetime 
(Otte et al., 2016).  
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The approximate heritability of depression is estimated to be 35% (Geschwind and Flint, 2015), 
however genome-wide associated studies so far achieved limited success in identifying 
significant and replicable genetic polymorphisms associated with depression (Ripke et al., 
2013). The failure of genomic studies has been attributed to highly polygenic nature of the 
disease with many genes displaying small effects, as well as high heterogeneity of the disorder 
requiring large sample sizes to achieve significance (Hyman, 2014).  In addition, gene-
environment interactions are likely to be required for some genetic polymorphisms to exert 
their effects (Caspi, 2003). Indeed, environmental factors play a major role in depression 
aetiology. Stressful life events, such as loss of income, severe medical problems, exposure to 
violence or bereavement,  have been identified as major risk factors for the development of 
depression (Kendler et al., 1999). Chronic stress, such as low socioeconomic status and social 
isolation also present a significant risk for disease development (Fava and Kendler, 2000). A 
specific link has been recognised between depression and stressful life events experienced in 
childhood, such as childhood maltreatment or separation from parents, as well as exposure to 
maternal depression (Bernet and Stein, 1999; Pawlby et al., 2011). 
 Pharmacological treatment available 
The first antidepressant medications imipramine and iproniazid were discovered by serendipity 
in the clinic in the 1950s (Lopez-Munoz and Alamo, 2009). Imipramine is a tricyclic compound 
with noradrenaline and serotonin reuptake inhibition properties, while iproniazid is an 
inhibitor of monoamine metabolising enzyme, monoamine oxidase (MAO). The observation 
that two drugs which increase monoamine availability within the synapse can improve 
depressive symptoms formed a foundation of the monoamine deficiency theory of depression 
neurobiology (Schildkraut, 1965). According to this theory, depression occurs due to the lack of 
monoamine signalling in the brain, thus compounds which increase monoamine availability 
exert antidepressant effects. Accumulating data on the particular importance of serotonin in 
depression prompted the industry to focus on the serotonin reuptake and to develop the first 
selective serotonin reuptake inhibitor (SSRI) fluoxetine (Lopez-Munoz and Alamo, 2009). The 
clinical success of fluoxetine asserted the role of serotonin signalling in depression. However, 
simple increases in serotonin levels within the synapse cannot explain some of the aspects of 
SSRI effect. For example, the rapid effect of fluoxetine on serotonin levels does not match the 
late onset of its antidepressant effect, which requires weeks of daily intake (Trivedi et al., 
2006). Individual difference in therapeutic efficacy of various antidepressants also cannot be 
explained by such a straightforward mechanism of action. Therefore, mechanisms of 
antidepressant action became the focus of intense scientific scrutiny, and led to the rise of 
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alternative theories, based on the idea that an increase in monoamine signalling is just the first 
step in a cascade of events leading to antidepressant effect (Elhwuegi, 2004).  
Currently all of the routinely prescribed antidepressants act on the monoamine 
neurotransmitter system. Yet monoaminergic drugs have a number of disadvantages, most 
importantly low response rates and late onset of clinical improvement, which frequently 
requires up to 12 weeks of treatment (Uher et al., 2011). It has been shown that only a third of 
depressed patients receiving antidepressants achieve complete remission after the first course 
of antidepressant therapy (Trivedi et al., 2006). Another study showed that antidepressant 
treatment only shows clinical efficacy in patients with severe depression, while for mild or 
moderate symptoms, the effect of antidepressants is close to that of placebo (Fournier et al., 
2010). Tham et al. (2016) showed that in elderly patients serotonin reuptake inhibitors (SSRIs), 
the most frequently prescribed group of antidepressants, are not more effective than placebo 
in achieving remission, although they were more effective in preventing relapse. Treatment-
resistant depression has been estimated to occur in up to 60% of patients (Fava, 2003), and 
sometimes requires up to 4 switches of medication before remission is achieved (Warden et 
al., 2007). Many factors could play a role in antidepressant resistance. Pharmacokinetic issues, 
such as hepatic metabolism (Mrazek et al., 2011) and blood brain barrier penetrance (Uhr et 
al., 2008) have been suggested to be involved. Specific aspects of depression neurobiology are 
also likely to play a role. Factors such as genetic background affecting serotonin metabolism 
and neural plasticity (Kocabas et al., 2011; Le François et al., 2008), as well as comorbid 
conditions with inflammatory (Scherrer et al., 2012) or neurodegenerative component (Price 
et al., 2011) have been associated with increased incidence of treatment resistance. Therefore 
currently most depression researchers agree that to overcome the drawbacks of 
monoaminergic antidepressants, novel compounds need to be designed to target other 
aspects of depression neurobiology (Belzung and Billette de Villemeur, 2010; Willner et al., 
2014). 
 Neurobiology of depression 
 The role of the hypothalamic-pituitary-adrenal (HPA) axis in 
depression 
The hypothalamic-pituitary-adrenal (HPA) axis is the primary stress response system of the 
body, which regulates the systemic levels of corticosteroid hormones (cortisol in humans and 
corticosterone in rodents) (see Figure 1). Stressful stimuli reach the hypothalamus via the 
amygdala and the subgenual prefrontal cortex (PFC) and activate the release of corticotropin-
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releasing hormone (CRH) (Gold, 2015). CRH is produced by the hypothalamic paraventricular 
nucleus (PVN) and released into the local hypothalamic-pituitary blood circulation system. Via 
this system CRH reaches the anterior pituitary, where it stimulates the production of 
adrenocorticotropic hormone (ACTH), which is subsequently released into the systemic 
bloodstream. Once in the circulation, ACTH stimulates the release of glucocorticoids (cortisol 
in humans and corticosterone in rodents) by the adrenal glands. Cortisol acts on 
mineralocorticoid (MR) and glucocorticoid receptors (GR) which are widely expressed in many 
tissues of the body (Holsboer, 2000). This allows cortisol to coordinate the stress response of 
different body systems. Its primary role is to mobilise energy metabolism and to prevent 
harmful consequences of the primary stress response triggered by catecholamines and 
immune system overactivation in case of injury (de Kloet et al., 2005). In the brain cortisol 
activates the amygdala to induce arousal, adaptive anxiety and fear response (Gold, 2015). The 
HPA axis has a negative feedback mechanism which prevents its overactivation. This 
mechanism functions via the GR receptors highly expressed in the PVN and the hippocampus, 
which activation by systemic cortisol is thought to  trigger hippocampal suppression of the CRH 




Figure 1 Stress response by the hypothalamic-pituitary-adrenal (HPA) axis 
Stressful signals reach the hypothalamus from the activated amygdala and stimulate release of the corticotrophin-
releasing hormone (CRH) from the paraventricular nucleus (PVN). CRH promotes the synthesis and secretion of 
adrenocorticotrophin (ACTH) by the pituitary. ACTH in turn stimulates the release of the glucocorticoid cortisol from 
the adrenal glands. Cortisol in the systemic circulation reaches many tissues throughout the whole body and the 
brain, where it activates intracellular nuclear mineralocorticoid and glucocorticoid receptors (MR and GR). GR is also 
widely expressed in the hippocampus, PVN, and anterior pituitary, where its activation by systemic cortisol 
terminates the stress response, thereby forming a negative feedback loop of HPA axis regulation. From Raabe, F. J. & 
Spengler, D. Epigenetic Risk Factors in PTSD and Depression. Front. Psychiatry 4, 80 (2013). 
Multiple lines of clinical evidence suggest that in depression regulation of the HPA axis is 
disturbed. Depressed patients are consistently found to have increased blood and salivary 
levels of cortisol (Knorr et al., 2010). Increased levels of CRH have also been recorded in the 
cerebrospinal fluid (CSF) collected from depressed subjects (Nemeroff et al., 1984). To directly 
test the state of the negative feedback inhibition mechanism, researchers use the 
dexamethasone suppression test, wherein HPA axis activation is mimicked by the 
administration of the GR agonist dexamethasone. In healthy subjects dexamethasone 
administration should lead to a decrease in cortisol levels via the negative feedback loop 
mechanism. However in depressed patients cortisol levels are not decreased, indicating 
dysfunctional negative feedback regulation of the HPA axis, a condition called glucocorticoid 
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resistance (Pariante and Miller, 2001; Sher et al., 2013). Glucocorticoid resistance has also 
been observed in lymphocytes collected from depressed patients, in which proliferation and 
cytokine release was not suppressed by dexamethasone (Nikkheslat et al., 2015; Wodarz et al., 
1991).  Depression has also been associated with altered diurnal rhythm of cortisol release. In 
particular, depressed subjects display higher cortisol awakening response, the physiological 
elevation of cortisol shortly after awakening (Hardeveld et al., 2014). Such response is also 
associated with some of the key risk factors for depression, such as childhood trauma (Lu et al. 
2016) and coronary heart disease (Nikkheslat et al., 2015). Importantly, antidepressants have 
been shown to reduce cortisol levels in the course of the treatment, which further confirms 
the importance of cortisol release in disease progression (McKay and Zakzanis, 2010). 
Chronically elevated cortisol levels can negatively affect many processes related to depression 
neurobiology. Rodents chronically treated with corticosterone display depressive-like 
behaviour and reduction of adult hippocampal neurogenesis (David et al. 2009). Some of the 
metabolic abnormalities that are frequently associated with depression, such as obesity and 
insulin resistance, have been partly attributed to chronic cortisol elevation (Krishnan and 
Nestler, 2008). It is important to note however, that the relashionship between HPA axis 
regulation and obesity has not been completely understood. While many human studies report 
an association between hyperactive HPA axis and obesity, reports of hypoactive HPA axis in 
overweight subjects also exist (Incollingo Rodriguez et al., 2015). Interestingly, such 
dissociation is mirrored by rodent studies.  Mice exposed to chronic stress, which is known to 
induce elevated levels of corticosterone, typically show lower weight gain than their 
undisturbed counterparts (Ducottet et al., 2003). Smilarly, exposure to chronic social defeat 
leads to slower weight gain in rats (Becker et al., 2008).  However, chronic administration of 
corticosterone leads to increased weight in mice (Darcet et al., 2016; David et al., 2009). It is 
noteworthy that both effects have been shown to be reversed by chronic antidepressant 
treatment in the studies cited above.  
Dysregulation of the HPA axis has been linked to the impaired function of the GR (Holsboer, 
2000). Low expression of the GR or dysfunction of its nuclear translocation or mediation of 
gene expression, which prevent its response to cortisol, could explain the malfunctioning 
negative feedback and consequently lead to persisting elevated cortisol levels, as seen in 
depressed individuals. Reduced expression of the GR has indeed been shown in clinical and 
preclinical studies of depression. For example, reduced expression of the main GR transcript in 
peripheral blood cells was shown in depressed patients  (Matsubara et al., 2006). Epigenetic 
changes in the GR promoter which could prevent its expression have been found in the 
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hippocampus of suicide victims with a history of childhood abuse, one of the main 
predisposing factors of depression (McGowan et al., 2009). Animal studies confirmed that 
deletion of the GR in the hippocampus and the pituitary is sufficient to induce HPA axis 
hyperactivity and depressive-like behaviour (Boyle et al., 2005; Schmidt et al., 2009). 
Moreover, it has been shown that antidepressant treatment increases GR expression in the 
hippocampus (Yau et al., 2007) and in fibroblast and neuronal cell cultures in vitro (Pariante et 
al., 2003). Therefore GR has been also implicated in antidepressants’ mechanism of action 
(Anacker et al. 2011). 
 Structural and functional abnormalities in the depressed brain 
Chronic elevation of glucocorticoid levels has also been implicated in some of the structural 
brain changes seen in depression. Due to high levels of GR expression in the hippocampus, this 
area is predicted to be one of the most sensitive areas to elevated cortisol levels. In line with 
this, reduction in hippocampal volume is consistently described in the structural brain imaging 
studies of depressed patients (Campbell et al., 2004). While this finding has been confirmed to 
be the most robust in a recent meta-analysis of neuroimaging studies which included 1728 
depressed patients and 7199 controls, it also showed that the observed reduction is of low 
magnitude (less than 2% difference), which raises the question of its functional significance 
(Schmaal et al., 2016). Yet hippocampal volume was also found to significantly negatively 
correlate with the duration of the disease (Colla et al., 2007). Chronic exposure to elevated 
glucocorticoids can negatively affect many other brain regions involved in mood regulation. 
For example, a number of post-mortem and neuroimaging studies have reported decreased 
volume and activity in the PFC (Drevets et al., 1997; van Tol et al., 2014).  
The hippocampus and the PFC belong to the limbic circuit, which has been implicated in 
emotional regulation and mood disorders. The limbic system can be divided into two 
functional domains: an emotional domain primarily comprised of ventral structures such as the 
amygdala, the ventral hippocampus, the ventral striatum, the insular cortex, the ventral part of 
the PFC including the subgenual anterior cingulate cortex (ACC) in humans and orbital PFC; and 
a cognitive or memory domain, involving the dorsal hippocampus and the dorsal (pregenual) 
parts of the PFC such as pregenual ACC and the dorsolateral PFC (Willner et al., 2013) (see 
Figure 2). All limbic regions within the two domains communicate via reciprocal connections, 
with the hippocampus and the PFC suggested to be key regulators of emotional control (Maier 
and Watkins, 2010; Willner et al., 2013). PFC, nucleus accumbens and the amygdala also 
receive dopaminergic inputs from the ventral tegmental area (VTA) implicated in reward and 
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anhedonia. The VTA is in turn highly receptive to the hypothalamic inputs including those 
regulated by gut metabolic hormones ghrelin and leptin (van Zessen et al., 2012).  
 
Figure 2 Corticolimbic circuit implicated in depression 
A schematic representation of the main structures implicated in depression. Anterior cingulate cortex (ACC), 
amygdala (Amyg) and the anterior hippocampus (Hipp) form the emotional domain, while dorsolateral prefrontal 
cortex (dlPFC) and posterior hippocampus form the basis of the cognitive domain. Ventral tegmental area (VTA) and 
substatia nigra (SN) connected with nucleus accumbens (NAcc) form the reward/anhedonia complex. Caud – 
caudum, Put –Putamen, VP – ventral pallidum, Glu - glutamate. Adapted from Treadway and Pizzagalli (2014) 
Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis. Biology of 
Mood & Anxiety Disorders 4(1):5. 
Functional imaging studies in depression generally show decreased activity of the cognitive 
domain, potentially underlying cognitive deficits, and overactivation of the emotional domain 
(Willner et al., 2013). In fact, increased connectivity and amplified activation of the amygdala is 
one of the most consistent functional neuroimaging findings in depression, while hyperactivity 
of the ACC and anterior insula have also been reported (Hamilton et al., 2012). At the same 
time, the dorsal PFC displays signs of hypoconnectivity, which can underlie an attention deficit 
seen in depressed patients (Kaiser et al., 2015). The nucleus accumbens has been shown to 
display reduced response to reward in depressed subjects, which could underlie anhedonia in 
depression (Pizzagalli et al., 2009).  
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The anatomy of the limbic circuit is well-preserved among mammalian species due to its 
ancient evolutionary origins allowing direct parallels between human and rodent studies of 
limbic regions. However such approach does not necessary apply when it comes to the 
structures of the neocortex such as the PFC, as it has undergone significant expansion in the 
course of the evolution of human primates (Rakic, 2009). Nonetheless, the neuroimaging 
findings in depression have been supported by animal studies which have found that chronic 
stress exposure leads to dendritic atrophy in the PFC, sparing the neurons that connect to the 
amygdala (Shansky et al., 2009). In the amygdala, chronic stress increases dendritic 
arborisation and growth (Vyas et al., 2002). These effects were attributed to the combined 
influence of catecholamines and glucocorticoids (Arnsten, 2015; Cerqueira, 2005).  
Despite the findings highlighting the role of many brain regions in depression, hippocampus 
remains the focus of many depression-related studies due to one particular process taking 
place in the region of the dentate gyrus (DG), the adult hippocampal neurogenesis (AHN).  
 Adult hippocampal neurogenesis 
AHN takes place in the subgranular zone (SGZ) of the DG and signifies a process of continuous 
birth of new neurons from neural stem cells throughout adult life. SGZ is the most well-
described neurogenic region, however new methodological advances in tracing adult-born 
neurons continue to fuel the debate regarding the confinement of neurogenesis to certain 
brain areas in mammals in general and in humans in particular (Ernst and Frisen, 2015). 
Subventricular zone (SVZ) is another well-established neurogenic niche, which in rodents gives 
rise to the olfactory bulb neural progenitors, thus contributing to the olfaction-dependant 
behaviours (Lim and Alvarez-Buylla, 2016). However a recently developed technique to 
determine the age of cells in post-mortem tissue based on carbon dating did not confirm the 
presence of olfactory bulb neurogenesis in humans (Bergmann et al., 2012), which might 
reflect the limited role olfaction plays in human behaviour. Instead it has been suggested that 
the SVZ - derived neural progenitors in humans migrate to the striatum and give rise to striatal 
interneurons which delpletion is implicated in Hungtington’s disease (Ernst et al., 2014), 
however more post-mortem studies are needed to confirm this hypothesis. Importantly, 
carbon dating studies of human tissue confirmed the presence of a relatively high (700 
cells/day) rate of neurogenesis in adult humans (Spalding et al., 2013). 
SGZ is a thin layer on the border of the DG and the hilus, which provides a neurogenic 
microenvironment permissive of the proliferation of neural stem cells and their differentiation 
into granule neurons throughout adult life. Apart from radial glial-like neural progenitors and 
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immature neurons at different stages of differentiation, SGZ contains glial progenitors, mature 
astrocytes and microglia, which are thought to define neural stem cells fate by releasing 
regulatory factors, including interleukins (Kempermann 2010). In addition, SGZ is a highly 
vascularised region, which provides an anatomical ground for the notion of plasma 
components influencing neural progenitors (Palmer et al., 2000) and allows factors such as 
vascular endothelial growth factor (VEGF) to regulate neurogenesis (Fournier and Duman, 
2012).  This specific microenvironment is often referred to as the neurogenic niche.  
 Stages of AHN 
Neural stem cells go through several stages of development on their way of becoming mature 
granule neurons. Detection of stage-specific marker expression, as well as characterisation of 
the morphological and functional properties, allowed a classification of the main stages of 
neuronal differentiation in the SGZ (see Figure 3).  
 
Figure 3 Developmental stages in AHN 
Neuronal development in the DG can be separated into 3 major stages, which can be identified by expression of 
stage-specific markers. Type 1 are radial glia-like cells, which proliferate rarely and asymmetrically; type 2 is 
amplifying progenitors, among which type 2a actively proliferate and retain some of the glia-like properties, while 
2b slightly less proliferative and express first markers of commitment to neuronal lineage. Type 3 neuroblast which 
undergo radial migration and begin dendritic tree development. From Kempermann, G. in Adult Neurogenesis 2, 1–
85 (Oxford University Press, 2010). 
Radial glia-like cells which express GFAP and possess many astrocytic properties are called type 
1 progenitors. These cells are capable of asymmetric division and selectively express neural 
stem cell markers, such as Nestin and Sox2.  The daughter cells of type 1 radial glial cells 
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comprise the most active proliferating population on the adult SGZ and have been named Type 
2 cells (Fukuda et al., 2003). Morphologically they lack radial appearance of type 1 and instead 
possess short processes oriented along the SGZ. During the type 2 stage a final determination 
of neuronal lineage occurs in proliferating cells. This prompted Kronenberg et al. (2003) to 
suggest a distinction between early type 2 cells or type 2a, which already lost radial 
morphology but still express stem cell markers such as Nestin, and late type 2 or type 2b, 
which continue to proliferate but already show commitment to neuronal lineage by expressing 
neuroblast marker doublecortin (DCX). DCX is a microtubule binding protein which is highly 
expressed in the developing brain where it is required for neuronal migration (Bai et al., 2003), 
while in the adult brain its expression is almost exclusively confined to the immature neurons 
of the neurogenic regions (Ming and Song, 2005). Therefore the initiation of the DCX 
expression in type 2 progenitors is associated with the commencement of neuronal 
differentiation and tangential migration (Sun et al., 2015).  
Late type 2b are not easily distinguishable from the next stage, type 3. These neuroblasts 
continue to express DCX but do not express any glial or precursor markers such as Sox2. Most 
importantly, they terminally exit the cell cycle. This phase is associated with significant 
morphological changes and with short-distance radial migration into the GZ. In healthy 
individuals, most neuroblasts remain in the SGZ and the inner third of the GZ and only few 
reach the outer layers of the GZ (Kempermann, 2003). Morphologically type 3 cells first 
develop apical dendrites. First apical dendrites reaching the molecular layer (ML) of the DG 
could be detected as early as 1 week after cell cycle exit. Branching of the dendritic tree is 
associated with a transition from a potentially proliferative state to the post-mitotic immature 
neurons, which eventually stop expressing DCX (Plümpe et al., 2006). In addition, more mature 
dendritic morphology suggests electrophysiological input, which indeed has been detected in 
the DCX-positive (DCX+) neuroblasts. First inputs detected in the dendrites within the GZ are 
GABAergic, while upon reaching the ML dendrites receive first glutamatergic inputs at about 3 
weeks after cell cycle exit (Ambrogini et al., 2004). Dendritic spines are first detected in the 
neuroblast’s dendrite at 2 weeks of post-mitotic development, and their density rapidly 
increases towards the end of the first month, before reaching a plateau by the end of the 2nd 
month (Aimone et al., 2014). During these 2 months immature neurons go through a period of 
high synaptic plasticity with spines being highly dynamic and particularly sensitive to neural 
activity. 
Upon maturation dendrites of the adult-born granule cells form synaptic connections with the 
fibers from the enthorhinal cortex, thereby reinforcing the first synapse of the core trisynaptic 
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hippocampal circuit (Kempermann, 2010). Alongside dendrite development, axon mossy fibres 
of the immature neurons undergo growth through the hilus until they reach the CA3 region. 
These axons join the mossy fiber tract that reaches the pyramidal neurons in CA3, where they 
terminate in a synapse with the pyramidal CA3 neurons. This synapse is a 2nd synapse in the 
trisynaptic core circuit of the hippocampus. The third synapse completes the circuit by 
connecting the pyramidal CA3 neurons with the CA1, however AHN does not contribute to its 
formation.  
In mice, the early post-mitotic stage of neuronal development is also characterized by the 
transient expression of a calcium-binding protein calretinin, which overlaps with DCX 
expression. Three to four weeks after cell cycle exit, calretinin gives way to expression of 
calbindin, a calcium-binding protein of mature granule cells (Brandt et al., 2003). 
Therefore, it takes about 2 months from the exit of the mitotic cycle for neuroblasts to reach 
morphological and functional maturity of granule neurons, and DCX expression accompanies 
most crucial stages of the new neuron development (Jessberger and Kempermann, 2003). 
During these stages neural precursors go through several windows of susceptibility, when 
intrinsic and extrinsic factors can significantly affect their fate.  
 Regulation of AHN 
2.3.2.1 Intrinsic factors affecting AHN 
Activity of the surrounding circuitry can influence AHN at different stages. For example, activity 
of the DG reflected in the GABA levels can affect proliferation of the radial glial cells. 
Overactivation of the DG and an increase in tonic levels of GABA has been shown to suppress 
proliferation of type 1 cells, rather than promoting their quiescence (Song et al., 2012). On the 
type 2 stage when progenitors receive first GABAergic inputs, these inputs induce excitation 
and calcium influx via voltage-gated calcium channels, which stimulate expression of neuronal 
differentiation promoting factors, such as NeuroD1 (Deisseroth et al., 2004).  
Glutamate plays an important role when immature neurons develop dendritic spines and start 
receiving glutamatergic inputs from the ML, which occurs approximately in the 3rd week of 
postmitotic development. During this critical period of neuronal survival, when many newborn 
cells which are not recruited into function undergo apoptosis, stimulation of the NMDA 
receptors is necessary for their survival (Tashiro et al., 2006).  
The role of another neurotransmitter, serotonin, was established by studies looking at the 
effect of SSRI on AHN. SSRIs have been shown to promote all three components of the AHN, 
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namely proliferation, differentiation and neuronal survival (Banasr et al., 2006; Malberg et al., 
2000). Effects of SSRIs were consistent with a direct effect of serotonin on proliferation that 
likely arises through the 5-HT1A receptor, with possible contributions through the 5-HT1B and 5-
HT2A receptors (Banasr et al., 2004; Samuels et al., 2015). Dorsal raphe nucleus is thought to be 
the main source of serotonin in the DG. However SSRI effect on neurogenesis has also been 
attributed to its effect on the GR signalling (Anacker et al. 2011). Dopamine has also been 
shown to play a role in neurogenesis, with dopamine D3 receptor blockade increasing cell 
proliferation in DG (Egeland et al., 2012). 
Glial cells play a major role in the regulation of neurogenesis. Astrocytes are largely 
responsible for the formation of the neurogenic niche. Not only do they share many 
similarities with the radial glial cells, they also envelop neural stem cells and endothelial cells, 
ensuring a specific neurogenic microenvironment (Plümpe et al., 2006; Seri et al., 2001). 
Astrocytes release many factors which play a key role in the regulation of neurogenesis. One of 
them is Wnt3a, which modulates AHN by upregulating the expression of NeuroD1, an essential 
transcription factor in the generation of glial cells and neuronal differentiation (Kuwabara et 
al., 2009). Astrocytes also release many neurogenesis-stimulating growth factors, such as 
brain-derived neurotrophic factor (BDNF), insulin growth factor 1 (IGF1) and VEGF (Fournier 
and Duman, 2012; Mu et al., 2010; Waterhouse et al., 2012). 
Microglia are another indispensable glial component of the neurogenic niche. Historically 
microglia’s role in AHN regulation has been studied in the context of inflammatory or other 
pathological conditions, wherein activated microglia contribute to the antineurogenic effects. 
However, recent studies provided insight into the role of unchallenged microglial cells in 
normal AHN regulation (see Figure 4). Sierra et al. (2010) showed that ramified surveillant 
microglia phagocytose type 2b progenitors during the critical period of transition into the type 
3 neuroblast stage, therefore being responsible for the regulation of survival in the AHN. 
Moreover, microglia have been shown to actively engulf synaptic components and therefore 
contribute to synaptic pruning during postnatal hippocampal development, suggesting that 
similar mechanism might be taking place during synaptogenesis in the adult DG (Paolicelli et 
al., 2011).  
However activated microglia attract more frequent attention of the AHN research, as it has 
been implicated in the antineurogenic effects of many extrinsic factors, including infection, 
stress, neurodegeneration and aging (Sierra et al., 2014). These extrinsic factors share one 
important aspect of their mechanism of action – they induce neuroinflammation, wherein 
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activated microglia play a major role. Neuroinflammation is associated with a deramified 
activated state of microglial cells, in which they release proinflammatory cytokines with potent 
antineurogenic properties.  Much of the insight into the effect of neuroinflammation on 
neurogenesis has been gained from the studies employing lipopolysaccharide (LPS) treatment. 
LPS is the main component of the outer membrane of Gram-negative bacteria and as such, it 
triggers a strong immune response without a resulting infection. Ekdahl et al. (2003) was one 
of the first to demonstrate that direct intracortical administration of LPS dramatically reduced 
the survival of newly generated neurons in the adult hippocampus. The detrimental effect of 
systemic LPS on neurogenesis via microglial activation has been demonstrated by Monje et al. 
(2003).  Other studies supported the role of individual cytokines in this process, demonstrating 
that overexpression of interleukin 6 (IL-6) and interleukin 1 beta (IL-1β) in the brain, as well as 
systemic administration of tumor necrosis factor alpha (TNF-α) can reduce cell proliferation 
and neuronal differentiation in the adult hippocampus, stimulating more progenitor cells to 
differentiate into astrocytes (Seguin et al., 2009; Vallières et al., 2002; Wu et al., 2012). An in 
vitro study which employed human hippocampal stem cell line confirmed that this effect also 
occurs in human hippocampal cells (Zunszain et al., 2012). Moreover, recruitment of new 
neurons into hippocampal networks has also been shown to be reduced by chronic exposure 
to LPS (Belarbi et al., 2012). This effect was accompanied by longer distance of radial migration 
of neuroblasts into the GZ.  
Currently, microglial activation and cytokine release are also suggested to be underlying 
mechanisms of neurogenic decline in non-infectious conditions such as Alzheimer’s disease 
and normal aging (Kohman and Rhodes, 2013). On the other hand, ramified microglia have 





Figure 4 The effects of ramified (surveillant) and activated (inflammatory) microglia at different AHN stages. 
In physiological conditions, ramified microglia phagocytose apoptotic newborn cells and aid pruning of developing 
neuroblasts. Microglia can release factors which can promote (green arrow) (insulin-like growth factor 1, IGF1) and 
supress (red line) (transforming growth factor β, TGF β) proliferation of neural stem cells (NSCs) and amplifying 
neural progenitors (ANPs). Stress, inflammation (including lipopolysaccharide (LPS) exposure) and other aversive 
conditions including Alzheimer’s disease (AD) on the contrary stimulate microglial activation, which leads to a 
release of proinflammatory cytokines interleukin 1β (IL-1β), tumor necrosis factor α (TNFα) and IL-6 and subsequent 
reduction of proliferation, survival, integration, and differentiation of the adult-born neurons. From Sierra et al. 
Neural Plast. 2014, 610343 (2014). 
2.3.2.2 Extrinsic factors affecting AHN 
Environmental enrichment (EE) is an enrichment of the housing conditions of laboratory 
animals, which provides them with social partners for interaction, novel objects and shelters to 
explore, as well as stairs and running wheels to stimulate locomotor activity. Enrichment 
significantly improves cell survival and neuronal differentiation in the DG, whereas wheel 
running profoundly increases cell proliferation (van Praag et al., 1999). Moreover, wheel 
running and EE are capable of rescuing neurogenesis impaired by genetic manipulation or 
exposure to detrimental extrinsic factors, such as chronic stress (Farioli-Vecchioli et al., 2014; 
Vega-Rivera et al., 2016). It is thought that the mechanism of these proneurogenic effects is 
related to the increased blood-brain barrier permeability, intensified cerebral blood flow, and 
accelerated glucose metabolism observed after exercise (Yancey and Overton, 1993). These 
changes might increase availability of the neurogenesis-promoting hormones and growth 
factors, such as VEGF and BDNF (Aimone et al., 2014). In addition, exercise has been shown to 
promote ramified state and IGF-1 secretion in microglial cells via chemokine fractalkine 
CX3CR1 receptor dependent mechanism (Vukovic et al., 2012). 
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Stress is another extrinsic factor potently regulating AHN.  However the effect of stress was 
originally discovered through the antineurogenic effect of an intrinsic factor, the steroid 
hormone of the HPA axis corticosterone (CORT), which supressed cell proliferation in the 
dentate gyrus of rats (Gould et al., 1992). The same researchers first showed that acute stress 
following exposure to an unfamiliar intruder, reduced cell proliferation in rodents and 
primates (Gould et al., 1997, 1998). Subsequently, another type of acute stress (inescapable 
foot shock) also has been shown to reduce cell proliferation in rats (Malberg and Duman, 
2003). Multiple studies demonstrated that proliferation, differentiation and survival of adult-
born neurons were reduced by chronic stress exposure in mice (R Alonso et al., 2004; Mineur 
et al., 2007; Santarelli, 2003b). This effect has also been attributed to an increase in CORT 
signalling and activation of the GR in the hippocampus, as chronic CORT administration 
exerted similar effect on AHN (David et al. 2009; Lussier et al. 2013). However, 
neuroinflammation induced by chronic stress has also been proposed to play a role in its 
antineurogenic effects. Indeed chronic stress induces microglial activation and 
proinflammatory cytokine production in the hippocampus (Hinwood et al., 2012; Wang et al., 
2015), therefore it is possible that these neuroinflammatory changes are partly responsible for 
AHN decline upon stress. 
 Functions of AHN 
As AHN takes place in the DG, its functional effect is closely related to DG functions. The DG 
has been implicated in cognitive processes such as spatial and contextual learning and 
memory, specifically in the pattern separation of contextual information. Pattern separation is 
the process whereby similar experiences received from the cortical inputs are stored and 
recalled as distinct memories, thereby minimizing interference among similar memory cues 
(Colgin et al., 2008).  
The role of adult-born granule neurons in pattern separation has been predicted by 
computational modelling (Rolls and Kesner, 2006) and was subsequently confirmed by 
behavioural studies showing a correlation between the level of AHN and performance in a 
spatial pattern discrimination task (Clelland et al., 2009; Sahay et al., 2011). It is thought that 
increased synaptic plasticity and excitability of young neurons during first few weeks of 
differentiation makes them particularly suited to encode novel information and mediate 
pattern integration and temporal encoding (Kempermann, 2010). 
Interestingly,  insufficient pattern separation has been suggested to play a role in 
overgeneralisation of fear thought to underlie post-traumatic stress disorder (Besnard and 
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Sahay, 2016). Pattern separation deficiency has been demonstrated in depressed patients 
(Déry et al., 2013; Shelton and Kirwan, 2013) and could explain some of the cognitive deficits 
seen in depression. 
An alternative functional theory suggests that AHN on the contrary aids forgetting (Frankland 
et al., 2013). Authors suggest that continuous integration of new granule cells modifies 
established hippocampal circuits which recorded the activity pattern at the time of memory 
acquisition, thereby aiding memory fading. Indeed, it has been recently shown that increasing 
AHN by providing mice with access to running wheels facilitates fading of existing memories, 
but only those in conflict with the new memories, which encoding is enhanced by increased 
AHN (Epp et al., 2016). Therefore, this function of AHN is still beneficial for memory abilities. In 
fact, the authors argue that this effect has an adaptive benefit of cognitive flexibility. In this 
case, neurogenic deficit could prevent the decay of traumatic memories, which in turn could 
predispose individuals to mood disorders. 
AHN has been also implicated in emotional regulation. Studies showing that AHN is reduced by 
stress initially suggested that it is also involved in stress effects on mood and behaviour, 
however this theory was not confirmed, as neurogenesis ablation did not cause stress-related 
behavioural changes (Santarelli, 2003a). Nonetheless, AHN has now been recognised to be 
required for some of the effects of antidepressant therapy (Surget et al. 2008; David et al. 
2009). In addition, Snyder et al. (2011) suggested that AHN promotes resilience towards 
repeated stress exposure, as mice with deficient neurogenesis showed slower rates of 
recovery from the effects of stress. The emotional function of AHN has been mostly attributed 
to the ventral subregion of the DG, as a number of observations suggested its specific role in 
anxiety and stress-related responses. For example, studies investigating the effects of a 
specific ablation of AHN in ventral DG in rodents showed its specific involvement in anxiety-
related tasks (Bannerman et al., 2002; Blanchard et al., 2005; Trivedi and Coover, 2004). In 
addition, some studies show that exposure to chronic stress preferentially affects the ventral 
subregion with minimal/no effect in the dorsal DG (Brummelte and Galea, 2010; Jayatissa et 
al., 2006; Oomen et al., 2010). Indeed anatomically, the ventral hippocampus is the area more 
closely connected to the mood-related brain areas, as it has reciprocal connections with the 
amygdala (Pitkänen et al., 2006) and the medial PFC (Thierry et al., 2000).  
 Neurogenic hypothesis of depression 
The accumulating knowledge about the extrinsic and intrinsic regulation of AHN, together with 
clinical evidence highlighting the changes in the hippocampal volume in depressed patients 
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(Kendler et al., 1999) led to the formulation of the neurogenesis hypothesis of depression 
(Jacobs et al., 2000). The hypothesis stated that stress-induced decline of neurogenesis plays a 
causal role in the development of depression, and antidepressants achieve a therapeutic effect 
at least partly due to their proneurogenic properties. The hypothesis was supported by studies 
showing that in chronic stress models antidepressant therapy was effective in rescuing AHN 
levels (Malberg and Duman, 2003). However, ablation of AHN did not lead to depressive-like 
behaviour (Santarelli, 2003a; Surget, Saxe, et al., 2008), while AHN was only required for 
antidepressant effects in selected tasks (David et al. 2009). Nonetheless, in most of the 
available post-mortem clinical studies AHN has been shown to be decreased in depressed 
patients and to increase after antidepressant therapy (Boldrini et al., 2009, 2012; Lucassen et 
al., 2010). To determine neurogenesis levels in post mortem samples these studies used 
immuhistochemistry for markers of neural stem cells (nestin) and cell proliferation markers 
such as Ki67 and the minichromosome maintenance protein 2 (MCM2), thus their assement 
was limited to the stem cell pool and the rate of cell proliferation, but does not reflect 
neuronal differentiation and survival of newborn neurons. A certain controversy exists in the 
clinical literature, as a number of studies also report no change in hippocampal cell 
proliferation as detected by the number of Ki67-positive cells (Reif et al., 2006) or an increase 
in a specific patient group of young women (Epp et al., 2013). The latter study was the only 
one which used the neuroblast marker doublecortin, however the average age of patients in 
this study was significantly lower than in the previous reports. The study by Reif et al. (2006) 
did not account for age, sex and duration of illness, which could have affected the outcome. 
Interestingly, depressed individuals also exhibit a defect in hippocampal recruitment during 
processing of a spatial navigation task (Gould et al. 2007; Cornwell et al. 2010), confirming the 
presence of impaired hippocampal function. In addition,  pattern separation deficits have been 
shown to correlate with depression scores (Déry et al., 2013; Shelton and Kirwan, 2013). 
Another indirect clinical evidence for the involvement of AHN in clinical depression comes 
from oncological studies, showing that depression and anxiety are frequent in cancer patients 
treated with drugs arresting cell proliferation, which are likely to impact AHN (Dias, Hollywood, 
et al., 2014). Therefore, while the primary causal role of AHN impairment in depression has not 
been sufficiently supported, numerous animal studies and indirect clinical evidence so far 
provided ample proof of the AHN involvement in depression pathogenesis and in the 
mechanism of antidepressant action (Miller and Hen, 2015). Future studies directly assessing 
AHN during the course of clinical depression and antidepressant treatment will allow more 
definitive conclusions to be made on the role of AHN in depression.   
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 The inflammatory theory of depression 
The immune system is another stress-response system of the body, which has been implicated 
in the neurobiology of mood disorders. The inflammatory theory of depression suggests that 
susceptibility factors such as chronic stress exposure, childhood trauma or comorbid 
conditions trigger immune system activation (Miller et al., 2009). Inflammatory processes 
subsequently contribute to, or potentially partly cause, deficiency in key systems regulating 
mood, such as neurotransmitter metabolism and the HPA axis (Raison and Miller, 2013). This 
hypothesis rests on ample clinical evidence of the presence of ongoing inflammatory processes 
in depressed patients, and experimental data showing that inflammation can trigger 
depression-like phenotypes and impact other systems involved in depression neurobiology.  
 Clinical evidence of inflammation in depression 
Multiple studies have reported increased peripheral blood levels of proinflammatory cytokines 
and their soluble receptors in depressed patients compared to healthy controls (Liu, Ho, and 
Mak 2012). In particular, elevation of tumour necrosis factor-α (TNFα), interleukin-6 (IL-6) and 
C-reactive protein (CRP) are among the most reliable findings among cytokines in depression 
studies (Dowlati et al., 2010). However many other cytokines, such as IL-1β, IL-2, IL-4 and IL-10 
have been reported to be elevated in depressed patients in individual studies (Maes et al., 
1995; Simon et al., 2008). Moreover, some studies have found significant associations between 
inflammatory biomarkers and the severity of depressive symptoms, such as insomnia, fatigue 
and cognitive impairment (Bower et al, 2002; Meyers et al, 2005; Motivala et al, 2005). 
Reduction in cytokine levels have been shown to accompany improvement of symptoms 
following successful antidepressant treatment. (Dahl et al., 2014; Lanquillon et al., 2000). 
However increased cytokine levels persist in patients not responding to the therapeutic 
interventions (O’Brien et al., 2007). Furthermore, a predictive role of inflammatory 
biomarkers’ levels was proposed in treatment resistance, as patients with increased 
inflammatory markers at baseline were found to display poorer response to treatment, 
suggesting a relationship between inflammation and treatment resistance (Cattaneo et al., 
2016; Lanquillon et al., 2000).  
Cytokines and chemoattractant cytokines known as chemokines are soluble signalling proteins 
produced by many cells comprising the immune system, such as neutrophils, monocytes, 
macrophages, B-cells, and T-cells. Their production is stimulated by an encounter of the 
immune cell with a pathogen. Endotoxin lipopolysaccharide, a component of the gram-
negative bacterial wall, is one of the potent inducers of cytokine release (Biesmans et al., 
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2016). The signalling pathway leading to cytokine production involves stimulation of 
transcription factor nuclear factor kappa B (NF-κB) and is discussed in more detail in Chapter 5 
LPS-based model). Cytokines act as regulators of inflammation, immune cell function and cell-
to-cell signalling. They affect multiple targets with various physiological consequences, and 
form a complex interactive network of regulators, which effect could be synergistic or 
antagonistic. As such, cytokines such as IL-1β, IL-6, IL-12 and TNFα are known to accelerate 
inflammatory response, while IL-10 prevents excessive immune activation by supressing 
macrophage function (Hiscott and Ware, 2011). IL-1β, IL-6 and TNFα are potent endogenous 
pyrogens, that is innate fever-inducing factors. IL-1β and TNFα activate vascular endothelium 
and increase vascular permeability, which allows entry of lymphocytes, complement and 
antibodies into the damaged tissues (Murphy et al., 2011). IL-1β, IL-6 and TNFα stimulate 
production of the acute phase proteins (APPs) such as CRP by the liver. Acute phase response 
is a complex and rapid innate body response to inflammation or tissue damage involving an 
increase in the production of APPs, which bind pathogens such as LPS and stimulate 
complement cascade (Schrodl et al., 2016). Other cytokines have their specific roles in immune 
response. IL-2 stimulates proliferation and differentiation of T-cells, while IL-12 activates 
natural killer cells and also contributes to the differentiation of T helper cells (Murphy et al., 
2011). 
In blood or other biological material collected from healthy subjects, cytokines either are not 
detectable or present at extremely low (picomolar) concentrations. Therefore elevated 
concentrations of cytokines are a useful indicator of ongoing inflammation (Dinarello, 2000) 
and their measurements are widely used in the clinic as biomarkers of inflammation, its 
detection and monitoring (Bienvenu et al., 2000). CRP is another common biomarker of 
inflammation routinely used in the clinic. 
Thus elevation of cytokines and CRP in depressed patients and their correlation with symptom 
severity emphasises the importance of immune system activation in disease progression, 
however it does not address the question of causality of inflammation in the development of 
depression. The evidence which can support this theory comes from another body of data, 
based on the effect of therapeutic chronic inflammatory cytokine administration on the mood 
of treated patients. Inflammatory cytokine interferon alpha (IFN-α) administration is routinely 
used in Hepatitis C treatment (Feld and Hoofnagle, 2005). It has been observed that within 3 
months, up to 50% of patients undergoing this treatment acquire depression symptoms which 
meet diagnostic criteria for major depression (Musselman et al., 2001; Raison et al., 2005). The 
IFN-α induced depression appears to be clinically similar to its natural counterpart (Capuron et 
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al., 2009). Moreover, pretreatment with antidepressants have been shown to prevent the IFN-
α induced depression (Musselman et al., 2001; Raison et al., 2007). Importantly, IFN-α 
administration has been shown to stimulate the production of the innate immune cytokines 
involved in depression, such as IL-6 and TNFα (Prather et al., 2009; Raison et al., 2010).  These 
data suggest that an increase in the levels of inflammatory factors might play a causal role in 
the induction of depression. Furthermore, with the advancement of neuroimaging techniques, 
clinical studies are starting to detect increased microglial activation marker translocator 
protein (TSPO) in the brain parenchyma depressed patients, and the first clinical trials for 
microglial activation supressing drug minocycline show promising results (Husain et al., 2015; 
Setiawan et al., 2015). 
Further support for the inflammatory theory comes from studies showing that many risk 
factors for depression are associated with increased inflammation. In particular, chronic stress 
as well as stressful life events experienced in early childhood has been strongly linked to the 
onset of depression. Both chronic stress during adulthood, such as caring for cancer patients, 
as well as history of childhood abuse or early life trauma have been shown to be associated 
with increased levels of IL-6 and CRP (Carpenter et al., 2010; Danese et al., 2008; Rohleder et 
al., 2009). This evidence provides a very important link between stress, depression and 
immune system activation. 
 Experimental evidence for the mechanism of inflammatory involvement in 
depression 
Another body of data which supports the inflammatory theory of depression comes from 
experimental studies looking at the mechanisms by which elevated cytokines and other 
inflammatory factors might influence the development of depressive symptoms. It has been 
demonstrated mostly by animal studies that cytokines interact with almost every system and 
process involved in depression, among them hypothalamic-pituitary-adrenal (HPA) axis 
regulation, monoamine metabolism and adult hippocampal neurogenesis (Raison and Miller, 
2011), the evidence for which will be reviewed in more detail below. 
2.4.2.1 Systemic inflammation induces depression-like behaviour 
Infection-induced behavioural changes in humans have features common with the symptoms 
of depression, such as fatigue, cognitive impairment, change of appetite and sleep. In addition, 
inflammatory response induced by LPS or typhoid vaccine in human experimental medicine 
studies confirmed its ability to alter mood in a depression and anxiety-like manner (Harrison et 
al., 2009; Reichenberg et al., 2001). Similarly, acute inflammation in animals is accompanied by 
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a behavioural syndrome called sickness behaviour, which includes some behavioural changes 
resembling human depression symptoms, such as hypolocomotion and loss of appetite and 
weight. Importantly, it has been observed that immune challenge also induces anhedonia 
towards social, sexual and food rewards, as well as behavioural despair in specific 
antidepressant-receptive tests, such as Porsolt swim and tail suspension tests (Biesmans et al., 
2013; O’Connor et al., 2009; Yirmiya, 1996). These depression-like behaviours have been 
shown to last beyond the duration of physical sickness, thereby representing a distinct 
depression-like behavioural phenotype (Frenois et al., 2007; Moreau et al., 2008; Painsipp et 
al., 2011). Therefore, stimulating the inflammatory response in animals allows us to study the 
neurobiology underlying these behavioural changes and the influence of inflammation on the 
other systems involved in depression.  
Several methods are utilised in preclinical depression research to induce an inflammatory 
response. Systemic or intracerebral LPS administration is one of the most common ways to 
model inflammation, as it provides an advantage of triggering a fast and transient immune 
response in an absence of a specific living pathogen. However, other methods such as 
administration of the viral mimetic polyinosinic:polycytidylic acid (polyI:C), suspension of living 
E.coli or vaccines such as bacillus Calmette-Guerin (BCG) are also employed in some studies 
(Bilbo et al., 2005; Cunningham et al., 2007). All of these interventions lead to increase of 
blood levels of proinflammatory cytokines, which effect on other relevant systems can 
subsequently be studied in experimental animals. 
2.4.2.2 Systemic inflammation acts beyond the blood-brain barrier 
Bloodstream cytokines which release is stimulated by proinflammatory stimuli such as LPS, as 
well as macrophages activated by LPS have been shown to act within the brain tissue (see 
Figure 5). Although cytokines are relatively large molecules and do not easily cross the blood-
brain barrier (BBB), their transport is possible through the saturable transport molecules or 
BBB regions of higher permeability, such as in the vasculature of the lateral ventricles (Banks, 
2007). Moreover, systemic inflammation increases the permeability of the BBB, allowing more 
molecules to pass through (D’Mello et al., 2009). Similarly, leaky BBB eases transport of blood 
macrophages, which recruitment into the brain parenchyma has been shown to be increased 
in chronic stress models (Reader et al., 2015). However, transmission of inflammatory signal 
does not necessary require transfer across the BBB – macrophages and cytokines can affect 
cells of the endothelial wall and perivascular macrophages, which upon stimulation release 
proinflammatory factors into the brain parenchyma. Furthermore, astrocytes can also be 
affected via this route, as astrocytic processes take part in the BBB assembly (Hodes et al., 
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2015). Indeed, systemic inflammation and stress exposure have been shown to affect 
astrocytic morphology and induce their release of chemokines, cytokines and growth factors 
(Biesmans et al., 2015; Camara et al., 2015; Norden et al., 2016).  
Once in the brain parenchyma, cytokines can activate resident microglia and act directly on 
neurons. Increase in peripheral cytokines is consistently associated with increase in microglial 
numbers and  its morphological changes typical for activated phagocytic phenotype (Buttini et 
al., 1996; Clark et al., 2015; Qin et al., 2007). These include enlargement of cell body, widening 
of primary processes and subtraction of distal processes, typically accompanied by increased 
production and release of proinflammatory cytokines (Colton, 2009). In addition to the effects 
of activated microglia on AHN described above, activated microglial cells can phagocytose 
axon terminals and destabilise dendritic spines of cortical neurons, thereby leading to dendritic 
atrophy (Kondo et al., 2011; Milior et al., 2016). However, it is thought that the main effect of 
microglial activation originates from the effect of cytokines released by activated microglial 
cells.  
Cytokines can act directly on neurons via neuronal cytokine receptors. For example, in 
glutamatergic neurons IL-6 and TNFα have been shown to increase synaptic excitation via 
GABA (Garcia-Oscos et al., 2012) and AMPA receptors (Beattie, 2002). In serotonergic neurons 




Figure 5 Systemic inflammation reaches the brain: mechanisms and consequences 
(a) Cytokines in the brain can affect neurons directly through activation of neuronal cytokine or Toll-like receptors 4 
(TLR4) and corticotropin releasing hormone (CRH) receptors. (b) Macrophages recruited into the brain (in green) 
release proinflammatory cytokines and can adopt microglia-like properties. (c) Increase in blood brain barrier (BBB) 
permeability allows cytokines to passively diffuse between endothelial cells, while macrophages actively tunnel 
through the BBB. Inflammatory signal can also be transferred via activation to cytokine receptors on endothelial 
cells, which subsequently release inflammatory factors into the brain. Bloodstream factors can also trigger release of 
cytokines by astrocytes, which processes come in contact with the blood vessels. Once in the brain parenchyma, 
cytokines cause microglial activation which can trigger further inflammatory escalation, synaptic atrophy and 
decline in AHN. From Hodes et al., Neuroimmune mechanisms of depression. Nat. Neurosci. 18, 1386–1393 (2015). 
2.4.2.3 Effects of the cytokines on serotonin metabolism 
The initial suggestion that there is an interaction between cytokines and monoamines, 
especially serotonin, came from the clinical evidence showing that selective serotonin 
reuptake inhibitors (SSRIs) can counteract and even prevent IFN-α induced depression. 
Cytokines affect serotonergic neurons via their ability to alter metabolism of serotonin 
precursor, tryptophan. A number of proinflammatory cytokines induce enzyme indoleamine 
2,3-dioxygenase (IDO), which converts tryptophan into kynurenine instead of serotonin, 
thereby decreasing production of the neurotransmitter (Wirleitner et al., 2003; Zunszain et al., 
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2012). Moreover, kynurenine metabolites have been associated with detrimental effects in the 
brain. As such, quinolinic acid have been associated with excitotoxicity and oxidative stress 
(Schwarcz, 2002), while kynurenic acid was implicated in glutamate and dopamine release 
(Felger et al. 2007; Kitagami et al. 2003). Importantly, IDO has been shown to mediate 
depressive-like effects of LPS exposure in mice (O’Connor et al., 2009). Clinical evidence also 
supports the role of kynurenine pathway in inflammation-induced depression. Indeed, it has 
been shown that tryptophan metabolism through the kynurenine pathway is increased in 
patients treated with IFNα, and kynurenine metabolites levels in the periphery as well as in the 
brain correlate with the development and severity of treatment-induced depressive symptoms 
(Capuron et al., 2003; Raison et al., 2010).  
2.4.2.4 Effects of the cytokines on the HPA axis 
Acute administration of proinflammatory cytokines including IFN-α treatment stimulates the 
production and release of the stress hormones of the HPA axis, such as ACTH and cortisol 
(Pace et al., 2007). While glucocorticoids are known in the clinic for their anti-inflammatory 
qualities in peripheral tissues, it has been suggested that in depression anti-inflammatory 
effect of cortisol is disrupted and in fact can even be replaced by pro-inflammatory action 
(Horowitz et al., 2013). This could be due to the impairment of glucocorticoid signalling known 
as glucocorticoid resistance, which has been attributed to the GR-mediated mechanism.  
Indeed, it has been shown that administration of proinflammatory cytokines can alter the 
transcription inducing function of the GR, a key player in the negative feedback mechanism of 
HPA axis regulation. For example, cytokines such as IL-1α and β have been shown to inhibit GR 
translocation to the nucleus (Engler et al., 2008), while IFNα has been shown to disrupt GR-
DNA binding (Hu et al., 2009). In addition, chronic administration of cytokines has been shown 
to reduce GR expression (Pace et al., 2007). Via these mechanisms cytokines can contribute to 
the glucocorticoid resistance thought to play a major role in HPA axis dysregulation seen in 
depression. On the other hand, it has been hypothethised that the pro-inflammatory effect of 
glucocorticoids is specific for the brain in adverse pro-inflammatory conditions, such as stress, 
injury and potentially depression (Sorrells et al., 2009).  
Experimental evidence described so far indicated many ways in which systemic inflammation 
can exert its effect on processes involved in the neurobiology of depression, thus supporting 
the causal role of inflammation in depression pathology. Additional support for the 
inflammatory theory comes from studies showing that other factors predisposing individuals 




2.4.2.5 Stress induces inflammation 
Many animal studies of depression use chronic stress exposure to induce depressive-like 
behaviour and mimic HPA hyperactivation seen in depressed patients. It appeared that these 
manipulations also induce an increase in proinflammatory cytokines such as IL-1β, TNFα and 
IL-6 in the blood and in mood-related brain areas, including the PFC, hippocampus and 
amygdala (J Lu et al., 2016; Xue et al., 2015; You et al., 2011).  Moreover, chronic stress 
exposure induces microglial activation and proliferation in the prefrontal cortex and the 
hippocampus (Couch et al., 2013; Hinwood et al., 2013). Pharmacological blockade of cytokine 
action or microglial activation has been shown to prevent development of depressive-like 
behaviour upon chronic stress exposure, asserting the causal role of neuroinflammation in 
chronic stress (Hinwood et al., 2012; Koo and Duman, 2008; Sahin et al., 2015). Moreover, it 
has been suggested that neuroinflammation could be an underlying mechanism through which 
chronic stress and ensuing glucocorticoid release exert their effect on AHN (Kreisel et al., 2014; 
Zunszain et al., 2011). It is thought that the immune system senses the stress via sympathetic 
and parasympathetic nervous systems, as immune cells express both adrenergic and 
glucocorticoid receptors and therefore can respond directly to sympathetic nerve signals and 
corticosteroid release (Marino and Cosentino, 2013; Tracey, 2015). 
To summarise, clinical evidence collected so far strongly suggests the presence of systemic and 
neuroinflammation in depressed patients and hints at its causal role in studies of 
proinflammatory treatment. Experimental evidence confirms the association between 
inflammation and depressive-like behaviour, and suggests mechanisms behind this reciprocal 
relationship. However, the exact time of disease development at which immune processes 
come into play remains elusive. It is possible that immune activation precedes other 
neurobiological changes and potentially increases susceptibility of individuals to environmental 
factors such as stressful life events. On the other hand, inflammation could be triggered by 
stress exposure and HPA axis activation in susceptible individuals, predisposing them to the 
development of symptoms and treatment resistance.  Future studies testing either scenarios 
will show if one of them is more prevalent than the other. In either case, it is clear that 
targeting systemic and neuroinflammation has a therapeutic potential for the patients 
suffering from inflammation-associated depression, as has been confirmed in recent clinical 
trials of microglia and cytokine inhibitors (Miyaoka et al., 2012; Raison et al., 2013).   
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 Animal models in depression research 
To further test the neurobiological theories of depression and to develop novel targets for 
drug discovery, valid animal models are required. The question of validity criteria of a 
successful model was raised very early on in the literature, with McKinney & Bunney (1969) 
setting out minimum requirements for an animal model of depression. The authors postulated 
that a suitable depression model should induce behavioural changes “reasonably analogous” 
to the human depression symptoms, which could be objectively quantified and reversed by the 
same treatment interventions used in clinical depression. Importantly, the requirement of 
reproducibility among research groups was also included in this assessment. Willner (1984) 
reformulated these requirements into two groups of validity types: face validity, or the 
similarity between the behavioural changes in the model and the symptoms of human disease, 
and predictive validity, which refers to the ability of a model to predict or replicate the efficacy 
of therapeutic interventions. Experimenting with stress exposure, Willner (1984) also added a 
third type, construct validity, which signifies the resemblance between the disease aetiology 
and interventions used to trigger behavioural changes in the model. 
Achieving these criteria in animal depression research proved to be a challenging task for a 
number of reasons. The difficulty in achieving the face validity stems primarily from the 
obvious interspecies differences between mice and men, as key depression symptoms, such as 
depressed mood and suicidal thoughts are uniquely human. What complicates the task even 
further is the heterogeneity of depression symptoms. Indeed a large variability of symptoms 
means that the clinical picture of the disease might vary significantly from patient to patient, 
and therefore it is not immediately clear which behavioural pattern needs to be reproduced in 
a model (Nestler and Hyman, 2010). To partly overcome this difficulty, genetic studies 
suggested endophenotype approach – the use of separate entities of behavioural and 
neurobiological traits, supposedly predetermined by a small number of genes (Gottesman and 
Gould, 2003). As the genetics of such traits is expected to be less complex than of behavioural 
domains corresponding to psychiatric symptoms, modelling and pharmacologically targeting 
separate endophenotypes instead of human disease traits is expected to be a more feasible 
task (Kas et al., 2007). 
The difficulty in achieving the construct validity is based on the fact that neurobiological 
aetiology of depression is not yet entirely understood and hence cannot be fully replicated. 
Therefore, an alternative approach has been suggested, to expose animals to a known 
environmental risk factor of the disease. As stress has been identified as a primary risk factor 
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for depression (Kendler et al., 1999), this strategy became widely utilised in animal depression 
studies using different types of stress exposure to induce depression-like behaviour.  
 Using stress to model depression 
To date many different types of stress have been found to induce various depression-like 
behaviours in rodents. One of the first forms of stress-based models was application of electric 
foot shock which resulted in behavioural response named learned helplessness (Seligman and 
Maier, 1967). This behavioural phenomenon signifies acquisition of a passive approach to 
coping with stress, which occurs after several exposures in unescapable conditions and 
manifests itself as a failure to flee the shock when a means of escape is provided. While 
construct validity of this model has been disputed (Willner, 1984), it identified uncontrollability 
of stressor as a necessary factor to trigger the helpless behaviour (Drugan et al., 1997).  
Passive coping has become a focus of attention in another model, Porsolt’s swim test (Porsolt 
et al., 1977), commonly referred to as a forced swim test (FST). Porsolt found that rats placed 
in an unescapable cylinder with water first display active attempts to escape and vigorously 
swim around the cylinder, however in a few minutes become less active and finally resort to 
passive floating, with minimal movement just enough to keep the head above the water. 
During the second immersion, the majority of rats spend most of their time in the cylinder 
immobile. This response has been dubbed “behavioural despair”, as it appears to reflect 
animals “giving up” on their chance to escape the water. Behavioural despair can also be 
triggered in a tail suspension test (TST), in which mice hung by the tail switch from initial 
struggling and climbing attempts to passive immobility (Steru et al., 1985).  
The validity claims of the three models rest mainly on their sensitivity to the antidepressant 
treatment. Indeed antidepressants from most classes administered acutely and chronically 
have been shown to delay the onset of learned helplessness and behavioural despair in FST 
and TST (Cryan et al., 2005; Petit-Demouliere et al., 2005). However, the construct and face 
validity of these models have been heavily criticised. In addition, in mice genetic background of 
different strains has been shown to significantly affect their response (Powell et al., 2012). 
Some authors recommend to view behavioural despair tests solely as screening tests of 
antidepressant activity rather than stand-alone models (Nestler and Hyman, 2010). Currently 
FST and TST are widely utilised as tests of depression-like behaviour, to establish if more 
aetiologically relevant chronic stress exposure facilitates display of behavioural despair.  
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 Chronic stress based models of depression 
Introducing the chronicity of exposure into the model significantly improves its construct 
validity, as depression is a chronic disorder which is unlikely to be triggered by a single or few 
days long event. Also the intensity of chronic stressors need not be very high, which again 
brings them closer to daily life stressors predisposing individuals to depression. An extra 
advantage is the time frame the length of the chronic stress exposure provides to apply 
chronic antidepressant treatment. There are many types of chronic stress used in animal 
depression studies. Chronic stress can be applied in early life, such as in the maternal 
separation model, if childhood origins of the disease are being studied (Korosi et al., 2012). In 
adulthood repeated or variable stressors can be used. Repeated stress can be social, such as 
social isolation or chronic social defeat, or physical, such as chronic restraint stress (Nestler 
and Hyman, 2010). While repeated stress models have been shown to induce depressive-like 
behaviour, their construct validity is limited by the use of a single type of stress, while human 
experience is not limited to a single stressor. Moreover, repeated exposure to stressors 
removes the unpredictability factor and is likely to induce habituation, which can diminish 
behavioural outcome (Girotti et al., 2006).  
Chronic unpredictable stress refers to protocols where a variety of stressors are applied. The 
stressors typically include alterations of housing conditions (removal of environmental 
enrichment and bedding, use of wet, novel or soiled bedding, tilt of cages), physical stressors 
such as shaking, immersion in cold water, restraint, tail suspension and lengthy periods of food 
and water deprivation. Other types of stressors could include alterations of the light/dark 
cycle, social isolation or exposure to intruder, exposure to predator cues (Willner, 2005). The 
severity of stressors can vary rather significantly between studies. Therefore, in this thesis I will 
distinguish between chronic unpredictable stress (CUS), which will be identified based on 
inclusion of more than one type of physical stressors, and unpredictable chronic mild stress 
(UCMS) mostly based on socioenvironmental stressors, which can include addition of a small 
amount of room temperature (RT) water at the bottom of the cage, restraint and food and 
water deprivation up to 24 hours (Willner et al., 1992). The UCMS model therefore has a 
construct validity advantage over other models, as it employs mild, variable and unpredictable 
stressors, more aetiologically relevant for risk factors of depression (Willner, 2005).  
The strength of the face validity of UCMS model lies in the wide range of depression-related 
behavioural and neurobiological changes it induces. Indeed, apart from the uniquely human 
symptoms such as depressed mood, feeling of guilt or suicidal ideations, UCMS replicated 
changes in every behavioural domain affected by depression. Behavioural changes induced by 
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UCMS, together with methods of their assessment and corresponding clinical symptoms are 
summarised in Table 1, and will be discussed in more detail in Chapter 2 UCMS model. UCMS 
also replicates the main neurobiological phenotypes seen in depression. These include 
reduction of hippocampal volume, HPA axis activation, suppression of adult hippocampal 
neurogenesis and proinflammatory cytokine profile described above (Luo et al., 2014; 
Santarelli, 2003a; You et al., 2011). 
Table 1 Symptoms of depression, corresponding behavioural changes induced by UCMS in rodents and behavioural 
tests used for their assessment  
(Adopted from Czéh, B., Fuchs, E., Wiborg, O. & Simon, M. Animal models of major depression and their clinical 
implications. Prog. Neuro-Psychopharmacology Biol. Psychiatry (2015))  
CLINICAL SYMPTOMS CHANGES INDUCED BY 
UCMS 
ASSESSMENT IN RODENTS 
DSM-5 criteria symptoms 
Depressed mood n/a n/a 
Markedly diminished interest 
or pleasure in activities 




suppressed feeding, intracranial 
self-stimulation, 
cookie test, measures of sexual 
drive, female urine sniffing 
Significant weight loss or 
weight gain, change of 
appetite 
Weight loss, changes in food 
intake 
Weight and food intake 
measurements 
Insomnia or hypersomnia Altered diurnal rhythm Activity measures during light 
and dark phases, sleep EEG 
measures 
Fatigue or loss of energy Hypoactivity, grooming deficit, 
behavioural despair 
Locomotor activity measures, 
coat state assessment; FST, TST 
Feelings of worthlessness or 
excessive or inappropriate 
guilt 
n/a n/a 
Diminished ability to think or 
concentrate, or indecisiveness 
Cognitive deficit Morris water maze, Y-maze, 
attentional set-shifting, novel 
object recognition 
Recurrent thoughts of death, 
recurrent suicidal ideation 
n/a n/a 
Psychomotor agitation or 
retardation 
Hypoactivity or hyperactivity, 
grooming behaviour 
Locomotor activity measures, 
coat state assessment, splash test 
Additional symptoms and comorbidities 
Anxiety Anxiety-like behaviour Open field test, light-dark box 
test, novelty suppressed feeding, 
elevated plus maze 




Social interaction test 
 
The predictive validity of UCMS is another strength of the model. Importantly, only chronic 
antidepressant treatment is effective in reversing behavioural and neurobiological deficits, 
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with most classes of antidepressants shown to exert therapeutic effect (Surget and Belzung, 
2009). 
However the replicability of the model has been called into question, as different laboratories 
reported conflicting outcomes and some struggled to replicate the model altogether (Nestler 
et al., 2002; Willner, 2005). Adaptation of the UCMS to mice and introduction of some of the 
new behavioural parameters such as coat state deterioration improved replicability in some 
laboratories (Griebel et al. 2002). Yet it has been shown that large difference in response to 
UCMS exists among different strains, with C57BL6 being one of the least responsive strains and 
BALB/c one of the most sensitive strain (Surget and Belzung, 2009). Moreover, within the same 
strain individual differences also exist in UCMS response, including inbred strains where the 
genetic background is identical within all test mice (Ducottet et al., 2004; Pothion et al., 2004). 
This difference is likely to be caused by slight variations in environment (e.g. parental 
behaviour, litter size and composition, experimental handling etc) between animals which 
could influence predisposing factors, such as state of the HPA axis or immune system of each 
individual animal. Thus while the UCMS model has significant advantages over many other 
models, it requires careful setup and validation in each laboratory. 
The issue of replicability goes hand in hand with the issue of phenotype assessment. Indeed 
valid and reliable ways to measure depression-like phenotypes of interest are required to 
allow the comparison of different animal models. Most studies use a battery of behavioural 
tests to assess a variety of behavioural phenotypes corresponding to main symptoms of 
depression. A lot of effort has been put into attempts to measure anhedonia, one of the core 
depression symptoms.  For this, animal’s drive for hedonic stimuli, such as palatable solutions 
or sexual cues is measured. Such tests have good face validity, and their predictive validity 
have been shown with major antidepressant classes (Surget and Belzung, 2009). On the other 
hand, tests of so-called behavioural despair, such as forced swim or tail suspention test, lack 
the advantage of face validity and mainly used for their sensitivity to serotonergic 
antidepressants (Nestler and Hyman, 2010). Another large group of tests frequently used in 
depression studies are tests of anxiety-like behaviour.  Indeed anxiety shows high comorbidity 
with depression, and antidepressant medications are now often used to treat anxiety disorders 
(Otte et al., 2016). Most tests of anxiety-like behaviour are based on the approach-avoidance 
task principle – exposure of a mouse to a novel yet open or well-lit arena to create a 
motivational conflict between two natural behaviours – an exploratory instinct and an aversion 
to areas of higher threat of exposure to predators. The examples of such tests are open field, 
elevated plus-maze and light-dark box. Measures of fearful threat-avoiding behaviours have 
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high face validity for anxiety, which is often characterised by avoidance of fearful objects 
(Cryan and Holmes, 2005). Importantly, these tests were developed based on their predictive 
validity for the first anxiolitycs benzodiazepines (Crawley and Goodwin, 1980), which further 
strenghethens their relevance. However not all tests used in depression research have been so 
well validated, which complicates interpretation of their results. Other tests used in UCMS 
research will be discussed in more detail in Chapter 2.  
 Thesis outline 
To summarise, the design of a valid animal model of depression remains a challenging task to 
this day. Yet the success of novel drug target development hugely depends on their validity, 
therefore reliable models incorporating neurobiological aspects described in non-
monoaminergic theories of depression are urgently required. In an effort to contribute to their 
development, in a series of experiments presented in the following chapters I revisit two 
animal models most frequently used in neurogenesis and the inflammatory depression 
research to pursue the following hypotheses. 
1) BALB/c mice are a suitable strain to be used for developing mouse models of depression. 
2) UCMS and its behavioural effects can be reproduced in a laboratory with no previous 
experience of UCMS research.  
3) UCMS can induce numerous aspects of depression-like neurobiology including a reduction in 
adult hippocampal neurogenesis and neuroinflammation, as well as to provide insight into 
other neurobiological mechanisms of chronic stress relevant for depression.  
4) LPS administration can be used to model chronic inflammatory state seen in depression and 
potentially induce some of the behavioural depression-like phenotypes. 
Thus the experiments described in the following chapters were designed to pursue specific 
aims derived from the hypotheses listed above. Chapters 2, 3 and 4 are dedicated to the 
detailed assessment of the UCMS model, including its optimal setup to induce antineurogenic 
and inflammatory endophenotypes. In Chapter 2 I describe the set-up of the UCMS model in 
BALB/c mice and assess the replicability of different behavioural phenotypes described in the 
UCMS studies. In addition, I assess if change in inflammatory biomarkers is among the 
endophenotypes induced by UCMS, thereby contributing to the notion of an associative role of 
inflammation in depression.  Chapter 3 is dedicated to the changes in AHN triggered by UCMS 
and possible inflammatory and endocrinal factors affected by UCMS, which could have 
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contributed to AHN modulation. In Chapter 4, a hypothesis-free approach of the genome-wide 
gene expression assay is used to investigate some of the molecular changes in relevant brain 
areas underlying behavioural and neurobiological phenotypes described in previous chapters. 
Finally, Chapter 5 explores the potential of proinflammatory agent LPS to model depression-
like chronic changes in the immune system, neurogenesis and behaviour, thereby also testing 





Chapter 2 UCMS model 
 Introduction 
The unpredictable chronic mild stress (UCMS) model of depression became the focus of the 
first chapter of this PhD thesis due to a number of important advantages it has over other 
available animal models, and to controversies surrounding the replicability of its behavioural 
and neurobiological readouts (Willner, 2005). Indeed etiologically it is one of the most realistic 
models of clinical depression (Wiborg, 2013). In this model depressive-like phenotype is 
induced by repeated employment of mild mostly socio-environmental stressors, over which 
order and longevity the animal has no control. The variable, episodic and chronic nature of 
stress employed ensures good construct validity, as it resembles chronic psychosocial stress 
predisposing individuals to developing depression (Kendler et al., 1999). UCMS induces a 
plethora of behavioural changes, including but not limited to anhedonia, anxiety, behavioural 
despair, sleep disturbance, weight loss and locomotor retardation. Such variety of behavioural 
phenotypes corresponds to heterogeneic symptoms of depression, thus providing face validity 
of the model (Willner, 1997). Behavioural symptoms are also accompanied by neurobiological 
changes relevant for depression neurobiology, such as imbalance of neurotransmitter 
metabolism, hypothalamic-pituitary-adrenal (HPA) axis deregulation, reduction of adult 
hippocampal neurogenesis and modification of the immune response (Hill et al., 2012). Finally, 
the effectiveness of chronic treatment with virtually all classes of antidepressants on UCMS 
confirms its predictive validity (Surget & Belzung 2009).  
Yet UCMS is surrounded by controversy, as many variations in the protocol exist, and many 
specific aspects of the protocol and outcome measurements, as well as laboratory conditions, 
have been shown to affect the results. Indeed, it seems that for every finding delivered by 
UCMS, there is at least one report showing opposing results (Willner, 2005). Such variation in 
UCMS findings among research groups brought about the need to adapt and validate the 
effectiveness of UCMS protocol for each laboratory wishing to utilise the model. Therefore, 
this study aimed to establish and optimise the UCMS protocol and its behavioural readouts for 
a mouse BALB/cAnNCrl strain and to conduct in depth study of behavioural phenotypes 
induced by UCMS and neurobiological changes underlying them. In terms of neurobiology the 
main focus of the study was on outcomes related to the two mechanisms currently appearing 
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most promising for future drug discovery, that is the activation of the immune system as 
indexed by cytokine levels, and on the level of adult hippocampal neurogenesis, which will be 
described in more detail in Chapter 3. The choice of the BALB/c strain was based on extensive 
literature suggesting specific sensitivity of this strain to stress and to antidepressant 
treatment. As such, it has been shown that this strain responds to stress exposure with 
hypersecretion of corticosterone (Zaharia et al., 1996), an effect which was attributed to low 
quality of maternal care in this strain (Anisman et al., 1998). BALB/c mice have been shown to 
display high anxiety levels in many approach/avoidance tests, such as open field, light-dark box 
and free exploration tests (Griebel et al., 2000; Kim et al., 2002; Kopp et al., 1999) In the 
comparison of UCMS response in 8 mouse strains conducted by Surget & Belzung (2009) 
BALB/c was one of the only 3 strains showing behavioural phenotype. BALB/c mice have also 
been shown to be highly responsive to antidepressant treatment. Dulawa et al. (2004) showed 
that BALB/c mice was the only strain out of four others which responded to chronic fluoxetine 
treatment with reduction of immobility in the forced swim test. Moreover, in the study by 
Ibarguen-Vargas et al. (2008) BALB/c was the only strain out of 8 compared in which 
antidepressant imipramine was effective in reversing UCMS-induced coat state alteration, 
anxiety in the novelty suppressed feeding test and increased levels of corticosterone. In 
addition, this strain has been reported to display increased immune system reactivity (Potter, 
1985). Therefore, BALB/cAnNCrl substrain available from a UK supplier was selected for the 
experiments described in this thesis.  
 Behavioural parameters of UCMS 
UCMS was developed by Willner (Willner et al., 1992) based on a study of the effect of severe 
repeated stress affecting locomotor activity and sucrose intake in rats (Katz, 1982). Willner 
modified intensive stress protocol used by Katz by removing the most severe physical 
stressors, such as footshock, cold water immersion and 48 hour food deprivation from the 
protocol, and by focusing attention on the behavioural readout measuring anhedonia, that is, a 
reduction of sucrose preference or consumption (Willner et al., 1987). The protocol which 
successfully reduced sucrose preference in rats during 5 to 9 weeks of exposure included 20-
hour food and water deprivation, overnight illumination, 45° cage tilt, housing in cages soiled 
with 100ml of water and intermittent pair housing. Subsequent experiments showed that 
combination of only three stressors was sufficient to induce anhedonia in rats, namely cage 
tilt, wet bedding and pair housing (Willner, 1997). However, in a mouse version of the protocol 
developed over the next 10 years, intermittent pair housing had to be removed to avoid 
induction of aggression and fighting between temporarily paired mice. Instead exposure to 
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another mouse’s cage in its absence was introduced, together with movement restriction and 
more ethologically relevant stressors such as predator odours and sounds (Surget and Belzung, 
2009).  
During the first decade of UCMS experiments the model caused some controversy as many 
laboratories struggled to replicate it (Nestler et al., 2002). However, since it was adapted to 
mice, numerous research laboratories successfully utilised it. Shortly after the first study by 
Kopp et al. (1999) describing  3 week UCMS protocol in mice, Griebel et al. (2002) suggested a 
new measure of the UCMS outcome: the physical state of the fur evaluated on a subjective 
rating scale. Griebel and coworkers (2002) showed that fur or coat state deteriorated during 7 
weeks of UCMS in mice, while chronic treatment with fluoxetine (10 mg/kg) significantly 
improved it. The authors drew a parallel between reduction of daily grooming in animals which 
leads to coat state deterioration and the struggle depressed individuals face trying to 
accomplish even the smallest daily tasks, including maintenance of personal hygiene.  Many 
laboratories adopted this measure, sometimes using it as a main behavioural readout 
(Ducottet et al., 2004; Mutlu et al., 2012). Belzung’s group suggested and validated a more 
precise scoring system than that originally suggested by Griebel et al (2002), where 7 body 
parts of a mouse are given a separate score of 0 for clean shiny fur, or 0.5 or 1 for spiky dirty 
fur depending on the level of deterioration, and a total sum of scores is used as a final readout 
(Nollet et al., 2013).  One of the big advantages of this measure is that unlike most behavioural 
tests including sucrose preference, which are  affected by multiple exposure of animals to 
sucrose (Strekalova et al., 2011), it can be safely conducted repeatedly in the same animal. 
Hence it allows a more sensitive within subject monitoring of depressive-like behaviour during 
the weeks of stress exposure and antidepressant treatment.  
Another measure which could be monitored during the stress is body weight. Most of the 
studies with UCMS in rats and mice report decreased body weight or reduced body weight 
gain, which is rescued by chronic antidepressant treatments (Bekris et al., 2005; Liu et al., 
2014). However a number of mouse studies do not detect any change in body weight 
(Strekalova et al., 2011). It is important to remember that many chronic stress protocols, 
especially at the beginning of CMS research in mice (Griebel et al., 2002), utilised food and 
water deprivation as one of the stressors, which could lead to weight change unrelated to 
psychological effects of stress (Lu et al., 2016). However the protocol used by Belzung and 
colleagues does not include any food deprivation, and their studies frequently report 
decreased weight gain in different mouse strains (Nollet et al., 2013), albeit not in every 
experiment (Ducottet and Belzung, 2005; Santarelli, 2003a). Surget & Belzung (2009) 
53 
 
speculated that such variability in effect could be due to the fact that like depressed patients, 
mice might be responding either with weight gain or loss, however when individual 
parameters are averaged for group statistical analysis, such effects can no longer be detected. 
A difference in body weight response has also been attributed to mouse inter-strain variations 
(Schweizer et al., 2009). 
Interestingly, variation in body weight response slightly resembles variation seen in another 
measure related to feeding, sucrose preference. While sucrose preference was at the centre of 
CMS research from the very first publication (Willner et al., 1987), not all studies report similar 
findings. In 2005 review Willner listed 38 different groups reporting decreases in sucrose 
intake (volume of sucrose consumed) or preference (percentage of sucrose consumed over 
total liquid volume consumed in two-bottle test)  in rats or mice, along with 4 studies which 
showed the opposite effect, albeit mostly reported in conference proceedings (Willner, 2005). 
This review also mentioned several unpublished communications regarding no effect of CMS 
on sucrose preference. Publication bias could explain why such paradoxical or negative 
findings are less represented in the literature, however the existence of variation in anhedonic 
behaviour is now widely accepted. It appeared that result of the sucrose preference test is 
highly strain- and concentration-dependent. For instance, Pothion et al. (2004) demonstrated 
differences in sucrose intake and preference among 11 mouse strains subjected to 7 weeks of 
UCMS and concentrations of sucrose which varied between 1 and 50% percent. Authors went 
on to compare effect of UCMS on sucrose consumption in 3 out of 11 inbred strains (CBA/H, 
C57BL/6 and DBA/2) chosen for stable and high level of sucrose consumption, and showed that 
only 2 strains (CBA/H and C57BL/6) responded to UCMS with a reduction in sucrose 
consumption. Lewis et al. (2005) compared intake of sucrose solutions ranged from 0.0001% 
to 20% sucrose in 12 inbred mouse strains and showed strong interstrain differences, with 
C57BL/6 being one of the greatest sucrose consumers and BALB/c classified as intermediate 
consumers.  Surget reported that 11 tested strains of mice only showed preference for sucrose 
concentrations of 4% and above (Surget and Belzung, 2009). This group also tested sucrose 
preference in 8 different mouse strains following the 6 week UCMS protocol, including 
BALB/cByJ, C57BL/6J, and DBA/2, and showed that stress had a supressing effect in only one of 
8 strains, in-house laboratory-reared inbred strain BA from the Institut de Transgenose, 
Orleans (Ducottet and Belzung, 2005). Inter-strain comparisons and genetic studies of the 
sucrose taste receptor showed the importance of genetic background in the ability to 
demonstrate a sucrose preference (Powell et al., 2012). In addition, in the protocol developed 
by Willner, rats are subjected to 24-hour food and water deprivation before the test, therefore 
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appetite and metabolism can affect caloric sucrose consumption in food-deprived animals.  To 
remove such confounding factor, Ducottet et al. (2004) performed the test in mice without 
food and water deprivation, and this protocol change could explain the results contradicting 
many studies showing decreased sucrose preference in mouse strains. Since then Belzung’s 
group avoided the use of sucrose preference as an anhedonic measure in mice, which did not 
prevent this laboratory from publishing breakthrough studies using UCMS model (Santarelli, 
2003a). Strekalova et al. (2011a) conducted a thorough investigation into the methodology of 
the sucrose preference measure during chronic stress in C57/BL6N mice, and pointed out 
many factors that could have influenced the outcome. These include individual variability of 
response in naïve animals, preventable by habituating animals to sucrose before the beginning 
of measurements; variation in liquid consumption during the time of day, which is highest in 
the active phase; habituation of animals to repeated exposures, counteracted by a change in 
concentration during chronic stress. Yet even when all these considerations are taken into 
account, the authors observed a large individual variation in the sucrose preference during 
chronic stress, which allowed them to divide stress-exposed animals into either susceptible or 
resistant to chronic stress effects (Strekalova et al., 2006). Importantly, this group utilises a 
chronic stress protocol which cannot be classified as mild as it consists of intense stressors 
such as tail suspension, social defeat and restraint. Intensification of stress could explain why 
the sucrose preference test is modulated by stress exposure in their studies.  
As anhedonia is a core diagnostic feature of depression, it plays a central role in modelling 
depression, and other tests are being used to detect it in UCMS studies. The study by Santarelli 
et al (2003) used novelty-suppressed feeding as a readout of anhedonia to assess the effect of 
4 different antidepressants in a 5 week UCMS protocol in mice and dependence of SSRI 
antidepressant activity on adult hippocampal neurogenesis, while a later study by the same 
group introduced a novel cookie test, which also measures motivation for a familiar, palatable 
and rewarding stimulus (chocolate cookie) in a novel arena (Surget et al., 2011).  
However, behaviours affected by UCMS are not limited to the anhedonic phenotype. In 
parallel with depression and anxiety comorbidity observed in clinical depression, some studies 
report increased anxiety in chronic stress-exposed animals. As such, increases in anxiety-like 
behaviour in mice were observed in the light-dark box (Mineur et al., 2006), elevated plus 
maze (Papp et al., 2013), and open field test (Franceschelli et al., 2015). However, opposite 
results also have been documented by the very same groups. As such, Ducottet et al. (2003) 
described an anxiolytic effect of 9 weeks of UCMS exposure in the light-dark box, while 
D’Aquila et al. (1994) described anxiolytic profile of chronically stressed rats in elevated plus 
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maze. Increased locomotor activity has been proposed as a cause of such paradoxical effects 
(Strekalova et al., 2005). Indeed a number of studies report hyperlocomotion induced by 
chronic stress exposure, which usually accompanies “anomalous anxiolysis” (Schweizer et al., 
2009). This effect also highlights inter-species differences, as it appears to be specific for mice 
and is opposed to the reduction of locomotor activity usually described in rats in response to 
chronic stress exposure. Change in locomotor activity has been attributed to the disturbance 
of circadian rhythms in mice. Indeed UCMS includes alteration of light/dark cycle, and many 
studies describe the change in circadian clock genes expression in the suprachiasmatic nucleus 
of the hypothalamus, the centre of circadian rhythm regulation (Jiang et al., 2011; Kinoshita et 
al., 2012). Logan et al. (2015) showed that chronic stress altered circadian fluctuation of 
activity in a way that stressed mice displayed hypoactivity in the dark phase and hyperactivity 
in the light phase. This together with existing evidence that light/dark phase of open field 
testing can significantly affect the activity outcome (Valentinuzzi et al., 2000) could explain 
existing controversies on locomotion and anxiety among UCMS studies. 
Hyperactivity has also been shown to affect the outcome of tests assessing depressive-like 
behaviour or so called behavioural despair. While in both forced swim and tail suspension tests 
chronic (6 weeks) stress exposure has been shown to increase depressive-like behaviour in rats 
and mice (Bessa et al., 2013; Khemissi et al., 2014), these results were not always replicated 
(Mineur et al., 2006). Moreover, behaviour in FST is known to be highly strain-dependant 
(Petit-Demouliere et al. 2005, Powell et al. 2012). Yet due to the high predictive validity of 
these tests for detecting antidepressant effect of serotonergic compounds, most studies 
include it in the behavioural testing batteries following chronic stress exposure.  
Behavioural changes described above do not complete a list of behavioural effects of chronic 
mild stress. Other behaviours previously reported in this paradigm include but are not limited 
to sleep disturbance, aggression, memory impairments and reduced sexual drive (D’Aquila et 
al., 1994; Erburu et al., 2015; Griebel et al., 2002). However, our experiments focused on 
behaviours most consistently reported in UCMS studies and most important for modelling 
depression and assessing the effectiveness of antidepressant treatment.  
 Effect of UCMS on systemic neurobiological parameters 
Chronic stress has been shown to have many neurobiological effects highly relevant for 
depression research, including changes in neurotransmitter signalling, neural plasticity, HPA 
axis regulation, adult hippocampal neurogenesis and the immune system.  However, in this 
chapter we will only focus on the systemic effects of UCMS which can be assessed in 
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peripheral blood, as separate chapters are dedicated to the molecular changes in the brain 
(see Chapter 3 for adult hippocampal neurogenesis and Chapter 4 for gene expression profiling 
of UCMS).  
The HPA axis has been implicated in the neurobiology of depression by numerous clinical 
studies, therefore it is a key neurobiological process that should to be altered in a 
relevant/valid animal model of depression. Indeed, an early study by Ayensu et al. (1995) 
described elevation of serum corticosterone following 4 weeks of chronic stress exposure in 
rats. Interestingly in this study changes in corticosterone were accompanied by a reduction in 
serum complement activity, providing the first evidence of the effect of chronic stress on the 
immune system. Many subsequent  studies replicated this finding in rats (Garcia et al., 2009; 
Liu et al., 2014), and complimented it with gene expression data showing increased CRH gene 
expression in the hypothalamus (Ge et al., 2013). Such a profile of HPA axis response suggests 
HPA axis hyperactivation arising from the malfunction of the negative feedback inhibition loop, 
which in health protects the body from excessive corticosteroid release. The negative feedback 
loop is thought to depend upon the hippocampal glucocorticoid receptor (GR). Decreases in GR 
expression or loss of function, named glucocorticoid resistance, has been implicated in the 
malfunction of the negative feedback mechanism of the HPA axis (de Kloet et al., 2005; 
Silverman and Sternberg, 2012). Indeed many studies show decreased GR expression upon 
UCMS exposure in the hippocampus and hypothalamus in rats and mice (Pan et al., 2010; 
Zhuang et al., 2016). Interestingly in the latter study by Zhuang et al (2016), a decrease in GR 
expression seen in mice after 8 weeks of UCMS exposure has been accompanied by an 
increase in proinflammatory cytokines TNFα and IL-6 expression in the same brain areas and in 
the peripheral blood.  
Yet as with the behavioural parameters, strain and study variations exist in corticosterone 
data. When 8 mouse strains were compared, only 2 strains including BALB/cByJ, showed 
significant elevation of faecal corticosterone, while another 2 strains showed a decrease, and 
no effect was observed in the remaining 4 strains. Interestingly, chronic imipramine treatment 
reversed the effect of UCMS on corticosterone levels in only 2 strains, BALB/cByJ and C57BL/6J 
(Ibarguen-Vargas et al., 2008). Moreover, inter-individual variability in HPA axis response to 
UCMS has also been documented. Khemissi and colleagues used the dexamethasone 
suppression test, a test of negative feedback inhibition, to divide stress-exposed animals into 
those with high- or low-reactive HPA axis (Khemissi et al., 2014). These authors went on to 
show that a group with impaired low-reactive HPA axis regulation failed to respond to 
fluoxetine treatment in some behavioural outcomes (NSF), thereby modelling antidepressant 
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resistance seen in depressed patients. Such a profile of HPA axis response also resembles the 
reduced HPA axis activity seen in atypical  depression (Gold, 2015). 
The HPA axis is closely linked with the immune system function, as its activation has been 
shown to induce immune activation and vice versa (Bellavance and Rivest, 2014; Silverman et 
al., 2005). As has been already mentioned above, plasma inflammatory markers have been 
shown to be affected by chronic stress alongside corticosterone and other HPA axis 
parameters. Kubera and coworkers showed that 3 weeks of UCMS in mice decreased thymus 
weight, a key organ in the immune response, and induced IL-1 release by unstimulated 
splenocytes (Kubera et al., 1998). In a study by You et al. (2011) elevation of pro-inflammatory 
cytokines (IL-1β, TNFα and IL-6) and decrease in anti-inflammatory cytokines (IL-10 and TGFβ) 
in the spleen were accompanied by corresponding changes in the hippocampus, cortex, and 
the hypothalamus of rats after 4 weeks of UCMS exposure. Elevation of proinflammatory 
cytokine levels has also been shown in the peripheral blood after 4 weeks of UCMS, again 
accompanied by increased IL-1β, TNFα and IL-6 expression and protein levels in the  rat 
hippocampus and prefrontal cortex (Lu et al., 2016). Similarly, Xue et al. (2015) showed 
increased IL-1β, TNFα, IL-6 and the NLRP3 inflammasome in the mouse hippocampus after 6 
weeks of UCMS. Moreover, in these studies chronic treatment with 10mg/kg fluoxetine 
reduced proinflammatory cytokines to control levels. The increase in proinflammatory 
cytokines is not merely correlational. For example, IL-1β has been shown to be essential for 
chronic stress to induce anhedonia in mice (Koo and Duman, 2008). Treatment of UCMS-
exposed rats with the TNFα inhibitor infliximab prevented cognitive decline induced by stress 
(Sahin et al., 2015).  It is thought that the main source of the increased proinflammatory 
cytokines in the brain during stress is activated microglial cells. Indeed various types of chronic 
stress have been shown to increase the number and activation markers of microglial cells in 
the prefrontal cortex and the hippocampus (Lu et al., 2014; Tynan et al., 2010; Wohleb et al., 
2011). It has been suggested that one of the ways through which microglia can sense stressful 
stimuli is via corticosterone activating its GR receptors (Carrillo-de Sauvage et al., 2013). In 
turn, microglial activation is thought to play a role in the behavioural outcome through its 
effect on adult hippocampal neurogenesis and synaptic plasticity (Kreisel et al., 2014; Wohleb 
and Delpech, 2016). The evidence supporting this notion will be reviewed in more detail in 
chapters 3 and 4.  
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 Study aims 
The aims of the UCMS experiments described in this chapter were to set up the UCMS protocol 
in our laboratory and explore its behavioural readouts, as previous literature highlighted above 
shows a large variation in the protocols used and the behavioural and neurobiological 
outcomes detected. An aetiologically relevant protocol without physical stressors, such as 
food/water deprivation, restraint or footshock, most closely resembling the protocol by Nollet 
et al. (2013) was utilised and optimised in the presented experiments. The outcome of 
behavioural tests relevant for depression, such as grooming, anxiety, anhedonia and 
behavioural despair was assessed. The systemic neurobiological effects of UCMS on the HPA 
axis and the immune system were measured in blood to evaluate the suitability of the UCMS 
model to study aspects of depression neurobiology with the aim of potentially identifying 
novel treatment targets.  
 Methods 
 Animal housing 
Male inbred BALB/cAnNCrl mice aged 7 weeks were purchased from Charles River (Margate, 
UK). All animals were housed in the Biological Services Unit (BSU) at the Institute of Psychiatry, 
Psychology & Neuroscience in standard conditions (19-22°C, humidity 55%, 12h:12h light:dark 
cycle with lights on at 8.30am, food [Rat and Mouse No. 1 Diet; Special Diet Services, Essex, 
UK] and water ad libitum). Animals were allowed to acclimatise to the animal facility for at 
least 7 days before the beginning of the experimental procedures. Standard mouse Techniplast 
cages (32cmx16cm x14cm) with sawdust as a bedding material (Litaspen premium, Datesand 
Ltd, Manchester, UK) or larger rat cages (59.5x38x20cm) were used for housing depending on 
the design of individual experiments. Unless otherwise stated minor cage enrichment, 
consisting of sizzlenest (Datesand Ltd, Manchester, UK) and a cardboard shelter (LBS Biotech, 
Horley, UK) was provided. The number of animals per cage varied among experiments, 
therefore is specified below in the experimental design sections for each experiment. Cages 
were never cleaned the day before, or on the testing day to minimize the potential effects of 
cage disturbance on the behaviour of the mice. All housing and experimental procedures were 
performed in compliance with the local ethical review panel of King’s College London under a  
U.K. Home Office project licence held in accordance with the Animals (Scientific Procedures) 
Act 1986 and the European Directive 2010/63/EU.  All efforts were made to minimize animal 
suffering and to reduce the number of animals used. 
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 UCMS protocol 
The UCMS protocols used were based on the methodology described by Nollet et al. (2013) 
and modified to accommodate the conditions of the animal facility and to improve the 
ethological relevance of the stress by decreasing its severity. As such, restraint in a tube 
limiting the body movement of mice was removed or replaced with a confinement in a wire 
mesh cup which allowed free movement of the animal (see Figure 6) to reduce the severity of 
the procedures. The reversal of the light/dark cycle was not possible in the facility due to 
lighting conditions, therefore stressors were applied in the light phase. For predator odour 
commercially available fox urine was used instead of rat feces which were unavailable in the 
facility. The exact schedule of UCMS exposure used in each experiment is summarised in the 
respective experimental design sections. The length and the number of stressors per day 
varied depending on the experiment, but the following stressors were included in all protocols: 
tilting of the cage by 45° for a period varying between 30 min to 3 hours (see Figure 6), 
frequent change of bedding (new bedding), removal of sawdust and minor enrichment for up 
to 2 hours, exposure to wet sawdust produced by an addition of 150ml of room temperature 
water to the cage for up to 6 hours, exposure to a cage of another mouse in its absence (cage 
swap) for up to 6 hours, exposure to the odour of intruder mouse, when mice were returned 
to their home cages after cage swap (return to cage with intruder’s odour up to 15 hours 
(overnight), exposure to predator’s odour (Shake Away 2852228 Fox Urine Granules, 15ml per 
cage) up to 1 hour, exposure to predator’s sounds (Birdsong CD (Birds of Prey and Crows), 
Music Digital 2009) for 30 minutes, replacement of sawdust with 1cm of water at room 
temperature for 30 minutes (water bath as shown in Figure 6), confinement in a restricted 
space for up to 1 hour (wire mesh cup 10cm height 8cm diameter alteration of light-dark cycle 
such as introduction of several intervals of daylight during the night (exact schedule is specified 
in individual experimental design sections). Control animals were always housed in a different 




Figure 6 Photographs representing some of the stressors included in the UCMS protocol 
Table 2 summarises the number of animals included in each UCMS experiment, including the 
numbers used for behavioural assessments, in the analysis of the blood and brain tissue and 
the number of animals which died during the UCMS exposure. 
Table 2 Number of mice used in UCMS experiments 1-4 
Experiment Total number of 






Number of mice 
died during 
UCMS 
UCMS Experiment 1 60, 12 per group 60 48 0 
UCMS Experiment 2 48, 12 per group 39 39 9 
UCMS Experiment 3 20, 10 per group 20 20 0 
UCMS Experiment 4 16, 8 per group 16 16 0 
 
 Behavioural assessments 
 Coat state assessment (Nollet et al., 2013) 
Animals’ weight and coat state were assessed during UCMS on a weekly basis. Coat state 
reflects an animal’s grooming behaviour, which could be interpreted as an analogue of human 
self-caring behaviours, including upkeep of personal hygiene and appearance, which could be 
affected in severe depression (DSM-5, 2013).  Control animals were brought into the UCMS 
housing room for coat state assessment to ensure blindness of assessment. Coat score was 
determined on a scale of 0 to 7 according to Nollet et al (2013) by a researcher blinded to 
experimental conditions. The total coat state score was the sum of the scores given to each of 
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the individual body areas (head, neck, back, abdomen, tail, forepaws and hindpaws). A score of 
0 was given if fur on a body area was smooth and shiny without spikes or patches, a score of 
0.5 was assigned to slightly spiky fur, and score of 1 was given to a body area covered with 
spiky and stained fur. Such coat state assessment has already been validated in UCMS studies 
and was shown to be responsive to antidepressant treatment (Khemissi et al., 2014). 
 Sucrose preference (Ducottet and Belzung, 2005) 
Sucrose preference is a test measuring the presence of anhedonic behaviour. In this test mice 
are given a choice of drinking water or a sucrose solution, which due to its sweetness 
possesses rewarding properties. The preference for sucrose solution over water is considered 
as hedonic behaviour. Sucrose solution in drinking water at room temperature was prepared 
from sucrose crystals (Sigma, UK) fresh before the test. The percentage of sucrose used varied 
between experiments and therefore will be specified in each experimental design sections. 
Identical bottles with both solutions were placed on either side of a cage lid instead of the 
regular water bottles with food surrounding the bottles on both sides (see Figure 7C). To 
account for volume spilled from the bottles, 3 sets of bottles with water and sucrose were set 
up on empty cages, and volume spilled from these bottles during testing time was calculated. 
To avoid side preference, the location of the bottles on housing cages was switched during the 
test. Bottles were weighted before and after the test to measure liquid consumption. After 
subtraction of average volume spilled in empty cages, sucrose preference was calculated using 






Equation 1 Sucrose preference calculation, 
where Volsucrose is consumed volume of sucrose solution and Volwater is consumed volume of water 
 
 Locomotor activity in a home cage (Lad et al., 2010) 
To assess locomotor activity of animals in a familiar environment during the active dark phase, 
their behaviour in a home cage was recorded (Lad et al., 2010). Mice were transferred to the 
test room in their own home cage 2 hrs before the beginning of the dark phase. Enrichment 
materials were removed from the cages and clear, acrylic lids were placed on top of the cage 
to allow video recording and subsequent activity tracking. Six wetted food pellets were added 
to the cages to provide food and water throughout the test. The lighting for video recording 
was provided by red LED cluster lights (LED cluster red light No. 310-6757; RS Components 
Northants, UK) of approximate wavelength 705 nm which provided minimal red light to allow 
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video recording of the test. The wavelength of the LED cluster lamps is barely visible to mice 
due to their limited photonic vision (Jeon et al., 1998). Activity was recorded at the beginning 
of the dark phase (8.30-11pm), in the middle hour of the dark phase (1-4 am), and at the end 
of the night (6-8:30 am) using an overhead camera. The distance travelled in the home cage 
was subsequently tracked using Ethovision software (version 3.1; Noldus IT, the Netherlands). 
 Open field test (Gould, 2009) 
The open field test is a common measure of general activity and anxiety-like behaviour in a 
novel environment. The anxiety aspect of this test is based on the conflict between exploratory 
drive and avoidance of a potentially threatening, novel and open space (Gould, 2009).  A 
circular (40cm diameter) open field arena was used (see Figure 7A). During the test the arena 
was evenly lit with low light (~20 Lux). Each mouse was taken from its cage and placed in the 
outer part of the arena, facing the outer wall. Behaviours were video recorded for 10 minutes. 
For the analysis, the automated tracking software EthoVision (Noldus IT, The Netherlands) was 
used. The time spent in the centre zone (inner 30cm diameter circle) as a measure of anxiety 
was calculated using EthoVision. In addition, the total distance travelled in the least anxiogenic 
zone of the area (the remaining outer zone) also was calculated using Ethovision to acquire a 
measure of locomotor activity which is least confounded by anxiety triggered in the central 
zone of the arena (Lad et al., 2010). 
 Novelty-suppressed feeding (Dulawa and Hen, 2005) 
Novelty-suppressed feeding (NSF) is a well-described test of anxiety and anhedonic behaviour 
(Dulawa and Hen, 2005). It is based on a choice faced by a food-deprived mouse forced into a 
novel environment between engaging in feeding or avoidance of a novel, potential threatening 
environment (neophobic behaviour). In our experiments mice were food-deprived for 24 hours 
prior to the test. A large (59.5x38x20cm) novel cage with a thin layer of fresh sawdust was 
used as a test arena. The food pellet was placed in the middle of the cage on a piece of white 
cardboard (see Figure 7B). Mouse behaviour in the test arena was video recorded for 5 min. 
The latency to feed was measured until the time the mouse started eating the pellet. If the 
mouse did not touch the pellet during the 5 min, its latency was recorded as 300 sec (less than 
3 animals per group). After the end of the test mouse was returned into the home cage with 
the pellet for another 10 min. The weight of the pellet before and after the test, as well as 




 Splash test (Surget and Belzung, 2009) 
The splash test is quantitative measure of grooming behaviour. It has been developed by 
Catherine Belzung’s group to be used in the UCMS model (Surget and Belzung, 2009). The test 
was performed once at the end of the UCMS paradigm according to Nollet et al. (2013). The 
animals were sprayed with approximately 0.5ml of 10% sucrose solution on the back and 
transferred to a novel cage devoid of any enrichment. Their latency to start, and time spent, 
grooming were recorded over 5 min.  
 Light-dark box (Crawley and Goodwin, 1980) 
The light-dark box is another test to measure exploratory behaviour in the anxiogenic 
environment of a brightly lit arena. Unlike the open field, animals have a choice whether to 
stay in a “safe” dark chamber or venture into the brightly lit (100 Lux) light chamber, with 
latency to enter, and time spent in, the light area used as measures reflecting the anxiety-like 
behaviour of the experimental animal (Crawley and Goodwin, 1980). For this test, a white 
acrylic box 44×21×21 cm was used. The box was separated by a white acrylic sheet, 21×50 cm, 
into a smaller dark chamber (15×21×21 cm) with low lighting (10–15 Lux) and a bigger brightly 
lit light chamber’ (100Lux) (see Figure 7D). The chambers were connected by a small entry 
within the partition (5×7 cm). At the beginning of the test, the mouse was taken from its home 
cage and placed into the dark chamber facing the wall opposite the partition. Activity in the 
light–dark box was video-recorded for 5 min. Latency to enter, the time spent and activity in, 
the light chamber were scored using the Ethovision software and manually scored. A mouse 
was considered to enter the chamber when all four paws crossed the partition.  
 Forced swim test (Lucki et al., 2001) 
The forced swim test originally developed in rats by Porsolt et al. (1977) is interpreted to 
reflect behavioural despair in an inescapable stress situation, with antidepressant drugs 
robustly reducing immobility in this test (Powell et al., 2012). Mice were placed in a clear 
acrylic cylinder filled with 40 cm of water at room temperature for 6 minutes (see Figure 7E). 
For each type of behaviour, the latency of first appearance and its duration throughout the 
test period were manually scored from the recordings using the Ethovision software. 
Swimming was defined as movement of the limbs and body in a horizontal posture, paddling 
as movement of 2 or more paws in a horizontal posture without directed body movement 
(Belozertseva et al., 2007). An animal was considered to be immobile if passive floating was 
observed with only movements necessary to keep the head above water. Finally, struggling 
also known as climbing (Cryan and Mombereau, 2004) was defined as vertical posture with 
limb movement.  To measure the HPA axis response to the swimming stress, tail vein blood 
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was collected 24 hours before (baseline measure) and 30 min after the forced swim test for 
subsequent corticosterone analysis.  
 Social interaction (Winslow, 2003) 
To investigate social behaviours, test mice were exposed to an unfamiliar, sex-matched 
juvenile conspecific. Study mice were placed into a clean cage with fresh sawdust where 
conspecifics were subsequently introduced. Behaviours were video recorded for 5 min.  
Subsequently various types of social and non-social behaviours were manually scored using 
Ethovision. Social behaviours included investigative (sniffing and following), affiliative 
(grooming) and play soliciting (pushing over or under the conspecific). Non-social behaviours 
were considered to be self-grooming, cage exploration and digging. Biting and tail rattling were 
scored as aggressive behaviours (Winslow, 2003). 
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 Buried cookie test (Yang and Crawley, 2010):  
Olfactory information is essential for a wide range of mouse behaviours, including social 
interaction and food reward behaviours. It is therefore important to assess ansomia (absence 
of sense of smell) to rule this out as a confounder. Small chocolate cookies (Nestle Cookie 
Crisp®, Welwyn Garden City, U.K.) were used as the palatable food as previously described 
(Grayton et al., 2013). A cookie was placed in the home cage of each mouse for three 
consecutive days to habituate them to the taste. On the day of the test, each mouse was 
placed into a clean cage containing 5cm of fresh sawdust (Litaspen premium, Datesand Ltd, 
Manchester) and left to habituate in the test room for 5 minutes. (The light level in the test 
room was 10 Lux). The mice were then removed from the cage while a cookie was hidden 2 cm 
below the surface of the sawdust at the top of the cage. The mouse was returned to the cage 
and placed facing the wall on the side of the cage furthest from the cookie. The latency for the 
mouse to find and start eating the cookie was recorded. 
 
Figure 7 Examples of some behavioural tests used in UCMS experiments. 
 (A) A 40cm diameter arena used in the open field test (B) Mouse approaching the pellet in the middle of a novel 
large cage used in  novelty-suppressed feeding test (C)Mouse exposed to a choice between sucrose solution and 
water in bottles set up for the sucrose preference test (D) A box separated into a smaller dark chamber  (10–15 Lux) 
and a bigger brightly lit light chamber (100Lux) with a small entry in between the compartments used in the light-
dark box test. (E) A mouse swimming in the inescapable cylinder filled with water in the Porsolt forced swim test 
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 Blood collection 
For cytokine and corticosterone analysis blood was collected by incision method from the 
lateral tail vein (Sadler and Bailey, 2013). The timing of blood collection was dependant on the 
experimental design and is specified in individual experimental sections. Whole blood (30-50 
µL) was collected into EDTA microvette CB 300 tubes (Sarstedt, Leicester, UK) and separated 
by centrifugation for 10min at 3000 rpm (4oC), after which plasma was manually transferred 
into a new sterile tube (1.5ml ‘Crystal clear’ microcentrifuge tube sterile, Starlab UK Ltd) and 
stored at -80°C. Blood was also collected by the cardiac puncture after the terminal general 
anaesthesia has been induced by the injection of 100 μL of Euthatal i.p. (Merial Animal Health 
Ltd, Harlow, UK) containing 20 mg of pentobarbital sodium. 100-200 μL of whole blood was 
collected using syringe injected into the cardiac cavity and subsequently processed as 
described above. 
 Corticosterone measurement 
Plasma corticosterone levels were measured using commercially available corticosterone 
enzyme-linked immunosorbant assay kit (ELISA, Enzo Life Sciences, Lausen, Switzerland) 
according to the manufacturer’s instructions for small sample volume. Briefly, 10µL of plasma 
was diluted 1:40 with steroid displacement reagent and ELISA buffer. To generate standard 
curve serial dilutions of 200ng/µL corticosterone were used. Technical duplicates of 40 
samples and 5 serial standard dilutions were added to the plate wells precoated with donkey 
anti-sheep IgG. Anti-corticosterone ELISA antibody raised in sheep was added to each well 
together with ELISA conjugate for 2-hour incubation on a shaker. After incubation wells were 
thoroughly washed with assay buffer and enzyme substrate was added to the wells. Reaction 
was stopped after 1 hour with trisodium phosphate solution. The optical density was read on a 
microplate reader at 450nm wavelength. Obtained data was analysed using five parameter 
logistic curve analysis using the My Assays online data tool, MyAssays Ltd., 
http://www.myassays.com/five-parameter-logistic-curve.assay. Specifically, the standard dilution 
data points (known concentration of standard dilution vs. obtained absorbance measurement) 
are plotted on semi-log axes and a 5 parameter standard curve is fitted through the points 
using logistical regression. The concentrations of the samples are then determined from the fit 
of the curve based on their obtained absorbance values. Background correction was applied by 
subtracting absorbance level obtained from blank wells in which no corticosterone was 




Figure 8 Example corticosterone ELISA standard curve fitted through the standard dilution datapoints. 
The datapoints were subsequently used to calculate unknown concentration of corticosterone in blood samples 
collected during the experiments based on their absorbance measurements in the assay. Datapoints for each 
standard dilution (20000, 4000, 800, 160 and 32 pg/ml) in technical duplicates are shown in red.  
Average intrassay coefficient of variability (%CV) for duplicates is estimated at %CV=11.  
Average interassay variability for ELISA plates is estimated at %CV=4.6. %CV was calculated 





Equation 2 %CV calculation for sample duplicates or control duplicates from different plates, where SD is standard 
deviation and mean calculated for the two sample duplicates included on a plate or controls on different plates. 
 Luminex 
The level of cytokines in the plasma was determined using the multiplex screening assay based 
on magnetic Luminex® xMAP® technology as described in Hye et al. (2014). For this assay 
custom-made pre-mixed multianalyte kit was purchased from RnD systems, Minneapolis, USA 
(catalogue N LXSAMSM). This kit contained multi-coloured magnetic microparticles pre-coated 
with antibodies to 10 selected analytes (granulocyte-monocyte colony stimulating factor (GM-
CSF), interleukins IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, tumour necrosis factor alpha (TNFα) and 
interferon gamma (IFNγ). C-reactive protein (CRP) and leptin were added to the panel in the 
UCMS Experiment 3. Sensitivity of the assay to each cytokine is presented in Table 3. To 
measure the fluorescent signal Luminex® 100/200TM system was used. Plasma samples were 
diluted 1:2 in calibration buffer, and all assay steps were conducted according to the 
manufacturer instructions. Due to small sample sizes technical replicates for plasma samples 
were not included. Intra-assay variability based on duplicates of the standard dilutions is 
































experiment were analysed on a single plate. Obtained data was analysed using five parameter 
logistic curve analysis using the My Assays online data tool, MyAssays Ltd., 
http://www.myassays.com/five-parameter-logistic-curve.assay. 
Table 3 Minimal detectable dose (MDD) of each analyte in the Luminex assay used in UCMS experiments for cytokine 
analysis as stated by the manufacturer 
Analyte MDD, pg/ml 
GM-CSF 1.64 










Leptin  12.6 
 
 Drug administration 
All injections were administered intraperitoneally (i.p.). Fluoxetine powder was purchased 
from R&D Systems (Abingdon, UK), and dissolved in 0.9% saline (Aquapharm, Argyll, UK) saline 
to a 2.5 mg/ml solution. Fluoxetine solutions were kept at -20°C and freshly thawed on the day 
of injections. Fluoxetine was administered at a volume of 8 ml/kg in the UCMS Experiment 1 
(20mg/kg) and 4 ml/kg in the UCMS Experiment 2 (10mg/kg) adjusted to individual mouse 
body weight. Both doses administered i.p. to BALB/c mice have been shown to effectively 
alleviate the depression-like behaviour and increase adult hippocampal neurogenesis 
(Santarelli et al. 2003; Surget et al. 2008). Vehicle-only treated groups received daily injections 
of saline at a volume of 8 ml/kg calculated for an average 25g mouse (200 µL in the UCMS 
Experiment 1 and 100µL in the UCMS Experiment 2).  
  Statistical analysis 
In the UCMS Experiments 1 and 2 data was analysed using either a 2-way ANOVA or a 2-way 
repeated measures ANOVA, as appropriate. The between-factors were stress exposure and 
drug treatment, and within-factors time or test session. For post-hoc analysis of significant 
factors and/or interaction Bonferroni multiple comparisons method was used. In the UCMS 
Experiment 3 a Student’s t-test or a Mann-Whitney test was used if assumption of normality 
was violated in a particular dataset. The only exception from these protocols was made for the 
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ordinal coat state data, which was analysed week by week using non-parametric Kruskal-Wallis 
test and Dunn’s multiple comparisons corrections for post-hoc between-group comparisons. 
Statistical tests were applied using IBM SPSS Statistics 22 (IBM SPSS Inc., USA) and GraphPad 
Prizm 6 (GraphPad Software Inc., USA) software. Data is presented as mean ± SEM, statistical 
significance was assumed at p≤0.05. 
 UCMS Experiment 1  
 Experimental design 
The aim of this pilot UCMS experiment was to test out the UCMS protocol and behavioural 
tests which results have been shown to be affected by UCMS in the previous literature. 
Chronic treatment with 20mg/kg fluoxetine (FLX), a dose which has been shown to counteract 
the UCMS effect on behaviour and adult hippocampal neurogenesis (Surget et al., 2011; Tanti 
et al., 2013), was used. The following treatment groups were included in this experiment 
(N=12 per group): CNTRL – pair housed animals in standard mouse cages with standard 
enrichment, injected with 0.9% saline daily from the 3rd week of UCMS exposure; UCMS – 
single housed animals exposed to 2 stressors per day in random-like order according to the 
protocol in Table 4, injected with 0.9% saline daily from the 3rd week of UCMS exposure; CNTRL 
FLX – pair housed animals in standard mouse cages with standard enrichment, injected with 
fluoxetine (20 mg/kg) daily from the 3rd week of UCMS exposure; UCMS FLX – single housed 
animals exposed to 2 stressors per day according to the protocol in Table 4, injected with 
fluoxetine (20 mg/kg) daily from the 3rd week of UCMS exposure; CNTRL NO INJECT - pair 
housed animals in standard mouse cages with standard enrichment, not injected. Timeline of 
experimental procedures is represented in Figure 9.  
 
Figure 9 Timeline of experimental procedures in the UCMS Experiment 1. 
Treatment groups (n=12) were exposed to UCMS or control conditions for 6 weeks; fluoxetine (20mg/kg/day) or 
saline injections commenced on the 2nd week of UCMS. All treatments ceased at the end of 6th week when 
behavioural testing began, followed by animal cull 
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Table 4 Schedule of stressors used in the UCMS Experiment 1. 
The schedule was developed based on protocols by (Mutlu et al., 2012; Surget and Belzung, 2009) with 
modifications. Control group animals were housed in a separate holding room to avoid exposure to stressors. All 
mice were weighed and their coat state was assessed each week on Monday morning (9am) before any stress 
exposure was applied. Fluoxetine and saline i.p. injections were administered each day on weeks 3-6 at 9am to 










Week 1  Week 4 FLX/Saline injections – 9am 
each day before the stress exposure 
 
day 1 coat state, 
weighing 
 cage tilt 15-18.00 day 1 coat state, 
weighing 
 cage tilt 15-17.30 
day 2 cage swap 10.00-
12.30 






day 3 cage tilt 13-15.00 lights on night 
time 
day 3 cage tilt 11-14.00 white noise 16-17.00 
day 4 water in 
the cage 
14-14.30 white noise 16-18.00 day 4 air puff 10-12.30 lights on night 
time 
day 5 wet 
bedding 




day 6 white noise 11.-13.00 nothing  day 6  wet 
bedding 
12-12.30 no bedding 12.30-
15.00 
day 7 air puff 14-16.00 lights on night 
time 
day 7 white noise 15.00-
17.00 
lights on night 
time 
Week 2  Week 5 FLX/Saline injections – 9am 
each day before the stress exposure 
 
day 1 coat state, 
weighing 
 water in 
the cage 
11-11.30 day 1 coat state, 
weighing 
 cage tilt 16-19.00 




day 3 cage swap 10-13.00 no bedding 13-15.00 day 3 wet 
bedding 
11-12.00 no bedding 12-14.30 
day 4 cage tilt 14-17.00 lights on night 
time 
day 4 cage tilt 12-15.00 lights on night 
time 
day 5 wet 
bedding 
13-14.00 no bedding 14-15.30 day 5 no bedding 10-12.00 water in 
the cage 
12-12.30 
day 6 air puff 12-14.30 lights on night 
time 
day 6 white noise 12-14.00 nothing  
day 7 nothing  nothing  day 7 air puff 15-17.00 lights on night 
time 
Week 3 Start of FLX/Saline injections – 9am 
each day before the stress exposure 
 Week 6 FLX/Saline injections – 9am 
each day before the stress exposure 
 
day 1 coat state, 
weighing 
 no bedding 16-17.30 day 1 coat state, 
weighing 
 cage tilt 15-18.00 




day 3 cage tilt 11-14.00 lights on night 
time 
day 3 wet 
bedding 
11-13.30 no bedding 13.30-
15.00 
day 4 water in 
the cage 
11-11.30 cage tilt 14-17.00 day 4 cage tilt 11-14.00 air puff 15-16.30 
day 5 wet 
bedding 
13-15.00 no bedding 15-17.30 day 5 water in the 
cage 
10-10.30 no bedding 10.30-
13.30 
day 6 air puff 11-13.00 nothing  day 6 air puff 14-15.00 lights on night 
time 
day 7 white noise 16-18.30 lights on night 
time 
day 7 nothing  white noise 16-16.30 
  
Behavioural were assessed during the UCMS (coat state score, locomotor activity in the home 
cage) and after its termination (all other behavioural tests). Coat state was assessed once a 
week as indicated in Table 4. For the locomotor activity assessment on the last week of the 
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UCMS exposure 10 animals were video recorded in their home cages each night for the 6 last 
nights of UCMS. Groups were counterbalanced across nights to minimise possible variations 
depending on the day of the UCMS. At the end of the UCMS exposure mice were not disturbed 
for 1 day (rest day) before their behavioural testing began. The order of behavioural tests and 
number of animals tested each day is indicated in Table 5. Groups were counterbalanced 
between 2 days for each test and throughout each day to minimise batch effect and effect of 
the time of day when testing was performed. All animals were tested between 9am and 4pm. 
Daily behavioural testing schedules were analogous to those shown in Table 7 and Table 9. For 
the sucrose preference test, 4% solution was freshly prepared on the day of the test. The 
concentration was selected based on a pilot test with 4 animals, which all showed strong 
preference for this concentration of sucrose over water. 
Table 5 Schedule of behavioural tests in the UCMS Experiment 1. 
Animals were left undisturbed for 1 day after the end of the UCMS protocol (Rest day), after which testing battery of 
anxiety and depression-related behavioural tests was applied. Numbers on grey background signify mouse 
identification numbers tested on particular day. FST – forced swim test 
TESTING 
DAY 
DAY1 DAY2 DAY3 DAY4 DAY5 DAY6 DAY7 
Rest day 1-30 31-60           
Open field 
  




feeding   
  1-30 31-60     
  
Sucrose 
preference   




collection   
      1-30 31-60 
  
Forced 
swim test           
1-30 31-60 
 Results 
 UCMS did not affect body weight of mice, but coat state of UCMS-exposed 
mice deteriorated from week 4 
UCMS did not affect weekly rise of body weight in experimental groups as shown by 2-way 
ANOVA analysis (Effect of Time F (7, 371) = 227.8, p< 0.0001; Effect of Treatment group F (3, 
53) = 1.032, p = 0.3859; Interaction F (21, 371) = 2.870, p < 0.0001).  However, it was observed 
that in FLX groups, there was no weight gain over the first week of FLX injections (see Figure 
10A). The coat state of UCMS-treated groups was significantly worse than in control groups 
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from week 4 of the protocol (see Figure 10A). More specifically, there was a significant effect 
of treatment group on coat state on week 4 (Kruskal-Wallis H(4)) = 10.8 p = 0.0129), week 5 
(Kruskal-Wallis H(4)) = 10.01 p = 0.0185) and week 6 (Kruskal-Wallis H(4)) = 10.17 p = 0.0172). 
A slight increase in the coat deterioration score was also observed in control groups, 
potentially due to cage mate fighting. Interestingly, coat state was significantly different 
between CNTRL and CNTRL NO INJECT group on week 6 (Mann-Whitney U=39.5, p=0.029), 
suggesting an effect of i.p. injections. FLX did not affect coat state in control or UCMS exposed 



















































Figure 10 Weight and Coat state change in the UCMS Experiment 1 
Weight and Coat state change of 8 weeks old male BALB/c mice exposed to unpredictable chronic mild stress (UCMS) 
or control conditions (CNTRL) for 6 weeks and treated with fluoxetine 20mg/kg (FLX) or saline i.p. daily for 4 weeks, 
n=12/group (A) Body weight measured weekly during the UCMS (n=12/group, data represents mean±SEM) (B) Coat 
state scored weekly on the coat deterioration score (Nollet et al., 2013) (*p < 0.05 derived from post-hoc Dunn’s 
multiple comparisons between groups joined by brackets on the figure; #p< 0.05 derived from Mann-Whitney test 
between CNTRL and CNTRL NO INJECT groups on week 6). Data presented as Median and interquartile range  
 UCMS did not affect home cage locomotor activity during the dark phase 
Locomotor activity data from early, mid and late (early morning) phases of the dark phase was 
analysed using 2-way ANOVA (Figure 11A, B and C). Neither UCMS nor FLX treatments affected 
locomotion in the early dark phase (UCMSxFLX F (1, 30) = 0.06885, p = 0.7948; FLX F (1, 30) = 
0.1600, p = 0.6920; UCMS F (1, 30) = 0.3134, p = 0.5798), mid dark phase (UCMSxFLX F (1, 30) = 
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0.001231, p = 0.9722; FLX F (1, 30) = 1.266, p = 0.2694; UCMS F (1, 30) = 2.459, p = 0.1273) or 
late dark phase (UCMSxFLX F (1, 30) = 0.4507, p = 0.5071; FLX F (1, 30) = 0.04166, p = 0.8397; 
UCMS F (1, 30) = 0.3290, p = 0.5705).    
Comparison between CNTRL and CNTRL NO INJECT groups conducted by means of unpaired t-
test also showed no effect of injections in the early (F(18)=1.068, p=0.9444), mid- (F(18)=2.487, 
p=0.1783) or late dark phase (F(18)=1.402, p=0.6716). 
 
Figure 11 Locomotor activity during dark phase in the UCMS Experiment 1 
Locomotor activity during dark phase of adult male BALB/c mice exposed to unpredictable chronic mild stress 
(UCMS) or control conditions (CNTRL) for 6 weeks and treated with fluoxetine 20mg/kg (FLX) or saline (VEH) i.p. daily 
for 4 weeks, n=12/group (A) Distance moved in the home cage in the early dark phase (B) Distance moved in the 
home cage mid-dark phase (C) Distance moved in the home cage of mice late in the dark phase. Data represents 
mean±SEM  
 UCMS did not induce anhedonia, but UCMS-exposed mice displayed reduced 
anxiety 
Anxiety-like behaviour was measured in a novel anxiogenic open field test arena. Analysis of 
the locomotion in the novel environment data by 2-way ANOVA revealed main effect of 
interaction (UCMS x FLX F (1,40) = 8.1, p = 0.007), and of UCMS exposure (UCMS F (1,40) = 
4.44, p = 0.04; FLX F (1, 40) = 0.031, p = 0.862) (see Figure 12A). 2-way ANOVA of the time 
spent in the centre zone, the measure of anxiety in the open field, showed significant effect of 
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UCMS (UCMS F (1,41) = 7.44, p = 0.009; FLX F (1, 41) = 0.112, p = 0.739; UCMSxFLX F (1, 41) = 
1.472, p = 0.232) (Figure 12B). 2-way ANOVA of NSF and sucrose preference data showed that 
neither treatment exerted any effect on the anhedonia-like behaviours measured in these 
tests (see Figure 12C and D) (NSF UCMSxFLX F (1, 41) = 0.045, p = 0.833; FLX F (1, 41) = 0.126, p 
= 0.725; UCMS F (1, 41) = 0.002, p = 0.963; Sucrose preference UCMSxFLX F (1, 40) = 0.842, p = 
0.364; FLX F (1, 40) = 0.008, p = 0.931; UCMS F (1, 40) = 1.429, p = 0.239). Comparison between 
CNTRL and CNTRL NO INJECT done by means of unpaired t-test did not reveal any significant 
difference (OF Distance t(21) = 1.814, p = 0.084; OF Centre time t(21) = 1.4, p = 0.17; Sucrose 
preference t(21) = 0.711, p = 0.485; NSF t(21) = 0.25, p = 0.807) 
 
Figure 12 Anxiety and anhedonia-like behavioural measures in the UCMS Experiment 1 
Anxiety and anhedonia-like behavioural measures of adult male BALB/c mice exposed to unpredictable chronic mild 
stress (UCMS) or control conditions (CNTRL) for 6 weeks and treated with fluoxetine 20mg/kg (FLX) or saline (VEH) 
i.p. daily for 4 weeks, n=12/group. (A) Distance travelled in the open field arena as a measure of locomotor activity 
(B) Time spent in the centre zone of the open field arena used as a correlate of anxiety-like behaviour (C) Latency to 
begin eating the pellet in the novelty suppressed feeding trial (D) Preference for 4% sucrose over water measured 
over 48 hours as an indicator of the anhedonia – like behaviour.  Data represents mean±SEM, *p > 0.05, **p>0.005 
derived from post-hoc Bonferroni multiple comparisons between groups joined by brackets in the figures.  
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 UCMS did not induce behavioural despair parameters in the forced swim 
test 
Latency of first immobility and time spent immobile during the FST where analysed as 
parameters of behavioural despair using 2-way ANOVA (see Figure 13A). Latency of immobility 
was not affected by any of the treatments (UCMSxFLX F (1, 40) = 0.738, p = 0.395; FLX F (1, 40) 
= 0.476, p = 0.494; UCMS F (1, 40) = 0.543, p = 0.465). However FLX was a significant factor in 
the time of immobility FLX F(1,40) = 12.61, p = 0.001; UCMSxFLX F (1, 40) = 3.119, p = 0.085; 
UCMS F (1, 40) = 0.017, p = 0.896). Interestingly, the time spent immobile was reduced in the 
CNTRL injected group compared to the non-injected control group (Unpaired t-test t(21) = 
2.626, p = 0.017, suggesting a potential effect of repeated injections (see Figure 13B). This 
effect however was not apparent in the analysis of the latency of immobility data between the 
two groups (t(21)=0.425, p = 0.6756).  
 
Figure 13 Forced swim test (FST) parameters measured in the UCMS Experiment 1 
 Forced swim test (FST) parameters measured in the adult male BALB/c mice exposed to unpredictable chronic mild 
stress (UCMS) or control conditions (CNTRL) for 6 weeks and treated with fluoxetine 20mg/kg (FLX) or saline (VEH) 
i.p. daily for 4 weeks, n=12/group. (A) Latency of first immobility (B) Total time spent immobile during the FST trial 
time. Data represents mean±SEM, **p>0.005 derived from post-hoc Bonferroni multiple comparisons between 
groups joined by brackets on the figure; #p=0.017 derived from unpaired t-test between CNTRL and CNTRL NO 
INJECT groups 
 Discussion 
While multiple studies have shown that UCMS can reduce the rate of body weight gain in mice 
(Nollet et al., 2011; Surget, Wang, et al., 2008), no effect of body weight gain was observed in 
this study. This might be suggestive of an insufficient intensity of stressors. At the same time 
some studies show effective UCMS in the absence of weight change (Mutlu et al., 2012; 
Surget, Saxe, et al., 2008). A study by Schweizer et al (2009) showed that the effect of UCMS 
77 
 
on body weight can be substrain-dependant, as one substrain of C57BL6 mice showed a 
reduction of body weight gain upon UCMS while another substrain did not. It is therefore 
possible that the Balb/cAnNCrl substrain used in this study does not respond to chronic stress 
with a change in body weight gain, as it differs from the BALB/cByJ substrain frequently used in 
UCMS studies. While describing the UCMS protocol, Nollet and colleagues (2013) pointed out 
that due to a varied effect of UCMS on body weight its change should not be a primary 
measure of the success of the UCMS protocol. Moreover, Strekalova and coworkers (2011a) 
suggested that body weight differences between groups are not desirable, as they might 
trigger difference in liquid consumption and subsequently alter the results of sucrose 
preference test, which assesses anhedonic behaviour. Therefore, absence of body weight 
differences among groups might be a positive finding. However, during the first week of 
injections, body weight remained constant in FLX treated groups. The weight reducing effect of 
fluoxetine at similar doses has been described previously in rodents. For example, Kroeze et al. 
(2015) showed that treatment of adult Wistar rats with 12mg/kg FLX by gavage significantly 
reduced their body weight from day 4 of treatment. Aggarwal et al. (2016) showed that 
treatment of albino rats with 20mg/kg FLX for 2 weeks led to their weight reduction, while 
treatment with 40mg/kg led to animal death associated with gastrointestinal adverse effects. 
In mice appetite-suppressing effects of SSRI were attributed to their activation of 5HT2C and 
5HT1B receptors in the hypothalamus (Nonogaki et al., 2007). While this effect did not lead to 
significant weight differences in FLX-treated groups, it suggested that the dose of fluoxetine 
used in the next experiment should be reduced.  
Coat deterioration score monitoring across the weeks of UCMS showed that UCMS increased 
in coat state score albeit only from the 4th week of treatment, while many studies report 
significant increase already after 2 weeks of stress exposure (Law et al., 2016; Mutlu et al., 
2012). Additionally, the score reached by the UCMS groups was somewhat lower than those 
reported in previous studies, again suggesting there may have been an insufficient intensity of 
the stress protocol used. Importantly, on the last week of UCMS exposure coat score in the 
injected control group was also significantly higher than that of the non-injected controls, 
indicating a level of stress induced by i.p. injections. Additionally, some fighting and increased 
aggression were observed in some of the paired housed control mice, which could have 
provided an additional source of stress.  
Results of the open field test showed that UCMS and FLX treatment affect anxiety-related 
behaviours in BALB/c mice. UCMS-exposed group treatment with the antidepressant displayed 
signs of hyperactivity in the open field arena, as demonstrated by increased distance travelled 
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and time spent in the anxiogenic centre zone. While UCMS has been shown previously to 
increase locomotion of exposed animals in the novel arena (Mineur et al., 2006), the role of 
FLX in these effects remains a concern. The absence of anxiety-like behaviour in UCMS-
exposed groups could be attributed to the low lighting conditions of the testing room, which 
could have limited the anxiogenic effect of the testing conditions. 
Similarly, the effect of FLX on the CNTRL group in the forced swim test suggests that chosen 
dose of FLX exerted effects in CNTRL mice. Such an effect of FLX in FST has been shown 
previously to be dose-dependent (Doosti et al., 2013), therefore it became apparent that a 
reduction of the FLX dose should be considered for the next experiment. At the same time 
comparison between injected and non-injected control groups showed that daily exposure to 
i.p. injections decreased immobility time in the FST trial. It is important to note that FLX-
treated mice displayed level of immobility similar to that of the non-injected group, resembling 
rescuing effect of the FLX treatment albeit in an unexpected direction. Indeed, considering 
disagreements in the interpretation of the FST which exist in the current literature (Nestler and 
Hyman, 2010) the unexpected direction of this effect may not readily diminish the implication 
of these findings.   
Finally, the lack of changes in the NSF and sucrose preference tests suggested that UCMS 
protocol utilised was not optimal and/or sufficiently intense to result in depression-like 
behaviours. At the same time, it is possible that lack of phenotype in these tests was due to 
the limitations of the behavioural methodology, such a single-day exposure to sucrose might 
have not allowed the animals to habituate to the taste of sucrose and display group 
differences in its preference. 
 UCMS Experiment 2 
 Experimental design 
In the design of the UCMS Experiment 2 the findings of the UCMS experiment 1 were taken 
into account. As such, to avoid fighting in control group, control animals were singly housed in 
standard mouse cages. To intensify the effect of UCMS, a new stressor schedule included 4 
stressors per day instead of 2 as was done previously (seeTable 6). To minimise the 
predictability of the stressors, the duration of each stress exposure was increased across the 
weeks of UCMS, but to avoid habituation during later weeks the stressors overlapped in time. 
Confinement in a wire mesh cup was added to the list of stressors used. Finally, the length of 
UCMS exposure was extended to 8 weeks. However due to increased mortality in the UCMS 
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group during 7th week UCMS exposure was terminated at the end of that week (see Figure 14). 
Unexpected adverse effects were discussed with the named veterinary surgeon and 
communicated to the Home Office by the project licence holder. After the commencement of 
increase in mortality in experimental groups additional monitoring of mice was introduced. 
This included daily checks for any adverse signs of ill-health or discomfort such as reduced 
mobility, piloerection, laboured breathing, hunched posture, excessive vocalisation, lack of 
normal movement in the cage or signs of infection. However, the onset of health deterioration 
was rapid as mice found dead in the morning did not show any signs of health deterioration 
the previous evening, therefore it was not possible to apply intervention procedures or 
humane endpoints to relieve animal suffering. The UCMS exposure was terminated 
immediately after the 3rd death (25%) occurred in the UCMS group, however 3 more mice 
died during the next week. The carcasses were subjected to post-mortem examination for 
gross anatomical abnormalities, however none were found. Behavioural testing was delayed 
for 3 days to allow animals to recover from UCMS exposure. 
To avoid the side effects of fluoxetine in CNTRL mice, its dose was reduced from 20 to 10 
mg/kg, as this lower dose has also been shown to be effective in reversing the behavioural and 
neurobiological effects of UCMS (Santarelli, 2003a; Tanti et al., 2012). In addition, FLX 
treatment continued during behavioural testing to avoid possible withdrawal effects. 
Experimental groups were the same as in the UCMS Experiment 1 (CNTRL, CNTRL FLX, UCMS, 
UCMS FLX, N=12 per group) with the exclusion of NO INJECT group, as the data on the effect of 
injections was already collected in the UCMS Experiment 1. In addition to behavioural 
measures, in this experiment blood samples were collected to assess the response of the HPA 




Figure 14 Timeline of experimental procedures in the UCMS Experiment 2. 
(A) Male BALB/cAnNCrl mice (n=12/group) aged 7 weeks at the beginning of the experiment were subjected to 
UCMS or CNTRL conditions for 7 weeks; fluoxetine (FLX) or saline injections commenced on the 3rd week of UCMS 
and continued during behavioural testing until mice were culled for brain tissue collection (B) Animal death occurred 
more frequently in UCMS group (50% by the end of the UCMS exposure), while death rate was lower in UCMS FLX-





















Table 6 Schedule of stressors used for UCMS Experiment 2 
Male BALB/cAnNCrl mice (n=12/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 7 weeks; fluoxetine (FLX) or saline injections commenced on the 3rd week of UCMS and 
continued during behavioural testing until mice were culled for brain tissue collection. In this experiment number of 
stressors per day was increased to 4 and their longevity was incrementally increased across weeks to avoid 
habituation as recommended by Nollet et al. (2013). In addition, a confinement stressor was added to the protocol 
to increase its intensity, however its severity was lower than that described by Nollet et al. (2013) as it allowed free 
movement of mice inside the confinement space to avoid physical impact; “+” sign next to the time of the stressor 
indicates that this stressor continued after the commencement of the next one 
Wee
k 
Stressor 1 Time Stressor 2 Time Stressor 3 Time Stressor 4 Time 
Week 1  
1 cage swap 30min new bedding   light off 30h predator sounds 15min 
2 weight, coat state confinement 15min cage swap 1.5h light on/off 2h 
3 cage tilt 30min wet bedding 30min no bedding 30 min new bedding   
4 predator 
odor 
15 min light on/off 1h light on/off 1h light on/off 1h 
5 bath 15 min no bedding 1h predator 
sounds 
30 min cage tilt 2h 
6 light on/off 3h light on/off 3h light on/off 3h light on/off 3h 
7 light on/off 3h light on/off 3h light on/off 3h light on/off 3h 
Week 2  
1 cage swap 30min+ cage tilt 1h lights off 30min+ predator odor 30 min 
2 weight, coat state  no bedding in 
new cage 
1h confinement 15min+ bath 15min  
3 wet 
bedding 
30min+ cage tilt 2h no bedding 2h new bedding   
4 light off 2h light on 2h lights off 2h+ confinement 30min 
5 cage swap 1h+ wet bedding 2h+ no bedding 1h+ tilt+ new bedding 1h 
6 light on/off 3h light on/off 3h light on/off 3h light on/off 3h 
7 light on/off 3h light on/off 3h light on/off 3h light on/off 3h 
Week 3 Start of FLX 10 mg/kg or saline injections - 9am, daily 
1 wet 
bedding 




2 weight, coat state  no bedding in 
new cage 
2h bath  15min+ confinement 15min 
3 light off 3h light on 2h lights off 3h +  predator odor 30 min 
4 cage swap 2h+ cage tilt 2h+ swap back   predator sounds o/n 
5 wet 
bedding 
2h+ confinement 30min no bedding 3h new bedding  o/n 
6 light on/off 3h light on/off 3h light on/off 3h light on/off 5h 
7 light on/off 3h light on/off 3h light off 3h+ light on/off 1h 
Week 4 FLX 10 mg/kg or saline injections - 9am, daily 
1 cage swap 2h+ wet bedding 3h no bedding 2h new bedding o/n 
2 weight, coat state  no bed  1h+ tilt 3h new bedding o/n 
3 light off 3h+ predator 
odor 
1h+ confinement 30min  light on/off 3h 
4 no bedding, 
new cage 
1h+ bath 2cm 30min  no bed  2h+ predator sounds 30min 
5 cage swap 2h tilt 2h return to flat 
cage 
1h tilt 2h 
6 light on/off 3h light on/off 3h light on/off 3h light on/off 5h 
7 light on/off 3h light on/off 3h lights off 3h light on/off 5h 
Week 5 FLX 10 mg/kg or saline injections - 9am, daily 





Stressor 1 Time Stressor 2 Time Stressor 3 Time Stressor 4 Time 
2 weight, coat state  no bedding in 
new cage 
3h confinement 30min+ bath 30min 
3 wet 
bedding 
3h+ cage tilt 3h no bedding 3h new bedding   
4 light off 3h light on 3h lights off 3h+ confinement 30min 
5 cage swap 2h+ wet bedding 2h+ no bedding 2h+ tilt 2h 
6 light on/off 3h light on/off 3h light on/off 30 min light on/off 5h 
7 light on/off 3h light on/off 3h light on/off 3h light on/off 5h 
Week 6 FLX 10 mg/kg or saline injections - 9am, daily 
1 wet 
bedding 
2h+ cage swap 3h+ cage tilt 3h return to empty 
cage 
3h 
2 weight, coat state  no bedding in 
new cage 
2h bath  30min+ confinement 30min 
3 light off 3h light on 2h lights off 3h +  predator odor 30 min 
4 cage swap 2h+ cage tilt 2h+ swap back   predator sounds night 
5 wet 
bedding 
2h+ confinement 30min no bedding 3h new bedding   
6 light on/off 3h light on/off 3h light on/off 3h light on/off 5h 
7 light on/off 3h light on/off 3h light off 3h+ light on/off 1h 
Week 7 FLX 10 mg/kg or saline injections - 9am, daily 
1 cage swap 2h+ wet bedding 4h no bedding 3h new bedding o/n 
2 weight, coat state no bedding 2h+ tilt 4h new bedding 0/n 
3 light off 3h+ predator 
odor 
1 h+ confinement 1hr  light on/off 3h 
4 no bedding, 
new cage 
3h+ bath 2cm 30min  no bed  3h+ predator sounds 30min 
5 cage swap 3h cage tilt 2h return 1h cage tilt 2h 
6 light on/off 3h light on/off 3h light on/off 3h light on/off 3h 
7 light on/off 3h light on/off 3h lights off 3h light on/off 3h 
Coat state was assessed once a week as indicated in Table 6. At the end of the UCMS 
procedure mice were left undisturbed for 1 day (rest day) before their behavioural testing 
began. The order of behavioural tests and number of animals tested each day is indicated in 
Table 7. All animals were tested in the light phase between 9am and 5.12pm according to the 
schedule indicated in. Groups were counterbalanced throughout each day to minimise effect 







Table 7 Schedule of behavioural testing in the UCMS Experiment 2.  
Male BALB/cAnNCrl mice (n=12/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 7 weeks and subsequently subjected to a series of behavioural tests in the following order: 
open field, sucrose preference (continuous 3-day measurement), splash test, novelty-suppressed feeding (NSF), 
























09:40 09:40 10:38 10:08 10:38 
2 UCMS 09:12 09:50 09:50 10:46 10:16 10:46 
3 CNTRL FLX 09:24 10:00 10:00 10:54 10:24 10:54 
4 UCMS FLX 09:36 10:10 10:10 11:02 10:32 11:02 
5 CNTRL 09:48 10:20 10:20 11:10 10:40 11:10 
6 UCMS 10:00 10:30 10:30 11:18 10:48 11:18 
7 CNTRL FLX 10:12 10:40 10:40 11:26 10:56 11:26 
8 UCMS FLX 10:24 10:50 10:50 11:34 11:04 11:34 
9 CNTRL 10:36 11:00 11:00 11:42 11:12 11:42 
10 UCMS 10:48 11:10 11:10 11:50 11:20 11:50 
11 CNTRL FLX 11:00 11:20 11:20 11:58 11:28 11:58 
12 UCMS FLX 11:12 11:30 11:30 12:06 11:36 12:06 
13 CNTRL 11:24 11:40 11:40 12:14 11:44 12:14 
14 UCMS 11:36 11:50 11:50 12:22 11:52 12:22 
15 CNTRL FLX 11:48 12:00 12:00 12:30 12:00 12:30 
16 UCMS FLX 12:00 12:10 12:10 12:38 12:08 12:38 
17 CNTRL 12:12 12:20 12:20 12:46 12:16 12:46 
18 UCMS 12:24 12:30 12:30 12:54 12:24 12:54 
19 CNTRL FLX 12:36 12:40 12:40 13:02 12:32 13:02 
20 UCMS FLX 12:48 12:50 12:50 13:10 12:40 13:10 
21 CNTRL 13:00 13:00 13:00 13:18 12:48 13:18 
22 UCMS 13:50 13:50 13:50 14:20 13:50 14:20 
23 CNTRL FLX 14:00 14:00 14:00 14:28 13:58 14:28 
24 UCMS FLX 14:12 14:10 14:10 14:36 14:06 14:36 
25 CNTRL 14:24 14:20 14:20 14:44 14:14 14:44 
26 CNTRL FLX 14:36 14:30 14:30 14:52 14:22 14:52 
27 UCMS FLX 14:48 14:40 14:40 15:00 14:30 15:00 
28 CNTRL 15:00 14:50 14:50 15:08 14:38 15:08 
29 CNTRL FLX 15:12 15:00 15:00 15:16 14:46 15:16 
30 UCMS FLX 15:24 15:10 15:10 15:24 14:54 15:24 
32 CNTRL 15:36 15:20 15:20 15:32 15:02 15:32 
33 CNTRL FLX 15:48 15:30 15:30 15:40 15:10 15:40 
34 UCMS FLX 16:00 15:40 15:40 15:48 15:18 15:48 
35 CNTRL 16:12 15:50 15:50 15:56 15:26 15:56 
36 CNTRL FLX 16:24 16:00 16:00 16:04 15:34 16:04 
37 CNTRL 16:36 16:10 16:10 16:12 15:42 16:12 
38 CNTRL FLX 16:48 16:20 16:20 16:20 15:50 16:20 
39 CNTRL 17:00 16:30 16:30 16:28 15:58 16:28 
 
 Results 
 Coat state of UCMS-exposed mice deteriorated from week 2, with no effect 
of FLX treatment 
UCMS significantly affected coat state of the exposed mice from week 2 of the protocol; 
however FLX treatment did not reverse this effect (Kruskal-Wallis H(4))= 30.66 (week 2), 25.37 
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(week 3), 27.52 (week 4) 28.27 (week 5), 24.98 (week 6), 22.36 (week 7), p<0.0001 for each 
week) (see Figure 15C). 2-way repeated measures ANOVA showed that body weight of animals 
was not affected by UCMS exposure or FLX treatment (Effect of Interaction F (21, 340) = 0.184, 
p>0.999; Time F (7, 340) = 27.24, p<0.0001; Treatment F (3, 340) = 0.054, p = 0.984) (Figure 
15A). 
 
Figure 15 Body weight change and coat state in UCMS Experiment 2 
Male BALB/cAnNCrl mice (n=12/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 7 weeks; fluoxetine (FLX) or saline (VEH) injections commenced on the 3rd week of UCMS and 
continued during behavioural testing until mice were culled for brain tissue collection (A) Weekly body weight 
measurements of experimental groups, data represents mean±SEM (B) representative photographs of coat state of 
CNTRL (top panel) and UCMS (bottom panel) mice (C) Coat deterioration score was measured every week 
throughout the UCMS exposure, **p<0.01,***p<0.001 derived from post-hoc Dunn’s multiple comparisons within 




 UCMS induced hyperactivity in the open field test, while FLX affected 
grooming of CNTRL 
In addition to the coat state measure, grooming behaviour was assessed in the splash test 
according to the protocol by Nollet et al. (2013). 2-way ANOVA showed that neither UCMS nor 
FXL were significant factors (FLX F (1, 36) = 2.285, p = 0.139; UCMS F (1, 36) = 0.398, p = 0.532, 
however the interaction between these two factors on duration of grooming was close to 
reaching statistical significance (UCMSxFLX F (1, 36) = 3.075, p = 0.088). 2-way ANOVA analysis 
of another outcome measure of the splash test, latency to first grooming, showed that FLX 
significantly affected latency to groom (FLX F (1, 35) = 5.856, p = 0.02; UCMS F (1, 35) = 2.664, 
p = 0.112; UCMSxFLX F (1, 35) = 1.474, p = 0.233) (see Figure 16A and B).  
2-way ANOVA analysis of the open field test showed that UCMS was a significant factor 
affecting locomotor activity in the novel environment (UCMS factor F (1, 36) = 25.78, 
p<0.0001; FLX F (1, 36) = 0.077, p = 0.783; UCMSxFLX F (1, 36) = 2.515, p = 0.122). Similarly, the 
time spent in the central zone was affected by UCMS (Effect of UCMS F (1, 34) = 5.025, 





































































































Figure 16 Grooming behaviour in the splash test and locomotion and anxiety measures in the open field test 
Male BALB/cAnNCrl mice (n=12/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 7 weeks; fluoxetine (FLX) or saline (VEH) injections commenced on the 3rd week of UCMS and 
continued during behavioural testing until mice were culled for brain tissue collection (A) Time mice spent grooming 
during  (B) Latency to begin grooming in the splash test trial (C) Distance moved around the arena in the open field 
test (D) Time mice spent in the anxiogenic centre zone of the open field arena. Data represents mean±SEM,  *p<0.05 
**p<0.005 derived from post-hoc Bonferroni multiple comparisons between groups joined by bracket lines 
 UCMS did not induce anhedonia or behavioural despair 
In NSF, 2-way ANOVA showed that UCMS exposure was a significant factor affecting the 
latency to start eating the pellet (UCMS factor F (1, 36) = 6.807, p = 0.013; FLX F (1, 36) = 3.237, 
p = 0.08; UCMSxFLX F (1, 36) = 1.505, p=0.228) (see Figure 17A). For sucrose preference test, 
mice were exposed to a choice of 4% sucrose solution or water continuosly for 3 consecutive 
days and measurements were taken every 24 hours. In all groups mice showed preference 
after 48 hours (2nd day) of exposure. While on day 3 more variability emerged among groups, 
repeated measures 2-way ANOVA showed no effect of treatment (Time F (2, 68) = 120.2, p < 
0.0001; Treatment F (3, 34) = 0.952, p = 0.426; Interaction F (6, 68) = 0.72, p = 0.635) (see 
Figure 17B). In the FST 2-way ANOVA showed no effect of treatment factors on the time mice 
spent immobile (UCMSxFLX F (1, 36) = 0.003, p = 0.96; FLX F (1, 36) = 0.043, p = 0.837; UCMS F 
(1, 36) = 0.059, p = 0.81) or on latency to first immobility (UCMSxFLX F (1, 36) = 0.882, p = 
0.354; FLX F (1, 36) = 0.5, p = 0.485; UCMS F (1, 36) = 0.039, p = 0.845). In addition, time spent 
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swimming was scored in this test, however no treatment effect was detected (UCMSxFLX F (1, 
36) = 0.042, p = 0.84; FLX F (1, 36) = 0.041, p = 0.841; UCMS F (1, 36) = 1.303, p = 0.261)  (see 
Figure 17 C, D and E).   
 
Figure 17 Anhedonia and behavioural despair in NSF, sucrose preference test and FST 
Male BALB/cAnNCrl mice (n=12/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 7 weeks; fluoxetine (FLX) or saline (VEH) injections commenced on the 3rd week of UCMS and 
continued during behavioural testing until mice were culled for brain tissue collection (A) Latency to approach and 
start eating the pellet in the novelty suppressed feeding  (NSF) test; (B) Sucrose preference over 24 hours measured 
for 3 continuous days; (C) Time mice spent immobile in the forced swimming test (FST) (D) Latency to first immobility 
in the FST;  (E) Time mice spent swimming during the FST trial. Data represents mean±SEM, *p<0.05 derived from 
post-hoc Bonferroni multiple comparisons 
 UCMS suppressed corticosterone response to acute stress but did not affect 
cytokine levels 
In this experiment plasma was collected by incision method from the lateral tail vein (Sadler 
and Bailey, 2013) to gain insight into neurobiological changes accompanying behavioural 
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effects of UCMS. To investigate the state of the HPA axis regulation, corticosterone (CORT) 
levels were measured 24 before the FST (PRE-FST) and 30 min after FST (POST-FST) to assess 
the HPA axis response to acute swim stress. Repeated measures 2-way ANOVA showed that 
both timepoint of collection (FST factor) and treatment group factor significantly affected 
CORT levels (Effect of Treatment X FST F(3, 32) = 15.69, Effect of FST F(1, 32) = 87.23, Effect of 
Treatment F(3, 32) = 12.84, p<0.001 for all effects)  (see Figure 18A).  
 
Figure 18 Plasma Corticosterone and cytokine levels in UCMS Experiment 2 
Male BALB/cAnNCrl mice (n=12/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 7 weeks; fluoxetine (FLX) or saline (VEH) injections commenced on the 3rd week of UCMS and 
continued during behavioural testing until mice were culled for brain tissue collection (A) PRE-FST plasma 
Corticosterone (CORT) levels were measured 24 hours before FST (PRE-FST) and 30 min after FST (POST-FST) to 
detect swimming stress-induced CORT (B and C) 10 cytokines were measured in the PRE-FST plasma to detect effect 
of treatment on the immune system. Among those only IL-2 and IL-12 shown were above detectable levels in 6 or 
more animals per group. Data represents mean±SEM, *p<0.05, **p<0.01, ***p<0.001 derived from post-hoc 
Bonferroni multiple comparisons between PRE-FST and POST-FST data points for each group 
To assess the effect of UCMS on the immune system, plasma levels of 10 cytokines were 
measured in peripheral blood in the PRE-FST samples collected 24 hours before the FST trial 
using the Luminex multiplex custom-designed assay (for details of the assay see section 3.6 of 
Methods on p67). Most cytokines (IL-6, TNFα, IL-1β, IL-4, IL-5, IL-10, GM-CSF, IFNγ) were not 
detectable, as most probably levels fell below the detection threshold of the assay (see Table 
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3). 2-way ANOVA of the levels of 2 cytokines (IL-2, IL-12), which were detectable in most 
samples (6 or more per group), showed that their levels were not affected by UCMS or FLX 
exposure (IL-2 UCMSxFLX F (1, 32) = 2.272, p = 0.142; FLX F (1, 32) = 2.309, p = 0.139; UCMS F 
(1, 32) = 2.413, p = 0.13; IL12 UCMSxFLX F (1, 24) = 0.005, p = 0.942; FLX F (1, 24) = 1.233, p = 
0.278; UCMS F (1, 24) = 0.099, p = 0.756) (see Figure 18B and C). 
 Discussion 
In this experiment, a modified version of UCMS Experiment 1 protocol, as well as modified 
conditions for control mice were used to optimise the model, increase the chance of detecting 
depression-like behaviours, and to look at the HPA axis and immune system response to 
UCMS. Single housing of control animals indeed ensured that coat deterioration score 
remained stable and low in control groups, while UCMS significantly increased coat state score 
from week 2 of stress exposure in line with previous studies (Surget et al. 2008). Yet FLX (10 
mg/kg) treatment failed to improve coat state in UCMS-exposed animals, although this has 
been shown to be effective in this model previously (Santarelli, 2003a). However, when 
grooming behaviour was assessed in the splash test, fluoxetine appeared to have a positive 
effect on grooming in the CNTRL group by prolonging the time animals spend grooming in a 
novel cage. It is possible to argue that anxiety also plays a role in this test as animals are faced 
with a choice of reacting to a change in environment (novel cage, testing room and researcher 
exposure) or engaging in self-grooming behaviour. Indeed Spruijt et al. (1992) argued that self-
grooming reflects the process of de-arousal due to termination of exposure, or habituation, to 
a stressful environment. The fact that FLX was improving grooming in controls might suggest 
that control animals experienced a level of anxiety or stress perhaps due to the social isolation 
as a result of single housing, and fluoxetine was able to reverse its detrimental effect. The 
ineffectiveness of FLX in the UCMS group could be explained by the fact that the level of stress 
experienced by UCMS group was beyond the therapeutic potential of the lower FLX dose used 
in this experiment. Indeed, loss of 50% of animals during last weeks of UCMS suggested that 
the UCMS protocol employed in this experiment was too severe. Interestingly FLX seemed to 
be protective of the fatal outcome (see Figure 15C).  
UCMS-exposed groups displayed a significant hyperlocomotion in the open field arena. 
Hyperlocomotion following UCMS has been described previously in BALB/c strain. Dournes et 
al. (2013) showed that the same dose of FLX (10mg/kg) was not able to reverse this effect, 
even though FLX was effective in restoring coat state in these animals. In a study by Couch et 
al. (2013) of male C57BL/6J mice exposed to 10 days of chronic stress which involved intruder 
exposure, restraint and tail suspension, increased locomotion was described as a behavioural 
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response specific to stress-susceptible animals, as determined by their loss of sucrose 
preference after the stress. At the same time, both stress susceptible and stress resilient 
groups in this study displayed anxiety-like behaviour in the light-dark box test. In a more recent 
study by this group the same stress paradigm induced increased amount of time animals spent 
in the open arms of the O-maze (Couch et al., 2016). This behavioural change was interpreted 
as a sign of impulsivity corresponding to the depression-like phenotype, and was not 
accompanied by a change in the locomotion measured in a novel cage. In another study (Ito et 
al., 2010), chronic restraint stress induced hyperlocomotion, which was linked to enhanced 
short-term and long-term synaptic plasticity in the anterior cingulate cortex possibly caused by 
reduced GABAergic inhibition observed in this study. However, glutamate signalling has also 
been shown to be involved in hyperlocomotion. As such, novelty-induced hyperlocomotion 
was described in glutamate AMPA receptor Glu1A subunit knockout mice along with 
depressive-like behaviour (Procaccini et al., 2011). This subunit is mostly expressed in the 
hippocampus, and behavioural changes in this model were attributed to excessive neuronal 
activation in the hippocampus in response to novelty, as measured by c-Fos expression. 
Interestingly, treatment with SSRI escitalopram did not reverse these effects. Ineffectiveness 
of SSRI antidepressants confirms the fact that stress-induced hyperactivity is not related to 
changes in serotonergic signalling. Indeed, Logan et al. (2015) showed that following UCMS 
exposure, hyperactivity during the light cycle was accompanied by hypoactivity detected 
during the active dark phase. Therefore, it is possible that the hyperactivity observed during 
testing was not present during the night. The absence of night time activity measure is a 
limitation of the UCMS Experiment 2 study. Moreover, it has been shown that the UCMS-
induced phenotype varies depending on the diurnal phase of its application, as has been 
demonstrated by Aslani et al. (2014). Many studies employing UCMS reverse light-dark cycle in 
the animal facility and hence apply the stressors during dark phase. For example, Mineur et al. 
(2006) showed an increase in locomotor activity in the open field test in C57BL/6J, BALB/cJ and 
DBA/2J mice exposed to UCMS in the dark phase, which was significant in female but not male 
mice. Yalcin et al. (2008) reported no change in locomotor activity in 8 mouse strains (including 
BALB/cByJ) exposed to UCMS during the dark phase. Thus it is possible that some of the 
behavioural effects which differed in this study from those commonly described in the 
literature derive from the fact that the stressors in these experiments were applied during the 
light phase. In fact, the absence of diurnal cycle reversal in our experiments might play a 
crucial role in occurrence of hyperactivity. Unfortunately, conditions in the animal facility 
where our experiments were conducted did not allow to effectively reverse the light/dark 
cycle due to technical issues with the lighting setup. 
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Similarly, UCMS reduced the latency to eat in NSF, a test of anhedonia influenced by changes 
in anxiety, indicating a state of a paradoxical reduced anxiety (or “anomalous anxiolysis”) in 
the mice. While this effect could be confounded by hyperactivity in the novel brightly-lit arena 
of the test, importantly FLX blocked this effect by increasing the latency in UCMS FLX group to 
control levels. As open field data showed that FLX was not capable of reducing hyperactivity, it 
is possible to argue that this effect was not in fact due to hyperactivity, but some other 
behavioural phenomenon, such as increased impulsivity or indeed increased appetite or drive 
towards food reward in UCMS-exposed animals. Activity measure in the NSF could have helped 
to distinguish these effects. However, the sucrose preference test results oppose the food 
reward behaviour change hypothesis, as stressed animals displayed control levels of 
preference for sucrose. On the other hand, the high level of sucrose concentration used in this 
study (4%), utilised to avoid low BALB/c strain preference for sucrose (Ducottet and Belzung, 
2005), might have produced a ceiling effect, so that all animals preferred it after initial 24 
hours of habituation.  
No change in the immobility time was observed in FST. Assuming FST also provided an 
exposure to novelty, it would be expected to see hyperactivity in this test as well, which would 
make mice less likely to appear immobile. While some studies report increased immobility 
after UCMS protocol in mice (Lu et al., 2014), Nollet et al. (2013) did not recommend it as a 
suitable behavioural outcome measure in a recent UCMS protocol review, and it does not 
appear in many recent UCMS studies. Therefore, current literature suggests that behavioural 
despair might not be a part of UCMS-induced behavioural phenotype. 
CORT was measured pre and post FST as forced swimming as an acute stressor is known to 
induce plasma corticosterone release (Anisman et al., 2001). Previous studies have shown that 
chronic stress modifies HPA axis regulation by increasing the baseline level of plasma CORT in 
BALB/c mice (Vega-Rivera et al. 2016) and increasing the CORT response to acute stress, which 
reflects increased reactivity and potentially impairment of negative feedback inhibition of the 
CORT release. Yet this effect is not universal – Ibarguen-Vargas et al. (2008) demonstrated that 
among 7 mouse strains only two including BALB/cByJ responded to UCMS with CORT increase, 
while 3 strains showed no change in CORT levels and two showed a decrease (C57BL/6J, 
DBA/2J). In this experiment baseline levels of CORT were similar to those reported for BALB/c 
strain in previous studies (Kubera et al., 2013; Law et al., 2016) and were not affected by 
UCMS. However, exposure to acute swim stress revealed modulation of HPA reactivity by 
chronic stress and FLX. As such, UCMS blocked corticosterone elevation following FST, while 
FLX treatment restored this effect in UCMS-exposed mice, even though the magnitude of CORT 
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elevation was smaller than in FLX-treated CNTRL group. At the same time, it appeared that FLX 
stimulated CORT release in controls, as elevation of CORT post-FST in CNTRL FLX group was 
higher and more significant than in CNTRL group. If to allow a possibility that control animals 
also experienced some level of stress, such modulation of CORT levels by FLX could be seen as 
a therapeutic effect of FLX restoring HPA axis reactivity to normal levels. Response of controls 
is then contrasted by UCMS-treated animals’ reduced level of HPA reactivity and a much 
smaller albeit significant response to FLX. In fact, published literature provides some evidence 
of a modification of FLX effect based on the state of HPA axis regulation. As such, a previous 
study by Khemissi et al. (2014b) divided mice into groups based on the level of HPA axis 
negative feedback measured by dexamethasone (DEX) suppression tests. The authors went on 
to show that animals with low negative feedback inhibition also had low levels of basal CORT 
during UCMS, and in contrast to high DEX suppressors, did not respond to FLX treatment 
during UCMS, especially in the NSF test. Such differences in response resembles the difference 
seen between the control and stressed groups in this study. It is interesting to speculate if 
UCMS exposure impaired the HPA axis regulatory mechanism so that the mice acquired 
features of low DEX suppressors, while limited amount of stress experienced by controls 
remained highly sensitive to antidepressant effect. 
Previous studies have shown that UCMS affects immune system function. Studies on rats 
exposed to UCMS showed increased serum complement (Ayensu et al., 1995) and 
proinflammatory cytokine levels (Lu et al. 2016). The latter study also showed increased IL-6, 
TNFα and IL-1β expression and protein levels in the hippocampus and prefrontal cortex. 
Kubera et al. (1998) showed that splenocytes extracted from stressed C57/BL6 mice responded 
to in vitro LPS stimulation with a strong increase in IL-1 secretion and a significant decrease in 
IL-2 secretion. In vivo Xue et al. (2015) showed increased IL-6, IL-1β, TNFα and NLRP3 in the 
hippocampus of male ICR mice. Moreover, in these studies chronic treatment with fluoxetine 
(10 mg/kg) reduced proinflammatory cytokines to control levels. Therefore, we assessed the 
plasma level of 10 most commonly studied pro- and anti-inflammatory cytokines to see if 
UCMS induced immune system changes in this experiment. However, the assay utilised did not 
detect the majority of the cytokines, and the ones above detection levels were not modulated 
by UCMS or FLX. It is possible that the Luminex assay used was not sensitive enough to detect 
subtle changes induced by UCMS. Indeed, Lu and colleagues (2016), reported very small 
increases (15-20 pg/ml) in the proinflammatory cytokines. It is also important to note that 
plasma levels of cytokines might not be representative of cytokine levels in the brain, 
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therefore our findings do not exclude the possibility that UCMS affected immune parameters 
in relevant brain areas, such as the hippocampus or prefrontal cortex. 
To summarise, the UCMS Experiment 2 showed that several experimental design factors need 
to be optimised to achieve a better outcome. First, single-housing of CNTRL group did avoid 
cage mate fighting and preserved coat state of mice, but also exposed them to social isolation, 
which can have detrimental effect on HPA axis and induce anxiety-like behaviour. Indeed, FLX 
improved behaviour of CNTRL mice in the splash and open field tests, which suggests that 
these mice were detrimentally affected during the experiment. Another possible source of 
stress could have been repeated injections. Next, the UCMS protocol might have been of 
excessive intensity, as fatality was higher in UCMS group, and FLX did not reverse any of the 
behavioural changes induced by UCMS. Third, hyperactivity potentially confounded the results 
of many behavioural tests, thus measures are needed to be taken to avoid its development or 
to access behaviours in activity-independent tests. Therefore, further optimisation of the 
control, UCMS and testing protocols was required. 
 UCMS Experiment 3 
 Experimental design 
The UCMS Experiment 3 was designed to address issues which arose in the previous study. To 
improve CNTRL conditions, mice in the control group were pair-housed with their siblings in 
large cages (59.5x38x20cm) to avoid social isolation and minimise home cage aggression. As 
data from the UCMS Experiment 1 showed that daily i.p. injections induce coat state 
deterioration and affect mouse behaviour in the forced swim test, it was decided not to 
expose animals to daily injections in this experiment to avoid interference with UCMS-induced 
phenotype.  Indeed, it has been shown previously that i.p. injections increase CORT levels in 
BALB/c mice and can interfere with psychological stress studies by affecting stress response of 
control groups (Drude et al., 2011). Therefore FLX treatment was not included in this 
experiment, which was solely focused on the effect of UCMS. The UCMS group was exposed to 
4 daily stressors as indicated in the protocol in Figure 19. The stressors were introduced in a 
random-like order which was repeated every week; however, the longevity of stressors varied 
from 30 min on week 1 to 4 hours towards the end of the UCMS protocol to avoid habituation. 
Overlap of the stressors was not included to avoid mortality seen in UCMS Experiment 2. 
Removal of i.p. injections in UCMS-exposed groups was also aimed to reduce stress exposure 
in these mice. 
94 
 
Significant changes were made to the way sucrose preference measurement was done in this 
experiment. Unlike in previous experiments, it was measured repeatedly once every two 
weeks. Animals were constantly housed with 2 bottles of water and food on both sides to 
avoid development of any side preference. According to recommendations by Strekalova et al. 
(2011b), before the first test of sucrose preference, mice were exposed to a single bottle with 
2.5% sucrose for 4 hours to habituate them to the taste of sucrose. For the actual test, 1% 
solution was used for weeks 0 and 2, and 2% for weeks 4 and 6. An increase of concentration 
was related to a loss of preference in the CNTRL group observed on week 2 and the data from 
the Strekalova et al. (2011b) study, which showed that mice habituate to the concentration of 
sucrose and in order to continue measuring sucrose preference, a change of concentration is 
required. Sucrose preference was measured across two consecutive nights but not during the 
days to capture the most active drinking phase, and sides of the sucrose and water bottles 
were switched between each night test. The average preference during the two nights was 
used for statistical analysis.  
To test if the development of hyperlocomotion was related to the longevity of stress, an open 
field test was performed after first 3 weeks of stress. In the final behavioural battery light-dark 
box test was included, as behaviour in this test is less likely to be affected by hyperactivity as it 
is a small arena. To assess aggressive behaviours social interaction test was added to the 
behavioural battery. As sense of smell plays an important role in social interaction as well as in 
appetitive behaviours, buried cookie test also was added to assess olfaction. In addition, leptin 
was added to the list of analytes in the Luminex assay to gain further insight into the appetite 
control of UCMS exposed mice. Blood collected from cardiac puncture before cull was added 
to ensure sufficient plasma volume for all measurements. Timeline of experimental procedures 






Figure 19 Timeline of experimental procedures in the UCMS Experiment 3. 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks, during which weight, coat state and sucrose preference were monitored weekly. After 
6 weeks of UCMS exposure mice were subjected to behavioural testing battery, at the end of which blood was 
collected and mice were culled for brain tissue collection. 
 
Table 8 Schedule of stressors used in the UCMS Experiment 3 
The schedule was repeated every week for 6 consecutive weeks. Male BALB/cAnNCrl mice (n=10/group) aged 7 
weeks at the beginning of the experiment were subjected to UCMS or CNTRL conditions for 6 weeks, during which 
weight, coat state and sucrose preference were monitored weekly. After 6 weeks of UCMS exposure mice were 
subjected to behavioural testing battery, at the end of which blood was collected and mice were culled for brain 
tissue collection 
Coat state was assessed once a week as indicated in Table 8. At the end of the UCMS 
procedure mice were left undisturbed for 1 day (rest day) before their behavioural testing 
began. The schedule of behavioural testing is shown in Table 9.  
Day Stressor 1 Duration Stressor 2 Duration Stressor 3 Duration Stressor 4 Duration 










Tue cage tilt 2h  
wet 
bedding 








2h confinement 2h 




















n/a  confinement 2 hr no sizzle nest 1h 
Sat light on/off 4h light on/off 4h light on/off 4h light on/off 4h 
Sun light on/off 4h light on/off 4h light on/off 4h light on/off 4h 
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Experiment 3 was conducted in parallel with Experiment 4 which followed an identical 
protocol, however was terminated after 4 weeks for fresh frozen brain tissue collection which 
was used to study effects of UCMS on gene expression, described in Chapter 4. 
Table 9 Schedule of behavioural testing in the UCMS Experiment 3.  
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks, during which weight, coat state and sucrose preference were monitored weekly. After 
6 weeks of UCMS exposure mice were subjected to behavioural testing battery which included open field test, splash 
test, novelty suppressed feeding (NSF), light-dark box (LD box), cookie test and forced swim test (FST) which included 



























8:58 13:12 14:00 10:14 9:30 14:20 13:50 14:20 
2 UCMS 
 
9:10 13:24 14:07 10:21 9:45 14:28 13:58 14:28 
3 CNTRL 
 
9:22 13:46 14:14 10:28 10:00 14:36 14:06 14:36 
4 UCMS 
 
9:34 13:58 14:21 10:35 10:15 14:44 14:14 14:44 
5 CNTRL 
 
9:46 14:10 14:28 10:42 10:30 14:52 14:22 14:52 
6 UCMS 
 
9:58 14:22 14:35 10:49 10:45 15:00 14:30 15:00 
7 CNTRL 
 
10:10 14:34 14:42 10:56 11:00 15:08 14:38 15:08 
8 UCMS 
 
10:22 14:46 14:49 11:03 11:15 15:16 14:46 15:16 
9 CNTRL 
 
10:34 14:58 14:56 11:10 11:30 15:24 14:54 15:24 
10 UCMS 
 
10:46 15:10 15:10 11:17 11:45 15:32 15:02 15:32 
11 CNTRL 
 
10:58 15:22 15:17 11:24 12:00 15:40 15:10 15:40 
12 UCMS 
 
11:10 15:34 15:24 11:31 12:15 15:48 15:18 15:48 
13 CNTRL 
 
11:22 15:46 15:31 11:38 12:30 15:56 15:26 15:56 
14 UCMS 
 
11:34 15:58 15:38 11:45 12:45 16:04 15:34 16:04 
15 CNTRL 
 
11:46 16:10 15:45 11:52 13:00 16:12 15:42 16:12 
16 UCMS 
 
11:58 16:22 15:52 11:59 13:15 16:20 15:50 16:20 
17 CNTRL 
 
12:10 16:34 15:59 12:06 13:30 16:28 15:58 16:28 
18 UCMS 
 
12:22 16:46 16:06 12:13 13:45 16:36 16:06 16:36 
19 CNTRL 
 
12:34 16:58 16:13 12:20 14:00 16:44 16:14 16:44 
20 UCMS  12:46 17:10 16:20 12:27 14:15 16:56 16:22 16:52 
 Results 
 UCMS impaired coat state and grooming behaviour in exposed mice 
UCMS induced a strong change in the coat state of the mice with significant deterioration 
detectable from week 4 of stress exposure (Mann-Whitney for week 0 U = 40 p = 0.65, for 
week 1 U = 26 p = 0.052; for week 2 U = 36, p = 0.342, for week 3 U = 38.5 p = 0.418, for week 
4 U = 2 p < 0.0001, for week 5 U = 21 p = 0.023, for week 6 U = 9 p = 0.004) (see Figure 20A). 
Repeated measures 2-way ANOVA showed that body weight of animals was significantly 
affected by week of exposure (Effect of Time F (6, 108) = 127.2 p < 0.0001) and UCMS X Time 
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interaction (F (6, 108) = 5.026 p = 0.0001; UCMS F (1, 18) = 2.397, p = 0.1389) (see Figure 
20B). In the splash test, two-tailed unpaired t-test analysis of group means showed that UCMS 
mice had higher latency to start (t = 2.515 df = 18 p = 0.022), and shorter time spent in, 
grooming (t = 3.304, df = 18, p= 0.004) (see Figure 20C and D). 

































































































Figure 20 Coat state and grooming behaviour in the UCMS Experiment 3. 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks, during which weight, coat state and sucrose preference were monitored weekly. After 
6 weeks of UCMS exposure mice were subjected to behavioural testing battery, at the end of which blood was 
collected and mice were culled for brain tissue collection (A) Weekly coat state deterioration score measurements 
from week 4, *p<0.05, **p<0.01 ***p>0.001 derived from Mann-Whitney U-test between CNTRL and UCMS, data 
represents median and interquartile range (B) Weekly weight monitoring, *p<0.05 derived from Bonferroni multiple 
comparison between CNTRL and UCMS group means at week 1 of UCMS  (C) Grooming latency in the splash test and 
(D) time animals spent grooming during the splash test trial  *p<0.05, **p<0.01 derived from two-tailed unpaired t-
test, data represents mean±SEM  
 UCMS - induced hyperlocomotion was present from week 3 in all anxiety-
related tests 
Statistical analysis of open field test data showed that UCMS induced hyperactivity in the open 
field test (see Figure 21A and C). The effect was already present after 3 weeks of UCMS 
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exposure (t = 9.868, p < 0.0001) and remained at 6 weeks (Mann-Whitney U = 16, p = 0.009). 
Hyperlocomotion was also accompanied by an anxiolytic-like increase in centre time in 
stressed animals, which was not significant at 3 weeks (Mann-Whitney U = 39, p = 0.425) but 
reached significance after 6 weeks of UCMS exposure (t = 4.491 p = 0.003)  (see Figure 21B and 
D). Similarly, in a light-dark box test UCMS group displayed reduced latency (Mann-Whitney U 
= 14, p = 0.008), however the time spent in the light zone was not significantly different 
between groups (Mann-Whitney U = 25.5, p = 0.111) (see Figure 21E and F). 
 
Figure 21 Hyperlocomotion in anxiety-related tests in the UCMS Experiment 3 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks, during which weight, coat state and sucrose preference were monitored weekly. After 
6 weeks of UCMS exposure mice were subjected to behavioural testing battery, at the end of which blood was 
collected and mice were culled for brain tissue collection (A) Locomotor activity in the open field (OF) arena after 3 
week of UCMS exposure (B) Time spent in the centre of the OF arena after 3 week of UCMS exposure (C) Locomotor 
activity in the open field (OF) arena after 6 week of UCMS exposure (D) Time spent in the centre of the OF arena 
after 6 week of UCMS exposure (E) Latency to enter the light zone of the light-dark box (LD box) (F) Time spent in the 
light zone during the light-dark box test trail **p<0.01 derived from Mann-Whitney test, ***p<0.001 derived from 
two-tailed unpaired t-test. Data represents mean±SEM  
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 UCMS induced anhedonia on week 4 in sucrose preference test, but not in 
the NSF 
On weeks 0 and 2 of UCMS, 1% sucrose solution was used for the test. Control and UCMS-
exposed groups showed only slight preference at first exposure (Figure 22A). On week 2, the 
percentage of sucrose consumption fell below 50%, while preference in UCMS group reached 
62%. Because of the low preference in the control group, sucrose concentration on week 4 was 
increased to 2%. The control group responded to 2% sucrose with 79% preference, while the 
UCMS-exposed group did not prefer it over water (46%). Interestingly on week 6, preference in 
controls fell to 49% and rose in the UCMS group to 55%, so the inter-group difference was no 
longer significant in the post-hoc Bonferroni multiple comparison applied post repeated 
measures 2-way ANOVA (Effect of Time x Stress F (3, 39) = 13.15, p < 0.0001; Time F (3, 39) = 
2.289, p = 0.094; UCMS F (1, 13) = 1.732, p = 0.211). In the NSF test UCMS-exposed group’s 
latency to feed was reduced compared to control group (unpaired two-tailed t-test t = 3.227, p 
= 0.005), while latency to find the chocolate cookie in the buried cookie test was not 
significantly affected by UCMS (unpaired two-tailed t-test t = 1.152, p = 0.264) (see Figure 22B, 
C). Food pellet used in the NSF test was weighted out straight after to the test to measure 
amount of food consumed by a mouse during the trial, and after first 10 min the mouse spent 
in its home cage after the end of the NSF test. Repeated measures 2-way ANOVA showed no 
effect of UCMS exposure on pellet consumption either during the NSF or upon return to the 
home cage (Effect of UCMSxTime interaction F (1, 15) = 0.952, p = 0.345; Time F (1, 15) = 2.69, 
p = 0.122; UCMS F (1, 15) = 0.302, p = 0.591). 
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Figure 22 Anhedonia in food reward related tests in UCMS Experiment 3 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks, during which weight, coat state and sucrose preference were monitored weekly. After 
6 weeks of UCMS exposure mice were subjected to behavioural testing battery, at the end of which blood was 
collected and mice were culled for brain tissue collection (A) Average sucrose preference measured over 2 
consecutive nights once every 2 weeks. (B) Latency to find and start eating a cookie in the buried cookie test (C) 
Latency to start eating the pellet in the novelty suppressed feeding test (D) Food pellet consumption in the NSF arena 
during the trial and in the home cage during first 10 min after the trial, **p<0.01 derived from unpaired t-test; Data 
represents mean±SEM 
 UCMS did not induce behavioural despair in FST, while isolated UCMS-
exposed animals displayed more social behaviours than controls 
In the FST, UCMS exposure did not affect duration of any of the four main types mouse 
behaviour, namely swimming, struggling, paddling also known as climbing, and immobility (see 
Figure 23A) (2-way ANOVA UCMS factor F (1, 60) = -1.279*1014, p>0.999; Type of behaviour F 
(3, 60) = 387, p<0.0001; Interaction F (3, 60) = 1.178, p = 0.326).  Social behaviours and 
aggression was evaluated during 5 min exposure to an unfamiliar conspecific juvenile mouse. 
2-way ANOVA showed the main effect of interaction between UCMS and type of behaviour 
(Interaction F (7, 144) = 6.001, p< 0.0001; UCMS F (1, 144) = 0.001, p = 0.975; Behaviour type F 
(7, 144) = 97.87, p<0.0001). Post-hoc Bonferroni multiple comparisons showed that UCMS-
exposed animals spend more time engaging in social behaviours targeted at an unfamiliar 
animal, such as sniffing and allogrooming, while CNTRL animals spent more time in non-social 
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behaviours, such as digging and rearing. UCMS did not significantly increase aggression in mice 
(see Figure 23B).  
 
Figure 23 Behavioural despair and social behaviours in the UCMS Experiment 3 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks, during which weight, coat state and sucrose preference were monitored weekly. After 
6 weeks of UCMS exposure mice were subjected to behavioural testing battery, at the end of which blood was 
collected and mice were culled for brain tissue collection (A) Duration of each type of mouse behaviour during the 6 
min forced swim test trial (B) Social behaviours evaluated during 5 min exposure to an unfamiliar conspecific mouse. 




 UCMS did not affect plasma corticosterone response to FST but increased 
plasma CRP and reduced plasma leptin levels   
Results showed that UCMS did not affect the baseline level of CORT or response to swim stress 
(Effect of FST F (1, 16) = 108.6, p< 0.0001; UCMS F (1, 16) = 0.288, p = 0.599; FSTxUCMS F (1, 
16) = 2.98, p = 0.103) (see Figure 24A).  
A panel of 10 cytokines was also measured in the plasma derived from cardiac blood, however 
none of the analytes reached the detection level of the assay apart from C-reactive protein 
(CRP), which was significantly elevated in UCMS-exposed group (unpaired two-tailed t-test t= 
2.508, p = 0.023) (see Figure 24B). Leptin levels were also measured in plasma to gain insight 
into hormonal regulation of appetite. Leptin levels were significantly decreased in UCMS group 
























































































Figure 24 Plasma parameters measured in the UCMS Experiment 3 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks, during which weight, coat state and sucrose preference were monitored weekly. After 
6 weeks of UCMS exposure mice were subjected to behavioural testing battery, at the end of which blood was 
collected and mice were culled for brain tissue collection (A) Plasma corticosterone (CORT) response to forced wim 
test (FST) measured 24 hours before (PRE-FST) and 30 min after (POST-FST) the test (B) Plasma levels of the C 
reactive proteie (CRP) in the blood collected by the cardiac puncture at the end of the behavioural testing battery  (7 
days after termination of the UCMS protocol) (C Plasma levels of leptin in the blood collected by the cardiac puncture 
at the end of the behavioural testing battery (7 days after termination of the UCMS protocol). Data represents 





The results of the UCMS Experiment 3 showed that the protocol utilised in this study was 
sufficient to induce low grooming phenotype, however ensured mild severity of the protocol 
and 100% survival of animals. Indeed, grooming behaviour was strongly affected, however 
visible changes of coat state only appeared on week 4. The delay with a change in coat state 
was probably due to a decrease in the intensity of the protocol compared to UCMS Experiment 
2, as the overlap of the stressors was not utilised to reduce its severity. In addition, daily 
injections and therefore drug administration was not included in this protocol with the same 
aim of reducing its severity. This was based on the comparison between saline injected and 
non-injected mice conducted earlier (see Figure 10) which showed that daily injection reduce 
grooming in BALB/c mice, supported by previous studies showing stress-like effect of daily 
injections (Drude et al., 2011; Meijer et al., 2006). Despite the late onset of low grooming 
phenotype, in this experiment UCMS group displayed significantly lower weight on week 1 
confirming the effectiveness of the protocol used. The absence of this effect on later weeks 
could be related to habituation of mice to UCMS exposure. 
In this experiment, we wanted to determine if novelty-induced hyperlocomotion appears 
already after 3 weeks of stress exposure. The results of open field test showed that 
hyperlocomotion was already strongly present at week 3. Moreover, it was accompanied by a 
significant increase in the centre time. This data suggests that hyperactivity is not related to 
the longevity of stress, but more likely to the frequent nature and unpredictability of stressors. 
As it has been shown previously that behaviour in a light-dark box test is less affected by 
hyperlocomotion (Ito et al., 2010), this test was added to the behavioural battery in this 
experiment. However, in the light-dark box, the UCMS group also displayed reduced anxiety 
(“anxiolysis-like behaviour”). This observation allows to suggest that the reduced anxiety 
induced by UCMS might not be fully dependent on hyperactivity. Interestingly, the very first 
paper to describe UCMS in mice also showed that mice spent more time in the light zone of 
the test, which was interpreted as a decreased sensitivity towards affective environmental 
stimuli (Kopp, Vogel, MC Rettori, et al., 1999). Other studies interpret reduced anxiety induced 
by UCMS as impulsivity reminiscent of impulsive behaviour in psychiatric patients (Couch et al., 
2016).  
Sucrose preference measurements during weeks of UCMS provided interesting data. On week 
1, when animals were exposed to 1% solution, both groups showed a small preference, which 
could be explained by a low percentage of sucrose and low sensitivity of BALB/c. On week 2 
CNTRL animals did not prefer sucrose, which could be a result of habituation. Interestingly the 
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UCMS group showed a small preference on this week, although the difference between the 
groups was not statistically significant. Finally on week 4, when sucrose concentration was 
raised to 2%, CNTRL showed preference while the UCMS group did not. This could be a 
consequence of the UCMS exposure, as on this week coat state of mice also significantly 
deteriorated. On week 6 the difference was no longer present, which again can be a result of 
habituation on a second exposure to the same dose. Therefore, anhedonia observed on week 
4 in sucrose preference coincided with a significant increase in coat deterioration score on this 
week and could be reflecting a true effect of UCMS. Indeed suppressing effect of UCMS on the 
preference for 2% sucrose in BALB/c mice has been shown previously (Liu et al., 2010). 
As in previous experiments, the UCMS group also showed a decreased latency to approach and 
start eating the pellet in the NSF. While this effect could be attributed to hyperlocomotion, a 
change in food reward behaviours could also play a role in this effect. Importantly, in 
Experiment 2 FLX reversed this effect in NSF but did not have any effect on hyperlocomotion, 
suggesting a distinct mechanism for the two behavioural phenotypes. This observation 
supports the notion of a potential change in non-locomotor activity related behaviour, such as 
the drive towards food rewards. To see if this notion could be supported by neurobiological 
evidence, plasma levels of the appetite-controlling hormone leptin was measured and found to 
be reduced in the UCMS group. Low levels of leptin could explain a higher drive for food 
rewards, as leptin is known to act as a negative feedback inhibitor released by adipose tissue 
to regulate food consumption through leptin receptors in the hypothalamus (Ahima and Osei, 
2004). Such an effect of chronic stress on leptin levels has been previously documented in the 
literature. Ge et al. (2013) described a decrease in plasma leptin levels and a decrease in 
hypothalamic leptin receptor levels following UCMS in rats, while Liu et al. (2015) showed a 
suppressing effect of chronic mild stress on mRNA leptin levels in the rat prefrontal cortex. In 
this study the authors also connected leptin and ghrelin signalling to a stress-induced increase 
in inflammatory factors such as NLRP3 and GSK-3β, which might have particular relevance for 
this experiment in light of the increased inflammatory biomarker detected in the UCMS group. 
Moreover, another study reported an antidepressant effect of leptin on sucrose preference 
and FST immobility in unpredictable chronic mild stress and social defeat models (Lu et al., 
2006). In this study stress exposure was also accompanied by a decrease in plasma leptin 
levels. Therefore, decrease in leptin levels plays an important role in UCMS-induced phenotype 
and could potentially underlie changes in food-reward related behaviours. The change in leptin 
might be reflecting a shift in circadian rhythm which affected the time of feeding drive and 
levels of hormones regulating it. Indeed it has been shown previously that mice with circadian 
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rhythm gene knockouts or exposed to disrupted light-dark cycles show changes in leptin levels 
throughout light and dark phases (Kettner et al., 2015). 
One important limitation to the study of food reward related behaviour in this experiment is 
the lack of food consumption data during the UCMS exposure, which could have helped to 
distinguish between appetite-related and motivation-related changes in behaviours towards 
food reward such as those measured in NSF and sucrose preference tests. However, the 
measure of pellet consumption during the NSF test and upon return to the home cage did not 
show any difference between UCMS and CNTRL group, suggesting no difference in appetite 
both in stressful and familiar environment. 
In the UCMS Experiment 3, as well as in previous UCMS experiments described in this chapter, 
no change in immobility or any other behaviours during the FST was observed. Similarly, FST 
induced a significant plasma CORT increase 30 min after the trial in both CNTRL and UCMS 
groups. Interestingly, the levels of stimulated POST-FST CORT in this experiment were higher 
than the corresponding levels in the UCMS Experiment 2, especially in the UCMS group. More 
robust CORT response in the last experiment could be explained by the absence of daily 
injection in this study. Indeed it has been shown previously that BALB/c mice exposed to daily 
injections and repeated psychosocial stress show lower levels of plasma CORT compared to 
non-injected repeatedly stressed mice (Drude et al., 2011). 
In this experiment the social behaviour of animals was assessed, as some aggression during 
handling was observed in the UCMS Experiment 2. However, single-housed animals spent 
more time engaging in social behaviours and less time - in non-social activities compared to 
CNTRL group. While social isolation in juvenile mice is often described to induce social 
withdrawal and reduce social affiliation (Liu et al., 2016; Okada et al., 2015), some studies do 
show increase in social behaviours (Naert et al., 2011; Orikasa et al., 2015). It is therefore 
possible that aggression observed previously in UCMS-exposed group could be a result of daily 
exposure to injections, which were not present in the UCMS Experiment 3. 
Lastly, this experiment provided evidence for the involvement of cytokines in the UCMS 
response. Plasma levels of CRP were elevated in the UCMS-exposed group. CRP is an acute 
phase protein  widely used in the clinic as an inflammatory biomarker, and it has been found 
to be elevated in depressed patients (Cepeda et al., 2016). As has been mentioned above, 
chronic stress in rodents has already been shown to increase level of proinflammatory 
cytokines in the blood as well as in stress-responsive brain areas, such as the hippocampus, 
prefrontal cortex and the amygdala (Guan et al., 2015; Wang et al., 2015). However, changes in 
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CRP have not yet been reported. This could be partly explained by the fact that most of the 
proinflammatory markers in UCMS studies have been done in rats, in which unlike in mice, CRP 
has not been detected in the acute phase response (Schreiber et al., 1989). The fact that CRP 
was the only protein found to be elevated out of a panel of 9 proinflammatory cytokines, 
which included those previously found to be affected by chronic stress (IL-6, IL-1β and TNFα), 
could probably be explained by a low sensitivity of the Luminex assay utilised. Unlike 
cytokines, CRP is normally present in the blood in higher concentration, which could explain 
why the assay selectively detected its elevation. Therefore, elevation of CRP provides an 
evidence of modulation of the immune system state by chronic stress, which due to 
prevalence of clinical CRP data could be of potential translational value. Yet in the future 
studies a usage of high sensitivity assay could be recommended. 
 Discussion 
UCMS experiments 1,2 and 3 showed that adult male BALB/cAnNCrl mice respond to UCMS 
with reduced grooming and novelty-induced hyperactivity. Manipulation of the control 
conditions throughout the UCMS experiment showed that sibling pair housing in large cages as 
used in Experiment 3 is the most optimal housing condition for control group to avoid social 
isolation stress and reduce risk of cage mate fighting. Daily intraperitoneal injections are not 
recommended as a drug delivery route as they appear to also add to the allostatic load of 
control and stress - exposed groups and appear to suppress HPA axis response to acute stress 
as reflected by a difference in post-FST CORT levels between Experiments 2 and 3.  
Experimentation with a schedule of stressors during UCMS showed that 2 stressors per day is 
not sufficient to induce significant behavioural changes, while 4 stressors can successfully 
affect behavioural outcome. However, UCMS Experiment 2 showed that a combination of 4 
overlapping daily stressors with daily i.p. injections exceeded the severity of the protocol and 
increased risk of fatality in the stress-exposed group to 50%. In this experiment animal welfare 
was prioritised as soon as fatality reached 25% and all measures were taken to reduce animal 
suffering, including preliminary end of the UCMS exposure, however more deaths occurred 
after UCMS termination potentially due to its long-term effects. Subsequently UCMS 
Experiment 3 was designed to reduce stress exposure and ensure welfare of animals. 
The behavioural phenotypes induced by our protocol included an increase in coat 
deterioration score, indicative of reduced grooming, and a reduction in grooming time in the 
splash test as shown in Experiments 2 and 3. Also novelty-induced hyperactivity was a 
phenotype consistent across all 3 experiments and with previous literature (Strekalova et al., 
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2005). It appeared that hyperlocomotion potentially skewed changes in behavioural tests of 
anxiety, such as the open field and light-dark box, as anxiety in these tests is evaluated based 
on the time animals spend moving around potentially threatening areas. Yet it is possible that 
this reduced anxiety (“anxiolysis-like behaviour”) was not solely a result of hyperactivity, as the 
time spent in light box has been shown to be less affected by the hyperactivity of animals. If 
so, one could speculate that reduced anxiety behaviour in these animals stems from the lack of 
environmental awareness or an increase in impulsivity. Such hypothesis could be tested in 
tests assessing impulsive behaviours, such as five-choice serial reaction time task. A study of 
signalling pathways activated by UCMS in stress-responsive brain areas could shed light on 
molecular and neurotransmitter mechanisms underlying these behaviours.   
Regarding anhedonia, assessed in the sucrose preference tests as a loss of preference to 
sweetened water, it was detected only when animals were first exposed to 2% sucrose 
solution in the UCMS Experiment 3. It is possible that 4% solution used in previous 
experiments triggered ceiling effect in all animals, therefore no effect of stress was observed in 
the UCMS Experiment 1 and 2. In addition, in these experiments sucrose preference was 
measured during the whole 24-hour cycle, while in the last experiment most of the 
measurement was done in the dark phase. The fact that the difference was more apparent in 
the dark phase suggests the possibility that circadian rhythm alteration might have shifted the 
dark phase and main period of activity of the UCMS-exposed animals. Sucrose measurements 
taken separately in light and dark phases would be able to confirm or oppose this notion. One 
important limitation to the sucrose preference data across all experiments is a lack dose-
response type data comparing effect of UCMS or CNTRL conditions on BALb/c mice preference 
for sucrose solution with different concentrations of sucrose. 
However, contrary to expectations, in NSF test animals consistently displayed an increased 
drive to food reward instead of anhedonia in Experiments 2 and 3. Importantly locomotion can 
also affect the outcome of the NSF test, as the latency to approach the food pellet in the 
centre of large arena is the outcome measure. At the same time as animals are food-deprived 
for 24 hours before the test, appetite and metabolism can also influence the result. Indeed, 
changes in the plasma level of leptin detected in stressed animals confirmed the possibility of 
increased appetite. However, a profound change in appetite would be expected to lead to a 
weight change, which was not observed in these experiments. Moreover, pellet consumption 
measurements conducted in the Experiment 3 during the NSF trial and upon return to the 
home cage did not show any difference between CNTRL and UCMS groups.  Interestingly in the 
same experiment repeated sucrose preference measures showed an opposing dynamic of 
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habituation to sucrose in control and stressed animals, whereby the latter acquired preference 
to sweet solution with repeated exposures while the former displayed preference only during 
first exposure. A shift in circadian rhythms induced by UCMS also could have played a role in 
these effects. If daily disturbance of mice by stressors during the light phase shifted their 
resting time towards the night, it could explain why they appeared more active and driven to 
palatable stimuli during the day time testing compared to CNTRL animals. This could also 
explain why apparent increase in appetite was not accompanied by weight change, if the mice 
only shifted their feeding to day time, but did not increase overall food consumption. In this 
case reversal of light/dark cycle and application of stressors during the dark phase could have 
avoided development of such effects. However, to confirm this hypothesis sleep cycle 
monitoring and circadian rhythm measures, as well food consumption measurements during 
the light and dark phases would be required. The latter could also help to distinguish between 
appetite-driven and hedonic reward – driven motivation for food stimuli. Indeed motivation 
towards food rewards is regulated by both dopaminergic mesocorticolimbic circuit responsible 
for reward behaviours, as well as by the metabolic state of the body, encoded in the brain by 
insulin, ghrelin, leptin and orexin neuropeptide signalling, which influence appetite centres in 
hypothalamic and hindbrain areas (Fulton, 2010). As these pathways closely interact with each 
other and could both be affected by stress, their distinction requires careful consideration.  
As for behavioural despair, no change in immobility was observed in FST in any of the 
experiments. It is possible that the absence of increased immobility was related to 
hyperlocomotion of mice. While interpreting the results of the FST, it is important to 
remember that this test has been developed as a screening tool for monoaminergic 
antidepressant activity (Porsolt et al., 1977) and its main strength lies in its predictive validity, 
as indeed it is sensitive to all classes of antidepressants and can distinguish antidepressants 
from other classes of psychopharmacological compounds (Gould, 2009). While Porsolt et al. 
(1978) claimed it to possess face validity, its interpretation as a model of behavioural despair 
has received significant criticism. West (1990) argued that immobility in the FST can be 
interpreted as an adaptive, energy conserving response to inescapable conditions, more 
indicative of the cognitive functions of the animal rather than of its mood state. Therefore, 
some authors urge to limit its use to screening antidepressant compounds (Nestler and 
Hyman, 2010; Petit-Demouliere et al., 2005). Indeed, in the UCMS Experiment 1 Fluoxetine but 
not UCMS was a significant factor affecting immobility time. In light of this, the absence of the 
UCMS effect in FST in the UCMS Experiment 3, where antidepressant treatment was not 
109 
 
included, does not necessary compromise the validity of the UCMS protocol used in this 
experiment. 
Lastly, plasma corticosterone measures did not show an increase in HPA axis activity described 
as a consequence of UCMS in the literature. In fact, the opposite effect was observed in the 
UCMS Experiment 2 where UCMS prevented elevation of POST-FST CORT levels but FLX 
treatment restored CORT response to control levels. Interestingly, attenuation of the CORT 
response during chronic restraint stress exposure has already been described in BALB/cAnNCrl 
substrain (Sadler and Bailey, 2016), which could suggest a strain-specific response of the HPA 
axis to chronic stress. However, limitations of the single CORT measure taken during the light 
phase rather than in the active phase might have affected the outcome. Importantly it has 
been described that release of corticosterone follows a diurnal rhythm, therefore a single 
corticosterone measure does not capture the full profile and is not representative of the 
overall dynamics of the HPA axis. Indeed Aslani et al. (2014) showed that corticosterone is 
lowest during the light phase, when most of our blood collection was done, so it is possible 
that the data would differ had the blood been collected during the active period. CORT 
measured at various time points during the 24 hours would improve the understanding of the 
HPA axis regulation in this study. 
Yet the corticosterone data taken together with the FLX treatment data allows speculation 
that UCMS in these experiments might have triggered an impairment of HPA axis regulation, 
which has been linked to antidepressant resistance (Khemissi et al., 2014; Surget et al., 2016). 
Dexamethasone suppression test would be able to show if indeed UCMS triggered alteration of 
the HPA axis negative feedback inhibition. As in the latter study this phenotype also included a 
modification of the effect of FLX on adult hippocampal neurogenesis, a histological study will 
investigate this hypothesis further. Finally, measures of plasma inflammatory biomarkers 
detected elevation of only one analyte, CRP. This analyte was only included in the assay in the 
last experiment, therefore it is not possible to assess if this finding was consistent across 
experiments. Given the insufficient sensitivity of the assay to the small changes typically 
induced by chronic stress, it was not possible to assess whether other key cytokines were 
altered in UCMS. While analysis of blood samples with hypersensitive assays in the future 
might provide more evidence for the involvement of the immune system, the presence of CRP 
elevation, frequently used in the clinic, is already suggestive of occurring immune system 
involvement. Investigation of protein or mRNA levels of proinflammatory factors in the stress-
responsive brain areas could show if such systemic effect corresponds to the changes in the 




To summarise, data collected from the experiments described in this chapter provide a basis 
for recommendations on the improvement of the UCMS protocol and behavioural testing for 
the future studies, particularly if using a stress-susceptible strain such as BALB/c. Control 
groups should be housed in large cages with their siblings to avoid social isolation and cage 
mate fighting. It is preferable that the light/dark cycle is reversed in the facility to allow to 
carry out UCMS protocol, behavioural testing and blood collection in the active phase and 
avoid a shift in the circadian rhythm in UCMS-exposed mice, which could have triggered 
hyperactivity in experiments described here. At the same time day time exposure to UCMS 
likely disrupts light phase rest in mice therefore might have an advantage of resembling 
disturbed sleep also seen in depressed patients (Motivala et al., 2005), which could be relevant 
for some studies. The schedule of stressors used in the UCMS Experiment 3 could be 
recommended for future studies. Furthermore, it would be recommended to carry out sucrose 
measurement during the last weeks of UCMS, with 2% solution being optimal for the 
BALB/cAnNCrl mice. Separate light and dark phase measurements might provide extra insight 
into anhedonic behaviour. While NSF and FST did not prove to be very informative in our 
experiments, prevention of hyperactivity could allow for better results in activity-dependant 
tests, such as open field, NSF and FST. In addition, food consumption measurements during 
light and dark phases could add extra insight into appetite changes and help distinguish 
appetite – related motivation from hedonic motivation toward food rewards.  
As for neurobiological measures, specific assessment of HPA axis negative feedback regulation, 
such as dexamethasone suppression test, could be beneficial for a future study. While no 
elevation of plasma proinflammatory cytokines was detected in my experiments, a use of high 
sensitivity assay might be able to show if small changes could by triggered by UCMS. However, 
assessment of the brain tissue would provide a better insight into the effect of chronic stress 
inflammatory processes in the CNS, as will be partly done in the next chapter by looking at the 
effect of UCMS on hippocampal microglia. Next chapter will also complete the study of 
neurobiological effects of UCMS in the brain by exploring the effects exerted by UCMS 
exposure on adult hippocampal neurogenesis and relating these effects to the phenotypes 




Chapter 3 Adult hippocampal 
neurogenesis in the UCMS model 
1 Introduction 
Investigating adult hippocampal neurogenesis (AHN) has become an indispensable part of 
preclinical depression research ever since the neurogenic hypothesis of depression was 
postulated by Jacobs et al. (2000). Extensive research into the role of AHN in depression 
highlighted its involvement in disease development and in the mechanism of actions of 
antidepressant medications (Tanti and Belzung, 2013). AHN is seen as a promising target for 
novel drug discovery, therefore assessing its status and involvement in an animal model of 
depression is of particular importance.  
1.1 Adult hippocampal neurogenesis in UCMS studies 
Much of the research on the role of neurogenesis in depression has been conducted using the 
UCMS model. Specifically, the model remains instrumental in deciphering the role of AHN in 
the mechanism of antidepressant action. As such, Santarelli et al. (2003) used UCMS to show 
that when neurogenesis is ablated, fluoxetine (FLX) treatment is not effective in improving 
depression-like behaviours such as anhedonia in the NSF or reduction of grooming following 
UCMS. However, ablation of neurogenesis on its own does not promote development of these 
behaviours. These findings asserted the role of neurogenesis in antidepressants’ mechanism of 
action, however questioned the causal role of neurogenesis decline in the development of 
depression. Yet later studies showed that  UCMS is capable of reducing cell proliferation and 
neuronal differentiation (Alonso et al., 2004; Mineur et al., 2007). Mineur et al. (2007) also 
hypothesised that decline of neurogenesis would correlate with a decline in hippocampal-
dependent contextual memory. However such a link was not found, again questioning the 
functional consequences of neurogenic deficit. To address the role of neurogenesis in UCMS-
induced behavioural deficits Surget et al. (2008) ablated neurogenesis with focal irradiation in 
mice before UCMS exposure. The results showed that the absence of neurogenesis did not 
induce depressive-like behaviour and did not prevent UCMS effects. However, neurogenesis 
ablation prevented reversal of UCMS-induced behavioural deficits in grooming and anhedonia 
by FLX and imipramine. Interestingly, corticotrophin-releasing factor 1 (CRF1) receptor 
antagonist, SSR125543, was still effective in irradiated mice (Surget et al., 2011; Surget, Saxe, 
et al., 2008). As a compound directly affecting HPA axis did not require neurogenesis to 
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produce an antidepressant effect, the authors concluded that suppression of the HPA axis 
might be the mechanism through which neurogenesis promotes the therapeutic action of 
monoaminergic antidepressants. Moreover, the latter study also showed that neurogenesis is 
required for fluoxetine to repair UCMS-induced hypothalamo-pituitary-adrenal (HPA) axis 
dysregulation and hyperactivity, asserting the role of neurogenesis in antidepressant effect on 
the HPA axis function (Surget et al., 2011).  
A study by Snyder et al. (2011) supported this notion by showing that genetic ablation of 
neurogenesis in mice is sufficient to cause impaired negative feedback inhibition, and some 
behavioural deficit in behavioural despair and anhedonia. Yet the biggest effect of 
neurogenesis ablation became apparent after animals’ exposure to acute restraint stress – 
neurogenesis-depleted animals showed more profound deficits in anhedonia than their 
neurogenesis-intact counterparts. These results prompted the authors to conclude that the 
role of neurogenesis is to protect the mouse against the effects of acute stress by supporting 
the negative feedback inhibition of HPA axis, but repeated stress exposure and neurogenesis 
decline increase stress susceptibility. Such a hypothesis could explain why ablation of 
neurogenesis on its own does not cause any behavioural deficits in many studies which 
employed various neurogenesis ablation strategies in both rats and mice (Bessa et al., 2009; 
Jayatissa et al., 2009; Lagace et al., 2010). 
Indeed, the interplay between the AHN and the HPA axis has been extensively studied. As has 
been mentioned above, increasing glucocorticoid levels has been shown to reduce AHN in vivo 
as well as in vitro (Anacker et al., 2011). The glucocorticoid receptor (GR) is thought to play a 
key role in this effect. Indeed, GR is highly expressed in the hippocampus and in neural 
progenitor cells (Egeland et al., 2015). Treatment with the GR antagonist mifepristone has 
been shown to block the antineurogenic effect of glucocorticoid administration as well as of 
CUS exposure (Mayer et al., 2006; Oomen et al., 2007). At the same time GR downregulation in 
the hippocampus has been linked to HPA axis hyperactivity and depression-like behaviours. 
Mice with a deletion of GR in the forebrain neurons, including the hippocampus, display 
impaired feedback inhibition, HPA axis hyperactivity and depression-like behaviour (Boyle et 
al., 2005). Taken together these studies suggest that GR dysfunction in the hippocampus leads 
to HPA axis hyperactivity and elevated level of systemic corticosterone (CORT). Moreover, it 
has been shown that antidepressants increase neurogenesis via a GR-dependent mechanism 
(Anacker et al., 2011). 
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The relationship between the HPA axis and AHN was further investigated in the study by David 
et al. (2009) where depressive-like behaviour was induced by chronic CORT injections. In this 
model, a behavioural deficit was accompanied by a decline in neurogenesis, and both were 
reversed by chronic fluoxetine treatment. Similar to the UCMS studies, ablation of 
neurogenesis did not prevent a depressive effect of CORT, but it blocked the therapeutic effect 
of fluoxetine (FLX) on anhedonia in the NSF test. Furthermore, in this study neurogenesis was 
not required for FLX-induced reversal of the anxiety and behavioural despair. Therefore, this 
study further confirmed that neurogenesis is dispensable for the induction of a depression-like 
phenotype by HPA axis hyperactivity, but it is required for reducing anhedonia by 
antidepressants. A distinction between neurogenesis-dependent and independent behaviours 
was further confirmed in a UCMS-based study, where animals were separated into hyperactive 
and hypoactive HPA axis groups based on the state of their HPA regulation (Khemissi et al., 
2014). FLX elevated anxiety and behavioural despair in both groups, but exerted 
antidepressant effect on anhedonia in the NSF only in a group where it also increased 
neurogenesis levels, the hyperactive HPA axis group. This study further highlighted the 
complex relationship between HPA axis, AHN and the effect of antidepressant drugs. 
Interestingly a recent study by Hill et al. (2015) showed that increasing AHN with an inducible 
transgenic model could reduce anxiety and depressive-like behaviours induced by chronic 
CORT, but did not improve HPA axis regulation. It is important to note however that in the 
CORT model, as opposed to the UCMS model, HPA axis shows hypoactive response to acute 
stress (David et al., 2009). Therefore, the absence of increased neurogenesis in this model 
does not exclude the possibility that increased neurogenesis could improve regulation of the 
hyperactive HPA axis. 
1.2 Dendritic morphology of adult born and prenatally born neurons in 
chronic stress models 
Bessa et al. (2009) suggested a different approach to the role of neuronal plasticity in the 
effects of chronic stress and antidepressants. Their study confirmed the division between 
neurogenesis dependent and independent effects of antidepressants outlined by Santarelli et 
al. (2003) and David et al. (2009). However, the authors went beyond neurogenesis by showing 
that chronic stress also caused deterioration in dendritic morphology and spine density in 
mature neurons of the dentate gyrus (DG), cornu ammonis (CA) 3 and the prefrontal cortex 
(PFC). These changes persisted and were elevated by antidepressants in the absence of 
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neurogenesis, suggesting that dendritic remodelling not only in the hippocampus, but also in 
the PFC, might underlie effect of stress and the mechanism of antidepressant action.  
Indeed, several other studies support the neuroplasticity hypothesis. Sousa et al. (2000) 
described reduction of dendritic length and branching density in hippocampal granule and 
pyramidal neurons following chronic stress, and linked these effects to the elevation of CORT 
levels. Similarly Lussier et al. (2013)  showed that chronic CORT treatment reduced the number 
of DCX+ cells with complex dendritic morphology. In this study classification of DCX+ cells 
based on the dendritic tree architecture, similar to that suggested by Plümpe et al. (2006), was 
utilised to detect dendritic changes. The authors showed that chronic CORT exposure 
selectively depleted the population of DCX+ cells with a more developed dendritic tree 
extending into the molecular layer but no effect on dendritic architecture of the mature 
neurons was found. These results were replicated in a UCMS study which  also classified DCX 
cells based on their morphology and found that chronic stress led to a reduction in DCX+ cells 
with complex dendritic arborisation, which was attributed to a rise of CORT levels (Vega-Rivera 
et al., 2016). However, in this study dendritic remodelling of mature neurons was not 
investigated. Nonetheless, the ability of chronic stress to induce dendritic atrophy and 
reduction in spine density in mature neurons was documented multiple times in different 
areas of the hippocampus, as well as in the PFC, amygdala and nucleus accumbens (Hains et 
al., 2009; Liston et al., 2006; Qiao et al., 2016; Yuen et al., 2012). 
The role of glucocorticoid signalling in neuroblast maturation was further elucidated in a study 
by Fitzsimons et al. (2012). The authors showed that GR knockdown in the neurogenic niche in 
vivo accelerates dendritic maturation and increases spine density and maturation in newborn 
neurons, as well as promoting radial migration of neuroblasts into the external layers of the 
GZ. These changes were accompanied by hippocampal-dependant contextual memory deficits. 
This data suggests that GR activation could be limiting the speed of dendritic maturation and 
migration of neuroblasts, which in normal conditions is necessary to support hippocampal 
function, but pathological overstimulation of the GR by excessive CORT levels might be 
reducing the rate of neuroblast maturation below the level necessary to buffer effects of 
stress. 
1.3 The role of microglia in AHN changes upon UCMS 
Another mechanism through which chronic stress might lead to a dendritic deficit is through 
the dendritic loss triggered by activated microglia. In healthy adult brains, microglia residing in 
the neurogenic niche play an important role in maintaining functional neurogenesis by 
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phagocytising apoptotic neural progenitors at an early stage of their transition into the 
postmitotic neuroblasts (Sierra et al., 2014). Interestingly, this phagocytosis has been shown to 
be carried out by unchallenged microglia with resting state-like morphology (Sierra et al., 
2010). However when activated by an inflammatory stimulus, microglia have been shown to 
exert detrimental effect on neurogenesis directly or via release of proinflammatory cytokines 
capable of reducing the rate of cell proliferation and differentiation (Ekdahl, 2012). As such, 
Ekdahl et al. (2003) showed that treatment with the microglia-supressing drug minocycline 
prevents antineurogenic effects of systemic LPS injections. Microglia-derived cytokines such as 
IL-1β, IL-6 and TNFα have been shown to be instrumental in the effect of inflammation on AHN 
(Cacci et al., 2005; Koo and Duman, 2008; Monje, 2003). 
Indeed chronic stress exposure has been shown to increase the number of microglial cells in 
various brain areas where dendritic atrophy was observed, including DG, CA1, CA3 and the PFC 
(Hinwood et al., 2012; Tynan et al., 2010; L Zhu et al., 2015). Moreover, some studies report 
increases in the number of microglial cells displaying activated phagocytic morphology or an 
increase in the expression of activation markers, such as CD11b or MHCII (Liu et al., 2015; Lu et 
al., 2014). The functional importance of microglial activation in the effect of chronic stress has 
been demonstrated in a chronic social defeat study where treatment with minocycline 
prevented development of depression-like behaviour (Chijiwa et al., 2015). However it is 
important to note that a complete consensus over the effect of chronic stress on microglial 
activation has not been reached in the literature. For example, Kopp et al. (2013) showed that 
14 days of UCMS unlike homotypic chronic restraint stress did not induce microglial activation 
in the PFC in rats. These negative results could be explained by the time-dependent dynamics 
of microglial response to stress observed by Kreisel et al. (2013). This study reported that in 
C57BL6 mice microglial proliferation and activation induced by the first few days of CUS 
exposure is then followed by reduction of microglial numbers due to apoptosis and dystrophic 
changes in microglial morphology, such as shortened processes and small cell body size in the 
hippocampus after 5 weeks of continuous CUS exposure.  
Nonetheless, a recent study demonstrated that housing rats in a stressful environment leads 
to an increase in phagocytic morphology and showed an increase in microglia phagocytosing of 
axon terminals and dendritic spines (Milior et al., 2016). In another study, microglia activated 
by systemic LPS exposure caused destabilisation of spines and reduction of spine density in the 
neocortex (Kondo et al., 2011). Microglia might be affecting dendritic remodelling not only via 
direct interaction, but also through the effect of proinflammatory factors released from 
microglia in the activated state. For example, the proinflammatory cytokine IFNγ has been 
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shown to induce dendritic retraction and reduction in the rate of synapse formation in 
hippocampal cultures in vitro (I-J Kim et al., 2002).  Thus microglial activation could play a role 
in dendritic atrophy seen in chronic stress animal models of depression.  
Overall chronic stress has been shown to reduce neurogenesis and dendritic maturation of 
immature neurons, as well as causing dendritic remodelling in the mature cells. Glucocorticoid 
signalling, microglial activation and proinflammatory cytokines were implicated in these 
effects.  
2 Study aims 
The aim of the analyses described in the Results section of this chapter was to assess AHN 
changes in UCMS-exposed mice, and to attempt identification of neurobiological parameters 
affected by UCMS which modulate these changes. AHN was assessed in two experiments: the 
UCMS Experiment 2, where single-housed mice were exposed to CNTRL or UCMS conditions 
for 7 weeks and treated with FLX 10mg/kg or saline for 6 weeks; and the UCMS Experiment 3, 
wherein sibling pair-housed CNTRL group was compared to UCMS group exposed to stressors 
for 6 weeks. AHN assessment was not conducted in the pilot UCMS experiment as UCMS did 
not induce a strong behavioural phenotype, and therefore was not expected to induce 
detectable neurobiological changes. 
In both experiments, the density of DCX-positive cells in the dentate gyrus was used as an 
estimate of a level of AHN. DCX is a marker of migrating neuroblasts and is expressed from the 
stage of late type 2 progenitors (type 2b) as a sign of neuronal lineage determination 
(Kronenberg et al., 2003). In DCX-positive cells transition from proliferating progenitors into 
immature neurons occurs, as reflected by neuritogenesis, migration into the granular zone 
(GZ) and increasing electrophysiological input received by these cells (Steiner et al., 2006). 
Indeed, most of the dendritic tree develops during the period of DCX expression. Importantly, 
most of cell death also occurs in the DCX+ cells (Plümpe et al., 2006). DCX expression seizes on 
the last stage of neuronal maturation, when granule neurons transition from calretinin to 
calbindin expression, a marker of mature granule neurons (Brandt et al., 2003). Therefore, 
DCX+ cell population comprises a wide variety of progenitors at different stages of neuronal 
maturation. To gain insight into the DCX+ cell subtypes most affected by UCMS, classification 
of DCX+ cells based on dendritic morphology according to Plümpe et al. (2006) was used to 
distinguish between different levels of neuroblast maturation. This analysis together with 
migration distance estimates were conducted only in the tissue collected during the UCMS 
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Experiment 3, as in this experiment satisfactory CNTRL conditions were achieved and 
behavioural effects of the UCMS exposure were the most consistent.  
For the above-mentioned reasons only AHN changes in the UCMS Experiment 3s were 
followed by the assessment of possible factors involved in the modulation of neurogenesis. 
This assessment included the determination of the changes in the density of hippocampal 
microglia, which could reflect microglial proliferation as a result of its activation. To assess the 
combined and individual contribution of plasma parameters reported in the previous chapter, 
multiple regression analysis approach was utilised. This approach has a number of advantages 
over other statistical approaches. Firstly, it is able to evaluate not just associative, but 
predictive relationship between independent and dependent variables. Secondly, it 
simultaneously assesses the contribution of a group of factors rather than a single factor to the 
modulation of the dependent variable, which is likely to be relevant for the complex effects 
occurring in the heterogeneous UCMS model. Finally, stepwise regression method utilised 
allows to compare predictive ability of different factors and to use exploratory approach to 
selecting the combination of measures best predicting the outcome variable (Miles and 
Shelvin, 2001). As the effect of a combination of immune, corticosteroid and metabolic factors 
on AHN in UCMS has not been evaluated before, such exploratory approach appeared to be 
most suitable to meet the aims of the analysis.  
3 Methods 
3.1 Brain tissue collection 
To collect fixed tissue, animals were anaesthetised with Euthatal i.p. (Merial Animal Health Ltd, 
Harlow, UK) at a dose of 40 mg/kg pentobarbital sodium. Deep anaesthesia was confirmed by 
the loss of righting and pain reflexes and slowing of the rate of respiration. Animals were 
subsequently transcardially perfused with 30ml of saline and 50ml of 4% paraformaldehyde 
(Paraformaldehyde, prills, 95%, 441244, Sigma-Aldrich, Poole, UK) in phosphate-buffered 
saline (pH = 7.4 from PBS tablets, 18912-014, Gibco by Life Technologies, Paisley, UK) through 
the left cardiac ventricle. Brains were post-fixed overnight in 4% PFA at 4°C for 24 hours, and 
subsequently stored at 4°C in 30% sucrose (Sigma-Aldrich, Poole, UK) in PBS until sectioning (1-
3 weeks). 
3.2 Immunohistochemistry 
Serial coronal sections of 40μM thickness were cut on a HM430 sliding freezing microtome 
(Thermo Scientific) and stored in tris-buffered saline (TBS, pH=7.4) with 30% v/v glycerol, 15% 
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w/v sucrose and 0.05% w/v sodium azide (all Sigma Aldrich, UK) to prevent bacterial growth 
and for cryoprotection at -20°C during subsequent freezer storage. For immunohistochemistry 
on free floating sections every sixth section was used. Free floating sections were treated with 
1% hydrogen peroxide (Sigma-Aldrich, UK) for 30 minutes to block endogenous peroxidase 
activity within the tissue. After a triple wash in phosphate buffered saline (PBS pH=7.4, Gibco 
LifeTechnologies UK) sections were incubated in blocking solution containing 10% normal goat 
serum (Vector Laboratories, Peterborough, UK) and 0.01% Triton X (Sigma-Aldrich, UK) to 
prevent non-specific staining. After subsequent 3 washes in PBS sections were incubated in 
primary antibodies dilutions in blocking solution overnight at 4°C. For neuroblast detection 
anti-DCX antibody (Ab18723 raised in rabbit, Abcam, UK, 1:1000 dilution) was used; for 
microglia immunostaining antibody for Iba1 (019-19741, Wako, Japan, 1:500 dilution) was 
used. Separate sections were incubated in PBS without primary antibody to act as a negative 
control for immunostaining, see Figure 25 for representative images of immunohistochemical 
staining performed with and without primary antibodies. Next day sections were rinsed in PBS, 
incubated with an appropriate biotinylated secondary antibody (goat anti-rabbit or rat, 1:200, 
Vector Laboratories, Peterborough, UK) diluted in blocking solution for 2 hr, followed by signal 
amplification step with an avidin-biotin complex (Elite ABC kit, Vector Laboratories, 
Peterborough, UK). The staining was visualized with 0.05% diaminobenzidine (DAB) solution 
(Sigma-Aldrich, UK). When stained, sections were mounted on Superfrost Plus glass 
microscope slides (Thermo Scientific, UK) in anatomical order. Mounted sections were air dried 
for 24 hours and subsequently dehydrated in ethanol and cleared in xylene for 10 min. Slides 




Figure 25 Examples of photomicrographs of immunostaining reactions performed with primary antibodies and in 
their absence for negative control (Neg con)  
(A) Photomicrographs of tissue immunostained according to the protocol for doublecortin (DCX) omitting the 
primary antibody (B) Photomicrographs of tissue immunostained according to the protocol for DCX with the primary 
antibody (C) Photomicrographs of tissue immunostained according to the protocol for and ionized calcium-binding 
adapter molecule 1 (Iba1) omitting the primary antibody (D) Photomicrographs of tissue immunostained according 
to the protocol for Iba1 with the primary antibody; scale bar = 500 µm, 10x magnification 
3.3 Stereological analysis of immunopositive cell density 
For microscopy, the Axioskop 2 MOT Plus Miscroscope (Zeiss) with automated stage connected 
to Stereoinvestigator v.7 (MBF Bioscience, US) software was used. Immunopositive cell density 
was determined using the volume and cell population number estimated by semi-automated 
Optical Fractionator method applied by the stereological software. For this analysis an equal 
number of sections per brain were used. The region of interest (ROI) was delineated under 10x 
magnification and overlaid with a grid (X=94.6μm, Y=182.5μm) for systematic random 
sampling, a method of unbiased selection of virtual counting frames with equal distance in X 
and Y directions between them. The size of a counting frame was set at 50μmx50μm with 50 
desired sampling sites per ROI, according to parameters previously validated for the study of 
hippocampal neurogenesis (Dias, Bevilaqua, et al., 2014). The number of immunopositive cells 
within each frame was manually counted from the camera image at 40x magnification based 
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on their morphological appearance and position in relation to acceptance and rejection lines of 
the counting frame (Gundersen, 1977). Subsequently the optical fractionator was applied in 
the Stereoinvestigator software, a method which estimates the total volume based on the 
known sections thickness (15μm) and intersection distance (240μm) and cell population by 
extrapolating the number of cells counted within the counting frames to the total estimated 
volume of ROI (Slomianka and West, 2005). Subsequently cell density was calculated by diving 
the estimated population number by the estimated total volume. 
3.4 DCX cell classification based on dendrite morphology 
The DCX positive cells were visually classified according to the categorization of Plumpe et al. 
(Plümpe et al., 2006). The AB group included cells with no, or short, plump processes, most 
closely resembling the morphology of late type 2b amplifying progenitors (see Figure 3), which 
are already committed to the neuronal lineage as reflected by their DCX expression, yet are 
still capable of proliferation (Kempermann, 2010); the CD group included cells with medium 
length processes without branching usually directed along SGZ and not extending beyond the 
granular zone, most likely representing the cells in transition from amplifying progenitors to 
the postmitotic stage of neuronal maturation with first neuritogenesis occurring; the EF group 
comprised cells with long branching dendrite(s) reaching the molecular layer (see Figure 26). 
These cells are likely to be the type-3 postmitotic progenitors which already receive 
electrophysiological input (Ambrogini et al., 2004). The density of each type of cells was 




Figure 26 Morphological classification of DCX+ neuroblasts. 
(A) Timeline of neuronal development in the subgranular zone of the dentate gyrus showing type 2 amplifying 
progenitors and type 3 neuroblasts at different stages of dendritic tree maturation with corresponding timeline, 
from Aimone et al. Physiol Rev 2014;94:991-1026; (B) Photomicrographs show three types of DCX+ cells used in the 
dendritic morphology classification. Arrow on the left-hand panel shows type AB DCX+ cells, with no or very short 
processes; centre panel shows CD type cell with short plump processes often growing along the SGZ; right-hand 
panel arrow points at the EF-type DCX+ neuroblast with a long, branching dendritic tree reaching into the molecular 
layer of the DG 
3.5 Morphometric analysis of dendrites 
EF-type neurons from each section were selected for morphometric analysis of dendrites. For 
this sections were imaged using a 40× objective, and micrographs were acquired using a Zeiss 
AxioCam MR Rev3 camera. Primary, secondary and tertiary dendrites were manually traced 
using the NeuronJ plugin for ImageJ developed by Meijering (Meijering et al., 2004)  and 
measured using image pixel to mm calibration as has been done previously (Dias, Bevilaqua, et 
al., 2014; Srivastava et al., 2012).  
3.6 Migration distance of DCX+ cells 
To estimate relative distance of DCX+ cells migration through the granular zone, the height of 
the GZ has been divided into 10 bins, and a relative distance of migration was estimated by 
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assigning a score from 0 to 1 to each DCX+ cell based on the position of its cell body relative to 
the borders of the GZ (see Figure 27). For example, cells positioned in the subgranular zone 
were assigned 0 distance, cells in the middle of the GZ height were assigned 0.5, and those on 
the border between granular zone and molecular layer were given a score of 1, as has been 
done previously (Han et al., 2016). The average percentage of cells positioned within each 
distance bin for each brain was used in statistical analysis.  
 
Figure 27 Relative neuroblast cell migration scale through the height of the Granular zone of the hippocampal 
dentate gyrus 
 ML – molecular layer, GZ – granular zone, SGZ - subgranular zone, immunostaining for doublecortin 
3.7 Statistical analysis 
For histological analysis presented in this chapter, tissue was collected from mice in 
Experiments 2 and 3 after completion of behavioural testing (12 days after termination of 
UCMS in Experiment 2 and 7 days after termination of UCMS in Experiment 3). In experiment 2  
6 animals per group were included into the histological analysis due to animal loss described in 
Chapter 2 (section 5.1) Behavioural and serological parameters of these animals were reported 
in Chapter 2 sections 5.2.1-5.2.4. In Experiment 3 9 animals per group were included into the 
histological analysis. Behavioural and serological parameters of these animals were reported in 
Chapter 2 sections 6.2.1-6.2.5. 10 sections at 240µM interval which included dentate gyrus 
were included into the stereological analysis for each animal. For statistical analysis in the 
UCMS Experiment 2 two-way ANOVA was used and post-hoc Bonferroni multiple comparisons 
between individual groups were applied. For the UCMS Experiment 3, unpaired two-tailed t-
test was used after normal distribution of the data was confirmed with the Kolmogorov-
Smirnov test for single measures. For related measures, such as DCX+ cells, dendritic 
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morphology types and migration distance groups two-way ANOVA was used with post-hoc 
Bonferroni multiple comparisons within each type or distance group.   
To determine collective and individual contributions of available neurobiological measures to 
the changes in DCX+ cell density, multiple linear regression approach was used. Multiple linear 
regression with the stepwise backward method of predictor entry was conducted using SPSS 
software (IBM SPSS Statistics version 22, USA). DCX+ cell density was entered as a dependant 
variable, and baseline and post-anaesthetic CORT measures, Iba+ microglial cell density, leptin 
and CRP levels as independent predictors. To meet the assumption of no multicollinearity, 
prior to regression absence of correlations among predictors was confirmed by Pearson’s 
correlation analysis in all possible pairs of independent variables. 
 
4 Results 
4.1 UCMS and FLX modify hippocampal DCX+ cell density  
The effect of 7 weeks of UCMS exposure and 5 weeks of chronic fluoxetine treatment with 
10mg/kg was investigated in UCMS Experiment 2 (for experimental design see Chapter 2). In 
the UCMS Experiment 2 the level of adult hippocampal neurogenesis was estimated based on 
the density of DCX-positive neuroblasts. 2-way ANOVA showed that FLX was a significant factor 
affecting density of DCX+ cells in the hippocampal dentate gyrus (FLX factor F (1, 17) = 11.17, p 
= 0.0039; UCMS x FLX factor F (1, 17) = 3.514, p = 0.0781; UCMS factor F (1, 17) = 3.410, p = 
0.0823) (see Figure 28). As the effect of UCMS was not significant, and the behavioural 
phenotype of UCMS-exposed mice was not sufficiently distinct from CNTRL mice, further 




Figure 28 Density of doublecortin-positive (DCX+) cells in the UCMS Experiment 2 
Male BALB/cAnNCrl mice (n=6/group, 10 sections per animal) aged 7 weeks at the beginning of the experiment were 
subjected to UCMS or CNTRL conditions for 7 weeks; fluoxetine (FLX) 10mg/kg or saline (VEH) i.p. injections 
commenced on the 3rd week of UCMS and continued during behavioural testing until mice were culled for brain 
tissue collection; DCX+ cell density calculated using stereological analysis reflects the level of adult hippocampal 
neurogenesis in experimental mice. Data represented as mean±SEM, *p<0.05 derived from post-hoc Bonferroni 
multiple comparisons UCMS vs UCMS FLX. 
4.2  In Experiment 3 UCMS reduces the density of DCX+ neuroblasts and 
their dendritic morphology  
Two-tailed unpaired t-test of DCX+ cell density in CNTRL and UCMS groups showed that in the 
UCMS Experiment 3 stress-exposed group displayed a reduced number of DCX+ neuroblasts in 
the hippocampal dentate gyrus (t=2.954, p=0.01)  (see Figure 29 A and B for representative 
photomicrographs and C for data analysis). To investigate which stage of neuroblast 
maturation was particularly susceptible to UCMS effect, DCX+ cells were classified based on 
the level of maturity of their dendritic tree. 2-way ANOVA for UCMS and neuroblast type 
showed that bith factors significantly affected the density of each type in treatment groups 
(Effect of type F(2,28)=17.3, p<0.001; Effect of UCMS F (1, 14) = 8.725, p = 0.01) Post-hoc 
Bonferroni multiple comparisons between CNTRL and UCMS showed that the density 
reduction was specific to the populations of cells with “EF” type mature-like dendritic trees, 
with their branches reaching into the molecular layer of the DG (see Figure 29 A and B for 
representative photomicrographs and C for data analysis). However, when the dendritic trees 
of these cells were analysed, no difference in the number of processes (two-tailed unpaired t-
test t=0.31, p=0.76) or their length was detected between groups (two-tailed unpaired t-test 




Figure 29 Effect of UCMS on the density and morphology of doublecortin-positive (DCX+) neuroblasts in the UCMS 
Experiment 3 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks. After UCMS exposure mice were subjected to behavioural testing battery, at the end 
of which blood was collected and mice were culled for brain tissue collection. 10 sections per brain were used in 
immunohistochemical staining for DCX as a marker of immature neuroblasts in the hippocampal dentate gyrus. 
Representative photomicrographs of the hippocampal GZ of mice exposed to CNTRL (A) or UCMS (B) conditions show 
DCX+ cells and their dendritic trees, scale bar = 500µm (C) The density of all DCX+ neuroblasts (TOTAL) and of the 
“AB”, “CD” and “EF” types classified based on their dendritic tree morphology (D) Average length of DCX+ dendrites 
of all DCX+ cell types (TOTAL) and separately for each neuroblast type (E) the number of processes in “EF” type 
neuroblasts. Data presented as mean±SEM, *p<0.05 derived from unpaired t-test CNTRL vs UCMS; #p<0.05 derived 
from post-hoc Bonferroni multiple comparisons CNTRL vs UCMS 
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4.3 UCMS reduces the percentage of DCX+ cells residing in the SGZ 
As adverse environment has been previously shown to affect migration of the adult-born 
neuroblasts, the effect of the UCMS Experiment 3 on migration distance of the DCX+ cells was 
analysed. For this granular zone was divided into 10 equal migration distance bins, with cells 
bin 0 assigned to the subgranular zone and bin 10 to the layer of GZ bordering with the 
molecular layer of the dentate gyrus. Each DCX+ cell was assigned to the distance bins 
according to the position of its nucleus. 2-way ANOVA of average percentages of cells residing 
in each bin showed that interaction between bin distance and UCMS exposure significantly 
affected cell position (Effect of Interaction F(10,170) = 1.99, p = 0.037; Effect of UCMS F(1,17) = 
1.57, p = 0.227; Effect of distance F(10,170) = 622, p<0.0001). Post-hoc Bonferroni multiple 
comparisons UCMS vs CNTRL within each bin showed that UCMS reduced the percentage of 
DCX+ cells residing in the SGZ (p = 0.005), and a trend towards increase in the percentage of 
cells residing within several relative distance units was found in the UCMS group (see Figure 
30A). Photomicrographs in Figure 30B show examples of DCX+ cells in the DG of the UCMS-
exposed mice which are residing further from the SGZ. However, the average relative distance 
cell bodies of DCX+ neuroblasts migrated from the SGZ was not significantly different between 




Figure 30 Migration parameters of the doublecortin-positive (DCX+) cells in the UCMS Experiment 3 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks. After UCMS exposure mice were subjected to behavioural testing battery, at the end 
of which blood was collected and mice were culled for brain tissue collection. 10 sections per brain were used in 
immunohistochemical staining for DCX as a marker of immature neuroblasts in the hippocampal dentate gyrus. (A) 
the number of neuroblasts residing in the SGZ (0) and in 10 different layers of the granular zone (0.1-1) (GZ) (B) 
photomicrographs of the DCX+ cells in the hippocampal GZ of the UCMS-exposed mice. Arrows point at cells with a 
high relative migration distance (C) Average relative migration distance of DCX+ cell bodies). Data presented as 
mean±SEM, *p<0.05 derived from unpaired t-test; #p<0.05, ##p<0.01 derived from post-hoc Bonferroni multiple 
comparisons CNTRL vs UCMS 
4.4 UCMS does not affect the number of Iba1+ microglia in the 
hippocampal GZ, but increases its density in the mPFC 
To detect signs of microglial activation accompanying decline of AHN, analysis of the number 
of Iba1+ hippocampal microglia in the GZ was conducted. Unpaired two-tailed t-test of 
microglial density showed that no significant effect of UCMS on the number of microglial cells 
was found (t = 1.384, p = 0.187) (see Figure 31A). However, unpaired two-tailed t-test showed 
that density of Iba1+ microglia was increased in the mPFC of the UCMS-exposed group 
compared to control (t = 3.139, p = 0.006) (see Figure 31B). For this analysis, region of interest 
was defined as a 5000µmX5000µm area between stereotactic coordinates +1.70 and +1.90 
relative to Bregma which includes some prelimbic, infralimbic and cingulate cortex (Franklin 




Figure 31 Iba1-positive microglia in the hippocampal GZ and mPFC in the UCMS Experiment 3 
Male BALB/cAnNCrl mice (n=10/group) aged 7 weeks at the beginning of the experiment were subjected to UCMS or 
CNTRL conditions for 6 weeks. After UCMS exposure mice were subjected to behavioural testing battery, at the end 
of which blood was collected and mice were culled for brain tissue collection. 10 sections per brain were used in 
immunohistochemical staining for Iba1 as a marker of resident microglia (A) Density of the Iba1+ cells in the 
granular zone (GZ) of the dentate gyrus (DG) (B) Density of Iba1+cells in the medial prefrontal cortex (mPFC) (C) 
Representative photomicrographs of the microglia in the GZ in CNTRL (top panel) and UCMS (bottom panel) groups, 
10x magnification, scale bar = 500 µm (D) Representative photomicrographs of the microglia in the mPFC region in 
CNTRL (left panel) and UCMS (right panel) groups, scale bar = 500 µm. Top panels show region of interest were 
mPFC microglia was quantified at 2.5x magnification, between stereotaxic coordinates Bregma +1.70 and +1.90. 
Bottom panels show representative images at 10x. Data presented as mean±SEM, **p<0.01 derived from unpaired 
t-test CNTRL vs UCMS. 
5 Discussion 
In this chapter, effect of UCMS on a number of parameters reflecting the state of AHN, as well 




5.1 Possible reasons for paradoxical neurogenic effects in the UCMS 
Experiment 2 
In the UCMS Experiment 2 contrary to expectations, the DCX+ cell density was increased by 
UCMS exposure, an effect which was blocked by FLX treatment. There are a number of reasons 
which could have caused such an effect. Firstly, behavioural data suggested that the CNTRL 
group in this experiment also experienced a level of stress, potentially due to single housing 
and daily injections. Single housing has been shown previously to reduce AHN and impair 
negative feedback inhibition of the HPA axis (Evans et al., 2012; Spritzer et al., 2011). Indeed 
DCX+ cell density of CNTRL group in this experiment is strikingly similar to DCX+ cell density 
reported previously in UCMS-exposed BALB/c mice (Khemissi et al., 2014). On the other hand, 
UCMS-exposed animals were found to be hyperactive, and physical activity such as voluntary 
running has a very strong proneurogenic effect (Farioli-Vecchioli et al., 2014; van Praag et al., 
1999). Therefore, it is possible that if these mice spent more time moving around the cage, it 
could have had a stimulating effect on their neurogenesis. If this is the case, it is unclear why 
FLX treatment reversed this effect, as FLX did not reverse UCMS-induced hyperactivity in other 
behavioural tests. One possible explanation could come from the understanding of the HPA 
axis state of these animals. As was shown in Chapter 2, both CNTRL and UCMS-exposed 
animals displayed hypoactive HPA axis which responded to acute stress with suppressed CORT 
elevation, and FLX was only able to restore normal HPA axis response in the CNTRL group. This 
hypoactive HPA axis profile resembles the profile of antidepressant-resistant mice in a 
previous UCMS study (Khemissi et al., 2014). In this study a subgroup of mice displayed similar 
hyporesponsive HPA axis, which coincided with absence of FLX effect on some behavioural 
deficits including anhedonia in the NSF, and on AHN, thereby suggesting that hyporesponsive 
HPA axis leads to antidepressant resistance. The level of DCX+ cell density in antidepressant 
resistant mice was comparable to that in the FLX-treated groups in UCMS Experiment 2. 
Moreover, a recent study also showed that in a group of mice with hyporesponsive HPA axis 
FLX reduced cell proliferation and caused a trend towards decline in DCX+ cells, resembling the 
present data (Surget et al., 2016). Therefore, it is possible to suggest that in the BALB/cAnNCrl 
strain of mice, UCMS induces a fluoxetine-resistant phenotype attributed to hypoactivity or 
hypersuppression of the HPA axis. Factors such as single housing and stress of daily injections 
in control groups additionally complicated this data, therefore another UCMS experiment with 
improved control conditions was necessary to disentangle observed effects.  
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5.2 AHN in the UCMS Experiment 3 
In a UCMS Experiment 3 control animals were pair housed and no antidepressant treatment 
was applied to avoid effect of daily injections while a valid UCMS protocol was being 
established (for experimental design see p.93). This time, in line with previous studies, UCMS 
exposure reduced the number of DCX+ neuroblasts in the dentate gyrus. As DCX comprises a 
wide variety of neuronal progenitors at different stages of neuronal maturation, the DCX+ cells 
were classified into subtypes based on their dendritic morphology to estimate which stage of 
maturation was most affected by UCMS. Data analysis showed that UCMS selectively reduced 
the number of neuroblasts with more mature dendritic tree appearance (EF type), potentially 
corresponding to postmitotic type 3 progenitors. This finding is in line with two previous 
studies which also identified a reduction in DCX+ cell population with complex dendritic 
morphology following UCMS or chronic CORT exposure (Lussier et al., 2013; Vega-Rivera et al., 
2016). 
Several potential mechanisms might underlie the UCMS effect on EF-type DCX+ cell 
population. Low number of DCX+ cells with developing dendritic trees might be reflecting low 
rate of neuronal maturation, higher cell death among maturing neuroblasts, reduced 
dendritogenesis or dendritic atrophy. A number of previous studies showed a reduction in 
dendritic length or branching following chronic stress exposure in mature granule neurons of 
DG and in other areas, such as CA3 and the mPFC, suggesting that this effect is not specific to 
immature neurons and therefore is more likely to be a result of occurring atrophy rather than 
aberrant development (Bessa et al., 2009; Sousa et al., 2000).  Moreover, in the latter study, 
mPFC was the only region where dendritic atrophy was also accompanied by a reduction of 
spine density, suggesting that chronic stress might have a stronger effect on synaptic plasticity 
in this region. To detect if EF-type cells also showed signs of dendritic deficit, their dendritic 
length and branching was measured by manual tracing of dendritic trees visualised by DCX 
staining. However, no difference in the number or length of branches was identified. The 
absence of effect could be due to methodological limitations of this study. It is possible that 
applied methodology did not allow to detect dendritic tree changes as it was limited to DCX+ 
cells, while many studies reporting dendritic deficit previously utilised Golgi impregnation 
method which allows tracing of dendrites of prenatally-born as well as adult-born mature 
neurons. Moreover, DAB staining and 40µm thickness of sections in our study did not allow to 
trace the most distal parts of the dendritic tree. Unfortunately, it was not possible to perform 
Golgi impregnation in this study as the tissue was perfused with formaldehyde.  
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5.3 UCMS effect on neuroblast migration in the GZ 
A recent study of the pattern of cell migration in SGZ neuroblasts found that radial migration 
into the GZ was restricted to later stages of DCX expression most likely corresponding to EF 
type morphology (Sun et al., 2015). Therefore, we decided to assess if UCMS affected the 
migration pattern of DCX cells. For that, position of DCX+ cell bodies relative to the SGZ was 
estimated according to a method suggested by Han et al. (2016). The analysis showed that in 
the UCMS group, a significantly smaller percentage of cells remained in the SGZ, and a trend 
towards increase in the percentage of cells was observed in a number of deeper GZ layers. This 
data suggests that UCMS promoted radial migration of immature neuroblasts. While little is 
known regarding the effect of stress on neuroblast migration, a number of other pathological 
conditions have been shown to induce cell migration in the DG. The most well-characterised is 
the effect of kainic acid  - induced seizures used to model temporal lobe epilepsy. Jessberger et 
al. (2007) showed that kainic acid injections induced appearance of ectopical granular neurons 
on the hilar/CA3 border, which were suggested to contribute to increased excitability. While 
this phenotype has little in common with those observed in our study, it provides evidence 
that pathological stimuli can promote neuroblast migration. In addition, chronic 
neuroinflammation induced by intraventricular administration of LPS has been shown to 
increase migration distance of newly born neurons (Belarbi et al., 2012). Interestingly, 
increased neuroblast migration was described in a number of gene knockout phenotypes, 
some of which are highly relevant for the present study. Fitzsimons et al. (2012) described GR 
knockdown in neural progenitors in vivo, which resulted in increased neuroblast migration into 
the GZ, accompanied by hippocampal-dependant contextual memory deficits. This parallels 
the potential involvement of glucocorticoid signalling in observed effects. Moreover, a 
knockdown of two schizophrenia-related genes, disrupted in schizophrenia 1 (DISC1) and 
phospholipase C-β1(PLC- β1), was also accompanied by increased neuroblast migration (Duan 
et al., 2007; Manning et al., 2012). Interestingly PLC-β1 knockdown also induced spatial 
memory impairment and hyperlocomotion, while mutations in DISC1 have been linked to 
mood disorders (Thomson et al., 2014). Therefore, evidence exists that increased migration in 
the DG could have negative consequences for hippocampal-dependent behaviour and might 
be linked to glucocorticoid signalling.  
5.4 Microglial density and its possible link with AHN changes  
As microglial activation has been implicated in the effect of chronic stress on adult 
hippocampal neurogenesis, we wanted to investigate if microglia might be involved in the 
observed effects of UCMS. As microglial activation frequently leads to increase in microglial 
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density due to proliferation of these cells or recruitment of macrophages from the 
bloodstream, the number of Iba1+ cells is often used as an estimate of the level of microglial 
activation. However, no significant change in microglial number in the dentate gyrus has been 
observed in this study. While several studies showed increase in microglial number upon 
chronic stress exposure (Farooq et al., 2012; Tynan et al., 2010), other studies report decrease 
in the number of microglial cells and appearance of dystrophic hyperramified phenotype which 
follows initial microglial activation, subsiding after weeks of chronic stress exposure (Hinwood 
et al., 2012; Kreisel et al., 2014). Walker et al. (2013) argues that these discrepancies could be 
due to the methodology used to assess the number of Iba1+ cells. Some studies employ 
thresholding method to quantify the immunostaining, as opposed to estimating cell density 
based on cell counts, as it was done in the UCMS Experiment 3. Unlike cell counting, threshold 
analysis does not distinguish between increase in the immunostained surface due to enlarged 
cell body or cell numbers, as it would be in case of microglial activation, and increases in the 
number and length of processes, as in the case of dystrophic hyperramification (Walker et al., 
2013). Moreover, evidence exists that chronic stress paradigms involving heterotypic stressors 
as opposed to repeated stressors such as restraint or social defeat may not induce microglial 
activation (Kopp et al., 2013). This difference was attributed to a higher corticosterone levels 
induced by heterotypic stress, known to limit microglial activation upon stress (Sugama et al., 
2013). Finally, some studies show that chronic stress exerts its main effect on microglial 
activation in areas other than dentate gyrus, such as nucleus accumbens, amygdala and the 
prefrontal cortex (Couch et al., 2013; Tynan et al., 2010). Indeed, the number of microglial cells 
was increased in the PFC of UCMS-exposed mice in this experiment, confirming that 
methodology used was capable of detecting stress-induced microglial proliferation. Previously 
chronic stress-induced microglial activation has been described to take place simultaneously in 
the hippocampus and the PFC (Wohleb et al., 2012), therefore it is somewhat surprising that 
microglial density was selectively increased in the PFC area. However, previous studies also 
suggested that the PFC is more sensitive to chronic stress than the hippocampus, as indicated 
by the suppression of glutamatergic transmission upon repeated stress which was present in 
the former but not the latter region (Yuen et al., 2012). At the same time PFC has been shown 
to be less prone to microglial dystrophy following chronic stress, which could be another 
reason why microglial increase was still present at the time of sacrifice in this area (Kreisel et 
al., 2014). Interestingly, dendritic atrophy in the PFC upon stress exposure is a well-described 
phenomenon (McEwen and Morrison, 2013; Radley et al., 2008). In light of this it is interesting 
to speculate if observed increase in microglial density could be related to this phenomenon 
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and if potential increase of proinflammatory signalling in the PFC could have indirectly 
influenced dendritic development in the hippocampal DG. 
5.5 Contribution of systemic factors to the antineurogenic effects of UCMS 
Next the combined predictive relationship and individual contributions of plasma measures 
reported in the previous chapter, microglial number and AHN has been evaluated using the 
explorative approach of a stepwise multiple linear regression. Stepwise multiple linear 
regression with backward method of predictor entry eliminates factors which do not improve 
the prediction of the dependant variable and presents the combination of factors which best 
explains changes in the outcome. UCMS exposure and neurobiological changes observed in 
this study, including CRP and leptin plasma levels, Iba1 hippocampal density and plasma levels 
of CORT measured in unstimulated animals and physically stressed animals were initially 
included into the model. However multiple regression showed that leptin and Iba1 did not 
contribute to the variation in the density of DCX+ cells, while UCMS exposure factor combined 
with unstimulated CORT and post physical stress CORT levels and plasma CRP significantly 
predicted almost 90% of variation in the density of DCX+ cells. Beta coefficients show that 
baseline CORT and CRP had negative relationship with DCX levels, which is line with the notion 
that inflammation and overactivation of the HPA axis negatively impact AHN. However positive 
relationship with post-physical stress CORT suggests that excessive suppression of the HPA in 
response to acute stress, potentially caused by UCMS, was detrimental for neurogenesis. This 
notion is line with the previous studies showing that some mice respond to UCMS exposure 
with a hypersuppression of the HPA axis, which has linked to inability of antidepressants to 
exert their proneurogenic effects (Khemissi et al., 2014). As for the lack of predictive effect of 
the microglial number, the involvement of the immune system activation was nonetheless 
confirmed by the predictive ability of the CRP levels. Therefore, it is possible that a factor more 
specifically reflecting microglial activation rather than proliferation, such as activation marker 
expression, would show a stronger role of microglia in these effects.  
5.6 Limitations to the study of neurogenesis in UCMS experiments 
In the studies described in this chapter density of DCX+ cells measured 7 to 9 days after the 
end of UCMS was used as an estimate of the level of adult neurogenesis, which presents a 
number of limitations. DCX is frequently used as a correlate of AHN, as its expression in the 
adult brain is almost exclusively confined to the immature neurons of the neurogenic regions 
(Ming and Song, 2005). However a single measure of DCX levels 7 days after the end of UCMS 
exposure might have a limited ability to reflect the changes in AHN which occurred during 
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previous weeks of UCMS. On the other hand, as DCX is expressed during different stages of 
neuronal differentiation, the population of DCX+ cells is likely to include a mixed population of 
cells which began differentiation 3 days to 4 weeks before the time of sacrifice (Kempermann, 
2010). Importantly, DCX levels give only an indirect indication of the changes to the level of cell 
proliferation and survival in the dentate gyrus, as it is not possible to decipher from this data 
wether reduction in DCX levels was due to reduced proliferation, increased cell death or 
reduced commitment of cells to neuronal lineage. Bromohydroxyuridine (BrdU) administration 
during the UCMS exposure could have allowed to investigate these processes in more detail.  
Another limitation to the study of adult neurogenesis is the absence of any behavioural data 
reflecting the state of neurogenesis-dependent cognitive functions. Indeed, it has been shown 
previously that reduction of neurogenesis in mouse models of depression is associated with 
behavioural deficit in spatial and associative memory tasks which have been shown to be 
neurogenesis-dependent (Darcet et al., 2016). For instance, Surget et al. (2016) showed 
improvement of spatial memory in the Morris water maze by fluoxetine treatment only in 
antidepressant responders which also displayed increased neurogenesis, but not in 
antidepressant-resistant UCMS exposed BALB/c mice. Darcet et al. (2014) showed cognitive 
deficits in mice exposed to the neuroendocrine model of depression (chronic corticosterone 
administration) in contextual fear conditioning and Barnes maze, which have been previously 
associated with AHN (Deng et al., 2010). Inclusion of these tests in our UCMS experiments 
could have demonstrated whether reduction in neurogenesis seen in Experiment 3 had 
behavioural consequences for neurogenesis-dependant cognitive functions. 
6 Conclusions 
Overall, these data show that behaviourally validated UCMS exposure compared to 
appropriate control conditions in BALB/cAnNCrl mice, reduced the level of immature 
neuroblasts, with the most mature population of the DCX+ cells being the most affected by the 
UCMS. As the maturity of the DCX+ cells was evaluated based on their dendritic tree 
morphology, this finding also goes in line with studies showing the detrimental effect of 
chronic stress on dendritic and spine density. Next the results of this chapter showed that 
UCMS stimulated migration of immature neuroblasts away from the SGZ into deeper layers of 
the GZ. While other detrimental factors such as LPS and kainic acid exposure, as well as GR and 
schizophrenia related gene knockouts have been previously shown to increase the distance of 
DCX+ cell migration (Belarbi et al., 2012; Fitzsimons et al., 2012; Jessberger et al., 2007), this 
effect has not been shown in UCMS before. This finding extends the range of antineurogenic 
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effects known to be exerted by the UCMS. In the future studies, analysis of dendritic 
morphology of mature neurons in the hippocampus as well as in other stress-responsive brain 
regions, such as PFC, could show if effects of UCMS on dendritic morphology extend beyond 
immature neurons. Antidepressant drugs administered via a non-injection route could also 
help to evaluate if indeed UCMS induced an antidepressant-resistant phenotype in 





Chapter 4 Genome-wide gene expression 
changes in UCMS model 
1 Introduction 
Chapters 2 and 3 revealed a variety of behavioural and neurobiological phenotypes induced by 
UCMS protocols used, as distinct as hyperactivity and deficit in grooming behaviour, systemic 
proinflammatory changes and those localised to a particular brain area (PFC), reduction of 
hippocampal neurogenesis and in the level of appetite-regulating hormone leptin. Such a 
variety of changes suggested that UCMS might have affected multiple signalling pathways in 
different brain areas. Thus this chapter is dedicated to a study of these pathways and a search 
for common regulators interconnecting them to provide novel insights into the mechanisms of 
chronic stress response.  
One of the ways to study neurobiological mechanisms in their full complexity is to utilise 
hypothesis-free explorative approach of a genome-wide transcriptome changes in selected 
tissues and brain regions. This approach is currently being widely utilised in clinical depression 
research to discover novel genes and pathways involved in the neurobiology of depression 
based on post-mortem brain tissue (Gao et al., 2015) and peripheral blood (Hepgul et al., 
2016), and to detect biomarkers of depression subtypes (Xu et al., 2015) and of antidepressant 
response (Cattaneo et al., 2016) in peripheral blood cells. 
1.1 Brain regions implicated in depression and in chronic stress research 
The importance of a particular brain region in depression research is partly determined by the 
evidence of anatomical abnormalities in this region in depressed patients detected by 
neuroimaging studies. The majority of the research on depression focuses on the brain areas 
of the cortico-limbic circuit, which include the hippocampus, hypothalamus, amygdala, nucleus 
accumbens and the PFC (Wang et al., 2012). Reduction in hippocampal volume is one of the 
most consistent findings in the neuroimaging studies (Lorenzetti et al., 2009), however a 
number of post-mortem and imaging studies have reported decreased volume and activity in 
the PFC (Drevets et al., 1997; van Tol et al., 2014). The role of PFC in depression was further 
supported by the evidence from the deep brain stimulation (DBS) trials, showing that DBS over 
PFC and ACC produces an antidepressant effect (Berlim et al., 2014; Levkovitz et al., 2009). 
Investigation of PFC pathology in animal models of depression demonstrated that exposure to 
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chronic stress and increased glucocorticoid levels causes damage and neurodegenerative 
changes in the PFC, such as microglial activation (Hinwood et al., 2013), atrophy of pyramidal 
neurons (Cerqueira, 2005), dendritic atrophy (Dias-Ferreira et al., 2009; Liston et al., 2006) and 
reduction of synaptic proteins expression and synaptic currents (Li et al., 2011; Müller et al., 
2011). 
1.2 Gene expression changes induced by chronic stress in the rodent brain 
A number of previous animal studies took advantage of the availability of the brain tissue to 
study gene expression changes in brain regions previously implicated in depression. Most 
transcriptomic studies of chronic stress effects in rodents focused on the consequence of 
stress on gene expression in the hippocampus. Hippocampus has been shown to be 
particularly sensitive to stress potentially due to a high expression of the glucocorticoid 
receptor activated by CORT hormone released in the course of stress response (McEwen, 
1999). GR activation is thought to lead to an induction of long term potentiation observed in 
the hippocampus following stress (Datson et al., 2012). Taking into account hippocampal role 
in learning and memory it has been suggested that these changes underlie cognitive 
impairment and adaptive memory changes in response to stress exposure (Kim et al., 2006). In 
addition, gene expression in the hippocampus is investigated as a way to discover pathways 
involved the effect of chronic stress on adult hippocampal neurogenesis (Datson et al., 2012; 
Surget, Wang, et al., 2008).  
Thus a number of datasets incorporating hippocampal gene expression changes upon chronic 
stress are available to date. While these studies differ significantly in their experimental 
design, from the species and types of chronic stress used, to the microarray analysis methods 
employed, some general patterns could be detected in these studies. The total number of 
genes for which their expression is significantly affected by stress exposure varies from below 
50 to over 700, however fold changes reported rarely exceed 3-fold. Both rat and mouse 
studies find activation of immune response-related gene networks and signalling pathways 
often centred around nuclear factor kappa B (NF-kB). As such, Gray et al., (2014) showed that 
NF-kB pathway was activated in the hippocampi of adult male C57/BL6 subjected to 21 days of 
chronic restraint stress. Similar effect was observed in the hippocampi of four different  mouse 
strains including BALB/c and C57/BL6 exposed to chronic mild stress, whereby weighted gene 
co-expression network analysis identified activation of a gene network regulated by NF-kB1  
(Malki et al., 2013, 2015). The activation of inflammatory pathways could be related to the 
microglial activation described by some studies in this region upon chronic stress. A number of 
other studies investigating the effect of chronic mild or restraint stress on hippocampal gene 
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expression in rats and mice identified signalling pathways involved in cell fate, such as cell 
apoptosis (Bergström et al., 2007), proliferation and cell cycle control (Liu et al., 2010), axonal 
guidance and cell migration (Datson et al., 2012; Jungke et al., 2011; Zitnik et al., 2013). These 
findings go in line with dendritic atrophy and decrease in hippocampal neurogenesis known to 
be induced by chronic stress exposure.  
Another region frequently assessed in gene expression studies of chronic stress effect is  
frontal and prefrontal cortex. Similar to the studies on the hippocampus, studies looking at the 
gene expression in the frontal and prefrontal cortex found a variation in the number of 
affected genes. Involvement of cell proliferation, differentiation and apoptosis pathways have 
also been described in rats and C57/BL6 and BALB/c strains of mice exposed to chronic mild 
and restraint stress (Liu et al., 2010; Orsetti et al., 2008; Tordera et al., 2011). Interestingly one 
study investigating gene expression changes in PFC of C57/BL6 mice exposed to chronic mild 
stress found a strong evidence for the involvement of the circadian rhythm pathway as many 
circadian rhythm genes, such as Clock, Period 1 (Per1) and Per2 were downregulated in this 
region (Erburu et al., 2015). Expression of circadian rhythm genes has been also investigated 
individually in a number of previous studies, which showed their downregulation in the PFC as 
well as in the hippocampus of rats exposed to chronic mild stress (Calabrese et al., 2016). In 
addition, reduced amplitude in the Per2 expression upon UCMS has been found in the 
suprachiasmatic nucleus (SCN) of the hypothalamus in C57/BL6 mice (Jiang et al., 2011; Logan 
et al., 2015a). These findings go in line with data obtained from post-mortem tissue of 
depressed patients, which showed that circadian fluctuation of many genes including the clock 
genes is decreased in depressed patients in a number of limbic regions, including dorsolateral 
PFC, ACC and the hippocampus. 
Another region frequently included in gene expression analysis of chronic stress effects is the 
hypothalamus. The most obvious role of the hypothalamus in depression stems from the CRH-
releasing function of its paraventricular nucleus and its reciprocal connections with the 
amygdala and the hippocampus. Hypothalamus also receives neuroendocrine input from the 
gut metabolic hormones ghrelin and leptin and sends it to the VTA implicated in reward-
related behaviour (van Zessen et al., 2012). In addition, the SCN is a major regulator of the 
circadian clock, relevant for sleep disturbance and alteration of molecular circadian rhythms 
observed in depression (Li et al., 2013).  Jungke et al. (2011) found 152 transcripts differentially 
expressed in the rat hypothalamus upon chronic restraint stress exposure, with 
neurotransmitter signalling, oxidative stress and immune pathways being implicated. Another 
study investigating the effect of 15 days of chronic restraint in ICR mice focused on the food 
139 
 
intake related  genes, and found change in ghrelin and proopiomelanocortin gene expression, 
while decrease in plasma levels of leptin was not associated with gene expression changes in 
the hypothalamus (Jeong et al., 2013). Gene expression changes of ghrelin and leptin upon 
chronic stress exposure were also investigated in the PFC, where ghrelin and ghrelin receptor 
were found to be increased in contrast to leptin and leptin receptor which were decreased in 
UCMS-exposed rats (Liu et al., 2015). These findings implicate PFC in the weight and appetite 
changes induced by chronic stress in animal models of depression. 
1.3 Comparison of gene expression changes in different brain regions 
Very few genome-wide gene expression studies compared transcriptomic profiles of different 
brain regions upon chronic stress exposure. Surget et al. (2008) showed that in BALB/c 
exposed to UCMS more genes (292) were affected in the amygdala compared to 245 genes 
differentially expressed in the cingulate cortex and 158 in the hippocampal dentate gyrus. In 
the amydgala neurotransmitter signalling pathways such as GABA, glutamate and serotonin, as 
well as various kinase pathways were enriched among activated genes, while a strong 
enrichment of oligodendrocyte-related genes was observed among the downregulated 
transcripts. Interestingly, pathway analysis was inconclusive in other regions. Little overlap 
among the brain regions was observed in this study.  Similarly Liu et al. (2010) described bigger 
gene expression changes in BALB/c mice upon UCMS in the cerebral cortex (102 genes) 
compared to the hippocampus (60 genes). However, in this study a bigger overlap than in the 
study by Surget et al. (2008) between the two areas was observed, with 14 genes changed in 
the same direction in the two areas. These genes included those involved in glutamate 
signalling, apoptosis, neuronal differentiation and immune response. Authors also highlighted 
an overlap in cholecystokinin (Cck) upregulation in both areas, which relevance stems from the 
implication of Cck signalling in depression in the previous literature (Becker et al., 2008; Vialou 
et al., 2014). 
Many of the signalling pathways found to be involved in these studies are relevant for the 
behaviour and neurobiology observed in our UCMS experiments. This together with the 
behavioural and histopathological changes described in the previous chapters prompted us to 
study genome wide transcriptome of the three brain regions – the hippocampus, the PFC and 
the hypothalamus. The gene expression study was designed primarily as an explorative 
analysis aimed to identify novel molecular targets and pathways involved in UCMS effects in 
selected brain areas.  However, a number of more specific questions were expected to be 
resolved by the transcriptomic assay. Firstly, the gene expression study was expected to 
expose the extent of the HPA axis alteration by revealing GR and GR related genes expression 
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changes in the hippocampus and CRH expression in the hypothalamus. Secondly, we 
hypothesised that in line with the previous studies and our findings, we would see activation of 
the immune pathways in some of these regions, which could partly explain CRP elevation and 
neurogenesis decline in UCMS-exposed animals. Third, alteration of factors which could affect 
neurogenesis, such as brain derived neurotrophic factor (Bdnf) and serotonergic and 
glutamatergic signalling were also expected to be revealed in the hippocampus. 
2 Methods 
2.1 Experimental design of the UCMS Experiment 4 
In parallel to the UCMS Experiment 3, a separate  cohort of animals was subjected to control 
(n=8) and UCMS (n=8) conditions as described in the UCMS Experiment 3 section 6.1.1 
according to the UCMS schedule in Table 8 for 4 weeks as depicted in Figure 32. Behavioural 
testing for this group consisted of sucrose preference measured once weekly over 2 nights as 
described in section 3.3.2 of Chapter 2 and a short behavioural testing battery which included 
open field, splash test, light-dark box, novelty suppressed feeding and cookie test conducted as 
described in sections 3.3.4-3.3.7 and 3.3.10 of Chapter 2 according to the schedule in Table 10. 
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Figure 32 Experimental design of UCMS Experiment 4  
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (UCMS) or control (CNTRL) for 4 weeks 
(n=8/group) and subsequently tested in a short behavioural testing battery, after which fresh frozen brain tissue was 
collected and selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal cortex (PFC) were 















Table 10 Schedule of behavioural testing conducted in the UCMS Experiment 4  
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (UCMS) or control (CNTRL) for 4 weeks 
(n=8/group) and subsequently tested in a short behavioural testing battery shown, after which fresh frozen brain 
tissue was collected and selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal cortex (PFC) 




















8:58 13:12 14:00 10:14 12:30 
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9:10 13:24 14:07 10:21 12:45 
3 CNTRL 
 
9:22 13:46 14:14 10:28 13:00 
4 UCMS 
 
9:34 13:58 14:21 10:35 13:15 
5 CNTRL 
 
9:46 14:10 14:28 10:42 13:30 
6 UCMS 
 
9:58 14:22 14:35 10:49 13:45 
7 CNTRL 
 
10:10 14:34 14:42 10:56 14:00 
8 UCMS 
 
10:22 14:46 14:49 11:03 14:15 
9 CNTRL 
 
10:34 14:58 14:56 11:10 14:30 
10 UCMS 
 
10:46 15:10 15:10 11:17 14:45 
11 CNTRL 
 
10:58 15:22 15:17 11:24 15:00 
12 UCMS 
 
11:10 15:34 15:24 11:31 15:15 
13 CNTRL 
 
11:22 15:46 15:31 11:38 15:30 
14 UCMS 
 
11:34 15:58 15:38 11:45 15:45 
15 CNTRL 
 
11:46 16:10 15:45 11:52 16:00 
16 UCMS 
 
11:58 16:22 15:52 11:59 16:15 
 
2.2 RNA extraction 
After completion of the UCMS protocol and application of the shortened behavioural testing 
battery (4 days) animals were anaesthetised with Euthatal i.p. (Merial Animal Health Ltd, 
Harlow, UK) at a dose of 40 mg/kg pentobarbital sodium. After confirmation of a deep 
anaesthesia by the loss of righting and pain reflexes and slowing of the rate of respiration, 
dislocation of the neck was performed. Following decapitation brains were removed from the 
skull and placed dorsal side down on a wetted filter paper on a petri dish kept on ice. First the 
brain was placed with the dorsal side facing down and the hypothalamus was dissected as a 
rectangle along the lateral border 2 mm from either side of the third ventricle from the optic 
chiasm to the posterior border of the mammillary bodies, and the thalamus dorsally (Quennell 
et al., 2011). Next the brain was placed with the ventral side facing down and cortex exposed. 
The cerebral halves were opened out from the midline, after cutting through the corpus 
142 
 
callosum. Approximately 3 mm3 of tissue was cut from the anterior part of the frontal lobes 
(from 2.46 mm to 1.34 mm relative to bregma (Franklin and Paxinos, 2012), mainly containing 
the medial prefrontal cortex including some prelimbic cortex, infralimbic cortex, cingulate 
cortex and motor cortex (Spijker, 2011). For the hippocampal dissection, the cortical 
hemispheres were peeled laterally to expose the hippocampus, which was subsequently 
carefully rolled out with a brush. Whole hippocampi were used for RNA extraction. Right and 
left dissected areas were pooled for each sample, while brain tissue from each mouse was 
analysed as individual samples. Dissected brain areas were immediately flash frozen on dry ice. 
Total RNA was extracted from fresh frozen brain tissue by the guanidine isothiocyanate 
method (Chomczynski and Sacchi, 1987) with TRIzol reagent (Life Technologies, ThermoFisher 
Scientific Inc.) The tissue was homogenised using disposable tissue grinders before Trizol 
reagent was added to the sample tube. Next samples were transferred to Phase lock gel heavy 
tubes (Scientific Laboratory supplies, UK), and after short incubation at room temperature with 
chloroform (Sigma-Aldrich, UK) were centrifuged at 13000rpm to separate the nucleic acid 
phase. The top aqueous layer was transferred to a new tube and RNA was precipitated with 
isopropanol (Sigma-Aldrich, UK). After removal of isopropanol the precipitate was washed in 
ethanol and redissolved in DNA-RNAase free water. The quality of the extracted RNA was 
assessed using 1% agarose gel electrophoresis and spectrophotometry. The 260/280 ratio was 
over 2 in all samples indicating a high level of purity in the extracted nucleic acid samples. To 
remove contaminating DNA from RNA samples DNase digestion of samples was performed 
using the Qiagen Rnase-Free DNase Set (79254, Qiagen, UK) followed by column-based sample 
purification using RNeasy MinElute Cleanup Kit (74204, Qiagen, UK), both performed according 
to the manufacturer’s instructions. Subsequently, RNA integrity numbers (RINs) were assessed 
using the Agilent 2100 Bioanalyzer (G2938-90034, Agilent Technologies, UK) according to the 
manufacturers’ instructions. All samples had RINs of 8.8 or higher, indicating good quality of 
RNA. RNA concentrations were measured using the Quant-iT™ RiboGreen® RNA assay kit 
(R11490, ThermoFisher Scientific Inc.) following the manufacturer’s instructions.  
2.3 Running the microarray 
Genome-wide gene expression was assessed using the MouseWG-6 BeadChip Kit (Illumina, 
US), which measures the expression of 45290 transcripts.  This assay is based on direct 
hybridisation, whereby gene-specific probes are hybridised directly onto the complementary 
labelled cRNA in the samples, and their fluorescent intensity corresponding to the quantity of 
each transcript is subsequently measured by Illumina Scan System.  Sample labelling, 
hybridisation and signal detection and imaging were performed according to manufacturer’s 
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instructions. Briefly 300ng of sample RNA were prepared in 11µl nuclease-free H20 to be used 
for labelling and amplification using the Ambion TotalPrep-96 RNA Amplification Kit (4393543, 
Illumina, US). The concentration of labelled RNA was assessed using Quant-iT™ RiboGreen® 
RNA assay kit (R11490, ThermoFisher Scientific Inc.) and 1.5ug was loaded onto bead chips for 
hybridisation. The hybridisation occurred in the Illumina Hybridisation Oven at 58°C for 15 
hours 20 min. Next day the beads were washed in high temperature (55°C) buffer and ethanol, 
and Cy3-Streptavidin was added to bind the beads to allow for signal detection. Finally, laser-
induced fluorescent signal from the beads was recorded by iScan System Reader.  
2.4 Microarray data analysis 
Images were analysed using the GenomeStudio software (Illumina, US), where the initial 
quality control did not detect any outliers based on average signal intensities. Signal intensity 
data generated by GenomeStudio was pre-processed using the R package Lumi (Du et al., 
2008). Pre-processing included the following transformations using functions of the Lumi 
package. Background correction using bgAdjust function was applied to eliminate background 
signal intensity by subtracting an offset, which is estimated based on the quantile of the 
control probes. Variance stabilisation (vst function)  transformed the expression values based 
on the model of the mean-variance relationship of the within-array technical replicates at the 
bead level of Illumina microarray, taking advantage of the high number of technical replicates 
available on the Illumina platform to reduce variance of high and low intensity values (Lin et 
al., 2008). Quantile normalisation (LumiN, method=quantile) normalised the expression values 
by calculating the empirical distribution of the average sample quantiles and using it to index 
the empirical distribution of each original array; log-transformation normalised distribution of 
intensity values (LumiT, method=log2). For the effect of pre-processing on the distribution of 
sample intensities see Figure 33. 
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Only transcripts for which intensity values reached the detection threshold of p<0.01, and 
which were expressed in more than 4 samples to allow for individual variation in each 
treatment group were included into the final statistical analysis (19632 transcripts). Statistical 
analysis of differential expression was performed using the Statistical Analysis of Microarrays 
(SAM) method and R-based software (Tusher et al., 2001). This method identifies significant 
differential expression based on repeated permutations of the data to determine if expression 
of individual genes is related to the experimental group of the sample. It calculates gene-
specific fluctuations of expression in the dataset, and then estimates the ratio of change in 
gene expression between experimental groups to the standard deviation of expression of that 
particular gene. This ratio is represented by the observed score in Figure 39 F, while expected 
score is calculated based on permutations of the data. For genes which expression is 
independent on the group factor the scores are equal, so when their correlation is plotted, 
they align to the equality line (see Figure 39). However, those genes which expression is 
determined by experimental group factor, deviate from the equality line by a varying distance. 
The user adjusts the distance threshold beyond which the genes will be deemed significantly 
differentially expressed. The threshold will therefore determine the false discovery rate (FDR), 
Figure 33 Distribution of Intensity in microarray samples normalised by the pre-processing steps 
RNA samples from the UCMS Experiment 4 were run on a MouseWG-6 BeadChip Kit (Illumina, US) and images 
analysed by GenomeStudio software. Intensity values were than transformed used LumiR pipeline of pre-processing 
steps. Density plot of fluorescent signal intensities before (A) and after (B) pre-processing steps (X axis – density, Y 
axis – intensity units). Boxplot of sample intensities (X axis) before (C) and after (D) pre-processing steps 
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a percentage of genes identified as significant by chance. For PFC data, the threshold was 
adjusted to achieve FDR of 0. For hippocampal and hypothalamic gene expression, the 
threshold allowed FDR of 0.095 which corresponds to 0.05% chance of a false-positive finding 
frequently used in genome-wide gene expression studies (see Figure 39) (Bagot et al., 2016; 
Malki et al., 2016). The dataset for each brain region was analysed separately as a two-class 
unpaired data.  
2.5 Pathway analysis 
Significant pathway, function and upstream regulator analysis was conducted through the use 
of QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City USA, 
www.qiagen.com/ingenuity). IPA® utilised the right-tailed Fisher Exact Test to calculate the p-
value of a pathway, function or an upstream regulator. In this method, the p-value for a given 
pathway or function annotation is calculated by considering the number of differentially 
expressed genes that participate in that pathway and the total number of genes that are 
known to be associated with a given pathway in the selected reference set. The significance 
level for pathways and functions was set at p<0.05. IPA software was also used to generate 
figures illustrating this analysis.  
2.6 Microarray validation by quantitative real-time PCR 
To verify microarray data analysis, expression of 10 individual genes was independently 
assessed in the same mRNA samples using real-time quantitative polymerase chain reaction 
(qPCR). The genes were selected based on their fold changes (a range from the top up- and 
down-regulated genes to allow for the future correlation analysis with qPCR expression values) 
and their functional relevance, that is affiliation with one of the top pathways identified to be 
activated by the pathway analysis (Myl4, Tnnc, Cam2A, Calb2, Slc32a1, Gad1) or association 
with chronic stress or depression by the previous studies (Cck, Cckbr, Per2, Gng7).  
2.6.1 Reverse transcription of mRNA 
For this, firstly mRNA was converted to cDNA by reverse transcription with Superscript III 
reverse transcriptase (Invitrogen Thermofisher Scientific Inc.) following manufacturer’s 
instructions. Briefly 1µg of mRNA was combined with 250 ng of random hexamer primers (Life 
Technologies) and 1mM dNTP mix (Thermofisher Scientific Inc.), incubated for 5 minutes at 
65°C on a heated block to denature RNA secondary structure and quenched on ice for 1 
minute. Next, the following reagents were added to the reaction: 1x First Strand Buffer 
(Invitrogen), 5 mM dithithretiol (Life Technologies), 40 units RNaseOUT™ (Life Technologies) 
and 200 units SuperScript III Reverse Transcriptase. Samples were then incubated at 25ºC for 5 
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minutes, 50ºC for 1 hour, 55ºC for 30 minutes (to remove any secondary structures) and finally 
70 ºC for 15 minutes to terminate the reaction. 
2.6.2 qPCR primer design 
qPCR primers were designed using Integrated DNA Technology (IDT) software 
(Http://www.idtdna.com/primerquest/home/index) based on target genes DNA sequences 
obtained from the NCBI Gene database (Http://www.ncbi.nlm.nih.gov/gene). The primers 
were designed to amplify the exon region targeted by the Beadchip in the microarray. Several 
conditions were met in primer design: forward and reverse primers were selected to have 
minimal GC content, similar length, minimal self-complementarity and no complementarity to 
each other. The length of the amplicon was limited to 70 to 130 base pairs; the amplicon 
sequence melting temperature was tested for single peak melting curves using uMelt software 
(Https://www.dna.utah.edu/umelt/umelt.html). The specificity of the primers to the gene of 
interest was tested in the In silico PCR online software (Http://genome.ucsc.edu/cgi-bin/hgPcr) 
– only primer pairs replicating a single product from the target gene sequence in the in silico 
PCR were selected. Specificity was further confirmed by the melting curve analysis – conducted 
along with the qPCR. Only primer pairs resulting in a single clear peak at predicted 
temperatures in all tested samples were used for the data analysis (for examples of melting 
curves see Figure 34B). The primer oligonucleotides were synthetized by IDT Custom oligo 
synthesis service. On arrival, the oligonucleotides were re-suspended in nuclease-free H20 to a 
stock concentration of 100 μM and a working concentration of 2 μM. For primer sequences 
see Table 11. 
Table 11 Primer sequences used for qPCR to validate the gene expression values derived from microarray analysis of 
RNA collected in the UCMS Experiment 4.  






FORWARD PRIMER REVERSE PRIMER 
Myl4 NM_010858.4 103 TCTGGGTAAAGCACGTTTCTC AGAAGCCATGTGAGTCCAATAC 
Tnnc1  NM_009393.2 82 CCGTGGTAGGAGTGCAG GGAGAGAAAGTCCGGAAGG 
Cck NM_001284508.2 85 GGAGGTGGAATGAGGAAACAA GCACACTCTGGACAGATTTCA 
Camk2a NM_009792.3 102 CATCCTGAACCCTCACATCC GCATCCAGGTACTGAGTGATG 
Cckbr  NM_007627.5 94 TCTATAGTGCCCATAGCCTAGT TTCAGTGCTGGATAAGGAAGG 
Per2 NM_011066.3 94 GTAACAGGGAAGCCACAAGAG TGAGAGGATGTCAGGAGAGATG 
Calb2 NM_007586.1 75 GTGGATCTGGAAAGGAGAGATG CGCAGGCACAACTGTCTAT 
Gng7 NM_001038655.1 97 CCTTCCCTCTGCTTTGTGAA CAATAGTAACACTGGGAGAGTGG 
Slc32a1 NM_009508.2 116 GCGTTTCTGTCGTCCTTTCT  TTTGGTGGTGGTGGTGATG  
Gad1 NM_008077.5 102 CCCTCTTTACAGAACCAGAATCA CTTCAGTGAGATGGCCTAGATG  
Atp5b NM_016774.3 92 GCTGATAAGCTGGCAGAAGA CCTGAGCTCTCGCTTGATATG  
Cst3 NM_009976.4 97 GACTGACTGTCCTTTCCATGAC  CAGGGAGTGTGTGCCTTTC  
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2.6.3 qPCR and its data analysis 
qPCR reaction master mix was assembled in white 96 well qPCR plates (AB-0900/W, 
ThermoFisher Scientific Inc.). All samples assayed for the same gene were included on the 
same plate. The master mix consisted of 5x HOT FIREPol® EvaGreen® qPCR Mix Plus (no ROX) 
(Solis BioDyne), containing DNA polymerase which incorporates EvaGreen fluorescent dye into 
double-stranded DNA; 0.2µM forward and reverse primer mix and nuclease-free water. cDNA 
template (31.25ng) or water was added to the duplicate wells. The reaction was performed on 
a Chromo4 Real-time PCR detector (Bio-Rad Laboratories Inc.) according to the following 
programme: initial denaturation at 95°C for 15 minutes, 45 cycles of denaturation at 95°C for 
30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 30 seconds. Fluorescent 
signal was detected at the end of each cycle. At the end of the protocol a melting curve 
analysis was carried out by detecting the fluorescence during a heating step from 60°C to 95°C 




Figure 34 Example of an output of the quantitative polymerase chain reaction 
Example of an output of qPCRs conducted with primers for Myl4 (in red and orange) and reference genes Atp5b (in 
light and dark blue) and Cst3 (in light and dark green) sequences with aliquots of the same cDNA sample in 
duplicate. (A) Y axis – Log fluorescence detected, X-cycle number, the curves for Myl4 primers cross the threshold 
(dotted line) at around 23rd cycle (Ct=23), the curves for Atp5b and Cst3 cross the threshold at around 17th and 18th 
cycle respectively (CtAtp5b = 17, CtCst3 = 18) (B) Melting curves for each qPCR showing distinct shapes and single peaks 
at separate temperatures for each primer pair confirming their specificity to target amplicons, Y axis - fluorescence, 
X axis - temperature 
Data was extracted with Opticon Monitor 3 (Bio-Rad Laboratories Inc.) software. To calculate 
relative gene expression, cycle threshold (Ct) values for target genes were normalised to the 
reference genes Atp5b and Cst3, and expression ratio was calculated separately for each 
UCMS group sample relative to the average value of all CNTRL group samples using the Pfaffl 
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mathematical model according to the Equation 3 (Pfaffl, 2001). For examples of cycle 





Equation 3 Pfaffl mathematical model used to quantify relative expression of target genes in the qPCR, where E 
target is efficiency of a target gene and E ref is efficiency of a reference gene; ΔCt was calculated by subtraction of 
the Ct value of a replicon of each UCMS group sample (“sample”) from average Ct of this gene in all CNTRL group 
samples (“control”)  
For this analysis, 2 reference genes were selected based on low variation and high expression 
levels in the microarray dataset across all samples and regions accessed, as the reference gene 
is required to have a stable level of expression independent of treatment exposure. The 
variation of a gene’s expression was estimated by calculating its CV in all samples. Among 
genes with low CV only genes with high levels of expression (intensity values ≥12 in all samples 
across all tissues, for distribution of intentisity values across all samples for all genes see Figure 
33B) were considered for reference role to ensure stable PCR results. Based on these two 
parameters, Atp5b and Cst3 emerged as reasonable candidates. Moreover, Atp5b has been 
previously validated as a suitable reference gene for gene expression analysis in a mouse brain 
(Cleal et al., 2014), therefore these two genes were used as reference genes in the Pfaffl 
equation. Fluorescent intensities for both reference genes across all samples are shown in 
Table 12. 
Table 12 Fluorescent intensity values for reference genes ATP5B and CST3 in all samples.  
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (UCMS) or control (CNTRL) for 4 weeks 
(n=8/group) and subsequently tested in a short behavioural testing battery shown, after which fresh frozen brain 
tissue was collected and selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal cortex (PFC) 
were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform.Table shows 
fluorescent intensity values across all samples for ATP5B and CST3 genes used as reference genes in 1PCR analysis 
due to their stable expression in all samples. 
ILLUMINA SAMPLE ID BRAIN REGION GROUP ATP5B CST3 
100994700031_A HIPPOCAMPUS UCMS 13.13213 12.87719 
100994700031_B HYPOTHALAMUS UCMS 13.05731 12.96203 
100994700031_C PFC UCMS 13.3127 12.93862 
100994700031_D HIPPOCAMPUS CNTRL 13.15525 12.69969 
100994700031_E HYPOTHALAMUS CNTRL 12.98834 12.78428 
100994700031_F PFC CNTRL 13.13213 13.03099 
100994700036_A HIPPOCAMPUS UCMS 13.10425 12.93862 
100994700036_B HYPOTHALAMUS UCMS 12.93862 13.00695 
100994700036_C PFC UCMS 12.96203 12.93862 
100994700036_D HIPPOCAMPUS CNTRL 13.05731 13.00695 
100994700036_E HYPOTHALAMUS CNTRL 12.80279 12.93862 
100994700036_F PFC CNTRL 12.82541 12.93862 
100994700042_A HIPPOCAMPUS UCMS 13.03099 12.84687 
100994700042_B HYPOTHALAMUS UCMS 13.00695 12.82541 
100994700042_C PFC UCMS 12.93862 13.03099 
100994700042_D HIPPOCAMPUS CNTRL 13.18544 12.71966 
100994700042_E HYPOTHALAMUS CNTRL 12.91753 12.84687 
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ILLUMINA SAMPLE ID BRAIN REGION GROUP ATP5B CST3 
100994700042_F PFC CNTRL 13.03099 12.93862 
100994700047_A HIPPOCAMPUS UCMS 13.03099 12.84687 
100994700047_B HYPOTHALAMUS UCMS 12.96203 12.80279 
100994700047_C PFC UCMS 12.98834 12.91753 
100994700047_D HIPPOCAMPUS CNTRL 13.39013 12.93862 
100994700047_E HYPOTHALAMUS CNTRL 13.03099 12.7431 
100994700047_F PFC CNTRL 13.15525 12.84687 
101070120027_A HIPPOCAMPUS UCMS 13.08105 12.96203 
101070120027_B HYPOTHALAMUS UCMS 13.00695 12.93862 
101070120027_C PFC UCMS 12.93862 12.89598 
101070120027_D HIPPOCAMPUS CNTRL 13.08105 13.00695 
101070120027_E HYPOTHALAMUS CNTRL 12.87719 13.03099 
101070120027_F PFC CNTRL 13.08105 12.71966 
101070120039_A HIPPOCAMPUS UCMS 13.10425 12.7431 
101070120039_B HYPOTHALAMUS UCMS 12.75958 12.96203 
101070120039_C PFC UCMS 13.13213 12.84687 
101070120039_D HIPPOCAMPUS CNTRL 13.18544 12.87719 
101070120039_E HYPOTHALAMUS CNTRL 12.96203 12.87719 
101070120039_F PFC CNTRL 13.10425 12.98834 
3998594044_A HIPPOCAMPUS UCMS 13.27599 12.82541 
3998594044_B HYPOTHALAMUS UCMS 13.08105 13.05731 
3998594044_C PFC UCMS 13.03099 12.71966 
3998594044_D HIPPOCAMPUS CNTRL 13.21062 12.91753 
3998594044_E HYPOTHALAMUS CNTRL 12.89598 12.75958 
3998594044_F PFC CNTRL 13.27599 12.89598 
3998594077_A HIPPOCAMPUS UCMS 13.00695 12.89598 
3998594077_B HYPOTHALAMUS UCMS 13.00695 13.03099 
3998594077_C PFC UCMS 13.03099 12.78428 
3998594077_D HIPPOCAMPUS CNTRL 12.93862 12.7431 
3998594077_E HYPOTHALAMUS CNTRL 12.82541 12.87719 
3998594077_F PFC CNTRL 13.00695 12.80279 
 
The average of ratios normalised to the two reference genes were used in statistical analysis. 
Average group ratio for each gene was compared to the relative control expression level set at 
1 with a 1-sample t-test. To compare the expression values derived from the microarray from 
those obtained with a qPCR, Pearson’s correlation has been conducted between microarray 
values for each target gene and corresponding qPCR-derived group average gene expression 
ratios. 
 Results 
 Behavioural characteristics of the gene expression cohort of the UCMS 
Experiment 4 were similar to that of the UCMS Experiment 3 cohort 
To confirm the presence of behavioural changes in the UCMS Experiment 4 cohort used in the 
gene expression study, mice were subjected to selected behavioural tests from the UCMS 
Experiment 3 testing battery prior to fresh frozen tissue collection. Similar to the results 
described in Chapter 2, UCMS induced deterioration of the coat state and reduction of 
grooming in the splash test in the exposed mice, although in this cohort the onset of effect 
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occurred already after one week of UCMS exposure (Mann-Whitney U = 45, p>0.995 on week 
0; U = 3, p = 0.0002 on week 1; U=5, p = 0.0003 on week 2; U=5, p=0.0002 on week 3; U=28.5 p 
= 0.181 on week 4) (see Figure 35B). Changes in coat state were not accompanied by group 













































Figure 35 Weekly measures of coat state, weight change and sucrose preference in the UCMS Experiment 4 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (UCMS) or control (CNTRL) for 4 weeks 
(n=8/group) and subsequently tested in a short behavioural testing battery, after which fresh frozen brain tissue was 
collected and selected brain regions were subjected to a genome-wide transcriptomic analysis using Illumina 
microarray platform. (A) weekly weight measures in UCMS and CNTRL groups (B) weekly coat state measures in 
UCMS and CNTRL groups (C) average weekly sucrose preference measures taken over 2 consecutive nights to allow 
for sucrose bottle side change; *p<0.05, **p<0.01, ***p<0.001 CNTRL vs UCMS derived from Mann-Whitney U-test 
(coat state) or post-hoc Bonferroni multiple comparisons (sucrose preference). Data represents mean ± SEM 
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Unlike the UCMS Experiment 3, UCMS-exposed group in Experiment 4 did not display 
differences in the locomotor activity measured by distance travelled in the open field arena 
(Student t-test t = 1.385 df = 17, p = 0.184) and in the anxiety measured in the open field test 
(Student t-test t = 0.4193 df = 17, p = 0.68; see Figure 36A,B). Similarly, no difference between 
CNTRL and UCMS groups was found in the anxiety-like behaviour in the light-dark box test 
(Student t-test of latency to enter the light box CNTRL vs UCMS t = 1.532, df = 170, p =0.144; 
Student t-test of time spent in the light box CNTRL vs UCMS t = 0.1437 df = 17, p = 0.887; see 
Figure 36C,D). However similarly to the UCMS Experiment 3, UCMS-exposed mice showed 
reduction of latency to start grooming (Student t-test CNTRL vs UCMS t = 2.67 df = 17, p = 
0.016) and overall grooming time (Mann-Whitney U = 10, p = 0.003) in the splash test (see 
Figure 36E,F). 
2-way repeated measures ANOVA of the sucrose preference showed significant effect of week 
x group interaction (Week X Stress F (3, 6) = 16.63, p = 0.003; Week F (3, 6) = 1.079, p = 0.426; 
Effect of Stress F (1, 2) = 5.759, p = 0.139). Interestingly in this experiment similarly to the 
UCMS Experiment 3 mice displayed weekly fluctuation of preference for sucrose. However 
unlike in the previous experiment, in the UCMS Experiment 4 anhedonia was detected already 
after 1 week of the UCMS exposure. However, upon repeated exposures to the same sucrose 
concentration (1%) the preference fluctuated during subsequent weeks, with UCMS group 





Figure 36 Anxiety and grooming behaviour in the UCMS Experiment 4 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (UCMS) or control (CNTRL) for 4 weeks 
(n=8/group) and subsequently tested in a short behavioural testing battery, after which fresh frozen brain tissue was 
collected and selected brain regions were subjected to a genome-wide transcriptomic analysis using Illumina 
microarray platform. (A) Total distance moved by mice (B) Time spent in the centre zone of the open field arena 
during 5 min test (C) Time spent in the light zone of the light-dark box during 5 min test (D) Latency to enter the light 
zone in the light-dark box test (E) Time spent grooming during 10 min splash test (F) Latency to start grooming in the 
splash; *p<0.05 derived from Mann-Whitney test CNTRL vs UCMS **p<0.05 derived from unpaired two-tailed 
Student t-test CNTRL vs UCMS. Data represents mean ± SEM 
In the novelty suppressed feeding test, UCMS group showed reduced latency to start eating 
the food pellet in the middle of the novel arena, identical to that observed in the UCMS 
Experiment 3 cohort described in Chapter 2 (Mann-Whitney CNTRL vs UCMS U=3, p = 0.0002; 
see Figure 37B). There was no significant difference in the amount of food mice consumed in 
the arena (Student t-test CNTRL vs UCMS t = 2.041, df = 17, p = 0.057) and during the first 10 
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minutes in the home cage (Student t-test CNTRL vs UCMS t = 1.119, df = 15, p = 0.281). UCMS-
exposed mice also showed reduced latency to find and start eating the cookie in the cookie 















































































Figure 37 Behaviour in the novelty suppressed feeding and cookie test in the UCMS Experiment 4. 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (UCMS) or control (CNTRL) for 4 weeks 
(n=8/group) and subsequently tested in a short behavioural testing battery, after which fresh frozen brain tissue was 
collected and selected brain regions were subjected to a genome-wide transcriptomic analysis using Illumina 
microarray platform. (A) Latency to start eating a hidden chocolate cookie in the cookie test (B) Latency to start 
eating the pellet in the middle of the anxiogenic novel arena in the novelty suppressed feeding test (C) Weight of 
pellet consumed by mice in the novel arena of the novelty suppressed feeding test and during the first 10 min on 
return to the home cage; *p<0.05 derived from unpaired two-tailed Student t-test CNTRL vs UCMS, ***p<0.05 
derived from Mann-Whitney test CNTRL vs UCMS. Data represents mean ± SEM 
 
 UCMS exerted the strongest effect on gene expression in the PFC 
For initial data overview hierarchical cluster analysis based on the top 500 variable genes was 
conducted in the R environment. It showed that samples primarily clustered based on the 
brain region they derived from, while within the regions some treatment group – based 
clustering was observed. The PFC samples clustered based on the UCMS exposure, apart from 
2 outlier samples which were excluded from subsequent analysis as can be seen in Figure 38. 
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In the hippocampus only a few control and UCMS-exposed samples clustered together, and no 
clear distinct pattern of expression could be seen on the heatmap for HIP UCMS and CNTRL 
samples. In the hypothalamus no clustering based on stress exposure was observed and the 
heatmap showed visibly uniform gene expression pattern among all hypothalamic samples 




Figure 38 Heatmap of cluster analysis based on the top 500 variable genes. 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (STRESS) or control (CON) for 4 weeks 
(n=8/group) after which fresh frozen brain tissue from selected brain regions (hippocampus (HIP), hypothalamus 
(HYP) and prefrontal cortex (PFC)) were subjected to a genome-wide transcriptomic analysis using Illumina 
microarray platform. The heatmap shows the clustering of samples (top connecting lines) and the heatmap pattern 
of expressionbased on intensity values of top 500 variable genes. The gradient of green and red represents the 
deviation of each sample intensity value for this gene from the mean intensity across all samples. Individual sample 
IDs and their groups highlighted at the bottom of the heatmap. 
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 Differential expression analysis using SAM package yielded the highest 
number of significant genes in the PFC  
Significance Analysis of Microarrays (SAM) method detected 467 differentially expressed genes 
between the UCMS and CNTRL groups in the PFC with FDR of 0. As such a low level of FDR was 
calling a very small number of genes in other regions, FDR level was relaxed to a recommended 
0.1 for the hippocampus and the hypothalamus. Such settings called 46 and 27 differentially 
expressed genes in the hippocampus and in the hypothalamus respectively (see Figure 34). 
 Pathway analysis revealed meaningful pathways, functions and 
predicted upstream regulators in the PFC dataset 
All 467 significantly differentially expressed genes in the PFC derived from the SAM analysis 
were entered into the Ingenuity software for pathway and gene network analysis. Table 9 lists 
top up- and downregulated genes selected based on their fold change (all genes with 
expression increased 1.5 fold and above and all genes with expression decreased 0.65 fold and 
below). 
 
Figure 39 SAM plot of differentially expressed genes in the PFC (A), the hippocampus (B) and the hypothalamus (C). 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress (UCMS) or control (CNTRL) for 4 weeks 
(n=8/group) and subsequently tested in a short behavioural testing battery shown, after which fresh frozen brain 
tissue was collected and selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal cortex (PFC) 
were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform. Figure shows plot of 
the expected (X axis) vs observed (Y axis) relative difference in expression of individual genes between CNTRL and 
UCMS conditions shows genes for which this relationship deviates from the equality line beyond the set threshold of 
false discovery rate (ΔFDR, broken line). FDR of 0 yielded 467 genes significantly increased (in red) or decreased (in 




Table 13 Top up and downregulated genes based on fold change estimation derived from SAM and annotated by Ingenuity based on Entrez gene database.  
Adult male BALB/c mice were exposed to unpredictable chronic mild stress or control for 4 weeks (n=8/group) after which fresh frozen brain tissue from selected brain regions (hippocampus (HIP), 
hypothalamus (HYP) and prefrontal cortex (PFC)) were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform. (For a complete list of the significantly differentially 
expressed genes, see Appendix Table 21). 
TOP UPREGULATED GENES IN THE PFC TOP DOWNREGULATED GENES IN THE PFC 
  GENE Fold 
Change 
Entrez gene name GENE Fold 
change 
Entrez gene name 
1 Myl4 2.232 Myosin, light chain 4 Rgs9 0.285 Regulator of G-protein signalling 9 
2 Tnnc1 2.149 Troponin C type 1 (slow) Tac1 0.286 Tachykinin, precursor 1 
3 Nrgn 2.071 Neurogranin Pcp4l1 0.304 Purkinje cell protein 4-like 1 
4 C17orf96 2.063 Chromosome 17 open reading frame 96 Calb2 0.346 Calbindin 2 
5 Fezf2 2.019 FEZ family zinc finger 2 Cartpt 0.368 CART prepropeptide 
6 Cpne9 1.965 Copine family member IX Gng7 0.373 Guanine nucleotide binding protein (G protein), 
gamma 7 
7 Mef2c 1.878 Myocyte enhancer factor 2C Cartpt 0.481 CART prepropeptide 
8 Dkk3 1.869 Dickkopf WNT signaling pathway inhibitor 3 Slc32a1 0.515 Solute carrier family 32 (GABA vesicular 
transporter), member 1 
9 Ldb2 1.864 LIM domain binding 2 Chn2 0.521 Chimerin 2 
10 Satb1 1.817 SATB homeobox 1 Cacng5 0.526 Calcium channel, voltage-dependent, gamma 
subunit 5 
11 Stx1a 1.785 Syntaxin 1A (brain) Lmo3 0.538 LIM domain only 3 
12 Pvalb 1.765 Parvalbumin Scg2 0.541 Secretogranin II 
13 Nfix 1.737 Nuclear factor I/X (CCAAT-binding transcription 
factor) 
Gad1 0.545 Glutamate decarboxylase 1 (brain, 67kda) 
14 9130024f11rik 1.721 RIKEN cdna 9130024F11 gene Hap1 0.547 Huntingtin-associated protein 1 
15 Zbtb18 1.715 Zinc finger and BTB domain containing 18 Apod 0.560 Apolipoprotein D 
16 Lamp5 1.708 Lysosomal-associated membrane protein family, 
member 5 
Slc17a6 0.561 Solute carrier family 17 (vesicular glutamate 
transporter), member 6 
17 Cck 1.672 Cholecystokinin Slc17a6 0.568 Solute carrier family 17 (vesicular glutamate 
transporter), member 6 
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TOP UPREGULATED GENES IN THE PFC TOP DOWNREGULATED GENES IN THE PFC 
  GENE Fold 
Change 
Entrez gene name GENE Fold 
change 
Entrez gene name 
18 Galnt9 1.648 Polypeptide N-acetyl-galactosaminyltransferase 9 Gad1 0.569 Glutamate decarboxylase 1 (brain, 67kda) 
19 Arhgap32 1.632 Rho gtpase activating protein 32 Tf 0.570 Transferrin 
20 Ccl27a 1.627 Chemokine (C-C motif) ligand 27A Zcchc12 0.571 Zinc finger, CCHC domain containing 12 
21 Ddit4l 1.584 DNA-damage-inducible transcript 4-like Pcp4l1 0.573 Purkinje cell protein 4-like 1 
22 Tex40 1.584 Testis expressed 40 Adra2a 0.577 Adrenoceptor alpha 2A 
23 Sytl2 1.576 Synaptotagmin-like 2 Mobp 0.581 Myelin-associated oligodendrocyte basic protein 
24 Dgkz 1.574 Diacylglycerol kinase, zeta Tiam1 0.587 T-cell lymphoma invasion and metastasis 1 
25 Tshz3 1.568 Teashirt zinc finger homeobox 3 Bcl11b 0.592 B-cell CLL/lymphoma 11B (zinc finger protein) 
26 Camk2a 1.565 Calcium/calmodulin-dependent protein kinase II α Tpbg 0.593 Trophoblast glycoprotein 
27 Pcsk2 1.561 Proprotein convertase subtilisin/kexin type 2 Mag 0.594 Myelin associated glycoprotein 
28 Osbpl1a 1.550 Oxysterol binding protein-like 1A Ppp1r2 0.596 Protein phosphatase 1, regulatory (inhibitor) 
subunit 2 
29 Nuak1 1.547 NUAK family, SNF1-like kinase, 1 Strip2 0.598 Striatin interacting protein 2 
30 Arpp19 1.544 Camp-regulated phosphoprotein, 19kda Meis1 0.600 Meis homeobox 1 
31 Cckbr 1.539 Cholecystokinin B receptor Cacng5 0.604 Calcium channel, voltage-dependent, gamma 
subunit 5 
32 Mapk11 1.538 Mitogen-activated protein kinase 11 Mbp 0.606 Myelin basic protein 
33 Pvrl3 1.537 Poliovirus receptor-related 3 Zic1 0.612 Zic family member 1 
34 Cobl 1.529 Cordon-bleu WH2 repeat protein Clic6 0.617 Chloride intracellular channel 6 
35 Slc17a7 1.528 Solute carrier family 17 (vesicular glutamate 
transporter), member 7 
H3f3a/H3f3b 0.626 H3 histone, family 3A 
36 Ccdc3 1.522 Coiled-coil domain containing 3 Btg1 0.634 B-cell translocation gene 1, anti-proliferative 
37 Arhgef25 1.514 Rho guanine nucleotide exchange factor (GEF) 25 Tmem255a 0.638 Transmembrane protein 255A 
38 Extl1 1.508 Exostosin-like glycosyltransferase 1 Cntnap2 0.650 Contactin associated protein-like 2 




 Canonical pathway analysis identified 17 pathways significantly activated in 
the PFC 
Canonical pathway analysis conducted by IPA™ mapped the differentially expressed genes on 
known canonical pathways, among which 17 were statistically significant (p<0.05) based on 
Fisher’s exact test analysis utilised by IPA. Table 14 lists the significant pathways relevant for 
the brain ordered by their significance level with the ratio showing the proportion of genes 
included in the pathways which were differentially expressed in the dataset, and z-score 
predicting up or downregulation whenever such a prediction could have been made based on 
fold changes of individual genes involved in the pathway. 
Table 14 Canonical pathways deemed significant in the PFC dataset by IPA pathway analysis  
Adult male BALB/c mice were exposed to unpredictable chronic mild stress or control for 4 weeks (n=8/group) after 
which fresh frozen brain tissue from selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal 
cortex (PFC)) were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform. The table 
shows canonical pathways deemed significant in the PFC dataset ordered by the log (p-value) derived from Fisher’s 
exact test, with dataset genes/pathway genes ratio and z-score of predicted pathway up or downregulation, 










2.61 0.05 - Ephb2, Tuba4a, Gng13, Sema4f, Robo3, 
Gng7, Tubb2b, Ephb6, Sema6d, Mag, 
Wnt10a, Efna5, Arhgef6, Lingo1, Mras, 
Myl4, Fzd5, Sema7a, Adamts4 
Glutamate Receptor 
Signalling 
2.12 0.10 - Slc17a7, Slc17a6, Homer1, Grm4, Gng7 
Calcium Signalling 2.03 0.06 2.45 Camk2a, Tnnc1, Myh3, Rcan3, Myl4, 
Mef2c, Itpr1, Camkk2, Camk2g 
Wnt/β-catenin 
Signalling 
2.01 0.06 0.33 Csnk2a2, Nlk, Wnt10a, Dkk3, Sox10, Fzd5, 
Acvr2b, Sox11, Tcf7l2 
GABA Receptor 
Signalling 
1.94 0.09 - Slc32a1, Gabrg1, Gad1, Mras, Ap2s1 
Paxillin Signalling 1.65 0.07 0.45 Actn2, Actb, Arhgef6, Mras, Itgb4, Mapk11 
Thrombin Signalling 1.64 0.05 1.89 Camk2a, Arhgef6, Mras, Myl4, Gng13, 
Itpr1, Mapk11, Gng7, Camk2g 
Gαq Signalling 1.63 0.06 1.13 Napepld, Adrbk1, Mras, Gng13, Arhgef25, 
Itpr1, Chrm3, Gng7 
Ephrin B Signalling 1.50 0.07 - Ephb6, Ephb2, Mras, Gng13, Gng7 
RhoGDI Signalling 1.49 0.05 -0.82 Dgkz, Arhgdig, Actb, Arhgef6, Mras, Myl4, 
Gng13, Gng7 
B Cell Receptor 
Signalling 
1.40 0.05 2.12 Synj2, Map3k10, Camk2a, Inpp5f, Mras, 
Mef2c, Mapk11, Camk2g 
CCR5 Signalling in 
Macrophages 
1.35 0.08 - Mras, Gng13, Mapk11, Gng7 
G Protein Signalling 
Mediated by Tubby 
1.34 0.09 - Mras, Gng13, Gng7 
Triacylglycerol 
Degradation 
1.33 0.14 - Faah, Mgll 
α-Adrenergic 
Signalling 
1.31 0.06 - Adra2a, Mras, Gng13, Itpr1, Gng7 
Glutamate Dependent 
Acid Resistance 
1.30 0.50 - GAD1 
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 Pathway analysis predicted a number of relevant upstream regulators 
Next, the predicted upstream regulators analysis was conducted using the IPA software. Table 
15 lists the top 15 predicted upstream regulators connected to 2 or more differentially 
expressed genes. In some cases, the software could also make a prediction of the direction and 
magnitude of up- or downregulation based on the fold changes data available for target genes 
(activation z-score). 
Table 15 Upstream regulators of differentially expressed genes in the PFC dataset predicted by the IPA software.  
Adult male BALB/c mice were exposed to unpredictable chronic mild stress or control for 4 weeks (n=8/group) after 
which fresh frozen brain tissue from selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal 
cortex (PFC)) were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform. IPA 
pathway analysis predicted upstream regulators in the PFC dataset shown in the table 
  UPSTREAM 
REGULATOR 
GENE NAME ACTIVATION 
Z-SCORE 
P-VALUE N OF TARGET 
GENES 
1 Htt huntingtin -0.004 0.0000 25 
2 Lep leptin -0.970 0.0000 8 
3 Myrf myelin regulatory factor  0.0001 3 
4 Mecp2 methyl-CpG binding protein 2 1.126 0.0001 7 
5 Bdnf brain-derived neurotrophic 
factor 
-0.181 0.0001 9 
6 Hdac4 histone deacetylase 4  0.0001 8 
7 Kmt2a lysine methyltransferase 2A 1.342 0.0002 5 
8 Ntrk2 neurotrophic receptor tyrosine 
kinase 2 
 0.0011 3 
9 Dcc DCC netrin 1 receptor  0.0018 2 
10 Pou4f1 POU class 4 homeobox 1  0.0022 4 
11 Comt catechol-O-methyltransferase  0.0035 2 
12 Mtor mechanistic target of rapamycin  0.0054 3 
13 Arntl aryl hydrocarbon receptor 
nuclear translocator like 
 0.0117 2 
14 Ascl1 achaete-scute family bHLH 
transcription factor 1 
 0.0123 3 
15 Bckdk branched chain ketoacid 
dehydrogenase kinase 
 0.0153 2 
The relationships between the main upstream regulators and their differentially expressed 




 Functional analysis identified functions related to dendritic morphology 
Next, we assessed if differentially expressed genes in the PFC dataset were linked to particular 
functions in the IPA database. IPA functional analysis recognised over a 100 significant 
functions related to the dataset genes, however some of them were not relevant for the brain 
or were based on only 1 gene. Table 16  lists only brain-relevant functions based on 2 or more 
Figure 40 The predicted network of upstream regulators and their target differentially expressed genes in the PFC, 
designed by the IPA software based on the upstream regulator analysis. 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress or control for 4 weeks (n=8/group) after 
which fresh frozen brain tissue from selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal 
cortex (PFC)) were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform. The 
diagram shows the network of upstream regulators linked to genes differentially expressed in the PFC dataset. The 
relative size of the upstream regulator molecules reflects their significance ranking with Huntingtin (Htt), Leptin 
(Lep), myelin regulatory factor (Myrf), methyl-CpG binding protein 2 (Mecp2) and brain derived neurotrophic factor 
(Bdnf) being the top 5 predicted upstream regulators. 
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genes, for which the software could make a prediction regarding its up- or downregulation. 
These functions fell in mostly 3 functional groups: those related to synaptic plasticity, such as 
long-term potentiation or synaptic depression, those related to dendritic morphology, such as 
neurite formation or neuritogenesis and branching of neurites, and those related to cell fate 




















Table 16 Predicted functions associated with the differentially expressed genes in the PFC dataset. 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress or control for 4 weeks (n=8/group) after 
which fresh frozen brain tissue from selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal 
cortex (PFC)) were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform.Pathway 
analysis in the PFC dataset was conducted using IPA software. The listed functions were selected based on their 
relevance for the brain, number of genes related to each function and the ability of the software to make a 
prediction regarding the direction of change (activation z-score). Functions related to synaptic plasticity, dendritic 












long-term potentiation of brain 0.005 -1.177 9 
long-term potentiation of 
cerebral cortex 
0.007 -0.923 8 
neurotransmission 0.009 -0.164 8 
long-term potentiation 0.013 -0.978 10 
release of 
 neurotransmitter 
0.016 -1.718 4 
synaptic depression 0.031 -0.527 6 
Cell Morphology, Cellular 
Assembly & Organization, 
Cellular Development, Cellular 
Function & Maintenance, 
Cellular Growth & Proliferation, 
Embryonic Development, 
Nervous System Development 
& Function, Tissue 
Development 
branching of neurites 0.004 -0.250 13 
Neuritogenesis 0.004 -0.250 15 
dendritic growth/branching 0.008 -1.342 11 
outgrowth of neurites 0.050 1.898 6 
Cellular Assembly & 
Organization, Cellular 
Development, Cellular Growth 
& Proliferation, Nervous System 
Development & Function, 
Tissue Development 
microtubule dynamics 0.003 -0.346 17 
growth of neurites 0.039 2.129 8 
Cellular Development, Cellular 
Growth & Proliferation, Nervous 
System Development & 
Function, Tissue Development 
proliferation of neuronal cells 0.013 0.995 11 
development of neurons 0.001 0.017 20 
Cellular Growth & Proliferation proliferation of cells 0.002 0.512 27 
generation of cells 0.000 0.101 22 
Cellular Development differentiation of cells 0.001 0.460 19 
Lipid Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry 
concentration of lipid 0.007 -2.400 7 
Nervous System Development 
& Function, Tissue Morphology 
density of neurons 0.014 -2.213 7 
Developmental Disorder, 
Neurological Disease, 
Organismal Injury & 
Abnormalities 
cerebral dysgenesis 0.024 0.931 4 
Behavior Behavior 0.037 0.687 8 
Cellular Movement, Nervous 
System Development & 
Function 




 qPCR data replicated the microarray analysis for 10 genes selected 
from the PFC dataset 
10 genes selected from the top differentially expressed genes in the PFC have been also 
measured using qPCR to validate the results of the microarray analysis. The average UCMS 
group relative expression of all 10 selected genes calculated against the expression of two 
reference genes Apt5b and Cst3 significantly differed from CNTRL (see Figure 41A). Moreover, 
relative expression values showed a strong correlation with fold change data derived from the 
microarray analysis (see Figure 41 B). 
 
 
Figure 41 Validation of microarray analysis by qPCR gene expression data 
Adult male BALB/c mice were exposed to unpredictable chronic mild stress or control for 4 weeks (n=8/group) after 
which fresh frozen brain tissue from selected brain regions (hippocampus (HIP), hypothalamus (HYP) and prefrontal 
cortex (PFC)) were subjected to a genome-wide transcriptomic analysis using Illumina microarray platform. (A)
Relative gene expression of 10 genes selected from the list of significantly differentially expressed genes in the 
microarray was evaluated using qPCR by Pfaffl method, normalised to the expression of 2 housekeeping genes 
Atp5b and Cst3. Average relative expression of each gene was significantly different from the control level (p<0.05 
for all genes, derived from 1-sample t-test) (B) For the 10 genes selected for validation by qPCR, there was a strong 




 Small number of differentially expressed genes in the hippocampus and 
the hypothalamus datasets limited the use of the pathway analysis 
In the hippocampus only 12 genes were significantly differentially expressed with FDR=0 (8 
upregulated and 4 downregulated), while in the hypothalamus only 4 downregulated genes 
were significant with FDR=0. As it is possible to adjust significance criteria in SAM, the datasets 
for hippocampus and the hypothalamus were analysed with FDR set at 0.095, which deems 
significant all genes with a q-value up to 9.95%. Such analysis settings yielded 46 significantly 
differentially expressed genes in the hippocampus and 26 in the hypothalamus (for the full list 
of genes see Appendix Table 22). However, such a small number of genes was not sufficient to 
produce meaningful results in the pathway analysis, thus it is not presented in this chapter. 
 Discussion 
 Overview of gene expression changes across the three regions 
One of the main findings of the microarray analysis was the observation that UCMS affected 
the expression of an overwhelmingly larger number of genes in the PFC than in the 
hippocampus and the hypothalamus. The PFC has been previously shown to be affected by the 
chronic stress exposure on structural and molecular levels, and is thought to play a crucial role 
in the response of the brain to chronic stress (Arnsten, 2015; McEwen and Morrison, 2013). 
However most previous gene expression studies in animal chronic stress models focused on 
the hippocampal changes, therefore a moderate response in this area was somewhat 
surprising.  
While only a handful of studies compared gene expression upon chronic stress in these two 
areas, some of them show results similar to those described above. At least two studies 
described in the Introduction section 1.3 above looking at the gene expression in the cerebral 
cortex and the hippocampus upon UCMS in BALB/c mice showed that more genes were 
affected in the cerebral cortex and the amygdala then in the dentate gyrus  or in the whole 
hippocampus (Liu et al., 2010; Surget, Wang, et al., 2008). Kaastrup Muller et al. (2011) 
showed that chronic restraint stress predominantly affected the expression of synaptic 
proteins involved in the exocytosis of synaptic vesicles in the prefrontal cortex with little effect 
in the hippocampus, reflecting the higher stress sensitivity of this region in chronic stress 
response. Similarly Yuen et al. (2012) showed that chronic restrained stress caused 
suppression of the glutamatergic neurotransmission in the PFC but not in the CA1 region of the 
hippocampus, which also prompted the authors to claim lower sensitivity of the hippocampus 
to chronic stress.  
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While the role of the hippocampus in chronic stress is undeniable, it is possible that the lack of 
gene expression response comes from the heterogeneity of the hippocampal tissue. Indeed, 
dorsal and ventral hippocampi are thought to be functionally and molecularly distinct regions. 
Expression pattern of certain genes have been shown to map onto the anatomical boundaries 
of the hippocampal regions (Fanselow and Dong, 2010). Moreover, some studies show that the 
two regions differ in their gene expression response to chronic stress. For example, the 
expression of HPA axis related genes Fkbp5 and GR has been shown to be affected by the 
UCMS in the ventral, but not in the dorsal hippocampus (Guidotti et al., 2013). At the same 
time maternal separation affected Bdnf expression in the dorsal, but not in the ventral region 
(Hill et al., 2014). Thus it is possible that the use of the total hippocampal tissue might have 
masked some of the gene expression effects which were present only in one of the 
hippocampal regions.  
The hypothalamus is another region which has been implicated in the chronic stress response 
due to its role in the HPA axis and the regulation of circadian rhythm. Jungke et al. (2011) 
found over 150 genes differentially expressed in the hypothalamus upon exposure to chronic 
restraint stress. Therefore it is also surprising that only a very small number of genes were 
affected in this area in our analysis. However it is possible that the distinct nature of restraint 
stress (physical repeated inescapable stress) could cause changes in this region specific to this 
type of chronic stress. At the same time, changes in the expression of clock genes following 
UCMS have been found specifically in the suprachiasmatic nucleus (SCN) of the hypothalamus 
and might not be apparent in total hypothalamic tissue (Jiang et al., 2011; Logan et al., 2015b). 
Interestingly, the clock gene Per2 was differentially expressed in the PFC as well as in the 
hippocampus as shown by the microarray analysis and the qPCR, suggesting that the circadian 
rhythm could nonetheless have been affected in the UCMS-exposed mice. This finding is in line 
with previous studies showing a change in Per2 expression in the PFC after UCMS (Calabrese et 
al., 2016; Erburu et al., 2015). Moreover, the translational value of this finding comes from a 
human post-mortem study which also showed that in depressed patients expression of clock 
genes is affected by the disorder in brain areas other than the SCN (Li et al., 2013).  
 Pathway and functional analysis of the PFC dataset suggests ongoing 
dendritic remodelling 
Pathway analysis is a useful tool to utilise for exploratory hypothesis-free approach. As a large 
number of genes were found to be differentially expressed in the PFC, pathway analysis was 
essential to gain insight into the potential systemic changes driving the expression of individual 
genes. Ingenuity canonical pathway analysis identified 16 significantly activated pathways 
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relevant for the brain. The top three canonical pathways identified by the pathway analysis 
were axonal guidance, glutamate signalling and calcium signalling. Differential expression of 
some of the genes belonging to these pathways (Tnnc1, Gng7, Myl4, Camk2a, Calb1) has been 
confirmed by qPCR. Involvement of axonal guidance pathway points out towards dendritic 
remodelling, which might be ongoing in the PFC as a consequence of the UCMS exposure. 
Indeed dendritic atrophy is perhaps one of the best-described consequences of chronic stress 
in the PFC (McEwen and Morrison, 2013; Qiao et al., 2016). For example, chronic restraint 
stress has been shown to reduce the length of apical dendrites of pyramidal neurons and the 
size of dendritic spines in the dorsal and medial PFC (Liston et al., 2006; Radley et al., 2008). 
Similarly chronic unpredictable stress with moderate stressors (rotation on shaker, placement 
at 4°C, food and water deprivation) in rats was shown to reduce spine density and expression 
of synaptic proteins in the mPFC (Li et al., 2011). The latter study implicated glutamate 
signalling in the mechanism of spine loss, as this effect of the chronic stress was rapidly 
reversed by administration of NMDA channel blocker ketamine. Indeed repeated stress is 
known to cause suppressed glutamate receptor expression and signalling in the PFC, which is 
thought to be linked to dendritic atrophy (Yuen et al., 2012). Many recent studies have 
explored the antidepressant potential of ketamine in chronic stress animal models of 
depression, strengthening the glutamatergic theory of depression (Sun et al., 2016; X Zhu et 
al., 2015). Therefore glutamate signalling pathway involvement is in line with this hypothesis.  
Interestingly, calcium signalling has also been implicated in dendrite remodelling via its effect 
on protein kinase A (PKA) and protein kinase C (PKC). Calcium is a necessary cofactor in the 
activation of PKA and PKC, and it has been shown that pharmacological suppression of the PKA 
and PKC activation prevented spine atrophy following chronic stress exposure (Hains et al., 
2009, 2015). PKA and PKC activation are thought to promote spine loss via their stimulatory 
effect on actin disassembly in the spine cytoskeleton (Arnsten, 2015). In light of these 
hypotheses it is interesting to note that calcium signalling was one of the few pathways for 
which strong activation was predicted by the Ingenuity pathway analysis software, as reflected 
by its positive z-score 2.45 (see Table 14). In addition, over 1.5 fold increase in Camk2a 
expression is confirmed by qPCR. Moreover, calcium and PKC signalling is supposed to be 
activated by stress via activation of alpha adrenoreceptors (αAR), while αAR signalling was also 
deemed a significant pathway in the PFC. Therefore, pathway analysis points towards dendritic 
and/or spine remodelling as a primary pathology occurring in the PFC upon chronic stress. 
Indeed, neurite morphology related functions, such as growth of neurites and microtubule 
dynamics, appeared most frequently in the list of Ingenuity pathway analysis predicted 
functions (see Table 16). The other two groups dominating functional analysis were synaptic 
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plasticity and functions related to neural cell fate, such as neuronal proliferation, 
differentiation, migration and neuronal density. It is interesting to draw a parallel between this 
analysis and the effect of UCMS on adult hippocampal neurogenesis described in Chapter 3, 
where a reduction in the number of neuroblasts with developed dendritic trees and their 
increased migration was observed in the UCMS-exposed group. The fact that signalling 
pathways relevant for these effects appeared to be altered in the PFC but not in the 
hippocampus might be suggesting that UCMS exerts its antineurogenic effect on the 
hippocampus indirectly, potentially via its PFC neuronal connections through the enthorinal 
cortex (Canto et al., 2008). 
 Predicted upstream regulators are highly relevant for observed UCMS-
induced pathology   
Additional insight into molecular changes occurring in the PFC was provided by the upstream 
regulators analysis. This type of analysis helps to approach a large pool of differentially 
expressed genes in a systemic way. Recently a transcriptomic study of chronic stress 
susceptibility in mice showed that so called hub genes can play an important role in the 
chronic stress response (Bagot et al., 2016). Similar to upstream regulators, these hub genes 
were defined as highly connected within the differentially expressed genes pool and capable of 
predicting the expression of many other target genes. In this study researchers selected three 
of such hub genes from a gene expression microarray analysis exploring differences between 
control, chronic social defeat stress-resilient and stress-susceptible mice for overexpression in 
the PFC and the ventral hippocampus. Even though one of these genes, Sdk1, was not 
differentially expressed in the original microarray, its overexpression affected animals’ 
susceptibility to chronic social defeat stress. This study verified the importance of regulatory 
genes in stress response regardless of the effect of stress on their own expressions levels. 
Therefore the most significant upstream regulators (p ≤ 0.0001) and their potential role in the 
chronic stress response are discussed below. 
 Htt and Bdnf 
In my dataset, Ingenuity pathway analysis predicted several highly relevant genes to be 
upstream regulators, even though most of them were not differentially expressed in the 
microarray analysis. Htt, the top regulator in the list, is thought to protect neurons against 
excitotoxicity-induced apoptosis (Leavitt et al., 2006). It is present at pre- and post-synaptic 
terminals, where it interacts with the proteins controlling exo- and endocytosis of synaptic 
vesicles, and consequently plays a role in neurotransmitter release and receptor activation 
(Zuccato et al., 2010). Htt also acts as an activator of the production and transport of Bdnf, 
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another highly significant upstream regulator in our analysis (Zuccato, 2001). It is noteworthy 
that in Huntington disease, caused by Htt mutation and loss of function, depression is very 
common and often precedes motor symptoms characteristic of this disease (Pla et al., 2014). It 
has been observed that in HD mouse models anxiety-like behaviour can also be detected. 
Importantly, a study by Pla et al. (2013) showed that targeted knockout of Htt in mature 
cortical and hippocampal neurons results in anxious phenotype accompanied by a decline in 
adult hippocampal neurogenesis. More specifically, Htt knockout in mature neurons was 
associated with reduced survival and dendritic arborisation in immature DCX+ neuroblasts. 
This effect was partly attributed to a reduction of Bdnf secretion and transport in hippocampal 
neurons. Bdnf on its own has been strongly implicated into the neurobiology of depression and 
of antidepressant action (Bjorkholm and Monteggia, 2016). It has been shown to be reduced in 
the hippocampus and the PFC in post-mortem tissue of depressed patients and upon chronic 
stress in preclinical models (Autry and Monteggia, 2012). In adult brain Bdnf affects synaptic 
plasticity and has been shown to increase spine density in hippocampal neurons (M Alonso et 
al., 2004), as well as to promote neuroblast differentiation and maturation in the dentate 
gyrus (Waterhouse et al., 2012). In light of these findings it is interesting to point out that in 
my dataset both Htt and Bdnf were predicted to be downregulated (see z-scores in Table 15 
Upstream regulators of differentially expressed genes in the PFC dataset predicted by the IPA 
software.Table 15), while in parallel UCMS experiment the number of DCX+ neuroblasts with 
mature dendritic tree was reduced. In fact, one previous study of gene expression upon CRS 
showed activation of Huntingtin disease related genes in the hippocampus (Andrus et al., 
2012). Although it is not clear why in our study these highly interrelated findings were not 
localised in the same brain region, they do support that the results of microarray analysis 
corroborate a vast majority of existing literature on neurobiology of chronic stress and 
depression. 
 Leptin 
The predicted upstream regulator leptin hints at the involvement of metabolic pathways in the 
effect of UCMS exposure. In the brain leptin mostly acts via leptin receptors in the 
hypothalamic neurons where it suppresses the release of orexigenic factors and induces the 
release of anorexigenic factors, which eventually leads to a reduction in food intake (Reichelt 
et al., 2015). However, leptin effects extend beyond hypothalamus. Leptin plays a role in the 
mesolimbic dopamine reward system by regulating the excitation of dopaminergic neurons 
projecting from the ventral tegmental area into the nucleus accumbens, the PFC, the 
hippocampus and the amygdala (van Zessen et al., 2012). Leptin receptors are also present in 
the PFC and the hippocampus (Wada et al., 2014). Leptin has been previously implicated in the 
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effect of chronic stress and its reversal. Various chronic stress paradigms were shown to 
reduce plasma and brain tissue leptin levels, while leptin administration has been shown to 
have an antidepressant effect (Liu et al., 2015; Lu et al., 2006). Moreover, leptin has also been 
shown to reverse the detrimental effect of stress and glucocorticoids on adult hippocampal 
neurogenesis (Garza et al., 2008, 2012), and to have a stimulating effect on dendritic branching 
in the hippocampus (O’Malley et al., 2007). These observations support the relevance of leptin 
signaling for the effect of UCMS. It is noteworthy that leptin signaling was predicted to be 
downregulated in our PFC analysis, which goes in line with reduced plasma levels of leptin 
described post UCMS in Chapter 2 UCMS model (see Figure 24). 
 Myelin regulatory factor Myrf 
While upstream regulators discussed above have already been linked to chronic stress in 
previous literature, little is known about the role of 3rd regulator in the list, the myelin 
regulatory factor or Myrf (see Figure 40). The few studies on Myrf describe its role in 
myelination processes occurring in the CNS during development and adulthood (Bujalka et al., 
2013). Myrf is an oligodendrocyte-specific target of Sox10, transcription factor which regulates 
myelination of axonal terminals. Upon Sox10 stimulation Myrf induces a myelinating program 
in the oligodendrocytes (Hornig et al., 2013). Interestingly, several studies report myelination 
deficit upon chronic stress. Yang et al. (2016) report reduced maturation of oligodendrocytes 
and myelination in the mPFC of mice subjected to chronic unpredictable stress. A diffusion 
tensor imaging (DTI) study found signs of demyelination upon UCMS in rats in the wide range 
of brain regions, including frontal cortex, hippocampus and the hypothalamus (Hemanth 
Kumar et al., 2014). Another study found shortening of myelin-formed nodes of Ranvier and in 
the corpus callosum of chronically stressed mice, which corresponded to the DTI data showing 
signs of white matter damage in the corpus callosum of depressed patients (Miyata et al., 
2016). Taken together, these findings suggest that prediction of Myrf as an upstream regulator 
could be pointing towards myelination deficit known to be induced by UCMS in animals and by 
clinical depression in patients. 
 Epigenetic factors 
Another interesting finding from the upstream regulator analysis was the presence of two 
proteins playing key roles in the mechanisms of epigenetic regulation, methyl-CpG binding 
protein 2 (Mecp2) and histone deacetylase 4 (Hdac4), involved in DNA methylation and 
histone deacetylation, respectively. Both mechanisms, if acting on a promoter or other 
regulatory region of a given gene, reduce expression of that gene, however the functional 
consequences of such regulation depend of course on a function of the gene in question. 
Nonetheless, it has been observed that chornic social defeat stress increases histone 
172 
 
acetylation in the limbic areas including the hippocampus and the PFC, and that administration 
of HDAC inhibitors produces an antidepressant effect on chronic social defeat-induced 
behavioural deficits (Iii et al., 2015). DNA methylation of various target genes has been 
extensively studied in early life stress research in an attempt to uncover mechanisms through 
which early life adversity predisposes individuals to psychiatric disorders including depression. 
Indeed DNA methylation of genes encoding such crucial for psychopathology proteins as GR, 
CRH and Bdnf has been shown to be modified by prenatal or early life stress exposure, often 
with behavioural consequences in adulthood (Provençal and Binder, 2014). While limited data 
exist on the effect of chronic stress on DNA methylation in adulthood, few studies set the 
precedent for the ability of chronic stress to modify methylation of individual genes and the 
genome-wide methylation levels. For instance, chronic social defeat was found to increase the 
level of DNA methyltransferases, enzymes catalysing DNA methylation, in the nucleus 
accumbens (LaPlant et al., 2010). On the individual gene level UCMS has been shown to alter 
DNA methylation of CRF gene promoter (Sterrenburg et al., 2011). Moreover, post-mortem 
study provided clinical evidence for the involvement of DNA methylation in depression, by 
demonstrating increased levels of GABAA receptor methylation in limbic brain regions of 
suicide completers (Poulter et al., 2008). Therefore, evidence of UCMS activating molecular 
networks involved in epigenetic regulation also goes in line with existing literature and suggest 
long-term consequences of UCMS exposure. 
 Cholecystokinine and its receptor were increased in the PFC 
One group of differentially expressed genes was not highlighted by the pathway analysis, 
however deserves special attention due to its relevance for chronic stress and some particular 
behaviours observed in this experiment. Both cholecystokinine (Cck) and cholecystokinine 
receptor B (Cckbr) were upregulated in the PFC of UCMS-exposed mice as shown by the 
microarray and the qPCR analysis. Cck is a gastropeptide and a neurotransmitter. Its CckA 
receptors are located in the gut and are thought to play a role in food intake regulation via its 
effect on vagal nerve terminals (Dockray, 2012). CckB receptors are located predominantly in 
the brain where they form a part of Cck signalling system, spread out across the prefrontal 
cortex, the amygdala, the hippocampus and the hypothalamus (Zwanzger et al., 2012). Cck 
signalling has been implicated in the fear and anxiety responses, and in the development of 
the panic disorder. Administration of the Cck agonist has been shown to induce panic attacks 
in healthy volunteers as well as in depressed patients (Koszycki et al., 2004). Cck is increased in 
the frontal cortex of animals subjected to chronic social defeat (CSD) (Becker et al., 2008). In 
the same study Cckbr antagonist has been shown to prevent development of behavioural 
deficit in the FST and the sucrose preference tests in socially defeated mice. Moreover, 
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blockade of Cckbr reversed a reduction of cell proliferation in the hippocampal dentate gyrus 
induced by this chronic stress paradigm. Another chronic social defeat study went on to show 
that the low level of Cckbr expression in the prefrontal cortex predicts animals’ resilience, 
while a high expression level was observed in mice susceptible to the effect of chronic social 
defeat (Vialou et al., 2010). Therefore, the observed increase in the expression levels of Cck 
and the Cckbr in our study supports the role of this neurotransmitter in the neurobiological 
changes induced by chronic stress and supports the induction of expression profile previously 
described in the PFC in chronic stress studies. Also the role of Cck in food intake control and 
the gut-brain axis suggests an intriguing possibility of the link between anxiety and appetitive 
behaviours. 
 Absence of HPA axis and immune pathways  
The additional aims of the gene expression study were to detect activation of the immune and 
HPA axis related signalling, which has been detected in the hippocampus in previous UCMS 
studies. However, the list of differentially expressed genes in the hippocampus and the 
hypothalamus did not include any GR or immune response related genes, such as NFkB or 
cytokines and their receptors. Moreover, a small number of differentially expressed genes in 
these regions limited the use of pathway analysis. It is possible that these negative results are 
related to the timing of tissue collection, as it has been done after the end of the UCMS 
protocol and thus might not reflect some of the short-term changes occurring earlier in the 
course of UCMS exposure.  In addition, analysis of the whole region tissue instead of its 
subregions, such as dorsal or ventral hippocampus or separate hypothalamic nuclei, might 
have prevented the detection of significant differences. On the other hand, the absence of GR 
or immune response signalling pathways activation goes in line with the absence of microglial 
activation in the hippocampus and activation of the HPA axis in UCMS-exposed groups. At the 
same time microglial activation in the PFC collocated with a large number of differentially 
expressed genes in this area, suggesting an association between the two phenomena. 
 Conclusions 
To summarise, the genome wide gene expression analysis provided a lot of insights into the 
molecular mechanisms involved in UCMS effects. It indicated that the gene expression changes 
were most apparent in the PFC among the 3 regions investigated. Many target genes, 
upstream regulators and signalling pathways involved could be linked to one of the well 
described effects of chronic stress on the PFC, dendritic remodelling and spine atrophy. Among 
them glutamatergic, calcium and Cck signalling, and Htt and Bdnf centred networks stood out 
as the most significantly involved. In addition, Cck and leptin signalling suggested a potential 
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modulation of anxiety and food reward related pathways. Evidence of circadian rhythm 
alteration was also present in the PFC as well as in the hippocampus. The limited number of 
differentially expressed genes in the hippocampus did not allow any hypotheses to be tested 
regarding the mechanisms affecting adult neurogenesis in this region. However, it is possible 
that signalling pathways affecting dendritic morphology in the PFC could be indirectly 
influencing hippocampal neurons via PFC-hippocampal connections. This notion is also 
supported by the enrichment of cell proliferation, differentiation and migration functions in 
the functional analysis of the PFC dataset. Dendritic tree and dendritic spine density 
measurements in the PFC and the hippocampus could show if these molecular changes led to 
dendritic morphology alteration in adult neurons in these two regions. Finally, genome wide 
gene expression analysis suggested the involvement of two mechanisms not predicted from 
the behavioural or immunohistochemical experiments carried out in this project, namely the 
modulation of myelination and epigenetic pathways. Future myelin measurements and DNA 
methylation and histone acetylation assays could show if indeed UCMS caused any functional 
changes in these domains. 
However, there are a number of limitations to the gene expression study. The conclusions 
drawn from the gene expression data need to be taken with caution, as hypothesis-free 
pathway analysis is interpreted based on already available evidence of the involvement of 
processes in question in the chronic stress response. In addition, the observed effects are 
limited to the time window of tissue collection, and therefore do not represent changes which 
might have occurred earlier during UCMS. Future experiments could address this issue by 
collecting the tissue at different time points during the UCMS exposure. The analysis could also 
benefit from separating the tissue into specific subregions based on their anatomical and 
functional significance in chronic stress response.  
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Chapter 5 LPS-based model 
1 Introduction 
As clinical evidence of the importance of the immune system in depression accumulated to 
form the neuroinflammatory hypothesis of the disease neurobiology (Hodes et al., 2015; 
Raison and Miller, 2011), the need to study neuroimmune mechanisms and their influence on 
depression-like behaviour in model organisms became apparent. While evidence exists that 
some chronic stress models are capable of inducing neuroimmune alterations, such as 
elevation of peripheral and CNS proinflammatory cytokines levels and microglial activation in 
the brain (Lu et al., 2016; Tynan et al., 2010), our study of the UCMS effects showed that 
neuroinflammatory changes were not a major part of the neurobiological phenotype induced 
by UCMS. Therefore, another type of manipulation was required to reproduce immune aspects 
of depression neurobiology.  
1.1 The behavioural effects of lipopolysaccharide (LPS) 
LPS exposure in animals has long been used to model depressive-like behaviour and relevant 
neurobiology. LPS is a glycolipid set in the outer membrane of Gram negative bacteria. 
Extracted from a bacterial culture, LPS acts as a proinflammatory agent which induces a 
behavioural and neurobiological inflammatory response similar to that seen in bacterial 
infection, but in absence of living pathogen (Alexander and Rietschel, 2001). Upon 
administration, LPS is recognized by leukocytes and other immunocompetent cell types via a 
surface toll-like receptor 4 (TLR4). Binding of LPS causes TLR4 dimerization and activation, 
which initiates downstream signalling via adaptor protein myeloid differentiation factor 88 
(MyD88) and Toll/IL-1 receptor homology domain-containing adaptor protein (TRIF). 
Recruitment of MyD88 to TLR4 results in the activation of a signalling cascade involving the IL-
1-receptor-associated kinases (IRAKs) and mitogen-activated protein kinases (MAPK), that in 
turn facilitate activation of the nuclear factor kappa B (NF-κB) pathway (Murphy et al., 2011). 
NF-κB translocates to the nucleus where it stimulates transcription of pro-inflammatory 
cytokines such as TNFα, IL-6 and IL-1β, as well as inducible nitric oxide synthase (Bohannon et 
al., 2013). TRIF on the other hand activates interferon regulatory factor 3 which ultimately 





Figure 42 Signalling pathways downstream of TLR4 activated by LPS.  
Presentation of lipopolysaccharide (LPS) induces Toll-like receptor 4 (TLR4) dimerization and subsequent activation 
of the MyD88-depedent signaling pathways, including Toll/IL-1 receptor homology domain-containing adaptor 
protein (TRIF) pathway and IL-1-receptor-associated kinases (IRAKs) and mitogen-activated protein kinases (MAPK) 
pathways. The signalling cascade eventually leads to activation of the nuclear factor kappa B (NF-κB), which 
translocates to the nucleus where it stimulates transcription of pro-inflammatory factors such as cytokines TNFα, IL-
6 and IL-1β and interferons such as IFNγ. From Bohannon et al., Shock 2013 40(6): 451–462 
Therefore, response to a single dose of LPS involves elevation of plasma cytokine levels, which 
have been shown to act within the brain tissue via several mechanisms, including transport 
across permeable regions of the BBB such as in the vasculature of the lateral ventricles (Banks, 
2007), transport aacross the leaky BBB induced by systemic inflammation(D’Mello et al., 2009) 
or by activating the cells forming the barrier, such as endothelial cells, perivascular 
macrophages and astrocytes (Hodes et al., 2015) (see Figure 5 in Chapter 1 section 2.4.2.2). 
Once transmitted to the brain, LPS signal triggers inflammation-like responses and behavioural 
changes commonly described as sickness behaviour. These behavioural changes include 
reduced food intake, weight loss, fever and hypolocomotion (Biesmans et al., 2013). While 
some of these behaviours already carry a degree of resemblance to symptoms of depression, 
LPS exposure also is known to potentiate depression-like behaviour in relevant behavioural 
tests. Yirmiya (1996) was one of the first to show that injection of 1mg/kg LPS induced 
anhedonia in a sucrose consumption and sexual behaviour test, conducted within the 4 to 12 
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hr time period after injection in LPS-exposed rats. Behavioural despair in the FST and tail 
suspension tests 24 hours after 0.33 mg/kg LPS injections was shown in BALB/c mice by 
Godbout et al. (2008). However in these two studies early behavioural assessment meant that 
these changes simply could be a result of sickness-induced hypolocomotion, which was 
documented to coincide with the behavioural testing in both studies. To disentangle these 
effects, Frenois et al. (2007) showed that ICR mice displayed hypolocomotion at 6, but not 24 
hours after exposure to 0.83mg/kg dose of LPS, while behavioural despair was detected in FST 
and TST at the 24-hour time point. While the time gap between sickness and depressive-like 
behaviour is now being widely used to demonstrate the independence of depressive-like 
changes from the physical sickness induced by LPS (O’Connor et al., 2009; Park et al., 2011), 
the short time window in which these behaviours occur limits its use for modelling chronic 
disease and testing chronic antidepressant therapy. However, a limited number of studies 
showed that LPS challenge can result in long-term consequences. For example, Painsipp et al. 
(2011) showed that group-housed female C57BL6 mice displayed increased immobility 28 days 
after 0.83mg/kg LPS injection. However, this effect was strain-dependent, as CD1 mice 
displayed only a short-term (24 hours) increase in immobility following LPS exposure. 
1.2 Neurobiological effects of LPS 
In addition to behavioural changes, LPS also mimics some aspects of depression neurobiology 
observed in clinical studies or other animal models of the disease.  Some studies implicated 
the elevation of indolamine 2,3-dioxygenase (IDO) metabolism, stimulated by proinflammatory 
cytokines, in the mechanism of depressive LPS effects. O’Connor et al. (2009) showed that 
blockade of IDO elevation following acute 0.83 mg/kg LPS administration also blocks increases 
in FST immobility in LPS-exposed CD1 mice. As IDO plays a key role in serotonin/kynurenine 
metabolism, a process already implicated in depression, behavioural changes in this study 
were attributed to the neurotransmitter imbalance. Interestingly, to block IDO in this study 
authors used pre-treatment with minocycline, a semisynthetic derivative of the antibiotic drug 
tetracycline, known to inhibit macrophage and microglial activation. Minocycline treatment 
has been previously shown to prevent development of sickness behaviour and anhedonia in 
the sucrose preference test in BALB/c mice repeatedly injected i.p. with 0.33mg/kg LPS (Henry 
et al., 2008). While in this study effect of minocycline was also attributed to blockade of IDO 
increase, it is possible that inhibition of microglial activation also played a role in minocycline’s 
mechanism of action.  
Indeed, it has been shown that systemic LPS exposure is capable of inducing microglial 
activation in the brain. Buttini et al. (1996) was the first to show morphological transition of 
resting ramified microglia to a round, CD11b-positive activated-like state in the rat 
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hypothalamus, thalamus and the brainstem during first 7 days following peripheral injections 
with 2.5 and 5 mg/kg LPS. Increases in activated Iba1-positive microglia also were  described in 
the hippocampus and frontal cortex of C57BL/6J mice 2 hours after an injection with 1mg/kg 
LPS (Qin et al., 2007). The same dose induced an increase in the number of Iba1-positive 
microglia in the hypothalamus of BALB/c mice 28 hours after injections (Clark et al., 2015). This 
dose has been also shown to increase another microglial activation marker density, CD68, in 
the hippocampal dentate gyrus of rats (Monje, 2003). This study was also one of the first to 
show that peripheral LPS injection can reduce the density of DCX positive cells in the 
hippocampus.  
Indeed, a decrease in the level of adult hippocampal neurogenesis is another neurobiological 
aspect which converges mechanisms of depression and LPS effects literature. LPS has been 
shown to reduce the level of neural stem cell proliferation, differentiation and survival in the 
hippocampus. For example, cell proliferation was shown to be reduced in the DG 24 hours 
after 1mg/kg LPS injections in rats (Fujioka and Akema, 2010). Neuronal differentiation was 
shown to be reduced in the DG 7 and 28 days after a 5mg/kg LPS injection to C57BL6 mice 
(Ormerod et al., 2013) (Ekdahl et al., 2003; Graciarena et al., 2013; Ormerod et al., 2013). 
Long-term effects of a single 1mg/kg LPS injection were investigated in a study where C57BL6 
mice were sacrificed 6 weeks after injections (Valero et al., 2014). At this time point cell 
proliferation was found to be increased in the DG, but proliferating cells expressed microglial 
CD11b rather than neuronal NeuN marker. At the same time the number of DCX+ cells was 
decreased, specifically the population with more mature dendritic tree structure (“EF” type). In 
addition, DCX+ dendritic tree volume, dendritic length and postsynaptic density (PSD95) 
puncta were decreased in LPS-exposed animals. Thus the last two studies showed that effect 
of LPS on AHN could be long-lasting. 
1.3 Limitations in the use of LPS to model depression 
Despite this extensive evidence for the value of LPS as a model for inducing depression-like 
behaviour and relevant neurobiology in rodents, there are a number of issues regarding the 
dose and duration of exposure to LPS. Firstly, many studies used very high doses of LPS (3-
5mg/kg) resulting in a drastic elevation in proinflammatory cytokines, as might be seen in 
sepsis, which might not be relevant for the more subtle increases seen in depressed patients 
(Anderson et al., 2016; Erickson and Banks, 2011). Secondly, most behavioural and 
neurobiological effects of LPS are short-lived (24 hours or less) and therefore their relevance as 
a model of a chronic disorder is limited (Godbout et al., 2007; Graciarena et al., 2013). 
Chronicity is an important aspect in depression neurobiology, as over half of all patients do not 
recover within 2 years and it is estimated that about 80% of patients experience at least one 
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relapse in their lifetime (Otte et. al., 2016). Moreover, existing evidence suggests that chronic 
inflammation years before the disease onset might be an important risk factor for depression, 
such as the Whitehall II study of over 3000 cases which showed that increased peripheral 
blood CRP and IL-6 concentrations significantly predicted depressive symptoms occurring 12 
years later (Gimeno et al., 2009). 
Therefore to prolong the effects of LPS some studies had employed a protocol involving 
repeated LPS injections at various time intervals. For example, ICR mice subjected to 16 daily 
injections with 0.83mg/kg of LPS displayed immobility in the FST and anhedonia in the NSF 
test, which was accompanied by increased IL-1β expression and decreased BDNF expression in 
the hippocampus and cortex (Guo et al., 2014). Another study compared the effect of a single 
0.6mg/kg LPS injection with 8 weeks of daily injection with the same dose in rats, and showed 
that chronically injected rats also displayed hypolocomotion and increased immobility in the 
FST. Behavioural results were accompanied by an increase in IL-1β and IFNγ in the 
hypothalamus, although no change in cytokine level was detected in the blood serum (Fischer 
et al., 2015). A different approach was used in a study by Kubera et al. (2013), where female 
C57BL6 mice were injected with a dose of LPS fluctuating between 0.75 and 1.25 mg/kg for 
five consecutive days each month for 4 months. Sucrose preference measurements showed 
that every month mice took progressively longer to recover from anhedonic effects of LPS 
injections with no recovery observed on the last month. However chronic fluoxetine treatment 
was able to reverse this effect.  While such protocols induced more relevant long-lasting 
phenotypes, repeated exposure is also known to result in a suppressed reaction of the immune 
system, known as LPS or endotoxin tolerance.  
LPS tolerance is a hyporesponsive state of the immune system in which there is an attenuated 
cellular and endocrine response to repeated LPS challenges, also leading to reduced sickness 
behaviour (López-Collazo and Del Fresno, 2013). This phenomenon was first described in 
patients who developed sepsis, and later replicated in animals injected with sublethal doses of 
proinflammatory agents, which survived subsequent exposures to doses known to be lethal to 
naïve animals (reviewed in López-Collazo and del Fresno, 2013). However similar modifications 
in response, or tolerance, are known to be induced by milder stimuli. For example, Rosenthal 
et al. (1996) showed attenuation of the fever response to a second and third LPS injections in 
rats, either injected with the same 0.02mg/kg or changed to higher or lower doses compared 
to the first injections. Attenuation of hypolocomotion and anxiety compared to the first 
exposure was observed in CD1 mice after a second injection with 0.025mg/kg LPS. In the 
immune system LPS tolerance is characterised by reduced proinflammatory cytokine (TNFα, IL-
1β and IL-6) expression  and increased expression of anti-inflammatory cytokines, such as IL-10 
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(Biswas and Lopez-Collazo, 2009). The mechanism behind this reaction is thought to be linked 
to the downregulation of a signalling pathway downstream of TLR4 (Morris et al., 2015) by 
inhibitors of MyD88 signalling pathway. For example, MAPK phosphatase-1 supresses the 
activation of MAPKs, IRAK-M disrupts the function of IRAKs, and  inhibitor of NF-κB (IκB) 
reduces nuclear translocation and decreases production of LPS-induced gene products 
(Bohannon et al., 2013). Such state of the immune system differs dramatically from the chronic 
activation seen in depression.  
To summarise, both single and repeated LPS exposure models have their advantages and 
disadvantages for modelling immune changes seen in depressed patients. More specifically, 
single injections with moderate doses induce very short-lived depression-like phenotypes 
sometimes indistinguishable from physical sickness. In contrast, repeated injections might 
result in more long-lasting changes, but can also lead to the development of LPS tolerance, a 
supressed state of the immune system response which has little in common with immune 
changes seen in depressed patients. Therefore, the main aims of the experiments described in 
this chapter were firstly, to establish the time line of sickness and depression-like behaviours 
following a single, moderate and frequently used dose of LPS and to evaluate if it causes any 
long-lasting behavioural and neurobiological changes relevant for depression, comparable to 
the timescale of the UCMS model.  The second aim was to develop a model of repeated 
injections which would induce long-term depression-like behavioural and immune changes, as 
well as affect neurobiological processes relevant for depression pathology, such as microglial 
activation and neuronal differentiation in the hippocampal dentate gyrus, but not trigger a 
supressed state of the immune system known as LPS tolerance.  
2 Methods 
2.1 Animals 
7-week old male BALB/cAnNCrl mice were obtained from Charles River (Margate, Kent, U.K.). 
.). All animals were housed in the Biological Services Unit (BSU) at the Institute of Psychiatry, 
Psychology & Neuroscience in standard conditions (19-22°C, humidity 55%, 12h:12h light:dark 
cycle with lights on at 7.30am, food [Rat and Mouse No. 1 Diet; Special Diet Services, Essex, 
UK] and water ad libitum). Mice were pair-housed with their litter mates in large cages 
45x28x13cm with environmental enrichment (small plastic and cardboard houses, cardboard 
tube, paper sizzle nest material; Datesand Ltd, Manchester, UK). Housing with litter mates was 
implemented to prevent fighting of cage mates observed in this strain in previous experiments 
(such as in CON group of UCMS Experiment 1).  
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2.2 LPS injections 
For all injections LPS from E.Coli Serotype O127:B8 (L3129, Sigma Aldrich, Poole, UK) was used. 
LPS powder was freshly dissolved prior to injections in sterile 0.9% saline (Aquapharm, Argyll, 
UK). All injections were administered i.p. in all experiments. In Experiment 1: Single LPS 
exposure mice from LPS group were injected with 0.33 mg/kg LPS, VEH group was injected 
with saline at a volume of 8 ml/kg calculated for an average 25g mouse (100 µL) (for 
experimental design see Figure 43). 
In Experiment 2: Repeated LPS exposure control group (SAL; n=10) received 100 µL of 0.9% 
saline each week; 0.1 LPS group (n=8) received 0.1mg/kg of LPS each week;  escalating LPS 
(0.33-0.83) group (n=8) received 0.33 mg/kg of LPS on weeks one and two, 0.53 mg/kg of LPS 
on week three, 0.63 mg/kg on week four, 0.73 mg/kg on week five, 0.83 mg/kg on week six; 
single LPS group (n=8) received 0.83 mg/kg on week one, and 100 µL saline on weeks 2-6 (for 
experimental design see Figure 46). 
2.3 Behavioural testing 
Body and food weight were measured immediately before the injections and at time points of 
interest post injections. The difference between the two data points was used as weight gain 
or food intake measures respectively. Open field test and forced swim test were performed as 
described in Chapter 2 (see p62 and 63). For home cage activity tests, enrichment materials 
were removed from the cages and clear, acrylic lids were placed on top of the cage to allow 
video recording and subsequent activity tracking. The movements were recorded for 5 
minutes. Distance travelled was measured using the automated tracking system (Ethovision, 
Noldus Information Technologies, Wageningen, The Netherlands). 
2.4 Blood collection  
Blood was collected by incision method from the lateral tail vein (Sadler and Bailey, 2013). 
Whole blood (30-50µL) was collected into EDTA microvette CB 300 tubes (Sarstedt, Leicester, 
UK) and separated by centrifugation for 10min at 3000 rpm (4oC), after which plasma was 
manually transferred into a new sterile tube (1.5ml ‘Crystal clear’ microcentrifuge tube sterile, 
Starlab UK Ltd) and stored at -80°C. Cytokine analaysis was conducted using the multiplex 
screening assay based on magnetic Luminex® xMAP® technology as described in Chapter 2 
Section 3.6. 
Another blood collection by method of cardiac puncture was utilised in Experiment 2: 
Repeated LPS. This collection occured after the terminal general anaesthesia had been induced 
by the injection of 40mg/kg of pentobarbital sodium i.p. (Euthatal, Merial Animal Health Ltd, 
182 
 
Harlow, UK). 100-200 μL of whole blood was collected using syringe injected into the cardiac 
cavity and subsequently processed as described above to measure corticosterone levels. 
2.5 Immunohistochemistry and microscopy 
For brain tissue collection, mice were anesthetised with 40mg/kg of pentobarbital sodium i.p. 
(Euthatal, Merial Animal Health Ltd, Harlow, UK) and subsequently transcardially perfused with 
saline and 4% paraformaldehyde (Paraformaldehyde, prills, 95%, 441244, Sigma-Aldrich, Poole, 
UK) in phosphate-buffered saline (pH = 7.4 from PBS tablets, 18912-014, Gibco by Life 
Technologies, Paisley, UK) through the left cardiac ventricle. Brains were post-fixed overnight 
in 4% PFA at 4°C, and subsequently stored at 4°C in 30% sucrose (Sigma-Aldrich, Poole, UK) in 
PBS.  
Brain tissue was cut on a HM430 sliding microtome (Thermo Scientific) into serial 40µm thick 
coronal sections and stored in tris-buffered saline (TBS, pH=7.4) with 30% v/v glycerol, 15% 
w/v sucrose and 0.05% w/v sodium azide (all Sigma Aldrich, UK) to prevent bacterial growth 
and for cryoprotection at 4°C. For immunohistochemistry on free floating sections, every 6th 
section was washed in PBS 3x5min, incubated in 1% hydrogen peroxide (Sigma Aldrich, UK) for 
30 mins with subsequent washing in PBS. Non-specific antibody binding was blocked by 
incubating sections in 10% NGS (Normal goat serum, S1000, Vector laboratories, UK)  in PBST 
(PBS with 0.25% TritonX (Sigma Aldrich, UK) for 1hr. Sections were incubated in primary 
antibodies  (anti- doublecortin (DCX) diluted 1:1000, ab18723, Abcam; Anti-Iba1 diluted 1:500, 
019-19741, Wako; anti CD68 diluted 1:2000, MCA 1957, ABD Serotec, Anti-Ki67 diluted 1:200, 
ab15580, Abcam; all made in rabbit) diluted in PBST with 10% NGS at 4°C, agitated on orbital 
shaker overnight. The next day sections were washed in PBS 3x5min and incubated in 
secondary antibody, biotinylated anti-Rabbit IgG made in goat (BA1000, Vector Laboratories, 
UK) for 2hrs at room temperature on an orbital shaker. Subsequently, sections were incubated 
in a solution containing avidin-biotin complex (Vectastain Elite ABC Kit, PK6100, Vector 
Laboratories, UK) for signal amplification. The staining was visualised with diaminobenzidine 
(DAB, Sigma Aldrich, UK). Sections were rinsed PBS 3x5min, mounted on Superfrost Plus 
microscope slides (Thermo Scientific), air-dried, dehydrated in serial ethanol dilutions, cleared 
in xylene (Sigma Aldrich, UK) and coverslipped using Distyrene Plasticizer Xylene (DPX) (Sigma-
Aldrich, UK).  
Stereological analysis 
Stereological method was used to quantify the density of immunopositive cells as described 
previously (Thuret et al., 2009). An Axioskop 2 MOT Zeiss microscope and a semiautomatic 
stereology system (StereoInvestigator, Microbrightfield Inc.) were used to estimate the volume 
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of the region of interest (ROI) and the total number of immunopositive cells in the ROI. For this 
estimation, the optical fractionator method in the StereoInvestigator software was used. The 
optical fractionator estimates the total volume of the ROI using the sectional ROI volume 
manually traced at x2.5 magnification and known intersection intervals (240µm). To estimate 
the number of positive cells, the software extrapolates the number of manually counted cells 
in the areas of chosen size (50 μm x50 μm counting frames placed over grid with chosen size of 
X: 94.59μm and Y: 182.53 μm) of the ROI selected by systematic random sampling to the 
sectional volume of the region of interest. A chosen set number of average sampling sites per 
section was 50, while for each brain, 11 sections between stereotactic coordinates -1.06mm 
and -3.80 relative to bregma (Franklin and Paxinos, 2012) were included into the optical 
fractionator analysis.  The density of Iba1 and DCX positive cells was calculated by dividing the 
estimated cell number by the estimated volume of the ROI.  
Classification of DCX positive cells by dendritic morphology 
The DCX positive cells were visually classified according to the categorization of Plumpe and 
co-workers (Plümpe et al., 2006). The AB group included cells with no or short plump 
processes, the CD group included cells with medium length processes without branching, and 
the EF group comprised cells with long branching dendrite(s) reaching the molecular layer. The 
density of each type of cells was determined using stereology as described in the previous 
section. 
Quantification of CD68 surface area 
For quantification of CD68 staining, digital images were taken using Zeiss Axioimager 
microscope and Zeiss AxioCam MR Rev3 camera at 40X magnification. Per each brain area 
(CA1, CA3, DG) identified using the Allen Mouse Brain reference coronal atlas, 1 image was 
taken from every 2nd section between stereotactic coordinates -1.06mm and -3.80 relative to 
bregma (Franklin and Paxinos, 2012) to achieve equal intersection intervals (80µm). ImageJ 
software (Schneider et al., 2012) and macros code were kindly provided by Lianne Hoeijmakers 
and Dr Aniko Korosi (Center for Neuroscience, Swammerdam Institute for Life Sciences, 
University of Amsterdam, Amsterdam, the Netherlands) were used to quantify the % surface 
area immunopositive for CD68.  
2.6 Statistical analysis 
In Experiment 1 repeated measures two-way ANOVA was used to analyse the timeline of 
sickness behaviour in the LPS compared to VEH group. Repeated measures one-way ANOVA 
was used to analyse the timeline of cytokine elevations in the LPS group compared to baseline 
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levels. Where single measures were taken, two-tailed unpaired t-test was used to analyse the 
difference between 0.33LPS and VEH groups. 
In Experiment 2 repeated measures two-way ANOVA was used to compare mean differences 
in weight gain, food intake and cytokine levels among treatment groups over weeks of 
injections. One-way ANOVA was used to compare mean differences in DCX and Iba1 
hippocampal cell density among treatment groups.  
The Bonferroni multiple comparisons method was applied for post-hoc analyses to determine 
individual differences between treatment groups and the control group. Normality of 
distribution within the datasets was confirmed by Kolmogorov-Smirnov test. 
3 Results 
3.1 Experiment 1: Single LPS exposure 
In this experiment, acute and long-term effects of a single exposure to 0.33mg/kg LPS injection 
were investigated. This dose was chosen as it has been consistently described to induce 
moderate sickness and depressive-like behaviour in BALB/c mice (Burton et al., 2011; Fenn et 
al., 2014; Godbout et al., 2007). Firstly, the dynamics of the sickness behaviour and plasma 
cytokine elevation was investigated following LPS injection over the first hours and days 
following exposure. For this mice were injected with either 0.33mg/kg LPS or saline 
(n=12/group) and locomotor activity in the home cage was assessed at baseline (5 min before 
the injections) and at 2, 4, 48 and 72 hours post injections (for schedule of experimental 
procedures see Table 17). Body weight change and food intake were assessed at 24, 48 and 72 
hours post injections. Immobility in the forced swim test was assessed at 24 and 48 hours post 
injections. A separate cohort of mice (n=6/group) injected at the same times was used for 









Table 17 Schedule of behavioural testing of acute effects in the Experiment 1: Single LPS exposure 
8 week old male BALB/cAnNCrl mice were injected with 0.33mg/kg LPS (0.33 LPS) or saline (VEH) i.p. and their 
locomotion was assessed in their home cages (HC) immediately before the injections (Baseline) and at 2, 4, 48 and 
72 hours after the injections according to schedules shown. Immobility in the forced swim test (FST) was also 













ID GROUP HC HC HC FST HC FST HC 
1 VEH 09:24 11:29 13:30 09:30 09:24 09:30 09:24 
2 0.33 LPS 09:34 11:42 13:40 09:40 09:34 09:40 09:34 
3 VEH 09:44 11:53 13:50 09:50 09:44 09:50 09:44 
4 0.33 LPS 09:54 12:05 14:00 10:00 09:54 10:00 09:54 
5 VEH 10:04 12:10 14:10 10:10 10:04 10:10 10:04 
6 0.33 LPS 10:14 12:20 14:20 10:20 10:14 10:20 10:14 
7 VEH 10:24 12:30 14:30 10:30 10:24 10:30 10:24 
8 0.33 LPS 10:34 12:40 14:40 10:40 10:34 10:40 10:34 
9 VEH 10:44 12:50 14:50 10:50 10:44 10:50 10:44 
10 0.33 LPS 10:54 13:00 15:00 11:00 10:54 11:00 10:54 
11 VEH 11:04 13:10 15:10 11:10 11:04 11:10 11:04 
12 0.33 LPS 11:14 13:20 15:20 11:20 11:14 11:20 11:14 
13 VEH 11:22 13:30 15:30 11:30 11:24 11:30 11:24 
14 0.33 LPS 11:35 13:40 15:40 11:40 11:34 11:40 11:34 
15 VEH 11:47 13:50 15:50 11:50 11:44 11:50 11:44 
16 0.33 LPS 11:59 14:00 16:00 12:00 11:54 12:00 11:54 
17 VEH 12:04 14:10 16:10 12:10 12:04 12:10 12:04 
18 0.33 LPS 12:14 14:20 16:20 12:20 12:14 12:20 12:14 
19 VEH 13:24 15:30 17:30 13:25 13:19 13:25 13:19 
20 0.33 LPS 13:34 15:40 17:40 13:35 13:29 13:35 13:29 
21 VEH 13:49 15:50 17:50 13:45 13:39 13:45 13:39 
22 0.33 LPS 14:04 16:00 18:00 14:00 13:54 14:00 13:54 
23 VEH 14:19 16:10 18:10 14:15 14:09 14:15 14:09 
24 0.33 LPS 14:34 16:20 18:20 14:30 14:24 14:30 14:24 
 
In the second part of the experiment, long-term consequences of LPS exposure for depressive-
like behaviour, HPA axis regulation, plasma cytokine levels and adult hippocampal 
neurogenesis were studied 8 weeks after injections. For the timeline of the experimental 




Figure 43 Experimental design of Experiment 1: Single LPS exposure 
8 week old male BALB/cAnNCrl mice were injected with 0.33mg/kg LPS (0.33 LPS) or saline (VEH) i.p. (n=12/group) 
and the dynamics of the sickness behaviour, depression-like behaviour and cytokine response were assessed during 
the next 7 days (Acute effect) and 8 weeks later (Long-term effect).   
3.1.1 Single LPS exposure produces acute sickness behaviour-like response, 
depressive-like behaviour, and elevation of plasma cytokines levels 
The dynamics of sickness behaviour parameters in the first cohort of mice were analysed by 
repeated measures two-way ANOVA. The results showed that single 0.33 LPS exposure 
induced weight loss within the first 24 hours, which returned to normal during the next 7 days 
(Effect of LPS X Time F (4, 88) = 30.24, p<0.0001, Effect of Time F (4, 88) = 25.29, p<0.0001, 
Effect of LPS F (1, 22) = 2.094, p = 0.162) (see Figure 44A). Single 0.33 LPS exposure also 
reduced food intake in the first 24 hours after injection which returned to control levels by 48 
hours (Effect of LPS X Time F (3, 63) = 6.456, p = 0.0007, Effect of Time F (3, 63) = 11.50, p < 
0.0001, Effect of LPS F (2, 125) = 1.555, p = 0.215) (see Figure 44B). Home cage locomotion was 
reduced in LPS injected group 2 and 4 hours post injection, but returned to normal by 48 hours 
(Effect of LPS X Time F (4, 32) = 4.316, p = 0.007, Effect of Time F (4, 32) = 2.94, p = 0.035, 
Effect of LPS F (1, 8) = 9.13, p = 0.017) (see Figure 44C). LPS-exposed mice showed increased 
immobility in the FST 24 but not 48 hours post injections (Effect of LPS x Time F (1, 22) = 0.044, 
p = 0.837, Effect of Time F (1, 22) = 0.974, p = 0.334, Effect of LPS F (1, 22) = 6.851, p = 0.016) 
(see Figure 44D).  
The second cohort injected with 0.33 mg/kg LPS (n=6/group) was used to measure plasma 
cytokine levels at 2, 4, 24 and 48 hours post injections. One-way repeated measures ANOVA of 
results showed that all 10 cytokines measured were elevated at 2 and 4 hrs time points, but 
most cytokine levels apart from IL-6 returned to baseline levels at 24hrs (see Figure 44E and 
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Table 18 for details of statistical analysis). IL-6 was still elevated at this time point, but also 
returned to baseline by 48 hrs. 
 
Figure 44 Acute effects of a single LPS exposure 
8 week old male BALB/cAnNCrl mice were injected with 0.33mg/kg LPS (0.33 LPS) or saline (VEH) i.p. (n=12/group) 
and the dynamics of the sickness behaviour, depression-like behaviour and cytokine response were assessed during 
the next 3 days.  (A)body weight measured at 0, 24, 48 and 72 hours and 7 days following injections (B) Food intake 
within 24 hours measured at 0, 24, 48 and 72 hours post injections (C) locomotion was assessed in the home cages 
(HC) at 0,  2, 4, 48 and 72 hours after the injections  (D) immobility in the forced swim test (FST) at 24 and 48 hrs post 
injections; (E) plasma cytokine levels measured at 0, 2, 4, 24 and 48  hours post injection, (measures which were 
above or below of the sensitivity range of the assay substituted with highest/lowest points of the standard curve for 
representation; for statistical analysis details see Table 18,  n=6, data presented as %change from baseline). Data 
represents mean±SEM, *p<0.05, **p<0.01, ***p<0.001 derived from post-hoc Bonferroni multiple comparisons test 
0.33LPS vs VEH  
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Table 18 One-way RM ANOVA and post-hoc Bonferroni multiple comparisons of plasma cytokine measures during 
first 48 hours post LPS injections.  
8 week old male BALB/cAnNCrl mice were injected with 0.33mg/kg LPS (0.33 LPS) or saline (VEH) i.p. (n=6) and  
peripheral plasma levels of a panel of 10 cytokines were assessed at 0,2, 24 and 48 hours post injections using 
Luminex technology and data analysed using repeated measures one-way ANOVA as shown in the table 
 
  
One-way ANOVA Bonferroni multiple comparisons  






Between Groups 2 
6.341 .017 41.2200 
2 above range 
Within Groups 5 4 above range 
Residual 10 24 88.38 0.2113 
Total 17 48 41.52 > 0.9999 
IL-4 
Between Groups 4 
16.820 .007 155.5000 
2 817.5000 .002 
Within Groups 5 4 818.7000 .082 
Residual 20 24 137.3000 > 0.9999 
Total 29 48 104.0000 > 0.9999 
IFN-γ 
Between Groups 4 
3.914 .017 58.0700 
2 140.3000 .963 
Within Groups 5 4 270.8000 .021 
Residual 20 24 53.3600 > 0.9999 
Total 29 48 50.0200 > 0.9999 
IL-12 
Between Groups 4 
12.250 .000 120.5000 
2 5820.0000 0.962 
Within Groups 5 4 above range  
Residual 20 24 144.2000 > 0.9999 
Total 29 48 92.9900 > 0.9999 
IL-1β 
Between Groups 4 
6.948 .000 118.4000 
2 431.5000 .063 
Within Groups 5 4 583.0000 0.004 
Residual 20 24 113.3000 > 0.9999 
Total 29 48 113.4000 > 0.9999 
TNFα 
Between Groups 4 
26.860 .001 23.0700 
2 above range  
Within Groups 5 4 819.7000 > 0.9999 
Residual 20 24 33.6100 > 0.9999 
Total 29 48 22.5100 > 0.9999 
IL-5 
Between Groups 2 
21.640 .003 32.3800 
2 159.5000 .001 
Within Groups 5 4 175.4000 .013 
Residual 10 24 below range  
Total 17 48 below range  
IL-2 
Between Groups 4 
27.900 .000 20.1100 
2 44.2100 < 0.0001 
Within Groups 5 4 44.2400 < 0.0001 
Residual 20 24 18.8900 > 0.9999 
Total 29 48 19.0700 > 0.9999 
IL-10 
Between Groups 2 
8.517 .023 36.6000 
2 102.8000 .010 
Within Groups 5 4 131.9000 .056 
Residual 10 24 below range 
Total 17 48 below range  
GM-CSF 
Between Groups 4 
38.290 .000 20.2300 
2 111.1000 < 0.0001 
Residual 20 4 110.7000 < 0.0001 
Within Groups 5 24 19.8200 > 0.9999 
Total 29 48 19.3900 > 0.9999 
3.1.2 Single LPS exposure did not induce long-lasting changes in depressive 
behaviour, HPA axis and adult hippocampal neurogenesis 
Long-term effects of a single LPS exposure was investigated 8 weeks after an injection with 
0.33 mg/kg LPS. To assess if the acute effect of LPS on immobility in the FST remained after 8 
weeks, FST test was conducted in the long-term cohort, however no difference was observed 
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between VEH and LPS groups (Student t-test t=0.1013, df=21, p=0.92) (see Figure 45A). 
Assessment of CORT levels before and after FST also showed that LPS did not have a long-
lasting effect on the HPA axis (Effect of LPS x FST F (1, 17) = 0.025, p = 0.876; Effect of LPS F (1, 
17) = 0.148, p = 0.706; Effect of FST F (1, 17) = 51.49, p < 0.0001) (see Figure 45B). To measure 
long-lasting plasma cytokine level changes, plasma was analysed using a 10-plex cytokine 
assay. However only two cytokines, IL-12 and IL-2, were detectable in the samples, and their   
were not affected by LPS (IL-12 Student t-test t=0.1298 df=12, p=0.9; IL-2 t=0.6084 df=18, 
p=0.5 t test) (see Figure 45D). Finally, density of DCX+ neuroblasts in the hippocampal dentate 
gyrus was analysed using immunohistochemistry. LPS did not significantly affect the level of 
DCX+ cells, but a trend towards increase (Student t-test t=2.051, df=9, p=0.07) was observed in 
the LPS-exposed group (see Figure 45C). 
 
Figure 45 Long-term effects of a single LPS exposure 
8 week old male BALB/cAnNCrl mice were injected with 0.33mg/kg LPS (0.33 LPS) or saline (VEH) i.p. (n=12/group) 
and long-term effects of a single exposure to 0.33 mg/kg were investigated 7 weeks later (A) LPS did not have a 
long-term effect on immobility in the forced swim test (FST) (B) LPS did not have a long-term effect on baseline and 
post-FST CORT levels, ***p<0.001 derived from Bonferroni multiple comparisons VEH vs LPS (C) the density of DCX+ 
cells, n=6/group (D) plasma leves of 2 out of 10 cytokines which could be detected in the Luminex assay, IL-2 and IL-
12, n=6/group  
3.1.3 Discussion of Experiment 1 results 
Thus this experiment showed that injection with 0.33mg/kg of LPS induces strong but transient 
response which included components of sickness behaviour, such as decreased locomotor 
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activity, food intake and weight loss. However most of these parameters returned to normal 
within 3 days. LPS exposure also stimulated a significant elevation of plasma cytokines levels in 
the first hours after injection, with the majority of cytokines returning to baseline levels at 24 
hrs post-injection. Yet at this time point LPS-exposed mice showed increased immobility in the 
FST, a behavioural change commonly interpreted as depression-like behavioural despair. 
However, 24 hours later (48 hours after injections) this effect was no longer significant, 
although a strong trend towards reduced immobility remained in LPS exposed group. An 
assessment of the long-term effects of the single LPS injection showed that no behavioural 
despair was present in exposed mice 8 weeks later. Also single LPS exposure did not have any 
long-lasting effects on neurobiological parameters relevant for depression, such as plasma 
CORT levels, CORT response to acute stress and the level of neuronal differentiation in the 
hippocampal dentate gyrus. In addition, no plasma cytokine level changes were detected at 
this time point. Taken together, this data showed that single injections with 0.33 mg/kg LPS 
can stimulate transient sickness behaviour and plasma cytokine changes, but do not induce 
any long-term effects on depression-related behaviour and neurobiology. Therefore, its use in 
modelling chronic immune system activation described in depressed patients and its potential 
behavioural and neurobiological consequences is limited by the short lifespan of its effects. 
These findings prompted the need to develop a mode of injections which would better model 
chronic inflammatory-like changes observed in depression. 
3.2 Experiment 2: Repeated LPS exposure 
The aim of Experiment 2 was to develop a protocol to induce long-lasting effects on immune 
and central nervous systems, which would make it suitable for studying the biological 
processes mediating depression and the role of the immune system in mood disorders.  
To develop such a protocol, we tested two different models of repeated LPS injections 
compared to a single injection of a relatively high dose of 0.83mg/kg LPS (single LPS group), a 
dose which has already been utilised in a model of depression (Painsipp et al., 2011). As 
repeated LPS injections are known to induce tolerance to LPS, several measures were taken to 
avoid its development: a weekly interval between injections was included to allow for immune 
system recovery; a relatively low dose 0.1 mg/kg of LPS was used in 0.1 LPS group; a weekly 
increment from initial 0.33 mg/kg to a final 0.83 mg/kg dose was used in the escalating LPS 
(0.33-0.83) group as dose increase has been shown to avoid habituation of immune response 
(Wickens et al., 2014). Sickness behaviour, plasma cytokine profile, and the state of adult 
hippocampal neurogenesis and microglial activation in the hippocampus were assessed weekly 




Sibling pairs were randomly assigned to one of the 4 treatment groups, which received the 
following intraperitoneal (i.p.) injections once a week for 6 weeks:  Control group (SAL; N=10), 
received 100 µL of 0.9% saline each week; 0.1 LPS group (N=8), received 0.1mg/kg of LPS each 
week; escalating LPS (0.33-0.83) group (N=8), received 0.33 mg/kg of LPS on weeks 1 and 2, 
0.53 mg/kg of LPS on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on week 5, 0.83 mg/kg on 
week 6; single LPS group (N=8), received 0.83 mg/kg on week 1, and 100 µL saline on weeks 2-
6. For an overview of experimental design see Figure 46. 
 
Figure 46 Experimental design of Experiment 2: Repeated LPS exposure 
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks . Experimental 
conditions included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating LPS group injected with 
0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on week 5 and 0.83 mg/kg 
on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and Saline on weeks 2-6; SAL group was injected 
weekly with 0.9% saline solution. Blood was collected 2 hours after LPS injections on weeks 1 and 6; locomotion was 
measured 6 hours after LPS injections on weeks 1 and 6; weight change and food intake were measured during a 24-
hour period after the LPS injections 
3.2.1 Repeated LPS injections induced sickness behaviour each week for 6 weeks 
Body weight change and food intake were measured 24 hours after LPS injections to assess the 
suppressant effects of the sickness behaviour response on feeding (Biesmans et al., 2013).  
Both the dose and chronicity of LPS affected the change in weight gain and food intake (see 







On week 1, LPS treated animals showed significantly reduced body weight gain and/or reduced 
food intake compared to the saline control group, with the magnitude of effect dependant on 
the dose of LPS injected (see Figure 47). On week 2, only the 0.1 LPS group had a significant 
reduction in body weight gain. There was no significant difference in body weight gain in any 
LPS groups at week 3 but from week 4 through to 6, there was a significant, reduction in body 
weight gain in the group receiving escalating doses (0.33-0.83) of LPS.  The effect of LPS on 
food intake remained significant each subsequent week for the escalating LPS (0.33-0.83) 
group, while 0.1 LPS group displayed a significant reduction again only on the 6th week. 
Locomotor activity also was assessed in the open field arena 6 hours after the LPS or saline 
injections on week 1 and week 6. On week 1, the escalating (0.33-0.83) LPS group displayed 
statistically significant hypolocomotion (effect of dose F(3,28)=3.19, p=0.039), but on week 6 
the reduction in locomotor activity did not reach significance in comparison with SAL group 
(effect of dose F(2,23)=1.6, p=0.22, Figure 47C). 
Table 19 Two-way repeated measures ANOVA outcomes for weight gain and food intake measures taken each week 
24hrs after either LPS or saline injections for six weeks.  
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; 
SAL group was injected weekly with 0.9% saline solution. 
Factor Effect size   (% of total variation) F DF DF Residual p 
Weight gain 
    
  
Dose 12.33 24.66 3 30 < 0.0001 
Time 18.36 11.29 5 150 < 0.0001 
Interaction 16.3 3.341 15 150 < 0.0001 
Food intake 
     Dose 34.45 24.6 3 13 < 0.0001 
Time 13.92 11.04 5 65 < 0.0001 




Figure 47 Short-term sickness behaviour induced by weekly LPS injections 
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating LPS group injected with 
0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on week 5 and 0.83 mg/kg 
on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL group was injected 
weekly with 0.9% saline solution (a) Weight change measured during first 24hrs after injections each week expressed 
as % change from a baseline measured immediately before the LPS injections. (b) Food intake during first 24hrs after 
weekly injections. (c) locomotor activity on weeks 1 and 6 measured 6hrs after LPS or SAL injections in the open field 
arena; p values derived from Bonferroni multiple comparisons test SAL vs 0.1LPS/Escalating LPS/Single LPS, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Data represents mean±SEM, n=8-10/group. 
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3.2.2 Depressive-like behaviour diminished on week 6 in the Escalating LPS 
(0.33-0.83) group 
As 0.33-0.83 LPS group showed sustained sickness behaviour across the 6 weeks, in a separate 
cohort (N=10/group) of mice depressive-like behaviour in the FST was investigated on weeks 1 
and 6, 24 hrs after injections to assess the influence of repeated exposure on the development 
of behavioural despair. Repeated measures 2-way ANOVA of results showed that LPS injection 
on week 1 induced increase in immobility, while on week 6 the difference between 0.33-0.83 
LPS and SAL was no longer significant, although a trend towards increased immobility was still 
present in LPS-exposed group(Effect of Week X Dose F (1, 18) = 0.802, p=0.382; Effect of Week 
F (1, 18) = 6.866, p = 0.017; Effect of LPS F (1, 18) = 9.448, p = 0.007 (see Figure 48A). 
Locomotion in the open field arena did not differ between groups at both timepoints although 
was affected by week of inejctions (Week X Dose effect F (1, 36) = 7.38; p = 0.01, Effect of 
Week F (1, 36) = 8.66, p = 0.006; Effect of LPS F (1, 36) = 2.76, p = 0.105 (see Figure 48B). 
 
Figure 48 FST Immobility and locomotion in the Escalating LPS (0.33-0.83) group on weeks 1 and 6 
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks (n=8). FST was 
performed on week 1 and 6 24 hours after injections in 0.33-0.83 LPS group injected with LPS at a dose escalating 
from 0.33mg/kg to 0.83 mg/kg weekly and SAL group injected with saline (A) Immobility in the FST performed 24 hrs 
after injections (B) Locomotion in the open field arena measured at the same time point. Data represents 
mean±SEM, *p<0.05, **p<0.01, ***p<0.001 derived from post-hoc Bonferroni multiple comparisons SAL vs 0.33-0.83 
LPS 
3.2.3 Repeated exposure modified cytokine response to LPS challenge  
To detect systemic cytokine response to LPS challenge, selected cytokines were measured in 
the peripheral blood collected 2hrs after injection on weeks 1 and 6. The time point of blood 
collection was chosen based on previous studies which showed that in mice exposed to LPS 
blood levels of most cytokines peak within the first two hours after exposure and subside at 
later time points (Biesmans et al., 2013; Browne et al., 2012). Animals responded to acute LPS 
exposure on week 1 with a profound elevation of pro-inflammatory cytokines IL-6 and TNFα. 
More specifically, IL-6 was elevated up to 700 fold compared to control levels depending on 
the dose of LPS injected, while TNFα showed elevations in the range of 20 to 35 fold (see 
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Figure 49 and Table 20). Interestingly, some other cytokines and inflammatory markers were 
not elevated at this time point, including CRP, IL-5 and IL-2, while others did not reach 
detection levels of the assay used (IL-4, IFNγ, IL-1β). IL-10 showed an elevation on week 1, 
which reached significance in the escalating LPS (0.33-0.83) and single LPS groups. GM-CSF also 
significantly increased in response to all doses of LPS on week 1. In response to the 6th 
injection the elevation of IL-6 and particularly TNFα was much reduced compare to week 1. 
However, the levels of these pro-inflammatory cytokines were still over 570 fold (IL-6) and 
over 9 fold (TNFα) increased in the escalating LPS (0.33-0.83) group compared to levels 
observed in the control group (see Figure 49). In contrast, IL-2 was over 4 fold elevated 
exclusively in response to the escalating LPS (0.33-0.83) group, accompanied by an increase in 
GM-CSF levels in this group even more robust than on week 1 (20-fold on week 1 vs 30-fold on 
week 6). Interestingly, CRP was 0.44 fold decreased compared to control in response to the 
final LPS dose in the escalating LPS (0.33-0.83) group. Moreover, when the cytokine levels 
were measured in the cardiac blood collected 7 days after the last injection, it appeared that 
CRP was decreased in all LPS-injected animals compared to control group, including the single 




Figure 49 Plasma cytokine profile in response to LPS injections 2hrs after exposure on weeks one and six.  
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating LPS group injected with 
0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on week 5 and 0.83 mg/kg 
on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; SAL group was injected 
weekly with 0.9% saline solution. Data shown as percentage change from control (SAL). P values derived from 
Bonferroni multiple comparisons test SAL vs 0.1LPS/Escalating LPS/Single LPS, *p<0.05, **p<0.01, ***p<0.001 









Table 20 One-way ANOVA and post-hoc Bonferroni multiple comparisons of plasma cytokine measures taken 2hrs 
after LPS/SAL exposure on weeks one and six.  
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and Saline on weeks 2-6; 
SAL group was injected weekly with 0.9% saline solution. 
 
3.2.4 Hippocampal microglia was not affected by LPS exposure 
The estimation of the number of Iba1 positive cells in neurogenic granular zone of the dentate 
gyrus, as well as in the whole hippocampus showed that the number of microglia was not 
altered in long term (7 days later) by LPS injections (Kruskal-Wallis one-way anova Effect of 
Cytokine_week df F p SAL group 
mean, pg/ml LPS groups Mean, pg/ml p
Between Groups 3 0.1LPS 13517.7875 .008
Within Groups 30 0.33-0.83 LPS 29908.7500 .000
Total 33 Single LPS 40395.0000 .000
Between Groups 3 0.1LPS 2749.1429 .039
Within Groups 28 0.33-0.83 LPS 5292.8750 .000
Total 31 Single LPS 58.7529 1.000
Between Groups 3 0.1LPS 125.1339 .032
Within Groups 30 0.33-0.83 LPS 221.6500 .000
Total 33 Single LPS 218.5625 .000
Between Groups 3 0.1LPS 31.2271 1.000
Within Groups 28 0.33-0.83 LPS 74.4538 .002
Total 31 Single LPS 5.4520 1.000
Between Groups 3 0.1LPS 112317.5000
Within Groups 30 0.33-0.83 LPS 105770.0000
Total 33 Single LPS 79503.7500
Between Groups 3 0.1LPS 55210.0000 .124
Within Groups 28 0.33-0.83 LPS 40051.2500 .006
Total 31 Single LPS 71444.2857 1.000
Between Groups 3 0.1LPS 16.7850 .024
Within Groups 30 0.33-0.83 LPS 35.1038 .000
Total 33 Single LPS 40.4513 .000
Between Groups 3 0.1LPS 12.0094 1.000
Within Groups 28 0.33-0.83 LPS 50.5975 .000
Total 31 Single LPS 2.1879 1.000
Between Groups 3 0.1LPS 18.3475
Within Groups 30 0.33-0.83 LPS 18.3050
Total 33 Single LPS 15.6600
Between Groups 3 0.1LPS 27.6700 1.000
Within Groups 28 0.33-0.83 LPS 75.3138 .000
Total 31 Single LPS 17.6369 1.000
Between Groups 3 0.1LPS 81.4938 .151
Within Groups 30 0.33-0.83 LPS 165.9275 .000
Total 33 Single LPS 272.3875 .000
Between Groups 3 0.1LPS 31.7650
Within Groups 30 0.33-0.83 LPS 32.4338
Total 33 Single LPS 29.9950
Between Groups 3 0.1LPS 30.1771
Within Groups 28 0.33-0.83 LPS 32.9788
Total 31 Single LPS 29.5943































treatment F(3,20)=0.45,p=0.72, see Fig.4A). The level of microglial activation was assessed by 
the density of CD68-positive puncta in the tissue. One-way ANOVA of results showed that LPS 
exposure did not have a long-term effect on microglial activation in any of the areas analysed 
(DG (F (3, 25) = 4.783, p = 0.009, CA1 F (3, 25) = 2.209, p = 0.112 and CA3 F (3, 25) = 2.918, p = 
0.054 (see Figure 50B). Additionally, we investigated whether systemic LPS exposure affected 
the level of plasma corticosterone. For this purpose blood was collected via cardiac puncture 7 
days after the last LPS injections as described in Methods section 2.4. High individual variability 
was observed in the systemic corticosterone levels and no statistical difference was detected 
among mean group levels by one-way ANOVA (F (3, 25) = 0.371, p = 0.775 (see Figure 50C). 
 
Figure 50 Hippocampal microglia and corticosterone levels in mice exposed to chronic LPS/SAL injections. 
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; 
SAL group was injected weekly with 0.9% saline solution. (a) Number of Iba1 positive cells in the dentate gyrus of the 
hippocampus was unaffected by LPS exposure, ns (b) CD68 positive surface area, detected in images taken from 
different regions of the hippocampus, also was unchanged by LPS exposure (DG – dentate gyrus, CA1 and CA3 – 
Cornu Ammonis areas), ns (c) Corticosterone levels detected in the cardiac blood 7 days after last LPS injections. 
Data represents mean±SEM. 
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3.2.5 LPS injections affected the number of postmitotic immature neurons in the 
hippocampal dentate gyrus.  
One-way ANOVA of Ki67-positive cell density showed that in the tissue collected 7 days after 
the last injections, the level of proliferating Ki67 positive cells was not altered (F (3, 22) = 
0.146, p=0.931 (see Figure 51A).  Also, it showed that the density of DCX positive immature 
neurons was  also not affected by LPS injections according to the  One-way ANOVA (F (3, 26) = 
1.862, p = 0.161). However, weekly LPS injections affected the number of “EF” type 
postmitotic DCX positive neurons (Effect of treatment F (3,26) =15.46, p<0.0001, RM one-way 
ANOVA). The density of other morphological types was not affected by treatment (Type AB F 
(3, 26) = 1.845, p=0.164, type CD F (3, 26) = 0.67 , p=0.579, RM one-way ANOVA) (see Figure 







Figure 51 Adult hippocampal neurogenesis in the LPS-exposed animals 
8 week old male BALB/cAnNCrl mice were injected with LPS or saline i.p. once a week for 6 weeks. Experimental 
conditions (n=8-10/group) included: 0.1 LPS group injected with 0.1 mg/kg LPS once weekly; Escalating (0.33-0.83) 
LPS group injected with 0.33mg/kg on weeks 1 and 2, 0.53mg/kg on week 3, 0.63 mg/kg on week 4, 0.73 mg/kg on 
week 5 and 0.83 mg/kg on week 6; Single LPS group injected with 0.83 mg/kg on week 1 and saline on weeks 2-6; 
SAL group was injected weekly with 0.9% saline solution. (a) Number of proliferating Ki67 positive cells in the 
dentate gyrus of the hippocampus was unchanged by LPS injections, ns (b) Representative micrographs of DG show 
DCX+ cells with their dendritic trees (in dark-brown), scale bar = 500 µm (c) Total number of DCX+ cells was not 
significantly changed by LPS injections; DCX+ cells were then classified according to their dendritic morphology: AB – 
no or short dendrites, CD – medium length dendrites without branching; EF – long branching dendrites reaching the 
molecular layer. Data represents mean±SEM; P values derived from Bonferroni multiple comparisons test SAL vs 
0.1LPS/Escalating LPS/Single LPS, *p<0.05, **p<0.01 
3.2.6 Discussion of Experiment 2 results 
This experiment showed that systemic exposure to escalating dose of LPS administered once a 
week for 6 weeks repeatedly induced main aspects of sickness behaviour, such as reduced 
food intake and weight gain. The significance of this finding stems from previous studies which 
show that LPS tolerance manifests with a reduction of sickness behaviour, such as absence of 
reduced food intake or hypolocomotion (Banasikowski et al., 2015). In contrast, the effect 
induced by the repeated 0.1 mg/kg LPS dose was present only intermittently, while a single 
injection of 0.83 mg/kg of LPS did not induce any long-lasting effect on behavioural parameters 
studied. However, locomotor activity data suggests that hypolocomotion displayed in the 
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escalating LPS (0.33-0.83) group on week 1 was absent on week 6. It is important to note that 
locomotor activity data was collected in a novel environment of an open field test arena 6 
hours after injections. Such comparatively late timing of assessment and repeated (second) 
exposure to the arena could have affected the outcome of this test. Equally, this data could 
indicate that a degree of tolerance in the effect of LPS on locomotor activity developed 
following repeated LPS challenge. However the presence of reduced food intake and weight 
loss at this time point suggests that if indeed present, this apparent tolerance was not 
substantial enough to affect all aspects of sickness behaviour response. Nonetheless, a loss of 
significant difference in depressive-like behaviour from week 1 to week 6 showed that the 
escalating dose of LPS was not sufficient to maintain depression-like state in exposed mice. 
Assessment of peripheral cytokine levels in response to LPS showed that chronic exposure to 
escalating LPS doses induced a distinct cytokine profile, while single and low dose of LPS did 
not induce any long-lasting changes in the blood cytokine levels. In naïve animals LPS injections 
induced elevation of pro-inflammatory cytokines, such as IL-6, TNFα, GM-CSF and anti-
inflammatory IL-10. Chronic injections with the escalating dose induced a rather distinct profile 
of cytokine response. On week 6, IL-6 and TNFα remained elevated, but the magnitude of 
effect was reduced. While this finding might suggest a certain degree of developing tolerance, 
a moderate elevation of these cytokines is in fact even more relevant for modelling 
depression, as depressed patients usually present with small elevation of IL-6 and TNFα levels 
(Dowlati et al., 2010).  Surprisingly, some cytokines were modulated exclusively by chronic 
exposure. CRP was unchanged on week 1 in all groups but reduced in escalating LPS (0.33-
0.83) group on week 6. As CRP is an acute-phase protein and is commonly used as a biomarker 
of inflammation, its reduction after 6 weeks might be suggestive of an increase in the anti-
inflammatory state of the immune system, perhaps in response to the large increase in pro-
inflammatory mediators observed on week 1. Subsequently this anti-inflammatory state may 
have been responsible for the reduction in pro-inflammatory markers observed at week 6. 
Interestingly IL-2 and GM-CSF appeared to be elevated by chronic exposure, with IL-2 being 
exclusively modulated by escalating LPS. IL-2 is known for its ability to stimulate proliferation 
of T-cells (Lemoine et al., 2009). IL-2 signalling has been shown to play an important role in the 
regulation of effector and regulator T-cells functioning, and its anti-autoimmune properties are 
currently being tested in the treatment of some autoimmune diseases (Bayer et al., 2013). 
GM-CSF stimulates proliferation of many leukocytes including macrophages and dendritic cells, 
as well as differentiation and immune response of T-cells, and has been historically considered 
to be a pro-inflammatory cytokine (Shi et al., 2006). The increase of these two cytokines in 
response to chronic injections may reflect an alternative state of immune system activation, 
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distinct from the conventional response to single LPS exposure. Of particular importance is the 
absence of an elevation in the anti-inflammatory IL-10 on week 6, as anti-inflammatory IL-10 
upregulation has been implicated in a classical endotoxin tolerance (Biswas and Lopez-Collazo, 
2009). Therefore, while this alternative profile possesses some features of supressed immune 
response, such as attenuated IL-6 and TNFα elevations and decrease in CRP levels, it does not 
fully resemble the previously described endotoxin tolerance. For example, a previous study 
which induced LPS tolerance in rats by way of repeated injections showed that blood levels of 
IL-6 and TNFα were at control levels 2 hours after an injection of 32mg/kg of LPS (Chen et al., 
2005). This substantially differs from the data in my study were a much lower dose still 
induced a significant elevation of these cytokines in the blood.  Another aspect of the cytokine 
profile described above which differs from previous studies of LPS tolerance is the absence of 
elevation of the anti-inflammatory IL-10, as for example has been shown previously in a mouse 
model of tolerance induced by intraplantar injection of LPS prior to intravenous challenge with 
0.35mg/kg (Bosnar et al., 2013).  Next the elevation of IL-2 observed in escalating LPS group 
has been previously associated with a mutation in NF-kB pathway enzyme A20 which led to a 
100% mortality of mutant mice in response to a challenge with 10mg/kg LPS, a dose which did 
not induce deaths in wild type mice (Xuan et al., 2015). These differences between the 
cytokine profile of escalating LPS group and cytokine response previously described in LPS 
tolerance studies suggest a distinct state of the immune system induced by escalating dose LPS 
injections. 
Elevation of IL-2 is of particular importance as IL-2 has been previously implicated in 
psychiatric conditions, including depression. Maes et al. (1995) found that depressed patients 
have elevated plasma levels of soluble IL-2 receptor, and later a consensus paper of the World 
Federation of Societies of Biological Psychiatry included soluble serum IL-2 receptor elevation 
into the list of depression biomarkers (Mössner et al., 2007).  This status was not subsequently 
confirmed in the later meta-analysis mainly due to appearance of a number of studies showing 
the opposite change in IL-2 levels (Dowlati et al., 2010). However more recent reports show 
elevation of IL-2 levels in the blood of bipolar patients during a manic episode (Brietzke et al., 
2009), as well as in chronic obstructive pulmonary disease patients with comorbid depression 
(Rybka et al., 2016). The involvement of IL-2 activation in psychopathology is further confirmed 
by the observation that IL-2 therapy in cancer patients is capable of inducing neuropsychiatric 
toxicity (Kammula et al., 1998). Interestingly, single 0.83 mg/kg dose did not induce any long-
lasting changes in the cytokine levels albeit this dose inducing long-lasting depression-like 
behaviour in a previous study (Painsipp et al., 2011). However, it is important to note that 
plasma cytokine levels might not be representative of the cytokine content in the brain. Indeed 
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several studies showed that after repeated LPS injections levels of peripheral blood pro-
inflammatory cytokines might return to control levels while the level of cytokine expression in 
the  brain remains high (Chen et al., 2005; Fischer et al., 2015; Norden et al., 2016).  
Due to the suggested role of adult hippocampal neurogenesis in depression neurobiology and 
in the mechanism of antidepressant action the effect of systemic chronic LPS exposure on the 
rate of AHN was investigated. It is important to note that the effects that are occurring in the 
tissue collected 7 days after the last LPS injections were studied, therefore the immediate 
effects of LPS would not be reflected in this analysis. While LPS did not affect cell proliferation 
in the DG in accordance with previously published studies (Belarbi et al., 2012; Ormerod et al., 
2013), LPS exposure altered the level of postmitotic maturation of neuroblasts in the dentate 
gyrus, with escalating dose causing a decrease in contrast with a potentially compensatory 
increase seen in the low dose and single LPS groups. It has already been shown that LPS can 
disrupt the morphological maturation of DCX positive cells (Valero et al., 2014). Interestingly, 
in this experiment LPS injections had an effect on the number of postmitotic, almost mature 
“EF”-type DCX positive neurons with multiple dendritic branching reaching the molecular layer. 
The number of these cells was significantly higher than control in 0.1 LPS and single LPS 
groups. This data might be suggesting a compensatory increase in maturation of DCX positive 
progenitors. It is possible that a single 0.83 mg/kg LPS dose, as well as repeated 0.1 mg/kg LPS 
doses allow the neurogenic niche to recover from the insult and compensate for the damage 
occurring immediately after exposure with an increase in maturation rate of DCX+ neurons. 
Indeed previous studies described the acute (within first 24 hours) reduction in cell 
proliferation following LPS treatment (Fujioka and Akema, 2010), while other studies described 
an increase in the number of proliferating cells in the hippocampus 7 days after LPS injections 
(Valero et al., 2014). Therefore it is possible that during the first week after LPS insult, an initial 
decline in cell proliferation gives way to a compensative increase, which subsequently results 
in an increase in the number of postmitotic immature neurons. Importantly considering the 
timeline of neuroblast maturation to the postmitotic “EF” morphological stage (approximately 
2-4 weeks according to Zhao et al. 2006), this group of DCX+ neurons most likely represents 
the neuroblasts which were generated on weeks 3 to 5 of the LPS treatment, which seems a 
likely time window for a compensatory effect. However, in the escalating LPS (0.33-0.83) group 
we observed a trend towards decline in the total number of DCX+ and a significant decrease in 
the number of postmitotic DCX+ neuroblasts in this group compared to control. These findings 
suggest that weekly increase of LPS dose from 0.33 to 0.83 mg/kg might be producing a 
damage for which compensation is no longer effective. It is possible that the dose range used 
in our study was not sufficiently high to induce changes which would also significantly reduce 
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the total number of DCX+ cells, as many studies which previously demonstrated the reduction 
of cell differentiation employed higher doses, such as 1 mg/kg or more (Graciarena et al., 
2013; Monje, 2003; Ormerod et al., 2013). Yet the effect on the postmitotic morphology is of 
importance, as it replicates the effect which chronic mild stress, another depression-modelling 
intervention in animals, exerts on dendritic branching of DCX-positive hippocampal cells (Vega-
Rivera et al., 2016). Moreover, it has been shown by previous studies that chronic stress and 
other models of depression in animals can cause similar changes in dendritic morphology of 
mature hippocampal neurons, such as dendritic atrophy and debranching (Qiao et al., 2016; 
Sousa et al., 2000; Vyas et al., 2002). Importantly this effect is thought to  underlie the 
reduction of hippocampal volume described in neuroimaging studies of depressed patients 
(Lorenzetti et al., 2009). As dendritic morphology is a form of neural plasticity, this effect could 
also be involved in a cognitive decline frequently observed in clinical depression (Femenía et 
al., 2012). Therefore observed changes in dendritic morphology emphasise the relevance of 
described LPS exposure for modelling depression-related neurobiology. However, 
experimental design limited the ability to follow the dynamics of neurogenic changes. Inclusion 
of groups injected with 0.83mg/kg and 0.1mg/kg shortly before tissue collection would permit 
a direct test of whether the neurogenic decline occurs acutely after exposure to these doses, 
and subsequently gives way to a compensatory increase observed in this experiment. 
Next the state of hippocampal microglia was assessed. It has been commonly described that 
systemic LPS exposure induces microglial activation in the hippocampus (Ho et al., 2015; Noh 
et al., 2014). Microglia in turn are known to have the ability to modulate neurogenesis during 
an inflammatory insult (Belarbi and Rosi, 2013; Ekdahl, 2012) potentially through a release of 
pro-inflammatory cytokines, which have been shown to exert a detrimental effect on neural 
stem cells proliferation and differentiation (Koo and Duman, 2008; Zunszain et al., 2012). 
However, in this experiment LPS exposure did not have a long-lasting effect on the 
hippocampal microglia. Indeed, no change in the number of Iba1 positive microglia neither in 
the whole hippocampus, nor in the neurogenic granular zone was observed. While some 
studies report an increase in the proliferation of microglia in response to LPS (Borges et al., 
2012), most of these effects have been observed shortly after LPS exposure. Importantly the 
change in population number does not necessary reflect the state of microglial activation, the 
commonly observed response of microglia to inflammatory stimuli. Indeed many studies 
describe activation of microglia in response to LPS without reporting any change in microglial 
number (Aid et al., 2010; Qin et al., 2007). Activation of microglia usually involves 
morphological changes in the shape and size of microglial soma and processes (Stence et al., 
2001), as well as increase in expression of activation markers, such as CD68 and CD11b (Ekdahl 
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et al., 2003; Sugama et al., 2009). In this experiment the average level of activation in the 
microglial population was assessed by determining the surface area of CD68 positive puncta. 
No change was observed in CD68 expression 7 days after the last LPS challenge in the DG, CA1 
and CA3 areas of the hippocampus, regions frequently shown to be responsive to systemic LPS. 
It is possible that the future morphological analysis could uncover signs of microglial activation 
not reflected by CD68 expression. At the same time it has been reported in the literature that 
the morphological state highlighted by the Iba1 marker might not coincide with the expression 
of proinflammatory genes by activated microglial cells (Norden et al., 2016). Therefore 
histological assessment of microglial activation used in this experiment might have its 
limitations in reflecting the functional activation of microglial cells. Future experiments 
determining the cytokine content in relevant brain areas could give a deeper insight into the 
effect of repeated LPS injections on intracerebral immune state. Moreover, measurements of 
IDO expression could have shown if LPS affected serotonin/kynurenine metabolism relevant 
for depression, as it has been shown in previous LPS studies (Godbout et al., 2008; O’Connor et 
al., 2009). 
Another notable finding in the biological parameters is the absence of an increase in blood 
corticosterone levels, which has been previously reported in response to acute (Browne et al., 
2012) and chronic LPS administration (Elgarf et al., 2014). The lack of hypercortisolism could 
account for the absence of decline in the hippocampal neurogenesis, as this has been 
attributed to the glucocorticoid receptor activation (Anacker et al., 2011). It also highlights the 
limited ability of the current chronic LPS administration paradigm to model depression 
neurobiology. Another important limitation of this study is the absence of data reflecting 
depression-like behaviour induced by LPS administration, which prevents us from drawing final 
conclusions on the relevance of this model for depression research. However, based on 
neurobiological phenotype, it is reasonable to suggest that whist this paradigm might be used 
to induce inflammatory aspects of depression neurobiology, it is likely to require co-exposure 
with other stimuli to produce a full depression-like phenotype in mice. 
4 Conclusions 
These experiments investigated the effect of single and repeated LPS injections at doses 
relevant for modelling mood disorders on systemic immune response and on adult 
hippocampal neurogenesis. Experiment 1 showed that the effects of a single 0.33 mg/kg LPS 
injection are transient and thus do not provide insight into chronic aspects of depression 
neurobiology. Therefore, in Experiment 2 we tested a new mode of injections designed to 
bypass the development of LPS tolerance and to induce neurobiological changes similar to 
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those seen in clinical depression. The results showed that the escalating LPS (0.33-0.83) group 
did not develop signs of LPS tolerance in sickness behaviour, although a loss of significant 
increase in FST immobility, which was present after the first injection, was observed 6 weeks 
later. The peripheral blood cytokine profile induced by escalating LPS suggested a mode of 
immune system activation distinct from an acute activation induced by single LPS exposure, 
with only minor signs of LPS tolerance importantly lacking the anti-inflammatory cytokine 
elevation. A comparison to a cytokine profile of a group specifically treated to induce tolerance 
could have allowed to draw more definitive conclusions regarding its presence. In addition, an 
investigation of molecular correlates of LPS tolerance, such as TLR4 expression, activation of 
MyD88 pathways inhibitors and nuclear translocation of NF-kB, would have provided extra 
insight into its presence and underlying mechanisms. 
Assessment of adult hippocampal neurogenesis, considered to play an important role in 
depression neurobiology, showed that exposure to escalating dose led to a reduction of 
neuroblast maturation in the dentate gyrus, in contrast to a compensatory increase seen in 
low dose 0.1 LPS group or a group exposed to a single 0.83mg/kg LPS injection. However the 
observed changes in neurogenesis were not accompanied by a change in microglial 
proliferation or activation around neurogenic regions. Therefore the lack of sickness behaviour 
tolerance and increase of anti-inflammatory cytokines, as well as changes observed in 
hippocampal neurogenesis suggest that weekly injections of LPS with dose increment might be 
a suitable model to utilise in future studies looking into immunological aspects of mood 
disorders. However, the loss of depressive effect of a single LPS exposure triggered by 
repeated injections shows that LPS on its own is not an intervention sufficient to solely induce 




Chapter 6 Discussion and Conclusions 
 Suitability of the mouse BALB/c strain for the use in 
animal models of depression 
This project was dedicated to the study and advancement of animal models of depression, 
with a specific focus on neurobiological changes including adult hippocampal neurogenesis and 
immune system markers. Initially most depression models and behavioural assessments of 
their outcome were developed in rats, however recent advances in mouse genetics and 
genetic tools arising from them demand the development of models suitable for the mouse. 
Moreover, mice present an advantage of relative ease and low cost of breeding and housing. 
To contribute to the advancement of mouse models, all experiments in this project were 
conducted in mice. A choice of the strain was directed by the known characteristics of BALB/c 
mice, that is high prevalence of anxiety–like behaviour in approach-avoidance tests, high 
sensitivity to UCMS and good responsiveness to antidepressant treatment. However 
behavioural assessments conducted throughout this project showed that some 
charachteristics of BALB/c response to chronic stress exposure are suboptimal for the use in 
depression model studies. Indeed hyperlocomotion induced by UCMS exposure acted as a 
limitation for evaluating the results of behavioural tests of anxiety, such as the open field, 
light-dark box and novelty-suppressed feeding, as anxiety in these tests is measured based on 
the time mice spend moving around potentially threatening areas.  
Another important aspect of BALB/c sensitivity to chronic stress is their response to chronic 
injections. The comparison between undisturbed mice and those chronically i.p. injected with 
saline in the UCMS Experiment 1 showed that chronic injections affected their coat state and 
behaviour in the FST. These findings suggest that peripheral injection route of drug 
administration is not suitable for chronic stress studies in this strain as it acts as an additional 
stressful factor. This conclusion further limits the use of BALB/c strain preclinical studies of 
depression which often employ i.p. injections to administer therapeutic compounds. 
 Reproducability of the UCMS and new insights into its 
outcomes 
The UCMS - dedicated chapters of this thesis which described the setup of the UCMS model 
demonstrated the challenges of this process. Indeed, it became apparent that the UCMS 
protocol needs to be carefully adjusted to a particular strain and facilities of the laboratory. 
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Nonetheless, the outcome of the optimisation process confirmed that an aetiologically 
relevant protocol which does not include physical stressors, such as food or water deprivation, 
restraint or footshock, most closely resembling the protocol by Nollet et al. (2013) can be 
effective in 8-week old male BALB/cAnNCrl to induce some behavioural changes relevant for 
depression. However due to high reactivity of this strain, control mice need to be housed in 
large cages with their siblings to avoid social isolation and cage mate fighting. The use of 
sibling pairs also additionally reduces genetic and environmental variability among animals, 
which has a potential to reduce individual variability known to be high in behavioural 
responses. At the same time it can be argued that sibling pairs do not represent true biological 
replicates. However animals from the same litters are often used in rodent studies, whether 
they are bred in house or by a supplier laboratory. Therefore the use of sibling pairs is unlikely 
to significantly modify the outcome compared to previous studies.  Experimentation with a 
schedule of stressors during UCMS showed that 2 stressors per day are not sufficient to induce 
significant behavioural changes, while 4 stressors can successfully affect behavioural outcome. 
Overlapping of stressors is not recommended as it appeared to be too severe, increasing the 
risk of death in the stress-exposed group. Such comparison among protocols also 
demonstrated that even small changes in the schedule of stress exposure can lead to 
significantly different outcomes, which could also explain variability seen among UCMS 
studies. Moreover, a comparison between UCMS Experiments 3 and 4 which employed 
identical protocol showed that some response variability exists between different cohorts of 
the same inbred strain mice. 
The behavioural phenotypes induced by our protocol included a reduction of grooming and a 
novelty-induced hyperactivity discussed above. Potently due to hyperactivity UCMS-exposed 
animals displayed paradoxical reduced anxiety in approach-avoidance tasks, which has been 
described by some previous studies (Couch et al., 2016; Schweizer et al., 2009). On the other 
hand it is possible that this reduced anxiety was not solely a result of hyperactivity, as some of 
these tests are known to be less dependent on activity levels, such as light-dark box and 
novelty suppressed feeding). If so, one could speculate that reduced anxiety behaviour in 
these animals stems from the lack of environmental awareness or an increase in impulsivity, 
which could be tested in tasks specific for these behaviours. Otherwise, it has been shown 
previously that mouse response in the novelty suppressed feeding test is dependent on the 
ambiguity of the previous experience of aversive stimuli and the state of adult hippocampal 
neurogenesis. Glover et al., (2017) demonstrated that neurogenesis-deficient mice which went 
through cued fear conditioning training where the cue was only 50% predictive of footshock, 
appeared less anxious in the novelty suppressed feeding than those exposed to training with a 
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100% cue – footshock association. This effect was attributed to the failure of neurogenesis 
deficient mice to generalise the aversive experience to novel environments. As UCMS-exposed 
mice did show a reduction in adult hippocampal neurogenesis in the UCMS Experiment 3, it is 
possible to argue that their response in the novelty suppressed feeding test arena, as well as in 
other anxiety test could be related to such deficiency of fear generalisation. This point brings 
up the complexity of interpretation of some of the available behavioural tests. Indeed in most 
mood and anxiety-related tests, a lot of behavioural aspects such as fearfullness, spatial 
memory and attention might affect the outcome and thus complicate the interpretation of 
results.  
In addition, gene expression data provided some indirect evidence for the disturbance of the 
molecular regulation of circadian rhythm in UCMS-exposed animals, which could have led to 
hyperactivity in these animals detected in the light phase compared to undisturbed controls. 
Therefore, in future experiments, manipulations which do not cause circadian rhythm shift, 
such as application of stressors as well as behavioural testing in the active phase, could be 
advised to avoid the confound of hyperactivity. However, sleep disturbances are typical for 
clinical depression (Motivala et al., 2005), therefore circadian rhythm alterations could be 
considered advantageous if this phenotype is of importance for the study design. 
Another controversy arose from the interpretation of the tests of anhedonic behaviour which 
involved appetitive rewards.  Contrary to expectations, sucrose preference test measurements 
showed that mouse response to this test can fluctuate significantly during the UCMS 
procedure and in control groups, and is rather sensitive to the concentration of sucrose used. 
2% sucrose solution successfully discriminated between UCMS and CNTRL groups in 
Experiment 3, but serial assessments showed that BALB/cAnNCrl mice show a level of 
habituation upon repeated exposure. At the same time, this habituation showed a different 
dynamic between CNTRL and UCMS mice, which was corroborated by some indirect evidence 
pointing at a possible imbalance in the appetite-regulating system of UCMS-exposed animals. 
This evidence consisted of a decrease in the plasma level of leptin detected in stressed 
animals, accompanied by a differential expression of some of the leptin-regulated genes. This 
effect became apparent via the pathway analysis of the gene expression data, which suggested 
that leptin is a significant upstream regulator of the genes found to be altered by UCMS. Leptin 
deficiency is usually associated with increased appetite which would be expected to lead to 
weight changes, not observed in our studies experiments. A supposed shift in circadian 
rhythms which could have been induced by UCMS also could have played a role in these 
effects, if daily disturbance of mice by stressors shifted their resting time towards the night 
and feeding time towards the day. This could also explain why an apparent increase in appetite 
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was not accompanied by weight change. In this case either measurements taken separately in 
light and dark phases, or a reversal of light/dark cycle and application of stressors during the 
dark phase should be considered in the future experiments.  
Another explanation of the observed changes is a selective increase in the appetite for 
palatable food rewards, which was only apparent in the sucrose preference and cookie tests 
and therefore did not lead to a considerable weight change. Importantly, a behavioural 
phenotype of increased drive towards pleasurable food rewards could be of translational value 
for modelling increase in refined sugar consumption observed in some depressed patients 
(Davison and Kaplan, 2012; Gangwisch et al., 2015). Moreover such observation could be of 
relevance to the observation that there is an increased risk of type 2 diabetes in the depressed 
population (Vancampfort et al., 2015).  
These considerations bring up an important point of appetite and appetitive motivation as a 
potential confounding factor in tests of anhedonia which involve palatable stimuli. As these 
tests are designed to measure mouse motivation for food rewards, a behavioural change in 
these tests might be driven by both change in motivation towards any rewarding stimuli 
(anhedonia) or appetite-affected specific motivation towards palatable stimuli. To disentangle 
these, assessment of motivation towards another rewarding stimuli, such as for example 
sexual cue, could have proven helpful and should be considered in the future experiments.  
In addition, some behavioural domains which could have been affected by UCMS were not 
assessed in the behavioural batteries employed. Cognitive functions have been previously 
shown to be affected in animal models of depression, which corresponds to cognitive deficit 
seen in depressed patients. Moreover, observed changes seen in adult hippocampal 
neurogenesis might be pointing at the deficit in hippocampus- and hippocampal neurogenesis-
dependent functions, such as spatial memory and pattern separation. Inclusion of relevant 
tests, such as Morris water maze and contextual fear discrimination learning, could have 
provided more insight into deficit in these behavioural domains.  
 UCMS affected adult hippocampal neurogenesis but the PFC emerged 
as the primary region of UCMS-induced gene expression changes  
In line with multiple previous studies, a successful protocol of UCMS exposure induced a 
decrease in the number of adult-born DCX-positive neuroblasts in our experiments. While the 
effect size in this study (15%) was somewhat lower than in previously reported UCMS studies, 
it is important to point out that the magnitude of suppressing effect of UCMS on adult 
hippocampal neurogenesis varies from study to study and is likely to be dependent on the 
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measure of adult neurogenesis used. For example, Mineur et al. (2007) reported about 50% 
reduction in proportion of BrdU/NeuN – positive cells upon UCMS exposure in BALB/c mice, a 
measure which represents combined effect of neuronal differentiation and survival. Several 
years later the same group reported around 35% decrease in the density of DCX+ cells in dorsal 
hippocampus and 65% decrease in ventral hippocampus after 9 weeks of UCMS exposure in 
BALB/c mice (Nollet et al., 2012). While this measure is analogous to the one used in the UCMS 
experiment 3, the baseline level of DCX+ cell density in this study is much lower than described 
here (11000 cells/mm3 vs 26000 cells/mm3). Regardless of the potential source of such 
difference (substrain differences, control conditions, methodological variations in 
immunohistochemistry or quantification methods), it is very probable that such variation 
might have affected the effect size.  
It is also interesting to compare the effect observed in my experiments to previously reported 
data from human subjects. Two studies have reported around 30% decline in neurogenic 
markers in depressed subjects compared to non-depressed controls (Boldrini et al., 2012; 
Lucassen et al., 2010). However both studies looked at cell proliferation and the density of 
nestin-positive proliferating neural progenitors rather than neuronal differentiation. It is likely 
that different progenitor populations would be differently affected by depression. Thus, it 
would be benefitial to assess the effect of UCMS on the pool of Nestin-positive type 1 
progenitors to see if the effect observed in clinical studies could be replicated in the current 
UCMS model. On the other hand is has now been shown that the overall rate of adult 
hippocampal neurogenesis in humans is likely to be higher than in rodents (Spalding et al., 
2013), therefore even a small decline in a mouse model might be of translational value for 
human disease research. Nonetheless, the sole use of DCX as a neurogenesis marker is a 
limitation to this study. Certain controversy over its ability to reliably reflect the state of AHN 
currently exists in the scientific community (Merz and Lie, 2013), therefore future studies 
should also employ other markers of immature neurons, such as Prox1 and NeuroD1, as well 
as assessment of the adult-born neurons population by BrdU/NeuN double-labelling (Nicola et 
al., 2015). 
However a significant advantage of using DCX is the fact that DCX+ cell population comprises a 
wide variety of progenitors at different stages of neuronal maturation. Thus to get some 
insight into the effect of UCMS on stage of neuronal maturation, further classification of DCX+ 
cells based on dendritic morphology according to Plümpe et al. (2006) was used to detect a 
stage of neuroblast maturation most susceptible to UCMS effects. The results showed that 
UCMS specifically depleted the pool of neuroblasts with the most mature dendritic tree. This 
finding is in line with two previous studies which also identified a reduction in DCX+ cell 
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population with complex dendritic morphology following UCMS or chronic CORT exposure 
(Lussier et al., 2013; Vega-Rivera et al., 2016). However, this assessment does not clarify 
whether a number of neuroblasts with a more developed dendritic tree was lower in the 
UCMS-exposed hippocampi due to slower maturation of neuroblasts, increase in their 
apoptosis or dendritic atrophy or remodelling induced by UCMS. Immunohistochemistry using 
markers of cell death such as caspase 3, as well as stage 3 progenitor markers such as 
calretinin and NeuN could have helped to disentangle this effect, however such analysis was 
not included in our initial experimental design.  
An indirect suggestion for potential dendritic atrophy came from the assessment of gene 
expression in the hippocampus and the PFC of UCMS-exposed animals. The decrease in DCX+ 
cells was indeed accompanied by a small reduction in the DCX gene expression in the 
hippocampus. While the hippocampal gene expression was otherwise not strongly affected by 
the UCMS, pathway analysis of a large number of genes differentially expressed in the PFC 
suggested activation of pathways involved in dendritic remodelling. These included glutamate 
receptor and calcium signalling, as well as the axonal guidance pathway.  In addition, 
functional analysis of the gene expression dataset predicted many dendritic morphology-
related functions to be affected by UCMS. Neurodegenerative changes in the PFC are well-
described in chronic stress research and include not only dendritic atrophy (Dias-Ferreira et al., 
2009; Liston et al., 2006), but also microglial activation (Hinwood et al., 2013) and atrophy of 
pyramidal neurons (Cerqueira, 2005). Moreover, it is in agreement with a number of post-
mortem and neuroimaging studies, which reported decreased PFC volume and activity in 
depressed patients (Drevets et al., 1997; van Tol et al., 2014). While assessment of the 
dendritic structure of PFC neurons was not included in the original aims of our study, analysis 
of microglial density showed an increased number of Iba+ microglia in the PFC, considered to 
be one of the signs of microglial activation. Therefore, available gene expression and 
immunohistochemical data suggest a degree of neurodegeneration occurring in the PFC. It is 
possible that this neurodegenerative signalling was then transmitted to the hippocampus and 
affected the maturation of adult-born neurons in the DG. Interestingly, increased hippocampal 
functional connectivity with dorsolateral PFC has been shown in older depressed patients by a 
resting-state functional connectivity MRI study (Goveas et al., 2011), suggesting that 
hippocampal-PFC connection might indeed be activated in depression.  
The question remains as to why UCMS did not induce more profound gene expression changes 
in the hippocampus along with the PFC. A number of transcriptomic studies of chronic stress 
effects described significant changes in the hippocampal gene expression (Bergström et al., 
2007; Gray et al., 2014; Malki et al., 2013). However some previous studies already showed 
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more gene expression changes in other brain regions than in the hippocampus upon UCMS in 
BALB/c mice (Liu et al., 2010; Surget, Wang, et al., 2008). Moreover, the PFC has been shown 
to be more sensitive to chronic stress than the hippocampus in studies of synaptic 
neurotransmission changes (Müller et al., 2011; Yuen et al., 2012).  It is possible that the use of 
the total hippocampal tissue might have masked some of the gene expression effects because 
of transcriptomic and functional heterogeneity of hippocampal regions. Indeed, dorsal and 
ventral hippocampus are thought to be functionally and molecularly distinct (Fanselow and 
Dong, 2010), and the two regions have been shown to differ in their gene expression response 
to chronic stress (Guidotti et al., 2013; Hill et al., 2014).  
The results of the neuroblast assessment also showed that UCMS stimulated migration of 
immature neuroblasts from the SGZ into deeper layers of the GZ. An increase in neuroblast 
migration distance has been previously shown to be induced by detrimental factors including 
neuroinflammation and ablation of the GR (Belarbi et al., 2012; Fitzsimons et al., 2012). 
However, this is the first time this effect is shown to be induced by chronic stress, providing 
further insight into the antineurogenic effects of UCMS. In future studies, analyses of the 
dendritic morphology of mature neurons in the hippocampus as well as in other stress-
responsive brain regions, such as the PFC, will show if the effects of UCMS on dendritic 
morphology extend beyond adult-born neurons.  
Lastly, the design of the UCMS experiments neither aimed nor allowed asnwering the question 
of the causality of adult neurogenesis decline in depression. The data shown here confirms the 
hypothesis that a major risk factor for depression, chronic stress exposure, leads to a reduction 
in neuronal differentiation in the hippocampal dentate gyrus, however its role in depression 
neurobiology remains unclear. To address this issue experiments involving specific 
manipulation of the level of adult neurogenesis, such as its ablation or stimulation along with 
stress exposure, would be required. However, the current state of the neurogenesis 
hypothesis of depression prioritises its role in antidepressant mechanism of action over its 
potential causality, which so far has not been confirmed (Miller and Hen, 2015). Thus a 
successful depression model would primarily require adult neurogenesis as a correlate of 
behavioural decline and recovery.   
 HPA axis was not overactivated by UCMS 
The assessment of the HPA axis activity provided some unexpected results. Plasma CORT 
measures did not show an increase in HPA axis activity previously shown to be induced by 
UCMS in the literature. In fact, the opposite trend towards a blunted HPA response to acute 
stress was observed, resembling a hypoactive state of HPA axis regulation. The hypoactive 
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response of the HPA axis to chronic stress has been linked to strain differences, individual 
variability and the effect of social isolation (Ibarguen-Vargas et al., 2008; Ieraci et al., 2016). 
Moreover, a hypoactive HPA axis is routinely observed  in a chronic CORT injection model 
(David et al., 2009; Hill et al., 2015). Interestingly, in the UCMS model a hypoactive HPA axis 
has been linked to antidepressant resistance in behavioural and neurogenesis domains 
(Khemissi et al., 2014; Surget et al., 2016). In line with this, FLX was not able to improve AHN in 
the UCMS-exposed animals in the UCMS Experiment 2. In addition, investigation of the 
predictive factors affecting AHN in the UCMS Experiment 3s also provided evidence for a 
negative effect of low CORT response to acute stress. Moreover, indirect support of a 
hypoactive HPA axis hypothesis came from the gene expression analysis, which again contrary 
to expectations did not show any activation of the HPA axis or GR-dependent pathways in the 
hippocampus.  
Therefore, it is possible to suggest that the BALB/cAnNCrl strain of mice responds to UCMS 
with a hypoactivity or hypersuppression of the HPA axis. Such a profile of HPA axis response 
resembles the reduced HPA axis activity seen in some depressed patients with comorbid 
cardiac conditions (Nikkheslat et al., 2015)  and those with atypical  depression (Gold, 2015). 
Further evaluation of antidepressant resistance in the future experiments with our UCMS 
setup would also confirm the validity of this model to study the mechanisms of antidepressant 
resistance seen in clinical practice, which currently presents a serious challenge in the 
treatment of depression (Thomas et al., 2013). 
Future experiments will be able to refine the assessment of the HPA axis, which was limited in 
our experiments.  The single CORT measure taken during the light phase could be replaced 
with a series of measures taken at various time points during the 24 hours to draw a 
comprehensive picture of the alterations in the CORT diurnal rhythm. Assessment of post-
acute stress CORT could also be extended to additional earlier and later time points to capture 
the dynamics of the acute stress response. A dexamethasone suppression test would be able 
to confirm if UCMS resulted in altered suppression of the HPA axis by the negative feedback 
regulation.  
 UCMS induced limited signs of the immune system activation 
One of the aims of the UCMS experiments was to evaluate the extent of immune changes 
induced by UCMS. Previous studies described elevation of blood proinflammatory biomarkers, 
increased cytokine gene expression and protein levels in the brain, as well as microglial 
activation in various brain areas. However, in our experiments only limited signs of immune 
system involvement were detected. Among the plasma inflammatory biomarkers only CRP was 
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increased in UCMS-exposed group, which could partly be attributed to the lack of sensitivity in 
the assays ran in this thesis. CRP elevation is widely used in the clinic as a biomarker of 
inflammation and therefore can serve as a sufficient proinflammatory evidence. However, the 
use of hypersensitive plasma cytokine assays in the future might be able to detect subtle 
changes in cytokine levels and therefore provide a more comprehensive picture of the blood 
proinflammatory profile. 
Yet gene expression data corroborated the plasma profile, as no increase in cytokine gene 
expression was found in the PFC or the hippocampus. This finding was also consistent with the 
absence of microglial activation in the dentate gyrus. At the same time the density of 
microglial cells was increased in the PFC, suggesting a level of microglial activation occurring in 
this area.  While chronic stress has been shown to induce activation of microglia in the 
hippocampus and the PFC (Wohleb et al. 2012; Tynan et al. 2010), hippocampus has been 
shown to be more prone to microglial dystrophy which replaces initial microglial activation in 
the course of a prolonged chronic stress exposure (Hinwood et al., 2012; Kreisel et al., 2014). 
The occurring dystrophy could have counterbalanced the original rise in microglial numbers 
and therefore result in no change in the final microglial density. At the same time, it is 
interesting to relate the absence of microglial activation in the hippocampus to the absence of 
HPA axis activation. Glucocorticoids have been shown to be responsible for the priming and 
proliferation of microglia upon stress exposure (Frank et al., 2014; Nair and Bonneau, 2006). 
Therefore, one could speculate if HPA axis resistance to chronic stress also prevented 
microglial activation specifically in the hippocampus, known for its high GR expression levels 
and involvement in the HPA axis regulation.  
The limitation to the current study is the fact that microglial activation was only estimated via 
the evaluation of the microglial density. In future studies, assessment of the morphological 
signs of activation or dystrophy, as well as detection of activation-specific markers will improve 
the precision of the analysis of the microglial state. 
 LPS – based model induced long-term neurobiological 
changes 
The limited evidence for proinflammatory changes induced by UCMS challenged its suitability 
to model neuroinflammatory aspects of depression neurobiology. Therefore, a separate 
intervention was required to model the proinflammatory changes seen in depressed patients, 
to allow future testing of the novel compounds designed to target this aspect of depression 
pathology. LPS is widely used to study the depression-inducing effects of the inflammatory 
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processes, however many studies focus on short-term phenotypes, whereby a distinction 
between sickness and depression-like behavioural changes is hard to define. As has been 
shown in the UCMS-dedicated chapters, parameters such as appetite and locomotor activity 
can significantly affect the outcome of tests designed to assess depression-like behaviour, and 
these parameters are known to be affected by ongoing inflammation. Thus, the interpretation 
of behavioural phenotypes in LPS-induced models is apriori confounded. Therefore, the LPS 
experiments described in this thesis were aimed to specifically attempt a model of long-term 
changes with a focus on neurobiology rather than the behavioural phenotypes.  
Experiments showed that a single injection of LPS is not sufficient to induce chronic change, 
therefore a new mode of repeated injections was proposed and tested. The results showed 
that weekly injections with an escalating dose of LPS (from 0.33mg/kg to 0.83mg/kg) induced a 
distinct profile of blood proinflammatory biomarkers with some cytokines showing lower and 
some higher elevation compared to the effect of a single dose. Repeated exposure to LPS is 
known to induce a reduction of inflammatory response known as LPS tolerance. Although 
measures were taken to avoid the development of LPS tolerance, some signs of tolerance were 
observed to be induced by this protocol.  Importantly one of them was the loss of behavioural 
despair in the FST observed on the first, but not on the last week of injections.  
AHN assessment showed that exposure to escalating doses led to a reduction in neuroblast 
maturation in the hippocampal DG similar to that induced by the UCMS. However, our 
protocol was not able to significantly reduce the total number of DCX+ cells. Moreover, the 
repeated LPS injections did not increase microglial proliferation or activation in the 
hippocampus. Therefore, the repeated injections with escalating dose of LPS proved to be 
suitable to induce elevation of some proinflammatory biomarkers, but were not sufficient to 
induce depression-like changes in the hippocampus or in the forced swim test for behavioural 
despair.   
The study design provided some limitations to the LPS study. Treatment groups included did 
not allow a comparison with LPS tolerant mice needed to draw definitive conclusions on the 
presence and extent of the tolerance to LPS. The depressive-like behaviour evaluated was 
limited to behavioural despair, therefore it is not known if other behavioural domains were 
affected by single or repeated LPS injections. AHN was assessed 7 days after the last LPS 
injections as long-term changes were the focus of this study, however this approach resulted 
in immediate effects of LPS most frequently described in the literature not be reflected in the 
current analysis.  
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 Conclusions and future directions 
The experiments described in this thesis have contributed towards the advancement of the 
knowledge and the methodology of the two commonly used models of depression, the UCMS 
model and the LPS exposure based model in BALB/c mice. Multiple UCMS experiments showed 
that following careful protocol optimisation for the substrain used, UCMS can be a reliable 
model to induce some of the depression-like behaviours and alterations in adult hippocampal 
neurogenesis. However, currently available depression and anxiety- related behavioural tests 
can be confounded by factors such as locomotor activity and appetite also affected by UCMS, 
and thus need to be interpreted with caution. Importantly, in male BALB/cAnNCrl mice UCMS 
is not associated with a profile of systemic inflammatory changes seen in depressed patients, 
even though some evidence of inflammatory processes has been collected. Interestingly, it 
appeared that the PFC but not the hippocampus responds to UCMS with profound gene 
expression changes and microglial activation, suggesting higher susceptibility of this region to 
chronic stress. In fact, hippocampal resistance to stress was further corroborated by the 
absence of HPA axis overactivation in response to the UCMS protocol, as HPA axis function is 
thought to depend on the GR signalling in the hippocampus. Some evidence of antidepressant 
resistance accompanying these changes was collected for this thesis, but further experiments 
incorporating antidepressant treated groups are needed to confirm this suggestion. These 
findings support an existing notion that other brain areas apart from the hippocampus play an 
important role in chronic stress response and perhaps deserve more attention in preclinical 
depression research (Willner et al., 2014). At the same time, observed hippocampal resistance 
might be suggesting that additional interventions are needed to increase susceptibility of mice 
to chronic stress effects and to achieve the desired depression-like response. 
The LPS experiments described in this thesis attempted to design a model of neurobiological 
changes typical for depression, specifically chronic inflammatory alterations and decline in 
adult hippocampal neurogenesis, potentially accompanied by some depression-like 
behaviours. While the mode of chronic escalating dose injections proposed did induce weekly 
elevations of proinflammatory biomarkers, it was not associated with a significant decline in 
AHN or neuroinflammation in the hippocampus. At the same time some detrimental changes 
in the neuroblast populations, resembling those induced by UCMS, have been observed. This 
suggests that LPS insult was targeting the pathways of interest, but perhaps was not 
sufficiently potent to cause tangible damage. In addition, this mode of injections did not cause 
a sustained behavioural despair response in the FST.  
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Therefore, both models induced some aspects of neurobiology relevant for inflammatory and 
neurogenic theories of depression, however none achieved the comprehensive phenotype 
required to fully test novel drugs targeting factors derived from these theories. It is possible 
that the combination of two models might be more successful in achieving this aim in the 
future. Indeed few previous studies showed that co-administration with LPS during the UCMS 
exposure triggered an exaggerated elevation of proinflammatory cytokines in the blood as well 
as in the hippocampus (Elgarf et al., 2014; Espinosa-Oliva et al., 2011).  The combination of 
manipulations  also was associated with microglial activation and profound neurodegenerative 
changes in this key region (Espinosa-Oliva et al., 2011). At the same time exposure to chronic 
stress before LPS or polyI:C injections prolonged the duration of depression-like behaviour in 
affected animals (Chijiwa et al., 2015; Couch et al., 2016). Thus it is possible to suggest that a 
double hit model combining manipulations of the stress and immune systems will trigger a 
required level of susceptibility to induce depression-like behaviour, as well as inflammatory 
and neurogenic changes sufficient to test novel antidepressant compounds targeting these 
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 Differentially expressed genes in the PFC 
Table 21 Significantly differentially expressed genes in the PFC. 
Fold change and q values derived from analysis conducted by Significance Analysis of Microarrays (SAM) method 
and R-package with FDR level set at 0 
PFC UPREGULATED GENES PFC DOWNREGULATED GENES 
Gene name Fold change Q-value 
(%) 
Gene name Fold change Q-value 
(%) 
Loc665506 2.61 0 Rgs9 0.28 0 
Myl4 2.23 0 Tac1 0.29 0 
Tnnc1 2.15 0 Pcp4l1 0.30 0 
Nrgn 2.07 0 Calb2 0.35 0 
E130012a19rik 2.06 0 Cart 0.37 0 
Zfp312 2.02 0 Gng7 0.37 0 
C330006p03rik 2.00 0 6330404f12rik 0.45 0 
Cpne9 1.97 0 Cartpt 0.48 0 
Mef2c 1.88 0 Loc100047385 0.49 0 
Dkk3 1.87 0 2810011l19rik 0.49 0 
Ldb2 1.86 0 Slc32a1 0.51 0 
Satb1 1.82 0 Chn2 0.52 0 
Stx1a 1.78 0 Cacng5 0.53 0 
Pvalb 1.77 0 Lmo3 0.54 0 
Nfix 1.74 0 Scg2 0.54 0 
Tcrb-v8.2 1.73 0 Gad1 0.54 0 
9130024f11rik 1.72 0 Hap1 0.55 0 
Zfp238 1.72 0 Loc100047583 0.56 0 
6330527o06rik 1.71 0 Slc17a6 0.56 0 
Cck 1.67 0 Slc17a6 0.57 0 
Ai850995 1.67 0 Gad1 0.57 0 
Galnt9 1.65 0 Trf 0.57 0 
Grit 1.63 0 Zcchc12 0.57 0 
Ccl27 1.63 0 Pcp4l1 0.57 0 
1700019n12rik 1.58 0 Adra2a 0.58 0 
Ddit4l 1.58 0 Mobp 0.58 0 
Sytl2 1.58 0 Tiam1 0.59 0 
Dgkz 1.57 0 Bcl11b 0.59 0 
Tshz3 1.57 0 Tpbg 0.59 0 
Camk2a 1.56 0 Mag 0.59 0 
Pcsk2 1.56 0 Ppp1r2 0.60 0 
Osbpl1a 1.55 0 D330017j20rik 0.60 0 
Nuak1 1.55 0 Meis1 0.60 0 
Arpp19 1.54 0 Cacng5 0.60 0 
Cckbr 1.54 0 Mbp 0.61 0 
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Gene name Fold change Q-value 
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Mapk11 1.54 0 Zic1 0.61 0 
Pvrl3 1.54 0 Clic6 0.62 0 
Cobl 1.53 0 H3f3b 0.63 0 
Slc17a7 1.53 0 Btg1 0.63 0 
Ccdc3 1.52 0 6430550h21rik 0.64 0 
D10ertd610e 1.51 0 Loc100046259 0.65 0 
Loc100047651 1.51 0 Cntnap2 0.65 0 
Extl1 1.51 0 Sez6 0.65 0 
Tmem178 1.49 0 6430550h21rik 0.65 0 
Ppme1 1.48 0 Sox11 0.66 0 
Gfod1 1.48 0 Spock3 0.66 0 
Arhgdig 1.48 0 Doc2b 0.66 0 
Syne1 1.47 0 Mog 0.66 0 
Zfp238 1.47 0 Hmgn2 0.66 0 
Loc100046044 1.47 0 Nrsn2 0.67 0 
Olfm1 1.45 0 Fa2h 0.67 0 
1110008p14rik 1.44 0 Loc100047827 0.67 0 
Ldb2 1.44 0 Ednrb 0.67 0 
Hapln4 1.43 0 Cldn11 0.67 0 
Car10 1.43 0 Dgkb 0.67 0 
Rilpl1 1.43 0 Prr18 0.68 0 
Actb 1.42 0 A230065h16rik 0.68 0 
Fezf2 1.42 0 Rcan3 0.69 0 
Acsl5 1.42 0 A230057m07rik 0.69 0 
Arhgdig 1.41 0 Tmem90a 0.69 0 
Atp1a1 1.41 0 Loc268934 0.69 0 
Actb 1.41 0 Krt10 0.70 0 
Itpr1 1.41 0 Eg574403 0.70 0 
Diras2 1.41 0 Mobp 0.70 0 
Homer1 1.40 0 Actn2 0.70 0 
Loc100047870 1.40 0 6430524c05rik 0.70 0 
A130090k04rik 1.40 0 Fgfr2 0.71 0 
Adrbk1 1.40 0 Lmo3 0.71 0 
Dgkz 1.40 0 Clic4 0.71 0 
Garnl3 1.40 0 Btg1 0.71 0 
Garnl4 1.39 0 Mog 0.71 0 
38596 1.39 0 Litaf 0.72 0 
Itpka 1.39 0 Slc6a9 0.72 0 
Sobp 1.39 0 Loc100042405 0.72 0 
Sidt1 1.38 0 Pigp 0.72 0 
Mpped1 1.38 0 Pigh 0.72 0 
Fbxw7 1.38 0 Lass2 0.72 0 
Camk2a 1.38 0 Nmbr 0.73 0 
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Extl1 1.38 0 Dbi 0.73 0 
Camk2n1 1.38 0 Fibcd1 0.73 0 
Tmem132a 1.37 0 Loc100047353 0.73 0 
Ly6e 1.37 0 Tubb2b 0.74 0 
Loc100045359 1.37 0 Rerg 0.74 0 
Tcap 1.37 0 Usp29 0.74 0 
Per2 1.37 0 Dock10 0.74 0 
Camta2 1.36 0 Ai851790 0.74 0 
Dab2ip 1.36 0 Pptc7 0.74 0 
Tspan17 1.36 0 Fhl1 0.75 0 
Lasp1 1.36 0 Slc25a5 0.75 0 
Mbp 1.36 0 Inpp5f 0.75 0 
Loc100044468 1.35 0 Dscr1l2 0.75 0 
Rab6 1.35 0 Sertad4 0.75 0 
6530418l21rik 1.35 0 Mobp 0.75 0 
Sema7a 1.35 0 Loc100044124 0.75 0 
Rspo2 1.35 0 2210013o21rik 0.76 0 
Syn1 1.34 0 Eg434280 0.76 0 
Nbl1 1.34 0 Dbi 0.76 0 
Diras2 1.34 0 Ndrl 0.76 0 
Tuba4a 1.34 0 Abat 0.76 0 
E430002g05rik 1.34 0 Pigp 0.76 0 
Epb4.9 1.33 0 Nrsn2 0.76 0 
Bc049806 1.33 0 Nnat 0.76 0 
Faah 1.33 0 Nsep1 0.77 0 
Stk16 1.33 0 Necab2 0.77 0 
Galt 1.32 0 C030048h21rik 0.77 0 
Rph3a 1.32 0 Sumo3 0.77 0 
Nfix 1.32 0 Cited2 0.77 0 
Etl4 1.32 0 Nsg2 0.78 0 
Flot1 1.32 0 Kcne1l 0.78 0 
Tpd52 1.31 0 Bex4 0.78 0 
Cux2 1.31 0 Slc44a1 0.78 0 
Mkx 1.31 0 B230369l08rik 0.79 0 
Car4 1.31 0 Anln 0.79 0 
Gng13 1.30 0 Psip1 0.79 0 
Anxa11 1.30 0 Lrrc8d 0.79 0 
D17wsu92e 1.30 0 5033414k04rik 0.79 0 
Myrip 1.29 0 6330500d04rik 0.79 0 
Sult4a1 1.29 0 Hnrpdl 0.79 0 
Mast3 1.29 0 6330500d04rik 0.79 0 
Slc2a6 1.29 0 Rbp1 0.80 0 
Chrd 1.28 0 B230312l03rik 0.80 0 
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Ccng1 1.28 0 Rnaset2b 0.80 0 
Kcnv1 1.28 0 Gcap27 0.80 0 
Pip5k1c 1.28 0 Eg433229 0.80 0 
Camkk2 1.27 0 Adamts4 0.81 0 
Kcnmb4 1.27 0 Dock10 0.81 0 
Iqgap2 1.27 0 2310014g06rik 0.81 0 
Cbln2 1.27 0 Eif2s2 0.81 0 
Eg244911 1.26 0 Sox10 0.82 0 
Unc13b 1.26 0 Loc100040919 0.82 0 
Ccl27 1.26 0 H2-ke6 0.82 0 
Mras 1.26 0 B3galt5 0.82 0 
Loc100043919 1.26 0 Doc2b 0.82 0 
Lingo1 1.26 0 Bc057371 0.82 0 
Foxp3 1.26 0 Htr1d 0.83 0 
A730017d01rik 1.25 0 Caprin1 0.83 0 
Gca 1.25 0 Spint1 0.83 0 
Khdrbs3 1.25 0 Ddc 0.83 0 
Chrm3 1.25 0 Acvr2b 0.83 0 
Cd6 1.25 0 1110018j23rik 0.83 0 
Echdc2 1.25 0 Nap1l1 0.83 0 
6030405a18 1.25 0 Ergic3 0.83 0 
St8sia5 1.25 0 Ppap2c 0.83 0 
Camk2g 1.25 0 Rab34 0.83 0 
Etv5 1.24 0 Amotl1 0.83 0 
E230013m07rik 1.24 0 Pbx3 0.84 0 
Vasn 1.24 0 Loc100048589 0.84 0 
Pop5 1.24 0 Xpa 0.84 0 
Ptprk 1.24 0 Pdlim2 0.84 0 
E2f1 1.24 0 Eg245190 0.84 0 
Xbp1 1.24 0 Mycl1 0.84 0 
Dact2 1.24 0 Gabrg1 0.84 0 
Mgll 1.23 0 Plekhg3 0.84 0 
Lin7b 1.23 0 C030027h14rik 0.84 0 
2310045a20rik 1.23 0 Kcnip1 0.84 0 
Zfpm2 1.23 0 Nts 0.85 0 
Hsd11b1 1.23 0 B430201a12rik 0.85 0 
Cd6 1.23 0 Kcna5 0.85 0 
Ephb6 1.23 0 Samd9l 0.85 0 
Atxn7l3 1.23 0 Hbp1 0.85 0 
Pou6f1 1.23 0 Bc031781 0.85 0 
Otx1 1.23 0 2010011i20rik 0.86 0 
3110047p20rik 1.23 0 Amy2-2 0.86 0 
Ppfia3 1.23 0 Lhfpl3 0.86 0 
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Myadm 1.23 0 Fzd5 0.86 0 
Dlk2 1.22 0 Inpp4b 0.86 0 
Loc100044376 1.22 0 Vps25 0.87 0 
Fbxo27 1.21 0 Gtf2ird1 0.87 0 
Ly6e 1.21 0 Bc025546 0.87 0 
Spcs3 1.21 0 Tmem117 0.87 0 
Cacnb4 1.21 0 2700007p21rik 0.87 0 
E430002g05rik 1.21 0 Sema6d 0.87 0 
Arhgap25 1.20 0 Rab34 0.87 0 
Slc26a4 1.20 0 Myt1 0.87 0 
Sema4f 1.20 0 Scl0004175.1_57 0.87 0 
Nuak1 1.20 0 Cpne2 0.88 0 
Rimbp2 1.20 0 9630031f12rik 0.88 0 
Iqwd1 1.20 0 Ai851790 0.88 0 
Csnk2a2 1.20 0 Dhrs7 0.88 0 
D4bwg0951e 1.20 0 Itgb4 0.88 0 
Atmin 1.20 0 Tcf7l2 0.88 0 
1700003e16rik 1.20 0 Lhfpl3 0.89 0 
Apba2 1.19 0 Dlx6 0.89 0 
Ubqln4 1.19 0 Ccbl1 0.89 0 
Iqsec2 1.19 0 Araf 0.89 0 
Efna5 1.19 0 Il13ra1 0.89 0 
D330001f17rik 1.19 0 Bdh2 0.89 0 
Dab2ip 1.19 0 Rps6ka5 0.89 0 
9030619k07rik 1.19 0 1110059g02rik 0.90 0 
Mast1 1.19 0 Efs 0.90 0 
Acap3 1.19 0 Sp9 0.90 0 
Dtx4 1.19 0 Ccno 0.90 0 
Lgals1 1.19 0 6330505n24rik 0.90 0 
A830021m18 1.19 0 Hist1h4h 0.91 0 
Loc244417 1.19 0 Rasgrp2 0.91 0 
Spag5 1.19 0 Arhgef6 0.91 0 
Dtx4 1.18 0 Xrcc3 0.91 0 
Arhgap15 1.18 0 Slc6a3 0.91 0 
Apba2 1.18 0 Apoc1 0.92 0 
Olfm2 1.18 0 1110012d08rik 0.93 0 
Ap3m2 1.18 0 Wdr68 0.93 0 
Ovol2 1.17 0       
Loc100044968 1.17 0       
Map3k10 1.17 0       
Kcnmb4 1.17 0       
Cpne9 1.17 0       
Tspan17 1.17 0       
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6330404c01rik 1.17 0       
Tmem198 1.16 0       
Tcap 1.16 0       
Loc381326 1.16 0       
D10ertd610e 1.16 0       
Acss2 1.16 0       
4632428d17rik 1.16 0       
Dkk3 1.16 0       
C77080 1.16 0       
9330175b01rik 1.16 0       
Shisa4 1.15 0       
B230339m05rik 1.15 0       
D8ertd82e 1.15 0       
Ovol2 1.15 0       
Wnt10a 1.15 0       
Glt8d2 1.14 0       
Map3k10 1.14 0       
Htatip2 1.14 0       
Loc100045780 1.14 0       
Adap1 1.14 0       
Robo3 1.14 0       
D230013b04rik 1.14 0       
Tle6 1.14 0       
Kcnk4 1.14 0       
Glt8d2 1.13 0       
Myd88 1.13 0       
Scl000490.1_983 1.13 0       
Cd6 1.13 0       
Olfm1 1.13 0       
Otud3 1.13 0       
Ccbp2 1.13 0       
Baiap2l1 1.13 0       
Megf11 1.13 0       
A830073o21rik 1.12 0       
9330102g19rik 1.12 0       
Myh3 1.12 0       
Nfix 1.11 0       
Synj2 1.11 0       
Rgs9bp 1.11 0       
Ramp3 1.11 0       
Gpr68 1.11 0       
Cbfa2t3h 1.11 0       
Ab112350 1.11 0       
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Tbc1d5 1.11 0       
H2afj 1.11 0       
Ephb2 1.11 0       
1810047k05rik 1.10 0       
D330038k10rik 1.10 0       
Dok5 1.10 0       
Chd5 1.10 0       
Ap2s1 1.09 0       
Kcnk6 1.09 0       
Clec11a 1.09 0       
Ramp3 1.09 0       
Ptprd 1.08 0       
6330540d07rik 1.08 0       
B230107j06rik 1.07 0       
Galnt9 1.06 0       
Kcng2 1.06 0       
 
 Differentially expressed genes in the hippocampus and the 
hypothalamus 













Mkks 1.17 0.00 C330006p03rik 1.10 4.99 
Per2 1.26 0.00 Uhrf2 1.21 4.99 
Mfsd2 1.22 0.00 Camk1 1.13 4.99 
Zfp207 1.13 0.00 Tsc22d3 1.12 4.99 
Htra1 1.21 0.00 Htra1 1.22 4.99 
1110057k04rik 1.15 0.00 Mfsd2 1.22 4.99 
Nrp1 1.14 0.00 Loc634015 1.15 4.99 
1190003m12rik 1.07 0.00 Mrrf 1.12 4.99 
Arpc2 1.30 5.83 Fam107a 1.29 4.99 
Pglyrp1 1.06 6.03 Chic1 1.04 4.99 
C1ql3 1.11 6.03 Agxt2l1 1.18 4.99 
1190005n23rik 1.10 6.03 Copg 1.17 4.99 
Fam13c 1.10 6.03 C2 1.07 4.99 
Tsc22d3 1.18 9.51 Loc665506 1.07 4.99 
Sh3md4 1.05 9.51 Dusp19 1.11 9.97 
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S3-12 1.08 9.51       
Hace1 1.13 9.51       













Bex4 0.90 0.00 Klhdc9 0.88 0.00 
B230373p09rik 0.88 0.00 Loc385256 0.85 0.00 
Hnrpdl 0.82 0.00 Nrxn2 0.88 0.00 
Loc100047427 0.89 0.00 Hdgfrp2 0.83 0.00 
Hint2 0.84 5.83 Gm129 0.94 9.97 
Klhdc9 0.85 5.83 Pcdh19 0.92 9.97 
Pllp 0.89 7.61 Vangl2 0.92 9.97 
Asphd1 0.90 7.61 Cacng5 0.91 9.97 
Sgcb 0.91 7.61 Dgat2 0.86 9.97 
Dcx 0.95 7.61 Loc100047427 0.88 9.97 
Tmem86a 0.92 7.61 Mbtps1 0.89 9.97 
Mrps28 0.90 7.61 Rab34 0.88 9.97 
0610007p22rik 0.81 7.61       
Slc4a3 0.88 7.61       
Hyal2 0.93 7.61       
Zfp46 0.85 7.61       
Haghl 0.85 10.29       
Krt1-12 0.89 10.29       
Blmh 0.88 10.29       
Gucy1a3 0.82 10.29       
Lmnb1 0.92 10.29       
Cyp4f13 0.95 10.29       
Wbp5 0.89 10.29       
Nr1d1 0.93 10.29       
Gdf10 0.90 10.29       
Setd5 0.89 10.29       
Ai836003 0.91 10.29       
 
 
